<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN">
<HTML>
<HEAD>
<!-- Created by: EDGAR Online, Inc. EDGAR Filing HTML Converter, Version: 4.65, http://www.edgar-online.com -->
<TITLE> ENZO BIOCHEM INC (Form: 10-K, Received: 10/13/2016 17:17:24) </TITLE>
<META NAME="TABLES" CONTENT="FIS_FORM **FIS_PART_I **FIS_BUSINESS **FIS_RISK_FACTORS **FIS_UNRESOLVED_STAFF_COMMENTS **FIS_PROPERTIES **FIS_LEGAL_PROCEEDINGS **FIS_MINE_SAFETY_DISCLOSURE **FIS_PART_II **FIS_MARKET **FIS_FINANCIAL_DATA **FIS_MANAGEMENTS_DISCUSSION **FIS_RESULTS_OF_OPERATIONS **FIS_LIQUIDITY_CAPITAL **FIS_MARKET_RISK **FIS_FINANCIAL_STATEMENTS **FIS_ACCOUNTING_CHANGES **FIS_CONTROL_AND_PROCEDURES **FIS_AUDITORS_OPINION **FIS_OTHER_INFORMATION **FIS_PART_III **FIS_DIRECTORS_AND_OFFICERS **FIS_COMPENSATION **FIS_SECURITY_OWNERS **FIS_OFFICER_TRANSACTIONS **FIS_ACCOUNTANT_FEES **FIS_PART_IV **FIS_EXHIBITS **FIS_SIGNATURES **FIS_AUDITORS_OPINION_2 **FIS_BALANCE_SHEET **FIS_INCOME_STATEMENT **FIS_STOCKHOLDERS_EQUITY **FIS_CASH_FLOW **FIS_NOTES_TO_FINANCIAL_STATEMENT **FIS_INCOME_STATEMENT_2 **FIS_INCOME_STATEMENT_3 **FIS_INCOME_STATEMENT_4 **FIS_VALUATION_AND_QUALIFYING_ACCOUNTS FIS_EXHIBIT_10 FIS_EXHIBIT_21 FIS_EXHIBIT_23 **FIS_EXPERTS_CONSENT FIS_EXHIBIT_31 **FIS_CERTIFICATION FIS_EXHIBIT_31_2 **FIS_CERTIFICATION_2 FIS_EXHIBIT_32 **FIS_CERTIFICATION_3 FIS_EXHIBIT_32_2 **FIS_CERTIFICATION_4 ">
<META NAME="DETECTED PAGES" CONTENT="123">
<STYLE TYPE="text/css">
<!--
	body          { background-color: white; color: black }
	.eolNewPage   { page-break-after: always; line-height: 0; height: 0; margin: 0; padding: 0 }
	.eolLeftAlign { text-align: left; margin-left: auto; margin-right: auto }
	.eolCenter    { text-align: center }
	a:link        { color: blue }
	a:active      { color: red }
	a:visited     { color: purple }
	
	@media print
	{
		@page           { margin: 0.25in }
		body            { font-size: 10pt }
		a               { text-decoration: none }
		thead           { display: table-header-group }
		tfoot           { display: table-footer-group }
		hr.eolPageBreak { display: none }
		.eolPrint50pt   { font-size: 5pt }
		.eolPrint55pt   { font-size: 5.5pt }
		.eolPrint60pt   { font-size: 6pt }
		.eolPrint65pt   { font-size: 6.5pt }
		.eolPrint70pt   { font-size: 7pt }
		.eolPrint75pt   { font-size: 7.5pt }
		.eolPrint80pt   { font-size: 8pt }
		.eolPrint85pt   { font-size: 8.5pt }
		.eolPrint90pt   { font-size: 9pt }
		.eolPrint95pt   { font-size: 9.5pt }
	}
-->
</STYLE>
</HEAD>
<BODY>
<A NAME="eolPage1"></A>
<A NAME="FIS_TOP_OF_DOCUMENT"></A>

<A NAME="C86264_10K_HTM"></A>
<EFX_FORM>
<A NAME="FIS_FORM"></A>
<!-- FIELD: RULE-PAGE -->
<DIV ALIGN="LEFT" STYLE="MARGIN-BOTTOM: 10PT">
<DIV STYLE="FONT-SIZE: 1PT; BORDER-TOP: BLACK 2PX SOLID; BORDER-BOTTOM: BLACK 1PX SOLID; WIDTH: 100%">
	&nbsp;
</DIV>
</DIV>
<!-- FIELD: /RULE-PAGE -->
<P STYLE="FONT: 11PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	UNITED
	STATES
</B>
</P>
<P STYLE="FONT: 11PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	SECURITIES AND EXCHANGE COMMISSION
</B>
</P>
<P STYLE="FONT: 11PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	Washington, DC 20549
</B>
</P>
<P STYLE="FONT: 11PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	FORM 10-K
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<U>
	(Mark one)
</U>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 5%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT: 10PT WINGDINGS">
	x
</FONT>
</TD>
<TD STYLE="WIDTH: 95%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	ANNUAL REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	For the fiscal year ended July 31, 2016
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	or
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 5%; FONT: 11PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT: 10PT WINGDINGS">
	o
</FONT>
</TD>
<TD STYLE="WIDTH: 95%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	TRANSITION REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	For the transition period from ______________ to ______________
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	Commission File Number 001-09974
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 25%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 50%; BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: CENTER; FONT-SIZE: 16PT">
<FONT STYLE="FONT: 16PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	ENZO BIOCHEM, INC.
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 25%; FONT-SIZE: 18PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; FONT-SIZE: 10PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	(Exact name of registrant as specified in its charter)
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
</TR>
</TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 40%; BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	New York
</FONT>
</TD>
<TD STYLE="WIDTH: 20%; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 40%; BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	13-2866202
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	(State or other jurisdiction
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	(I.R.S. Employer
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	of incorporation or organization)
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Identification No.)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: CENTER; FONT-SIZE: 8PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; FONT-SIZE: 8PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; FONT-SIZE: 8PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	527 Madison Ave.
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	New York, New York
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	10022
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	(Address of principal executive offices)
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	(Zip Code)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 25%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 50%; BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	(212) 583-0100
</FONT>
</TD>
<TD STYLE="WIDTH: 25%">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	(Registrant&rsquo;s telephone number, including area code)
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	Securities registered pursuant to Section
	12(b) of the Act:
</B>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 40%; BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	(Title of Each Class)
</FONT>
</TD>
<TD STYLE="WIDTH: 20%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 40%; BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	(Name of Each Exchange on Which Registered)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Common Stock, $.01 par value
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	The New York Stock Exchange
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Indicate by check mark if the registrant is a well-known seasoned
	issuer, as defined in Rule 405 of the Securities Act.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 17.3PT; TEXT-INDENT: -8.65PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Yes
</FONT>
<FONT STYLE="FONT-FAMILY: WINGDINGS">
	o
</FONT>
	&nbsp;&nbsp;&nbsp;
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	No
</FONT>
<FONT STYLE="FONT-FAMILY: WINGDINGS">
	x
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 17.3PT; TEXT-INDENT: -8.65PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Indicate by check mark if the registrant is not required to
	file reports pursuant to Section 13 or Section 15(d) of the Act.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 17.3PT; TEXT-INDENT: -8.65PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Yes
</FONT>
<FONT STYLE="FONT-FAMILY: WINGDINGS">
	o
</FONT>
	&nbsp;&nbsp;&nbsp;
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	No
</FONT>
<FONT STYLE="FONT-FAMILY: WINGDINGS">
	x
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 17.3PT; TEXT-INDENT: -8.65PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Indicate by check mark whether the registrant
	has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted
	and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant
	was required to submit and post such files).
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 17.3PT; TEXT-INDENT: -8.65PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Yes
</FONT>
<FONT STYLE="FONT-FAMILY: WINGDINGS">
	x
</FONT>
	&nbsp;&nbsp;&nbsp;
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	No
</FONT>
<FONT STYLE="FONT-FAMILY: WINGDINGS">
	o
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 17.3PT; TEXT-INDENT: -8.65PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Indicate by check mark whether the registrant (1) has filed
	all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or
	for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements
	for the past 90 days.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 17.3PT; TEXT-INDENT: -8.65PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Yes
</FONT>
<FONT STYLE="FONT-FAMILY: WINGDINGS">
	x
</FONT>
	&nbsp;&nbsp;&nbsp;
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	No
</FONT>
<FONT STYLE="FONT-FAMILY: WINGDINGS">
	o
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 17.3PT; TEXT-INDENT: -8.65PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Indicate by check mark if disclosure of delinquent filers pursuant
	to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of registrant&rsquo;s knowledge,
	in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this
	Form 10-K
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 17.3PT; TEXT-INDENT: -8.65PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Yes
</FONT>
<FONT STYLE="FONT-FAMILY: WINGDINGS">
	x
</FONT>
	&nbsp;&nbsp;&nbsp;
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	No
</FONT>
<FONT STYLE="FONT-FAMILY: WINGDINGS">
	o
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 17.3PT; TEXT-INDENT: -8.65PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Indicate by check mark whether the registrant is a large accelerated
	filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See the definitions of &ldquo;large accelerated
	filer,&rdquo; &ldquo;accelerated filer&rdquo; and &ldquo;smaller reporting company&rdquo; in Rule 12b-2 of the Exchange Act.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 25%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Large accelerated filer
</FONT>
<FONT STYLE="FONT-FAMILY: WINGDINGS">
	o
</FONT>
</TD>
<TD STYLE="WIDTH: 25%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Accelerated filer
</FONT>
<FONT STYLE="FONT-FAMILY: WINGDINGS">
	x
</FONT>
</TD>
<TD STYLE="WIDTH: 25%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Non-accelerated filer
</FONT>
<FONT STYLE="FONT-FAMILY: WINGDINGS">
	o
</FONT>
</TD>
<TD STYLE="WIDTH: 25%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Smaller Reporting Company
</FONT>
<FONT STYLE="FONT-FAMILY: WINGDINGS">
	o
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Indicate
	by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act of 1934). Yes
</FONT>
<FONT STYLE="FONT-FAMILY: WINGDINGS">
	o
</FONT>
	&nbsp;&nbsp;&nbsp;
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	No
</FONT>
<FONT STYLE="FONT-FAMILY: WINGDINGS">
	x
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	The aggregate market value of the registrant&rsquo;s voting
	stock held by non-affiliates of the registrant was approximately $202,791,000 as of January 31, 2016.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	The number of shares of the Company&rsquo;s common stock, $.01
	par value, outstanding at October 1, 2016 was 46,267,619.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	DOCUMENTS INCORPORATED BY REFERENCE
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Portions of the definitive Proxy Statement to be delivered to
	shareholders in connection with the Annual Meeting of Shareholders to be held on or about January 5, 2017 are incorporated by reference
	into Part III of this annual report.
</P>
<!-- FIELD: RULE-PAGE -->
<DIV ALIGN="LEFT" STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 0">
<DIV STYLE="FONT-SIZE: 1PT; BORDER-TOP: BLACK 1PX SOLID; BORDER-BOTTOM: BLACK 2PX SOLID; WIDTH: 100%">
	&nbsp;
</DIV>
</DIV>
<!-- FIELD: /RULE-PAGE -->
<!-- FIELD: PAGE; SEQUENCE: 1 -->
<DIV STYLE="MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: SILVER 4PX SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage2"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 10PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: LEFT; WIDTH: 100%">
<PAGE>
</PAGE>
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PX SOLID">
<B>
	TABLE
	OF CONTENTS
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT CAMBRIA, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 80%; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
<B>
	Description
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 8%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
<B>
	Page
</B>
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<A HREF="#C86264_10K_HTM_X2_C86264A001">
<FONT STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
<B>
	Part I
</B>
</FONT>
</A>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<A HREF="#C86264_10K_HTM_X2_C86264A002">
<FONT STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	Item 1.
</FONT>
</A>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<A HREF="#C86264_10K_HTM_X2_C86264A002">
<FONT STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	Business
</FONT>
</A>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	2
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<A HREF="#C86264_10K_HTM_X2_C86264A003">
<FONT STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	Item 1A.
</FONT>
</A>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<A HREF="#C86264_10K_HTM_X2_C86264A003">
<FONT STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	Risk Factors
</FONT>
</A>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	24
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP">
<A HREF="#C86264_10K_HTM_X2_C86264A004">
<FONT STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	Item 1B.
</FONT>
</A>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<A HREF="#C86264_10K_HTM_X2_C86264A004">
<FONT STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	Unresolved Staff Comments
</FONT>
</A>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	38
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP">
<A HREF="#C86264_10K_HTM_X2_C86264A005">
<FONT STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	Item 2.
</FONT>
</A>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<A HREF="#C86264_10K_HTM_X2_C86264A005">
<FONT STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	Properties
</FONT>
</A>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	38
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP">
<A HREF="#C86264_10K_HTM_X2_C86264A006">
<FONT STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	Item 3.
</FONT>
</A>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<A HREF="#C86264_10K_HTM_X2_C86264A006">
<FONT STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	Legal Proceedings
</FONT>
</A>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	39
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP">
<A HREF="#C86264_10K_HTM_X2_C86264A007">
<FONT STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	Item 4.
</FONT>
</A>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<A HREF="#C86264_10K_HTM_X2_C86264A007">
<FONT STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	Mine Safety Disclosures
</FONT>
</A>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	40
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP">
<A HREF="#C86264_10K_HTM_X2_C86264A008">
<FONT STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
<B>
	Part II
</B>
</FONT>
</A>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP">
<A HREF="#C86264_10K_HTM_X2_C86264A009">
<FONT STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	Item 5.
</FONT>
</A>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<A HREF="#C86264_10K_HTM_X2_C86264A009">
<FONT STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	Market for Registrant&rsquo;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities
</FONT>
</A>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	41
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP">
<A HREF="#C86264_10K_HTM_X2_C86264A010">
<FONT STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	Item 6.
</FONT>
</A>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<A HREF="#C86264_10K_HTM_X2_C86264A010">
<FONT STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	Selected Financial Data
</FONT>
</A>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	43
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP">
<A HREF="#C86264_10K_HTM_X2_C86264A011">
<FONT STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	Item 7.
</FONT>
</A>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<A HREF="#C86264_10K_HTM_X2_C86264A011">
<FONT STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operations
</FONT>
</A>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	44
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP">
<A HREF="#C86264_10K_HTM_X2_C86264A012">
<FONT STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	Item 7A.
</FONT>
</A>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<A HREF="#C86264_10K_HTM_X2_C86264A012">
<FONT STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	Quantitative and Qualitative Disclosures About Market Risk
</FONT>
</A>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	56
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP">
<A HREF="#C86264_10K_HTM_X2_C86264A013">
<FONT STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	Item 8.
</FONT>
</A>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<A HREF="#C86264_10K_HTM_X2_C86264A013">
<FONT STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	Financial Statements and Supplementary Data
</FONT>
</A>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	57
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP">
<A HREF="#C86264_10K_HTM_X2_C86264A014">
<FONT STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	Item 9.
</FONT>
</A>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<A HREF="#C86264_10K_HTM_X2_C86264A014">
<FONT STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	Changes in and Disagreements with Accountants on Accounting and Financial Disclosure
</FONT>
</A>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	57
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP">
<A HREF="#C86264_10K_HTM_X2_C86264A015">
<FONT STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	Item 9A.
</FONT>
</A>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<A HREF="#C86264_10K_HTM_X2_C86264A015">
<FONT STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	Controls and Procedures
</FONT>
</A>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	57
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP">
<A HREF="#C86264_10K_HTM_X2_C86264A016">
<FONT STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	Item 9B.
</FONT>
</A>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<A HREF="#C86264_10K_HTM_X2_C86264A016">
<FONT STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	Other Information
</FONT>
</A>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	60
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP">
<A HREF="#C86264_10K_HTM_X2_C86264A017">
<FONT STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
<B>
	Part III
</B>
</FONT>
</A>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP">
<A HREF="#C86264_10K_HTM_X2_C86264A018">
<FONT STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	Item 10.
</FONT>
</A>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<A HREF="#C86264_10K_HTM_X2_C86264A018">
<FONT STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	Directors, Executive Officers and Corporate Governance
</FONT>
</A>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	60
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP">
<A HREF="#C86264_10K_HTM_X2_C86264A019">
<FONT STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	Item 11.
</FONT>
</A>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<A HREF="#C86264_10K_HTM_X2_C86264A019">
<FONT STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	Executive Compensation
</FONT>
</A>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	60
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP">
<A HREF="#C86264_10K_HTM_X2_C86264A020">
<FONT STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	Item 12.
</FONT>
</A>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<A HREF="#C86264_10K_HTM_X2_C86264A020">
<FONT STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters
</FONT>
</A>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	60
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP">
<A HREF="#C86264_10K_HTM_X2_C86264A021">
<FONT STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	Item 13.
</FONT>
</A>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<A HREF="#C86264_10K_HTM_X2_C86264A021">
<FONT STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	Certain Relationships and Related Transactions, and Director Independence
</FONT>
</A>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	60
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP">
<A HREF="#C86264_10K_HTM_X2_C86264A022">
<FONT STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	Item 14.
</FONT>
</A>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<A HREF="#C86264_10K_HTM_X2_C86264A022">
<FONT STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	Principal Accountant Fees and Services
</FONT>
</A>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	60
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP">
<A HREF="#C86264_10K_HTM_X2_C86264A023">
<FONT STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
<B>
	Part IV
</B>
</FONT>
</A>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP">
<A HREF="#C86264_10K_HTM_X2_C86264A024">
<FONT STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	Item 15.
</FONT>
</A>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<A HREF="#C86264_10K_HTM_X2_C86264A024">
<FONT STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	Exhibits and Financial Statement Schedules
</FONT>
</A>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	60
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<A HREF="#C86264_10K_HTM_X2_C86264A025">
<FONT STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	List of Consolidated Financial Statements and Financial Statements Schedule
</FONT>
</A>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	F-1
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<A HREF="#C86264_10K_HTM_X2_C86264A026">
<FONT STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	Report of Independent Registered Public Accounting Firm
</FONT>
</A>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	F-2
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<A HREF="#C86264_10K_HTM_X2_C86264A027">
<FONT STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	Consolidated Balance Sheets
</FONT>
</A>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	F-3
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<A HREF="#C86264_10K_HTM_X2_C86264A028">
<FONT STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	Consolidated Statements of Operations
</FONT>
</A>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	F-4
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<A HREF="#C86264_10K_HTM_X2_C86264A029">
<FONT STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	Consolidated Statements of Comprehensive Income (loss)
</FONT>
</A>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	F-5
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<A HREF="#C86264_10K_HTM_X2_C86264A030">
<FONT STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	Consolidated Statements of Stockholders&rsquo; Equity
</FONT>
</A>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	F-6
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<A HREF="#C86264_10K_HTM_X2_C86264A031">
<FONT STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	Consolidated Statements of Cash Flows
</FONT>
</A>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	F-7
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<A HREF="#C86264_10K_HTM_X2_C86264A032">
<FONT STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	Notes to Consolidated Financial Statements
</FONT>
</A>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	F-8
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; FONT-SIZE: 12PT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<A HREF="#C86264_10K_HTM_X2_C86264A033">
<FONT STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	Schedule II - Valuation Accounts and Qualifying Accounts
</FONT>
</A>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	S-1
</FONT>
</TD>
</TR>
</TABLE>
<!-- FIELD: PAGE; SEQUENCE: 2 -->
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 6PT; PADDING-BOTTOM: 12PT; BORDER-BOTTOM: SILVER 4PX SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	1
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage3"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 10PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: LEFT; WIDTH: 100%">
<PAGE>
</PAGE>
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<EFX_PART_I>
<A NAME="FIS_PART_I"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; BORDER-BOTTOM: BLACK 1PX SOLID">
<B>
<A NAME="C86264_10K_HTM_X2_C86264A001">
</A>
	PART I
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_BUSINESS>
<A NAME="FIS_BUSINESS"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<A NAME="C86264_10K_HTM_X2_C86264A002">
</A>
	Item 1.
<U>
	Business
</U>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	Overview
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Enzo Biochem, Inc. (the &ldquo;Company&rdquo; &ldquo;we&rdquo;,
	&ldquo;our&rdquo; or &ldquo;Enzo&rdquo;) is a vertically integrated growth-oriented bioscience company focusing on delivering and
	applying advanced technology capabilities to produce affordable reliable products and services to allow our customers to meet their
	clinical needs. We develop, manufacture and sell our proprietary technology solutions and platforms to clinical laboratories, specialty
	clinics and researchers and physicians globally. Enzo&rsquo;s structure and business strategy represents the culmination of years
	of extensive planning and work. The Company now has the unique ability to offer low cost, high performance products and services
	in molecular diagnostics, which ideally positions it to capitalize on the reimbursement pressures facing diagnostic labs. Our pioneering
	work in genomic analysis coupled with our extensive patent estate and enabling platforms have positioned the Company to continue
	to play an important role in the rapidly growing molecular medicine marketplaces.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Enzo technology solutions and platforms and unique operational
	structure is designed to reduce overall healthcare costs to both government and private insurers.
<FONT STYLE="COLOR: #231F20">
	Our
	proprietary technology platforms reduces our customers&rsquo; need for multiple, specialized instruments, and offer a variety of
	throughput capabilities together with a demonstrated high level of accuracy and reproducibility. Our genetic test panels are focused
	on large and growing markets primarily in the areas of personalized medicine, women&rsquo;s health, infectious diseases and genetic
	disorders.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	For example, our AMPIPROBE&reg; technology platform can lead
	to the development of an entire line of nucleic acid clinical products that can allow laboratories to offer a complete menu of
	services at a cost that allows them to enjoy an acceptable margin. Our technology solutions provide tools to physicians, clinicians
	and other health care providers to improve detection, treatment and monitoring of a broad spectrum of diseases and conditions.
<FONT STYLE="COLOR: #231F20">
</FONT>
	In addition, reduced patient to physician office visits translates into lower healthcare processing costs and greater patient
	services.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	In the course of our research and development activities, we
	have built a substantial portfolio of intellectual property assets, comprising 314 issued patents worldwide, and over 146 pending
	patent applications, along with extensive enabling technologies and platforms.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	Operating Segments
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	We are comprised of three interconnected operating segments
	which have evolved out of our core competencies involving the use of nucleic acids as informational molecules and the use of compounds
	for immune modulation and augmented by the previous acquisitions of a number of related companies. Information concerning sales
	by geographic area and business segments for the years ended July 31, 2016, 2015 and 2014 is located in Note 15 in the Notes to
	Consolidated Financial Statements.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Below are brief descriptions of each of our operating segments:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
<U>
	Enzo Clinical Labs
</U>
</B>
	is a clinical reference laboratory
	providing a wide range of clinical services to physicians, medical centers, other clinical labs and pharmaceutical companies. The
	Company believes having a College of American Pathologists (&ldquo;CAP&rdquo;) certified medical laboratory located in New York
	provides us the opportunity to more rapidly introduce cutting edge products and services to the clinical marketplace. Enzo Clinical
	Labs offers an extensive menu of molecular and other clinical laboratory tests or procedures used in patient care by physicians
	to establish or support a diagnosis, monitor treatment or medication, and search for an otherwise undiagnosed condition. Our laboratory
	is equipped with state of the art communication and connectivity solutions enabling the rapid transmission, analysis and interpretation
	of generated data. We operate a full service clinical laboratory in Farmingdale, New York, a network of over 30 patient service
	centers throughout New York and New Jersey, a free standing &ldquo;STAT&rdquo; or rapid response laboratory in New York City and
	a full service phlebotomy, in-house logistics department, and information technology department. Given our license in New York
	State, we are able to offer testing services to clinical laboratories and physicians in the majority of states nationwide.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
<U>
	Enzo Life Sciences
</U>
</B>
	manufactures, develops and
	markets products and tools to clinical research, drug development and bioscience research customers worldwide. Underpinned by broad
	technological capabilities, Enzo Life Sciences has developed proprietary products used in the identification of genomic information
	by laboratories around the world. Information regarding our technologies can be found in the &ldquo;Core Technologies&rdquo; section.
	We are internationally recognized and acknowledged as a leader in the development, manufacturing validation and commercialization
	of numerous products serving not only the clinical research market but life sciences researchers in the fields of cellular analysis
	and drug discovery, among others. Our operations are supported by global operations allowing for the efficient marketing and delivery
	of our products around the world.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 3 -->
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 6PT; PADDING-BOTTOM: 12PT; BORDER-BOTTOM: SILVER 4PX SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	2
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage4"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 10PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: LEFT; WIDTH: 100%">
<PAGE>
</PAGE>
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
<U>
	Enzo Therapeutics
</U>
</B>
	is a biopharmaceutical venture
	that has developed multiple novel approaches in the areas of gastrointestinal, infectious, ophthalmic and metabolic diseases, many
	of which are derived from the pioneering work of Enzo Life Sciences. Enzo Therapeutics has focused its efforts on developing treatment
	regimens for diseases and conditions for which current treatment options are ineffective, costly, and/or cause unwanted side effects.
	This focus has generated a clinical and preclinical pipeline, as well as more than 115 patents and patent applications.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	The Company&rsquo;s primary sources of revenue have historically
	been from the clinical laboratory services provided to the healthcare community and product revenues and royalty and licensing
	of Life Sciences&rsquo; products utilized in life science research. The following table summarizes the sources of revenues for
	the fiscal years ended July 31, 2016, 2015 and 2014 (in thousands and percentages):
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_2"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID">
<FONT STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
<B>
	Fiscal year ended July 31,
</B>
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="6" STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
<B>
	2016
</B>
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="6" STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
<B>
	2015
</B>
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="5" STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
<B>
	2014
</B>
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="WIDTH: 32%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 3%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 7%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 7%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 3%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 7%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 7%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 3%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 7%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 7%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Clinical laboratory services
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	70,915
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	69
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	%
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	63,414
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	65
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	%
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	58,689
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;61
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	%
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Product revenues
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	30,337
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	30
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	31,690
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	32
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	32,850
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;34
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="PADDING-BOTTOM: 1PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Royalty and license fee income
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	1,521
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	1
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	2,495
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	3
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	4,408
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;5
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="PADDING-BOTTOM: 3PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Total
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	102,773
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	100
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	%
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	97,599
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	100
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	%
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	95,947
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;100
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	%
</FONT>
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	Markets
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	Clinical diagnostics
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	The U.S. clinical diagnostics market has been reported by industry
	sources to be greater than $23 billion annually and over $46 billion worldwide. It is comprised of a broad range of tests based
	on clinical chemistry, microbiology, immunoassays, genomics, proteomics, gene expression profiling blood banking, and cancer screening
	assays through histology as well as newer body fluid based approaches. Many of these tests employ traditional technologies such
	as cell culture technologies.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Immunoassays are based on the use of antibodies directed against
	a specific target, or antigen, to detect that antigen in a patient sample. Cell culturing techniques involve the growth, isolation
	and visual detection of the presence of a microorganism and often its susceptibility to FDA approved drugs.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	There are several drawbacks to these more traditional technologies.
	Immunoassays do not allow for early detection of diseases because they require minimum levels of antigens to be produced by the
	microorganism in order to be identified. These levels vary by microorganism, and the delay involved could be several days or several
	months, as seen in HIV/AIDS. Cell cultures are slow, labor intensive and not amenable to all microorganisms. For example, gonorrhoea
	and chlamydia are difficult to culture.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Molecular-based diagnostics have many advantages over the traditional
	technologies. Since gene-based diagnostics focus on the identification of diseases at the cellular level, they can identify the
	presence of the disease at its earliest stage of manifestation in the body. These tests provide results more rapidly, are applicable
	to a broad spectrum of microorganisms and can easily be automated in a multiplex platform.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Several advances in technology are accelerating the adoption
	of gene-based diagnostics in clinical laboratories. These advances include high throughput automated formats that minimize labor
	costs, non-radioactive probes and reagents that are safe to handle, and amplification technologies that improve the sensitivity
	of such diagnostics.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	According to industry sources, the market for molecular diagnostic
	tools, assays and other products is currently more than $7 billion per year, and is acknowledged as one of the fastest growing
	segments in the in-vitro diagnostic industry, growing at more than twice the rate of traditional diagnostics. Contributing to this
	growth is, among other factors:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 3%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</TD>
<TD STYLE="WIDTH: 97%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	the increasing number of diagnostic tests being developed from discoveries in genome research;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	advances in formats and other technologies that automate and accelerate gene-based diagnostic testing;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	growing emphasis by the health care industry on early diagnosis and treatment of disease and;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	application of gene-based diagnostics as tools to match therapies to specific patient genetics commonly referred to as pharmacogenomics or companion diagnostics.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
</B>
</P>
<!-- FIELD: PAGE; SEQUENCE: 4 -->
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 6PT; PADDING-BOTTOM: 12PT; BORDER-BOTTOM: SILVER 4PX SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	3
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage5"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 10PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: LEFT; WIDTH: 100%">
<PAGE>
</PAGE>
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	Diagnostic Products and Tools
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	There is a large and growing global demand by biomedical and
	pharmaceutical researchers for research and diagnostic tools that both facilitate and accelerate the generation of biological information.
	This demand can be met by gene and protein target based diagnostics for which a variety of formats, or tools, have been developed
	that enable researchers to study biological pathways. These tools can identify mutations in gene sequences and variations in gene
	expression levels that can lead to disease, or they can quantify biomarkers that provide insight to disease and potential therapeutic
	solutions. These techniques use instruments including DNA sequencing and genotyping instruments, microarrays, fluorescent microscopes,
	high content screening systems, flow cytometers and plate readers. Common among these instruments is the need for reagents that
	allow the identification, quantification and characterization, and interactions of specific genes or nucleic acid sequences, proteins,
	cells and other cellular structures and organelles.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	We believe this market will continue to grow as a result of:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 3%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</TD>
<TD STYLE="WIDTH: 97%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	long term commitment to research spending by academic, government and private organizations to determine the function and clinical relevance of the gene sequences and proteins that have been identified by genome research,
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	development of commercial applications based on information derived from this research; and
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	on-going advancements in tools that accelerate these research and development activities.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	Therapeutics
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	We believe our core technologies have broad diagnostic and therapeutic
	applications. We have focused our efforts on discovering how best to treat pathologies associated with bone or metabolic control,
	and immune-mediated diseases. Although the cause of disorders such as Crohn&rsquo;s disease, autoimmune uveitis and non-alcoholic
	steatohepatitis (NASH) remains unknown, various features suggest immune system involvement in their pathogenesis.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	We continue to test technologies we believe can serve as enabling
	platforms for developing medicines that genetically target and inhibit viral functions, as well as medicines that regulate the
	immune response. In addition to such therapeutic products, we continue to capitalize on our nucleic acid labelling, target and
	signal amplification, and detection technologies and intellectual property to develop diagnostic and monitoring tests for various
	diseases.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	We believe our expertise in developing and securing approvals
	of novel platform technologies will enable us to shorten the development time and capture meaningful market share.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	Strategy
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Our objective is to develop, manufacture and sell high through-put,
	high value and affordable reliable molecular diagnostic products and services using our proprietary technologies to allow our customers
	to meet their clinical needs. Our proprietary technology platforms, if successful, will alter the existing business models and
	improve economics across the healthcare industry. Our strong intellectual property estate provides freedom to operate and compete
	in a rapidly growing molecular diagnostic healthcare marketplace.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	We believe our expertise in developing and marketing proprietary
	technology platforms uniquely positions Enzo to provide products and services that will change the fundamental relationship between
	molecular diagnostic companies and clinical laboratories. Our technology platforms will provide economic and market optionality
	to use Enzo&rsquo;s products and services for margin improvement. As such, clinical laboratories will be able to compete and enter
	into markets that until now have been out of reach to do poor economics as a result of high costs of regents and equipment rental
	arrangements from molecular diagnostic companies coupled with lower reimbursement from governmental and commercial healthcare companies.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Our objective allows clinical laboratories to purchase low cost
	regents or kits to be run on open system platforms already in use in their labs, or use Enzo as a low cost reference laboratory.
	Enzo&rsquo;s integrated business model not only provides benefits to clinical laboratories but insurance providers will benefit
	from more clinical laboratories able to compete for testing services with national laboratories.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	In addition to selling these highly effective and compatible
	platforms and their assays, we are positioning ourselves as a reference lab for independent labs nationwide primarily by offering
	lower cost reference services.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Our commitment to utilize our proprietary technologies to develop
	clinically relevant diagnostics, while helping to relieve the cost pressures that independent laboratories are bearing is core
	to our strategy. It underscores the progress we are achieving in our strategy
</P>
<!-- FIELD: PAGE; SEQUENCE: 5 -->
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 6PT; PADDING-BOTTOM: 12PT; BORDER-BOTTOM: SILVER 4PX SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	4
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage6"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 10PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: LEFT; WIDTH: 100%">
<PAGE>
</PAGE>
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	of utilizing Enzo&rsquo;s integrated structure to produce diagnostic
	products and services relevant to today&rsquo;s dynamic and challenging healthcare marketplace.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	By developing a broad technology base, Enzo has positioned the
	Company for a robust flow of products and services that will provide medically relevant, cost effective solutions easily adaptable
	to the workflow of the clinical laboratory, and that its ability to do so is based on several factors, including:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 3%">
</TD>
<TD STYLE="WIDTH: 3%">
<FONT STYLE="FONT: 10PT SYMBOL">
	&middot;
</FONT>
</TD>
<TD STYLE="WIDTH: 94%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	The Company&rsquo;s integrated structure that enables it to internally
	develop and advance products seamlessly from innovation through commercialization validation via recent patent settlements of Enzo&rsquo;s
	intellectual property strength and ownership of basic patents that provide an economic advantage.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
</TD>
<TD>
<FONT STYLE="FONT: 10PT SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	In a steadily declining reimbursement environment the unique ability
	to deliver high performance, easily adaptable products and services that are also meaningfully cost effective for independent labs
	as well as Enzo&rsquo;s own clinical lab.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
</TD>
<TD>
<FONT STYLE="FONT: 10PT SYMBOL">
	&middot;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Ample finances with which to execute and follow through on the Company&rsquo;s
	integrated strategy.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
<I>
	Increase investment in research and development &amp;
	product development
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	We are increasing our research and development efforts to develop
	new leading edge solutions in the rapidly growing molecular diagnostic market place. Current technology platforms under development
	include:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 3%">
</TD>
<TD STYLE="WIDTH: 3%">
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&#183;
</FONT>
</TD>
<TD STYLE="WIDTH: 94%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	AMPIPROBE&reg; &ndash; easily adaptable, affordable, real time DNA
	amplification and detection
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&#183;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	FLOWSCRIPT&reg; &ndash; enhanced flow cytometry for signal cell analysis
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&#183;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Enhanced Immunohistochemistry &ndash; moving Pathology to the next
	generation
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: SYMBOL">
	&#183;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Enhanced Immunoassays &ndash; Pushing sensitivity to expand immunoassay
	applications
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Enzo&rsquo;s proprietary platforms and the assays developed
	based on them can provide more sensitive diagnostic information at lower costs than many other tests currently marketed. The Company
	designs its products to be able to work with lower specimen volume which not only allows the laboratories to run more tests off
	of a single clinical specimen, but also may reduce the need for patients to submit additional samples, thus reducing unnecessary
	physician visits. The Company&rsquo;s newly approved assays are the forerunners of a comprehensive line of diagnostic products
	under development by Enzo to address the critical needs of clinical laboratories that are often locked into closed-system contracts
	with molecular diagnostic suppliers that, with ever-declining reimbursements, reduce or even eliminate operating margins.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
<I>
	Continue to Commercialize New Platforms for Molecular
	Diagnostics via Multiple Channels
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	We have developed several enabling platform technologies that
	may have utility in the development of a new generation of molecular diagnostic products designed to meet the needs of the current
	clinical marketplace. Our lead platform is AMPIPROBE&reg; which is proprietary target amplification and detection technology that
	has been shown to require substantially less starting material than conventional methods such as polymerase chain reaction (PCR)
	based products. With AMPIPROBE&reg; it may be possible to increase the number of analytes that can be assayed for from a single
	clinical specimen, which in turn may reduce the need for physicians to recall patients to obtain additional clinical material for
	testing. In addition by increasing the number of analytes tested in a single clinical preparation, AMPIPROBE&reg; may be able to
	produce diagnostic tests at a significantly lower cost than conventional assays. Moreover, the need for less starting material
	may also lead to diagnostic tests with improved sensitivity, thus allowing detection of certain analytes present in minute quantities
	that are below the limit of detection of conventional assays.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	We have already introduced the first product using our FLOWSCRIPT&reg;
	platform technology for the identification of gene expression in clinical samples in detection of mRNA from Human papillomavirus
	(HPV) oncogenes, E6 and E7. Overexpression of these HPV oncogenes promotes the growth of malignant cells leading to the development
	of cervical cancer. The FLOWSCRIPT&reg; technology platform is a proprietary, flow cytometry-based, molecular detection system
	for the multiplex analysis of cell function and identity, and was developed by cross-functional teams at Enzo. The HPV E6/E7 assay
	is the first product to utilize this novel platform. Analysis is performed on a small volume of a liquid cytology specimen and
	can thus be easily incorporated as a reflex test measure following abnormal Pap smear results. The assay, and the platform on which
	it is based, allows for the simultaneous analysis of several different genes expressed in every cell in a given sample. In this
	manner, it is possible to produce clinically relevant data at the single cell level. Unlike other assays that study mRNA expression,
	FLOWSCRIPT&reg; assays are performed by a homogenous system that eliminates washing steps that can reduce fluctuation of results.
	Additionally, the assay&rsquo;s use of external control improves run-to-run consistency. As a result, both hands on time and the
	number of steps are reduced, allowing for improved economics. In data presented at a 2015 pathology conference in Italy, Enzo&rsquo;s
	assay was shown to produce reliable and consistent results near the limit of assay detection. Furthermore, Enzo anticipates applying
	this platform to a multiplicity of uses such as the study of other cancers, the evaluation of an individual immune state as well
	as products targeted to the drug development market, among others.
</P>
<!-- FIELD: PAGE; SEQUENCE: 6 -->
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 6PT; PADDING-BOTTOM: 12PT; BORDER-BOTTOM: SILVER 4PX SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	5
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage7"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 10PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: LEFT; WIDTH: 100%">
<PAGE>
</PAGE>
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	The FLOWSCRIPT&reg; platform is used to help guide providers in assessing the risk of progression to cervical cancer and whether
	colposcopy or follow-up screening should be the preferred course of action. This assay demonstrates Enzo&rsquo;s commitment to
	utilize our proprietary technology and bring forward clinically relevant diagnostics that can inform patient and physician decision-making,
	with potential to reduce spending associated with advanced stage disease. Moreover, it is indicative of how well we are executing
	on our strategy of utilizing our integrated structure to produce products that are relevant to today&rsquo;s evolving healthcare
	marketplace.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
<I>
	Maximize our resources by collaborating with others in
	research and commercialization activities
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	We enter into research collaborations with leading academic
	and other research centers to augment our core expertise on specific programs.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Our clinical trial of OPTIQUEL&reg; is a direct result of a
	research collaboration. We acquired the rights and intellectual property to this candidate drug and technology intended for use
	in the treatment of autoimmune uveitis. Working with scientists and physicians in the United States and abroad, Enzo continued
	drug development to the stage of a clinical trial now in further evaluation with the National Eye Institute of the National Institutes
	of Health in Washington DC.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	We have research and clinical collaborations with other institutions
	including Hadassah University Medical Center in Jerusalem, Israel relating to our immune regulation technology. Through collaborations
	such as these and other licensing agreements we continue to develop novel therapeutics for the stimulation and enhancement of bone
	formation and glucose control, among others. Such products, if any, emanating from this technology could provide potential therapy
	for bone disorders, including bone loss, bone fractures, periodontitis, diabetes and other indications. There can be no assurance
	that any of these collaborative projects will be successful.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Enzo Life Sciences maintains relationships with academic and
	commercial groups worldwide in sourcing and commercializing high value reagents developed by leading academics.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Similarly, we may seek to fully exploit the commercial value
	of our technology by partnering with for-profit enterprises in specific areas in order to act on opportunities that can be accretive
	to our efforts in accelerating our development program.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
<I>
	Exploit our marketing and distribution infrastructure
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Enzo Life Sciences has developed its sales and marketing infrastructure
	to directly service its end users such as clinical laboratories, researchers and pharmaceutical companies, while simultaneously
	positioning the Company for targeted product line expansion. Our global sales, marketing, manufacturing, product development and
	distribution infrastructure, have now been integrated and consolidated into a single global business. Enzo Life Sciences operates,
	under its own name, worldwide through wholly owned subsidiaries (in USA, Switzerland, Benelux, Germany, and the UK), a branch office
	in France and a network of third party distributors in most other significant markets worldwide. Our comprehensive product portfolio
	allows us to deliver integrated solutions to basic researchers, drug developers and clinical researchers around the globe. Our
	research allows us to provide solutions in all key research areas including: Genomics, Cell Biology Immunoassays and in a multitude
	of applied research markets including: Bioprocess, Personal Care, Cancer Research, and Neuroscience to name a few.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
<I>
	Expand and protect our intellectual property estate
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Since our inception, we have followed a strategy of creating
	a broad encompassing patent position in the life sciences and therapeutics areas. We have made obtaining patent protection a central
	strategic policy, both with respect to our proprietary platform technologies and products, as well as broadly in the areas of our
	research activities. During Fiscal 2016, we were issued 64 patents and expanded our patent estate in the area of nucleotides, amplification,
	labelling and detection, among others.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	Product Development and Pipeline
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Enzo is committed to delivering a robust line of products and
	services that will provide medically relevant, cost effective solutions that are easily adaptable to the workflow of clinical laboratories.
	The Company&rsquo;s integrated Life Science-Clinical Lab structure continues to be instrumental in its ability to seamlessly develop
	and advance products from innovation and manufacturing in our life sciences group and validation and commercialization through
	our clinical laboratory.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	The Company&rsquo;s development pipeline includes an extensive
	line of assays for detection of numerous women&rsquo;s health infectious agents as well as for the identification of other pathogens.
	The Company is also developing a proprietary line of products designed to aid pathologists in differentiating the characteristics
	of various tumors from biopsy specimens. The Company&rsquo;s molecular-based products and services are targeted at a market currently
	estimated to be in excess of $3 billion annually.
</P>
<!-- FIELD: PAGE; SEQUENCE: 7 -->
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 6PT; PADDING-BOTTOM: 12PT; BORDER-BOTTOM: SILVER 4PX SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	6
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage8"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 10PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: LEFT; WIDTH: 100%">
<PAGE>
</PAGE>
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	During fiscal 2016 and most recently, we
	successfully gained New York State Department of Health approval of a number of key products based on Enzo&rsquo;s proprietary
	technology platforms. On November 17, 2015, we announced approval of AMPIPROBE&reg; HCV Assay for the quantitative detection of
	Hepatitis C. This assay is based on the proprietary nucleic acid amplification and detection technology platform was the first
	in a line of products to be developed at Enzo to address the critical needs of the molecular diagnostics market and serves as validation
	of Enzo&rsquo;s unique business strategy and structure.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	On June 7, 2016, we were granted conditional approval of AMPIPROBE&reg;
	Candidiasis Assay. This multiplex assay is designed to identify the presence of five of the most common species of Candida from
	a single vaginal swab. Industry estimates put the number of tests performed for the identification of Candida at over 10 million
	per year in the US alone. It is also estimated that over 70% of women will develop a Candida infection during their reproductive
	lifetime. While an independent assay, it will also serve as a component of a comprehensive women&rsquo;s health panel currently
	under development.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	On September 20, 2016, we were granted conditional approval
	of PLAQPRO&trade; Lp-PLA
<SUB>
	2
</SUB>
	Assay. This is a biochemical activity assay designed to identify lipoprotein-associated phospholipase
	A2, a marker associated with the potential for coronary heart disease. The PLAQPRO&trade; Lp- PLA
<SUB>
	2
</SUB>
	Assay can be useful
	as part of a cardiac testing panel for individuals at intermediate or high risk for developing coronary heart disease. Early identification
	of increased risk of developing coronary heart disease offers the opportunity to adjust patient lifestyles or utilize medical interventions
	to reduce risk. The assay was developed using the Company&rsquo;s strong expertise in assay development, antibody production, small
	molecule chemistry, and detection technology. This cardiac assay delivers improved consistency and is designed to work on open
	platform clinical analysis instruments. The open platform configuration is one of the several factors that contribute to its cost
	effectiveness, which is vital to today&rsquo;s clinical labs that are confronted by shrinking reimbursements.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	These assays are an important addition to Enzo&rsquo;s expanding
	line of women&rsquo;s health products, while also helping to solidify Enzo&rsquo;s position as a leading full service women&rsquo;s
	health lab.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Products in the Company&rsquo;s development pipeline include
	an extensive line of assays for detection of numerous women&rsquo;s health infectious agents as well as for use in the identification
	of pathogens for other markets. The Company also reported that it expects to roll-out a line of products designed to aid pathologists
	in distinguishing the characteristics of various tumors from biopsy specimens using technology developed by Enzo scientists. The
	Company&rsquo;s molecular-based products are targeted at a market estimated to be in excess of $3 billion worth of laboratory service
	revenue.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Enzo is committed to delivering a robust line of products and
	services that will provide medically relevant, cost effective solutions that are easily adaptable to the workflow of clinical laboratories.
	The Company&rsquo;s integrated Life Science and Clinical Lab structure continues to be instrumental in its ability to seamlessly
	develop and advance products from innovation and manufacturing in our life sciences group and validation and commercialization
	through our clinical laboratory. Our product development activity and pipeline include the following products.
</P>
<!-- FIELD: PAGE; SEQUENCE: 8 -->
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 6PT; PADDING-BOTTOM: 12PT; BORDER-BOTTOM: SILVER 4PX SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	7
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage9"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 10PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: LEFT; WIDTH: 100%">
<PAGE>
</PAGE>
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_3"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
<TR>
<TD STYLE="WIDTH: 22%; TEXT-ALIGN: LEFT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-SIZE: 9PT">
	Product
	/ Test
<BR>
	Description
</FONT>
</TD>
<TD STYLE="WIDTH: 3%">
<FONT STYLE="FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 21%; TEXT-ALIGN: LEFT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-SIZE: 9PT">
	Expected
<BR>
	Availability(1)
</FONT>
</TD>
<TD STYLE="WIDTH: 3%">
<FONT STYLE="FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 51%; TEXT-ALIGN: LEFT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-SIZE: 9PT">
	Platform
</FONT>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD>
<FONT STYLE="FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: RGB(229,255,255)">
<TD>
<FONT STYLE="FONT-SIZE: 9PT">
	HPV E6/E7 Detection
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 9PT">
	Available
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 9PT">
	FLOWSCRIPT
<SUP>
	&reg;
</SUP>
	GENE EXPRESSION
</FONT>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD>
<FONT STYLE="FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: RGB(229,255,255)">
<TD>
<FONT STYLE="FONT-SIZE: 9PT">
	HCV Viral Load
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 9PT">
	Available
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 9PT">
	AMPIPROBE
<SUP>
	&reg;
</SUP>
	REAL-TIME AMPLIFICATION AND DETECTION
</FONT>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD>
<FONT STYLE="FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: RGB(229,255,255)">
<TD>
<FONT STYLE="FONT-SIZE: 9PT">
	Cardiac Marker
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 9PT">
	Available
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 9PT">
	ENHANCED IMMUNOASSAY
</FONT>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD>
<FONT STYLE="FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: RGB(229,255,255)">
<TD>
<FONT STYLE="FONT-SIZE: 9PT">
	Fertility Assay
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 9PT">
	Q1 2017
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 9PT">
	ENHANCED IMMUNOASSAY
</FONT>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD>
<FONT STYLE="FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: RGB(229,255,255)">
<TD>
<FONT STYLE="FONT-SIZE: 9PT">
	Women&rsquo;s Health Panel
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 9PT">
	Q4 2016 &ndash; Q1 2017
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 9PT">
	AMPIPROBE
<SUP>
	&reg;
</SUP>
	REAL-TIME AMPLIFICATION AND DETECTION
</FONT>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD>
<FONT STYLE="FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: RGB(229,255,255)">
<TD>
<FONT STYLE="FONT-SIZE: 9PT">
	HBV Viral Load
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 9PT">
	2017
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 9PT">
	AMPIPROBE
<SUP>
	&reg;
</SUP>
	REAL-TIME AMPLIFICATION AND DETECTION
</FONT>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD>
<FONT STYLE="FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: RGB(229,255,255)">
<TD>
<FONT STYLE="FONT-SIZE: 9PT">
	HIV Viral Load
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 9PT">
	2017
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 9PT">
	AMPIPROBE
<SUP>
	&reg;
</SUP>
	REAL-TIME AMPLIFICATION AND DETECTION
</FONT>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD>
<FONT STYLE="FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: RGB(229,255,255)">
<TD>
<FONT STYLE="FONT-SIZE: 9PT">
	IHC Detection
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 9PT">
	Available
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 9PT">
	ENHANCED DETECTION
</FONT>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD>
<FONT STYLE="FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: RGB(229,255,255)">
<TD>
<FONT STYLE="FONT-SIZE: 9PT">
	TH1/TH2
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 9PT">
	In development
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 9PT">
	FLOWSCRIPT
<SUP>
	&reg;
</SUP>
	GENE EXPRESSION
</FONT>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD>
<FONT STYLE="FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: RGB(229,255,255)">
<TD>
<FONT STYLE="FONT-SIZE: 9PT">
	Cancer AB Panel
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 9PT">
	In development
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 9PT">
	AMPIFLOW&trade; ENHANCED DETECTION LABEL
</FONT>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD>
<FONT STYLE="FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: RGB(229,255,255)">
<TD>
<FONT STYLE="FONT-SIZE: 9PT">
	Cancer Marker Panel
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 9PT">
	In development
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 9PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 9PT">
	FLOWSCRIPT
<SUP>
	&reg;
</SUP>
	GENE EXPRESSION
</FONT>
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 3%; FONT: 11PT/115% CALIBRI, HELVETICA, SANS-SERIF">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 9PT">
	(1)
</FONT>
</TD>
<TD STYLE="WIDTH: 97%; FONT: 11PT/115% CALIBRI, HELVETICA, SANS-SERIF">
<FONT STYLE="FONT-FAMILY: ARIAL, HELVETICA, SANS-SERIF; FONT-SIZE: 9PT">
	There
	can be no assurances these products can be successfully developed or within these timeframes or available on these dates.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	Core Technologies
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	We have developed a portfolio of proprietary technologies with
	a variety of research, diagnostic and therapeutic applications.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	Gene analysis technology
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	All gene-based testing is premised on the knowledge that DNA
	forms a double helix comprised of two complementary strands that match and bind to each other. If a complementary piece of DNA
	(a probe) is introduced into a sample containing its matching DNA, it will bind to, or hybridize, to form a double helix with that
	DNA. Gene-based testing is carried out by:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 3%; FONT-SIZE: 10PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&bull;
</FONT>
</TD>
<TD STYLE="WIDTH: 97%; FONT-SIZE: 10PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	amplification of the target DNA sequence (a process that is essential for the detection of very small amounts of nucleic acid);
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&bull;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	labelling the probe with a marker that generates a detectable signal upon hybridization;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 3%; FONT-SIZE: 10PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&bull;
</FONT>
</TD>
<TD STYLE="WIDTH: 97%; FONT-SIZE: 10PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	addition of the probe to the sample containing the DNA; and
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&bull;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	binding or hybridization of the probe to the target DNA sequence, if present, to generate a detectable signal.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	We have developed AMPIPROBE&reg; a broad technology base for
	the labelling, detection, amplification and formatting of nucleic acids for gene analysis which is supported by our significant
	proprietary position in these fields. This and other proprietary technologies become the building blocks of our Molecular Diagnostic
	platforms.
</P>
<!-- FIELD: PAGE; SEQUENCE: 9 -->
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 6PT; PADDING-BOTTOM: 12PT; BORDER-BOTTOM: SILVER 4PX SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	8
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage10"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 10PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: LEFT; WIDTH: 100%">
<PAGE>
</PAGE>
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	Amplification
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	In the early stages of infection, a pathogen may be present
	in very small amounts and consequently may be difficult to detect. Using DNA amplification, samples can be treated to cause a pathogen&rsquo;s
	DNA to be replicated, or amplified, to detectable levels. We have developed a proprietary amplification process for multicopy production
	of nucleic acid, as well as proprietary techniques for amplifying the signals of our probes to further improve sensitivity. Our
	amplification technologies are particularly useful for the early detection of very small amounts of target DNA. We have also developed
	isothermal amplification procedures that can be performed at constant temperatures, unlike polymerase chain reaction (PCR) the
	most commonly used method of target nucleic acid amplification. These platform technologies could thus potentially lead to assays
	with advantages over PCR-based tests which require expensive heating and cooling systems or specialized heat-resistant enzymes.
	Moreover, our AMPIPROBE&reg; Nucleic Acid Amplification Platform, because of the reduced amount of starting material needed for
	analysis, may lead to a next-generation of molecular-based diagnostics that can impart higher sensitivity at lower cost than currently
	available assays.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	Flow Cytometry
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	We have developed and launched our first product using our proprietary
	FLOWSCRIPT&reg;
<SUP>
</SUP>
	platform using flow cytometry to analyse messenger RNA ( mRNA) transcript expression in individual cells
	in a mixed cell population. By studying whether a gene or a set of genes is turned on or off, it is possible to obtain clinically
	relevant information at the single cell level. Our first product, the FLOWSCRIPT&reg;
<SUP>
</SUP>
	HPV E6/E7 Assay, examines the
	levels of E6/E7 mRNA transcripts from multiple high risk types which account for over 95% of cervical cancers. We are planning
	to develop and introduce other products based on this platform technology in the future for applications such as immune-mediated
	disorders, metabolic disorders patient monitoring, and other cancers.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	Non-radioactive labelling and detection
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Traditionally, nucleic acid probes were labelled with radioactive
	isotopes. However, radioactively labelled probes have a number of shortcomings. They are unstable and consequently have a limited
	shelf life. They are potentially hazardous, resulting in restrictive licensing requirements and safety precautions for preparation,
	use and disposal. Finally, radioactive components are expensive. Our technologies permit gene analysis without the problems associated
	with radioactively labelled probes and are adaptable to a wide variety of formats.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	Formats
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	There are various processes, or formats, for performing probe-based
	tests. In certain formats, the probe is introduced to a target sample affixed to a solid matrix; in others the probe is combined
	with the sample in solution (homogeneous assay). Solid matrix assays include: in situ assays in which the probe reaction takes
	place directly on a microscope slide; dot blot assays in which the target DNA is fixed to a membrane; and microplate and microarray
	assays in which the DNA is fixed on a solid surface, and the reaction can be quantified by instrumentation.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
<I>
	Therapeutic Platform Development
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	Cell Signalling Pathway
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	One area of Enzo&rsquo;s therapeutic platform development is
	related to the development of pharmaceutical agents that affect protein-protein interactions. Over the past several years, our
	scientists and collaborators have unlocked the secrets of a major cell signalling pathway thus producing a means to modify biologic
	activity in a number of physiological systems.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Further investigation into the design and control of this system
	has allowed our scientists and their collaborators to determine the structure of key regulatory proteins and to identify active
	sites that can then become targets for Enzo&rsquo;s proprietary technology generating system. Our technology is capable of generating
	active compounds that range from orally delivered small molecules to peptides, oligonucleotides or antibodies. We have performed
	pioneering work on the structure and function of lipoprotein receptor-related protein (LRP) and its ligands, developed a screening
	technology to identify active compounds, and have synthesized proprietary molecules capable of producing biological effects in
	cell-based systems and animal models of disease. Specifically, this system allows the Company to:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 3%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&bull;
</FONT>
</TD>
<TD STYLE="WIDTH: 97%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	generate biological, genetic, and structural information concerning LRP;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	determine the structure of LRP docking sites of its ligands;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	identify the functionally important residues via site-directed mutagenesis;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN: 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 10 -->
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 6PT; PADDING-BOTTOM: 12PT; BORDER-BOTTOM: SILVER 4PX SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	9
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage11"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 10PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: LEFT; WIDTH: 100%">
<PAGE>
</PAGE>
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 3%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&bull;
</FONT>
</TD>
<TD STYLE="WIDTH: 97%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	build the fine structure map and employ it as the basis for virtual screening;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	show that compounds specifically bind to wild type LRP5, but not to mutated LRP5;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	generate a cell-based assay capable of identifying active compounds; and
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	synthesize proprietary molecules that are active in animal models of disease.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Through this novel, proprietary, functional screening system,
	we have identified small molecules capable of reversing sclerostin-mediated inhibition of Wnt signalling. Preclinical animal studies
	with several candidate lead compounds produced the following results:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 3%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&bull;
</FONT>
</TD>
<TD STYLE="WIDTH: 97%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	significant increases in total and femoral bone density through new bone formation;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	significant reduction in alveolar bone loss; and
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	significant reduction in bone resorption.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	The anabolic induction of new bone formation and prevention
	of bone loss by our small molecule compounds may promise new paths for the treatment of osteoporosis. In addition, our proprietary
	technology has enabled the generation of novel chemical entities that have significant glucose lowering activity. These effects
	are separate from its effects on bone metabolism indicating a specificity of action conferred by the interaction of a particular
	compound with the cell signalling pathway. Therefore, this approach may be broadly applicable to the generation of therapeutic
	drug candidates for multiple indications.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	Oral Immune Regulation
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	We continue to explore a novel therapeutic approach based on
	immune regulation. Our immune regulation technology seeks to control an individual&rsquo;s immune response to a specific antigen
	in the body. An antigen is a substance that the body perceives as foreign and, consequently, against which the body mounts an immune
	response. This platform technology is being developed as a means to manage immune-mediated diseases, such as autoimmune uveitis
	and Crohn&rsquo;s disease.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	We have developed an immunomodulation agent EGS21 as a potential
	therapeutic for treating immune mediated disorders. EGS 21 is a glycolipid that has been shown by our scientists and collaborators
	to act as an anti-inflammatory agent in animal model systems and is being evaluated as a drug candidate in the treatment of various
	immune mediated diseases.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	Gene Regulation
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	We have developed an approach to gene regulation known as genetic
	antisense or antisense RNA. Our technology involves the introduction into cellular DNA of a gene that codes for an RNA molecule
	that binds to, and thus deactivates, RNA produced by a specific gene. To deliver our antisense gene to the target cell, in a process
	called transduction, we have developed proprietary vector technology.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	We believe, though there can be no assurance, that our vector
	technology has broad applicability in the field of gene medicine. This can be attributed to the following properties of our construct:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 3%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&bull;
</FONT>
</TD>
<TD STYLE="WIDTH: 97%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	the viral promoters are inactivated;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	insertional gene activation is prevented - a major safety factor;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	chromosomal integration; and
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	nuclear localization.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	There can be no assurance that we will be able to secure patents
	or that these programs will be successful. The potential therapies we are developing could be used, if successful for the treatment
	of a variety of diseases, including osteoporosis, osteonecrosis and other bone pathologies, diabetes, autoimmune uveitis and inflammatory
	bowel disease, including Crohn&rsquo;s disease and ulcerative colitis, among others.
</P>
<!-- FIELD: PAGE; SEQUENCE: 11 -->
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 6PT; PADDING-BOTTOM: 12PT; BORDER-BOTTOM: SILVER 4PX SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	10
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage12"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 10PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: LEFT; WIDTH: 100%">
<PAGE>
</PAGE>
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	Clinical Laboratory Services
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	We operate a regional clinical laboratory that offers extensive
	diagnostic services to the New York and New Jersey medical communities. Our clinical laboratory testing is utilized by physicians
	as an essential element in the delivery of healthcare services. Physicians use laboratory tests to assist in the detection, diagnosis,
	evaluation, monitoring and treatment of diseases and other medical conditions. Clinical laboratory testing is generally categorized
	as clinical testing or anatomic pathology testing. Clinical testing is performed on body fluids, such as blood and urine. Anatomic
	pathology testing is performed on tissues and other samples, such as human cells. Many clinical laboratory tests are considered
	routine and can be performed by most commercial clinical laboratories. Tests that are not routine and that require more sophisticated
	equipment and highly skilled personnel are considered esoteric tests and may be performed less frequently than routine tests.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	We offer a comprehensive and broad range of routine and esoteric
	clinical laboratory tests or procedures. These tests are frequently used in general patient care by physicians to establish or
	support a diagnosis, to monitor treatment or medication levels, or search for an otherwise undiagnosed condition.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Our full service clinical laboratory in Farmingdale, New York
	contains an infrastructure that includes comprehensive information technology applications, logistics, client service and billing
	departments. We have a network of over thirty strategically located patient service centers and a full service phlebotomy department.
	Patient service centers collect from patients the specimens as requested by physicians. We also operate a fully equipped STAT laboratory
	in New York City. A &ldquo;STAT&rdquo; lab has the ability to perform certain routine tests quickly and report results to the physician
	immediately.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Patient specimens are delivered to our laboratory facilities
	primarily by our logistics department accompanied by a test requisition form. These forms, which are completed by the ordering
	physician, indicate the tests to be performed and demographic patient information and in most instances are transmitted to us via
	EnzoDirect, our proprietary computer-based ordering and results delivery system. Once the information is entered into the laboratory
	computer system the tests are performed on the corresponding laboratory testing instrumentation and the results are uploaded primarily
	through an interface from the laboratory testing instrumentation or in some instances, manually entered into the laboratory computer
	system. Most routine testing is completed by early the next morning, and test results are reported to the ordering physician. These
	test results are either reported electronically via EnzoDirect to a physician office Electronic Medical Records (EMR) system or
	delivered by our logistics department directly to the ordering physicians&rsquo; offices. Physicians who request that they be called
	with a particular result are so notified by our customer service personnel.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	For fiscal years ended July 31, 2016, 2015 and 2014, respectively,
	approximately 69%, 65% and 61% of the Company&rsquo;s revenues were derived from the clinical laboratory. Revenues, net of contractual
	adjustment, from direct billings under the Federal Medicare program during the years ended July 31, 2016, 2015 and 2014 were approximately
	16%, 19% and 22% respectively, of the clinical laboratory segment&rsquo;s total revenue. The contractual adjustment is an estimate
	that reduces gross revenue, based on gross billing rates, to amounts expected to be approved and reimbursed. We estimate contractual
	adjustment based on significant assumptions and judgments, such as the interpretation of payer reimbursement policies which bears
	the risk of change. The estimation process is based on the experience of amounts approved as reimbursable and ultimately settled
	by payers, versus the corresponding gross amount billed to the respective payers. Other than the Medicare program, revenues from
	UnitedHealthcare and Oxford Health Plan represented approximately 30%, 28% and 25% of the Clinical Labs segment&rsquo;s net revenue
	for the fiscal year ended July 31, 2016, 2015 and 2014, respectively.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	At July 31, 2016 and 2015, approximately 71% and 68% for each
	year of the Company&rsquo;s net accounts receivable was derived from its clinical laboratory business. The Company believes that
	the concentration of credit risk with respect to the Clinical Labs accounts receivable is mitigated by the diversity of its third
	party payers that insure individuals. To reduce risk, the Company routinely assesses the financial strength of these payers and,
	consequently, believes that its accounts receivable credit risk exposure, with respect to these payers, is limited. While the Company
	also has receivables due from the Federal Medicare program, the Company does not believe that these receivables represent a credit
	risk since the Medicare program is funded by the federal government and payment is primarily dependent on our submitting the appropriate
	documentation.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Gross billings are based on a standard fee schedule we set for
	self-payers, all third party payers, including Medicare, health maintenance organizations (&ldquo;HMO&rsquo;s) and managed care
	providers. We adjust the contractual adjustment estimate quarterly, based on our evaluation of current and historical settlement
	experience with payers, industry reimbursement trends, and other relevant factors. The other relevant factors that affect our contractual
	adjustment include the monthly and quarterly review of: 1) current gross billings and receivables and reimbursement by payer, 2)
	current changes in third party arrangements, and 3) the growth of in-network provider arrangements and managed care plans specific
	to our Company. The clinical laboratory industry is characterized by a significant amount of uncollectible accounts receivable
	related to the inability to receive accurate and timely billing information in order to forward it on to the third party payers
	for reimbursement, and the inaccurate information received from the covered individual patients for unreimbursed unpaid amounts.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 12 -->
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 6PT; PADDING-BOTTOM: 12PT; BORDER-BOTTOM: SILVER 4PX SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	11
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage13"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 10PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: LEFT; WIDTH: 100%">
<PAGE>
</PAGE>
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Billing for laboratory services is complicated. Depending on
	the billing arrangement and applicable law, we must bill various payers, such as patients, insurance companies and the Federal
	Medicare Program, all of which have different requirements. In both New York and New Jersey, the law prohibits the Company from
	billing the ordering physician. Compliance with applicable laws and regulations, as well as internal compliance policies and procedures
	add further complexity to the billing process. We depend on the ordering physician to provide timely, accurate billing demographic
	and diagnostic coding information to us. Additional factors complicating the billing process include:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 3%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&bull;
</FONT>
</TD>
<TD STYLE="WIDTH: 97%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	pricing differences between our standard gross fee schedules and the reimbursement rates of the payers;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	disputes with payers as to which party is responsible for payment; and
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&bull;
</FONT>
</TD>
<TD>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	disparity in coverage and information requirements among various
	payers.
</P>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	differences in medical policies established by various payers&nbsp;&nbsp;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Most of our bad debt expense is primarily the result of inaccurate
	billing information on requisitions received from the ordering physician. In addition, the bad debts includes the balances, after
	receipt of the approved settlements from third party payers for the insufficient diagnosis information received from the ordering
	physician, which result in denials of payment and the uncollectible portion of receivables from self-payers, including deductibles
	and co-payments, which are subject to credit risk and patients&rsquo; ability to pay. We must perform the requested tests and
	report test results regardless of whether the billing or diagnostic coding information is inaccurate or missing. We subsequently
	attempt to contact the ordering physician to obtain and rectify incorrect billing information. Missing or inaccurate information
	on the requisitions adds complexity to and may slow the billing process, creates backlogs of unbilled requisitions, and generally
	decreases the collectability and increases the aging of accounts receivable. When all issues relating to the missing or inaccurate
	information are not resolved in a timely manner, the related receivables are fully reserved to the allowance for doubtful accounts
	or allowances for contractual adjustments or written off.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	We incur significant additional costs as a result of our participation
	in Medicare, as billing and reimbursement for clinical laboratory testing is subject to considerable and complex and stringent
	federal and state regulations including those relating to coverage, billing and reimbursements. Future changes in regulations could
	further complicate our billing and increase our billing expenses. These additional costs include those related to: (1) complexity
	added to our billing processes and change our reimbursements; (2) training and education of our employees and customers; (3) compliance
	and legal costs; and (4) costs related to, among other factors, medical necessity denials and advance beneficiary notices. The
	Centers for Medicare &amp; Medicaid Services, or CMS (formerly the Health Care Financing Administration), establishes procedures
	and continuously evaluates and implements changes in the reimbursement process.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	The established Medicare reimbursement rate for clinical laboratory
	services has been reduced by the Federal government in a number of instances over the past several years. In March 2010, U.S. federal
	legislation was enacted to reform healthcare. The legislation provides for reductions in the Medicare clinical laboratory fee schedule
	of 1.9% for five years beginning in 2010 and also includes a productivity adjustment which reduces the Consumer Price Index (&ldquo;CPI&rdquo;)
	market basket update beginning in 2011. Based on these calculations, the Medicare Fee Schedule was decreased in calendar year 2014
	by 0.75%, was unchanged in calendar 2015 and 2016. Under the Patient Protection and Affordable Care Act, expansion in the pool
	of covered lives may expand the market for clinical diagnostic testing while at the same time various policies aimed at reducing
	cost or bundling care may reduce the rates paid for such services, the net impact of these factors on the market for our tests
	is not clear. In April 2014, Congress passed the Protecting Access to Medicare Act of 2014 (PAMA), which included substantial changes
	to the way in which clinical laboratory services will be paid under Medicare. Beginning in 2018, Medicare payments for clinical
	laboratory services will be paid based upon private payer rates as reported by clinical laboratories across the US replacing the
	current system which is based upon fee schedules derived from historical charges for tests from approximately 30 years ago. The
	final regulation to implement Medicare laboratory payment reform was released on June 17, 2016 by CMS. Since Enzo&rsquo;s clinical
	lab receives more than 50% of its total Medicare revenue from the Part B Clinical Laboratory Fee Schedule and the Physician Fee
	Schedule and receives more than $12,500 in Medicare revenues per year, we are considered an &ldquo;applicable laboratory&rdquo;,
	and as such, must report private payor fee reimbursements for the period January 1, 2016 to June 30, 2016 to CMS by March 31, 2017.
	This data will be aggregated and utilized as the basis for the 2018 fee schedules that will be finalized in November 2017. At this
	time, the impact of the new payment system on rates for tests we perform or our customers&rsquo; tests that may use our products
	is not clear at this time.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	The Patient Protection and Affordable Care Act also imposes
	an excise tax on the seller for the sale of certain medical devices in the United States, including those purchased and used by
	laboratories, beginning in 2013 and establishes the Independent Payment Advisory Board (&ldquo;IPAB&rdquo;). If the projected growth
	in per capita Medicare costs exceeds a specified target level, the IPAB must submit proposals to reduce or eliminate the difference.
	For calendar years 2016 through 2019, the target growth rate is the projected average of the increases in the Consumer Price Index
	and the medical care expenditure category of the Consumer Price Index; for 2020 and thereafter, the target growth rate is the rate
	of increase in gross domestic product per capita plus one percentage point. If it is necessary for the IPAB to submit proposals,
	they will automatically be implemented unless Congress enacts alternative proposals that achieve
</P>
<!-- FIELD: PAGE; SEQUENCE: 13 -->
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 6PT; PADDING-BOTTOM: 12PT; BORDER-BOTTOM: SILVER 4PX SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	12
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage14"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 10PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: LEFT; WIDTH: 100%">
<PAGE>
</PAGE>
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	the same savings targets. We could
	experience a significant decrease in revenue from Medicare as a result of these pieces of legislation, which could have a material
	adverse effect on us. The IPAB currently has no appointees and it is unclear whether when and if it will become operational.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Also, HIPAA requires certain health care providers such as Enzo
	Clinical Labs and its physicians, to use certain transaction and code set rules for specified electronic transactions, such as
	transactions involving claims submissions. Commencing July 1, 2012, CMS required that electronic claim submissions and related
	electronic transactions be conducted under a new HIPAA transaction standard called Version 5010. CMS has required this upgrade
	in connection with another new requirement applicable to the industry, the implementation of new diagnostic code sets to be used
	in claims submission. The new diagnostic code sets are called the ICD-10. They were originally to be implemented on October 1,
	2013 (and CMS delayed the implementation date until October 1, 2014), but as part of the Protecting Access to Medicare Act of 2014,
	enacted on April 1, 2014, Congress prohibited the Secretary of Health and Human Services from implementing ICD-10 any earlier than
	October 1, 2015. CMS published a final rule on August 4, 2014 adopting the October 1, 2015 compliance date and requiring the use
	of ICD-9 code sets through September 30, 2015 The Company successfully transitioned to ICD-10 on October1, 2015, with no disruption
	in business, and has not experienced increased accounts receivable as a result of timing of billing and payments related to the
	implementation.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	Life Sciences
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Enzo Life Sciences is a manufacturer of labeling and detection
	technologies from DNA to whole cell analysis. Enzo&rsquo;s products are backed by innovative technology platforms and a deep patent
	portfolio. With 40 years&rsquo; experience, Enzo Life Sciences continues to provide integrated solutions for Life Sciences, Clinical
	Research, and Drug Development. Enzo Life Sciences offers a broad range of high-quality products to advance research including
	proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits. Enzo Life Sciences operates in a highly competitive
	and price-sensitive marketplace and is repositioning itself by narrowing its product mix to concentrate on improved profitability,
	while also adding staff who are more experienced in operations. We have become a specialized assay supplier as part of our integrated
	strategic plan to deliver highly efficient, cost effective diagnostics and assays for our own use and sale to independent labs.
	With direct sales operations in US, Switzerland, Germany, UK, France, and Benelux, Enzo Life Sciences also supports its over 9,000
	products through a global network of dedicated distributors.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	With a passion for genomics, Enzo was the first to develop non-radioactive
	labeling of nucleic acids. This technique was instrumental in the development of today&rsquo;s genomic analysis market. Our pioneering
	research in genetic modification medicine was the first to recognize that nucleic acids could be used as therapeutics. Our innovations
	in the detection of nucleic acids in solutions and solid matrices led to the development of technology platforms such as hybrid
	capture, as well as fluorescent and chromogenic
<I>
	in situ
</I>
	hybridization. Enzo remains at the forefront of target amplification
	technologies critical in the detection of infectious agents, cancer markers, and genotyping. Our work in the genomic space has
	resulted in technologies in gene expression and immune system regulation, which opened the door for the well-known molecular diagnostics
	assays used today.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	The products supplied by Enzo Life Sciences include small molecules,
	proteins, antibodies, peptides, probes, assay kits and custom services. Our comprehensive portfolio of high quality reagents and
	kits in key research areas are sold to scientific experts in the following fields:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_4"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 7%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 50%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Adipokines
</FONT>
</TD>
<TD STYLE="WIDTH: 43%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Interferons
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Antibiotics
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	In Vitro Toxicology
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Apotosis/Cell Death
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Kinases/Inhibitors
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Biologically Active Peptides
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Leukotrienes/Prostaglandins/Thromboxanes
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Bone Metabolism
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Microarray Labeling
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Cancer Research
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Multidrug Resistance
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Cell Death
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Natural Products/Antibiotics
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Cell Cycle
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Neuroscience
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Chemokines/Cytokines
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Nitric Oxide Pathway
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Cytoskeletal Research
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Nuclear Receptors
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Dependence Receptors
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Oxidative Stress
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	DNA Fragmentation/Damage/Repair
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Protein Aggregation
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	DNA Regulation
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Proteosome/Ubiquitin
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Epigenetics
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Receptors
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	FISH
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Signal Transduction
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Growth Factors/Cytokines
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Stem Cell/Cell Differentiation
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Hypoxia
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Stress Proteins/Heat Shock Proteins
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Immunology
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Toxicology
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Viral Signaling
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	TNF/TNF Receptor Superfamily
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Inflammation/Innate Immunity
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Transcription Factors
</FONT>
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 14 -->
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 6PT; PADDING-BOTTOM: 12PT; BORDER-BOTTOM: SILVER 4PX SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	13
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage15"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 10PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: LEFT; WIDTH: 100%">
<PAGE>
</PAGE>
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Enzo Life Sciences maintains acquired brands including Alexis,
	Biomol International, Assay Designs, and Stressgen. Enzo strategically uses these brands to complete our product portfolio, allowing
	us to offer complete solutions to researchers in all fields. These brands are complementary to our core expertise in genomics and
	molecular biology. The Company intends to maintain the rights to the acquired brands which have long product history. The Company
	believes the emphasis on the Enzo Life Sciences brand will result in stronger and clearer brand awareness and allow the Company
	to execute the sale of higher value products and promote more products into the drug development, clinical research and diagnostic
	markets.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
<I>
	Axxora.com -&ldquo;The Reagents Marketplace&rdquo;, Thousands
	of Reagents, One Marketplace
</I>
</B>
	Axxora.com is a proven distribution platform for original manufacturers of innovative research
	reagents. An increasing number of researchers use our unique marketplace to connect with over 40 specialty manufacturers and gain
	access to over 40,000 products.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	Research and Development
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Our principal research and development efforts are directed
	toward developing innovative new clinical research and diagnostic platforms, and selective expansion of our research product lines,
	given our manufacturing and distribution capability. We have developed our core research expertise in the life science field as
	a result of over 30 years of dedicated focus in this area. We conduct our research and other product development efforts through
	internal research and collaborative relationships.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	In the fiscal years ended July 31, 2016, 2015 and 2014, the
	Company incurred costs of approximately $3.5 million, $3.4 million and, $3.1 million, respectively, for research and development
	activities. During fiscal 2016, the Company&rsquo;s research and development program was refocused to areas that had greater opportunity
	to maximize revenues.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	Internal Research Programs
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Our professional staff, including 35 with post graduate degrees,
	performs our internal research and development activities. Our product development programs incorporate various scientific areas
	of expertise, including recombinant DNA, monoclonal antibody development, enzymology, microbiology, biochemistry, molecular biology,
	organic chemistry, and fermentation. In addition, we continuously review in-licensing opportunities in connection with new technology.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	External Research Collaborations
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	We have and continue to explore collaborative relationships
	with prominent companies and leading-edge research institutions in order to maximize the application of our technology in areas
	where we believe such relationship will benefit the development of our technology.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	Sales and Marketing
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Our sales and marketing strategy for Enzo Life Sciences is to
	sell our life science products through: (i) direct sales to end-users under the Enzo Life Sciences name, with direct recognition
	to our acquired brands (ii) direct sales to end users under the Axxora electronic market place name (iii) supply agreements with
	manufacturers and (iv) distributors in major geographic markets. We operate with an understanding of local markets and a well-functioning
	distribution network system across the globe. Scientists around the world who recognize the brands (Alexis, Assay Designs, Biomol,
	Enzo and Stressgen) now receive products directly from Enzo Life Sciences where we are recognized for innovative high quality products,
	supported directly by our qualified technical staff. We sell the same products through our Axxora electronic market place which
	is also the source for life science research reagents from over 40 original manufacturers. Our direct marketing and sales network
	includes fully-owned subsidiaries (USA, Switzerland, Germany, Benelux, and UK), a branch office in France and a network of third
	party distributors in most other significant markets worldwide.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	For Enzo Clinical Labs, we focus our sales efforts on obtaining
	and retaining profitable accounts. We market the clinical laboratory services to a broad range of ordering physicians in the metro
	New York and New Jersey region through our direct sales force who are supported by customer service and patient service representatives.
	We monitor and where appropriate, change the service levels and terminate ordering physician accounts that are not profitable.
	We are focusing our efforts to attract and retain clients who participate with the providers with whom we have regional contracts
	and are consistently looking to add higher value molecular and esoteric testing, both internally developed and with partners, to
	our menu to assist sales in new account penetration as well as to improve our level of service to existing clients.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	Distribution Arrangements
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	We also distribute our life science products internationally
	through a network of distributors. Through these arrangements, we are able to leverage the established marketing and distribution
	infrastructure of these companies in certain market places.
</P>
<!-- FIELD: PAGE; SEQUENCE: 15 -->
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 6PT; PADDING-BOTTOM: 12PT; BORDER-BOTTOM: SILVER 4PX SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	14
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage16"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 10PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: LEFT; WIDTH: 100%">
<PAGE>
</PAGE>
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	Competition
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	We compete with other life science and biotechnology companies,
	as well as pharmaceutical, chemical and other companies. Competition in our industry is intense. Many of these companies are performing
	research targeting the same technology, applications and markets. Many of these competitors are significantly larger than we are
	and have more resources. The primary competitive factors in our industry are the ability to create scientifically advanced technology,
	offer innovative products at the forefront of technological development to targeted market segments, successfully develop and commercialize
	products on a timely basis, establish and maintain intellectual property rights and attract and retain a breadth and depth of human
	resources.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Our clinical laboratory services business competes with numerous
	national, regional, and local entities, some of which are larger than we are and have greater financial resources than we do. Our
	laboratory competes primarily on the basis of the quality and specialized nature of its testing, reporting and information services,
	its reputation in the medical community, its reliability and speed in performing diagnostic tests, and its ability to employ qualified
	laboratory personnel.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	Intellectual Property
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	We consider our intellectual property program to be a key asset
	and a major strategic component to the execution of our business strategy. A broad portfolio of issued patents and pending patent
	applications supports our core technology platforms. Our policy is to seek patent protection for our core technology platforms,
	as well as for ancillary technologies that support these platforms and provide a competitive advantage.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	At the end of fiscal 2016 we owned or licensed 314 patents relating
	to products, methods and procedures resulting from our internal or sponsored research projects. There can be no assurance that
	patents will be issued on pending applications or that any issued patents will not be challenged (see Item 3, Legal Proceedings),
	or that they will have commercial benefit. We do not intend to rely on patent protection as the sole basis for protecting our proprietary
	technology. We also rely on our trade secrets and continuing technological innovation. We require each of our employees to sign
	a confidentiality agreement that prohibits the employee from disclosing any confidential information about us, including our technology
	or trade secrets.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Our intellectual property portfolio can be divided into patents
	that provide claims in three primary categories, as described below:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	Nucleic Acid Chemistry
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	We currently have broad patent coverage in the area of nucleic
	acid chemistry. We have done extensive work on the labeling of nucleic acids for the purpose of generating a signal that dates
	back over twenty years. Enzo has multiple issued patents covering the modification of nucleic acids at their sugar and phosphate
	sites. The claims contained in these patents cover products that incorporate a signaling moiety into a nucleic acid attached to
	a sugar or phosphate for the purpose of nucleic acid detection or quantification, including sequencing and real time nucleic acid
	amplification. Enzo also has patents directed to proprietary dyes that may be used to label the sugar, base or phosphate positions
	of nucleic acids.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	Signal Delivery
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	We also have a long history of innovation in the area of analyte
	detection using non-radioactive signaling entities. At the signaling entity itself, there are several Enzo patents that cover the
	formation of this structure. A patent which was allowed in 2006 covers the attachment of signaling molecules through the phosphate
	moiety of a nucleic acid, which is how the signal-generating enzyme is bound.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	Nucleic Acid Analysis Format
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	We also have patents with issued claims covering the use of
	arrays of single-stranded nucleic acids fixed or immobilized in hybridizable form to a non-porous solid support. These patents
	cover any product that uses arrays of nucleic acids for molecular analysis.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	In some instances, we may enter into royalty agreements with
	collaborating research parties in consideration for the commercial use by us of the developments of their joint research. In other
	instances the collaborating party might obtain a patent, but we receive the license to use the patented subject matter. In such
	cases, we will seek to secure exclusive licenses. In other instances, we might have an obligation to pay royalties to, or reach
	a royalty arrangement with, a third party in consideration of our use of developments of such third party.
</P>
<!-- FIELD: PAGE; SEQUENCE: 16 -->
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 6PT; PADDING-BOTTOM: 12PT; BORDER-BOTTOM: SILVER 4PX SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	15
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage17"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 10PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: LEFT; WIDTH: 100%">
<PAGE>
</PAGE>
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	REGULATION AFFECTING OUR BUSINESSES
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	Clinical Laboratory
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The clinical laboratory industry is subject
	to significant federal and state regulation, including inspections and audits by governmental agencies. Governmental authorities
	may impose fines, criminal penalties or take other actions to enforce laws and regulations, including, but not limited to, revocation
	of a clinical laboratory&rsquo;s certificate and/or license to operate a clinical laboratory. Changes in regulation may also increase
	the cost of performing clinical laboratory tests, increase administrative requirements, or decrease the amount of reimbursement.
	Our clinical laboratory and (where applicable) patient service centers are licensed and accredited as required by law.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	CLIA (The Clinical Laboratory Improvement
	Act of 1967, and the Clinical Laboratory Improvement Amendments of 1988) regulates virtually all clinical laboratories in the United
	States. Among other things, CLIA requires laboratories to earn certification from the federal government and comply with various
	operational, personnel and quality requirements intended to ensure that their clinical laboratory testing services are accurate,
	reliable and timely. CLIA does not preempt state laws that are more stringent than federal laws. As such, certain clinical laboratories
	must meet state specific standards and undergo proficiency testing and inspections. Clinical laboratory certificates or licenses
	are also required by various state and local laws.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	CLIA assigns test into one of three categories
	on the basis of complexity (waived, moderate complexity and high complexity) and establishes varying requirements depending upon
	the complexity category of the test performed. A laboratory that performs high complexity tests must meet more stringent requirements
	than a laboratory that performs only moderate complexity tests, while those that perform only waived tests may apply for a certificate
	of waiver that if granted, would exempt the laboratory from most CLIA requirements. Our facility is certified to perform high complexity
	tests. In general, regulations promulgated by the United States Department of Health and Human Services (&ldquo;HHS&rdquo;) require
	laboratories that perform high or moderate complexity tests to implement systems that ensure the accurate performance and reporting
	of test results, establish quality control and quality assurance systems, ensure that personnel meet specified standards, conduct
	proficiency testing by approved agencies, and undergo biennial inspections, among other requirements.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Clinical laboratories also are subject
	to state regulation. CLIA provides that a state may adopt different or more stringent regulations than Federal law, and permits
	states to apply for exemption from CLIA if HHS determines that the state&rsquo;s laboratory laws are equivalent to, or more stringent
	than, CLIA. The State of New York&rsquo;s clinical laboratory regulations contain provisions that are more stringent than Federal
	law, and New York has received exemption from CLIA. Therefore, as long as New York maintains a licensure program that is CLIA-exempt,
	laboratories in New York, including our laboratory, are regulated under New York law rather than CLIA. Our laboratory is licensed
	in New York and has continuing programs to ensure that its operations are in compliance with all applicable regulatory requirements.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Sanctions for non-compliance with applicable
	regulations may include, but are not limited to, suspension, revocation, or limitation of a laboratory&rsquo;s CLIA certificate
	or state license, as well as fines and criminal penalties. The loss of, or adverse action against, a certificate or license, the
	imposition of fines, penalties or other sanctions, or future changes in Federal, state or local laboratory laws and regulations
	(or in the interpretation of current laws and regulations) could have a material adverse effect on our business.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Billing and reimbursement for clinical
	laboratory testing is subject to complex federal and state laws, rules and regulations, the violation of which may include, but
	is not necessarily limited to: (1) exclusion from participation in federal health care programs (including Medicare and Medicaid);
	(2) asset forfeitures; (3) civil monetary penalties; (4) criminal fines and penalties; and (5) the loss of licenses, certificates
	and/or authorizations necessary to operate some or all of a clinical laboratory&rsquo;s business.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The health care industry has been undergoing
	significant change because third-party payers, such as Medicare, Medicaid, health maintenance organizations and commercial insurers,
	have increased their efforts to control the cost, utilization and delivery of health care services. To address the problem of increasing
	health care costs, legislation has been proposed or enacted at both the Federal and state levels to regulate health care delivery
	in general, and clinical laboratories in particular. Additional health care reform efforts are likely to be proposed in the future.
	In particular, we believe that reductions in reimbursement for Medicare services will continue to be implemented from time to time.
	Reductions in the reimbursement rates of other third-party payers, commercial insurer and health maintenance organizations are
	likely to occur as well. We cannot predict the effect that current and future health care reform measures, if enacted, would have
	on our business, and there can be no assurance that such reforms, if enacted, would not have a material adverse effect on our business
	and operations.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Containment of health care costs, including reimbursement for
	clinical laboratory services, has been a focus of on-going governmental activity. Clinical laboratories must bill Medicare directly
	for the services provided to Medicare beneficiaries and may only collect the amounts permitted under the Medicare Clinical Laboratory
	Fee Schedule. Under the Patient Protection and Affordable Act, expansion in the pool of covered lives may expand the market for
	clinical diagnosis testing while at the same time, various policies aimed at
</P>
<!-- FIELD: PAGE; SEQUENCE: 17 -->
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 6PT; PADDING-BOTTOM: 12PT; BORDER-BOTTOM: SILVER 4PX SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	16
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage18"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 10PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: LEFT; WIDTH: 100%">
<PAGE>
</PAGE>
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	reducing costs or bundling care may reduce the rates
	paid for such services; the net impact of these factors on the market for our tests is not clear . In April 2014, Congress passed
	the Protecting Access to Medicare Act of 2014 (PAMA), which included substantial changes to the way in which clinical laboratory
	services will be paid under Medicare. Beginning in 2018, Medicare payments for clinical laboratory services will be paid based
	upon private payer rates as reported by clinical laboratories across the US replacing the current system which is based upon fee
	schedules derived from historical charges for tests from approximately 30 years ago. The final regulation to implement Medicare
	laboratory payment reform was released on June 17, 2016 by CMS. Since Enzo&rsquo;s clinical lab receives more than 50% of its total
	Medicare revenue from the Part B Clinical Laboratory Fee Schedule and the Physician Fee Schedule and receives more than $12,500
	in Medicare revenues per year, we are considered an &ldquo;applicable laboratory&rdquo;, and as such, must report private payor
	fee reimbursements for the period January 1, 2016 to June 30, 2016 to CMS by March 31, 2017. This data will be aggregated and utilized
	as the basis for the 2018 fee schedules that will be finalized in November 2017. At this time, the impact of the new payment system
	on rates for tests we perform or our customers&rsquo; tests that may use our products is not clear at this time.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Future changes in federal, state and local
	regulations (or in the interpretation of current regulations) affecting governmental reimbursement for clinical laboratory testing
	could have a material adverse effect on our business. We cannot predict, however, whether and what type of legislation will be
	enacted into law. In addition, reimbursement disapprovals by the third party payers, commercial insurers and health maintenance
	organizations, reductions or delays in the establishment of reimbursement rates, carrier limitations on the insurance coverage
	of the Company&rsquo;s services or the use of the Company as a service provider could have a negative effect on the Company&rsquo;s
	future revenues. During calendar year 2013 the Medicare reimbursement rates were reduced by an additional 2% in connection with
	the government&rsquo;s sequestration cuts. During fiscal 2016 reimbursement rates have remained constant with 2015 levels.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	Anti Fraud and Abuse Laws
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Existing Federal and state laws also regulate
	certain aspects of the relationship among healthcare providers, including clinical laboratories, and their referral sources (i.e.,
	physicians, hospitals, other laboratories, etc.). One of these laws, known as the &ldquo;Anti-Kickback Statute,&rdquo; contains
	extremely broad prohibitions against giving, accepting, soliciting (i.e., asking for) or arranging for remuneration in any form
	(i.e., cash, gifts, certain discounts, cross-referrals between parties, etc.), either directly or indirectly, for the purpose of
	inducing or rewarding another party for referrals of items or services paid for by a federal government health care program. The
	Anti-Kickback statute is very broad and includes the purchasing, ordering, leasing or arranging for, or recommending the purchase,
	leasing or ordering of, services paid for by a federal health care program in exchange for remuneration (i.e., anything of value).
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Violation of the Anti-Kickback Statute
	may result in, among other things, a criminal conviction, significant monetary penalties and exclusion from federal health care
	programs (including Medicare and Medicaid). Any person or entity involved in a prohibited transaction is potentially subject to
	criminal and civil penalties. A laboratory that claims payment for business generated by the Anti-Kickback Statute may also be
	subject to prosecution for violating a separate civil statute, the federal False Claims Act.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The False Claims Act is also a broad statute
	that the government often utilizes to combat fraud and abuse in the health care environment. Among other things, the statute is
	violated by any person who knowingly presents, or causes to be presented, a false or fraudulent claim for payment or approval;
	knowingly makes, uses, or causes to be made or used, a false record or statement material to a false or fraudulent claim; conspires
	to commit the above (or other specified) violations; or knowingly makes, uses, or causes to be made or used, a false record or
	statement material to an obligation to pay or transmit money or property to the government, or knowingly conceals or knowingly
	and improperly avoids or decreases an obligation to pay or transmit money or property to the government. The False Claims Act also
	provides that private parties may bring an action on behalf of (and in the name of) the United States to prosecute a False Claims
	Act violation. These private parties (known as &ldquo;qui tam relators&rdquo;) may share in a percentage of the proceeds that result
	from a False Claims Act action or settlement. A person or entity found to have violated the False Claims Act may be held liable
	for a per claim civil penalty of not less than $5,500 and not more than $11,000, plus three times the amount of damages sustained
	by the government. A person violating the False Claims Act is also liable for the costs of the civil action brought to recover
	any such penalty or damages. Other consequences may also result from a violation of the False Claims Act. New York has also adopted
	its own False Claims Act statute, which closely mirrors its federal counterpart.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Another Federal law, commonly known as
	the &ldquo;Stark&rdquo; law, prohibits physicians who have a financial relationship with an entity that furnishes &ldquo;designated
	health services,&rdquo; which includes clinical laboratory services (including anatomic pathology and clinical chemistry services),
	from referring Medicare (and in certain instances Medicaid) beneficiaries to that entity for laboratory tests unless a specific
	exception applies.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	In addition, laboratories may not bill
	federal health care programs, or any other payor, for services furnished pursuant to a prohibited referral. Violation of the Stark
	law may result not only in denial of payment for the underlying testing services, but also the imposition of civil monetary penalties
	and, potentially, False Claims Act liability. New York State has adopted laws that are similar to the Federal Stark law, which
	contain similar prohibitions and penalties and apply regardless of payer.
</P>
<!-- FIELD: PAGE; SEQUENCE: 18 -->
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 6PT; PADDING-BOTTOM: 12PT; BORDER-BOTTOM: SILVER 4PX SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	17
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage19"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 10PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: LEFT; WIDTH: 100%">
<PAGE>
</PAGE>
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The Stark law and New York State regulations
	have also placed restrictions on the supplies and other items that laboratories may provide to their clients. These laws specify
	that laboratories may only provide clients with items or devices that are used solely to collect, transport or store specimens
	for the laboratory or to communicate results or tests. Items such as biopsy needles, snares and reusable needles are specifically
	prohibited from being supplied by laboratories to their clients. The Company has implemented procedures to ensure compliance with
	these laws and restrictions.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	In February 1997, the Department of Health
	and Human Services, Office of the Inspector General (OIG) released model voluntary compliance program guidance for laboratories.
	One key aspect of the model compliance guidance was an emphasis on the responsibility of laboratories to notify physicians that
	Medicare covers only medically necessary services. This requirement, and the likely effect on physician test ordering habits, focuses
	on chemistry tests, especially routine tests, rather than on anatomic pathology services or the non-automated tests, which make
	up the majority of the Company&rsquo;s business measured in terms of net revenues. Nevertheless, it could potentially affect physicians&rsquo;
	test ordering habits more broadly. The Company is unable to predict whether, or to what extent, these developments have impacted,
	or may impact, utilization of the Company&rsquo;s services.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The federal health care reform legislation
	adopted in March, 2010, known as the Patient Protection and Affordable Care Act, contains provisions requiring providers to establish
	compliance programs as a condition of enrollment in Medicare, Medicaid and the State Children&rsquo;s Health Insurance Program.
	Implementing regulations and guidance for clinical laboratories has not yet been issued yet by the Centers for Medicare and Medicaid
	Services. In addition, New York State has adopted mandatory compliance program requirements for certain specified providers, including
	those who directly or indirectly bill or collect more than $500,000 annually in Medicaid payments, and entities licensed under
	certain articles of the Public Health Law and Mental Hygiene Law, respectively. The Company has adopted its own Corporate Compliance
	Program based upon the OIG model program guidance and in accordance with New York State&rsquo;s requirements.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The Company&rsquo;s compliance program
	focuses on, among other things, establishing clear compliance standards; auditing and monitoring of the Company&rsquo;s billing
	and coding practices; training personnel on compliance standards, policies and procedures; preventing and detecting fraud, waste
	and abuse, enforcing a policy of non-retaliation and non-intimidation for good faith participation in the compliance program; and
	establishing good faith reporting of actual or suspected compliance violations.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The Company seeks to structure its arrangements
	with physicians and other customers in compliance with federal and state Anti-Kickback laws, Stark laws, False Claims Acts, and
	other applicable laws, rules and regulations, and to keep current on developments concerning their application to the Company,
	including consultation with legal counsel. However, the Company is unable to predict how such laws and regulations will be interpreted
	and applied in the future, and thus no assurances can be given that its arrangements or processes will not become subject to scrutiny
	by a governmental agency.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	Confidentiality of Health Information
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The Health Insurance Portability and Accountability
	Act of 1996 (&ldquo;HIPAA&rdquo;) included &ldquo;administrative simplification&rdquo; provisions designed to standardize common
	electronic transactions in health care and to protect the security and privacy of health information. Congress&rsquo; purpose in
	promulgating HIPAA was to increase the efficiency of health care transactions while, at the same time, protecting the confidentiality
	of patient information. Regulations have been adopted for electronic transaction, privacy security and breach notification standards
	and include the requirement to use a National Provider Identifier in electronic health care transactions. The National Provider
	Identifier is an identifier that replaced all other identifiers that are currently used or healthcare transactions (e.g., UPIN,
	Medicaid provider numbers, identifiers assigned by commercial insurers). The regulations promulgated under HIPAA have very broad
	applicability, including by specifically applying to health care providers, which include physicians and clinical laboratories
	that conduct an electronic transaction for which HIPAA has articulated standards. Together, health plans, health care clearinghouses
	and health care providers that conduct standard transactions subject to HIPAA are referred to as &ldquo;Covered Entities&rdquo;.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	The electronic transaction standards regulations created guidelines
	for certain common health care transactions. With certain exceptions, these standards require that, when we conduct certain transactions
	electronically with another health care provider, health care clearinghouse or health plan, we must comply with the standards set
	forth in the regulations. The regulations established standard data content and format for submitting electronic claims and other
	administrative health transactions. Health care providers and health plans are required to use standard formats when transmitting
	claims, referrals, authorizations, and certain other transactions electronically. The Company believes it is in compliance with
	these standards.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	Privacy, security and breach notification requirements regarding
	protected health information (&ldquo;PHI&rdquo;).
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	We are required to maintain numerous policies and procedures
	in order to comply with the HIPAA privacy security and breach notification requirements. Furthermore, we need to continuously ensure
	that there are mechanisms in place to safeguard the privacy of PHI that is transmitted or maintained in any format (e.g. oral,
	written, or electronic). Failure to comply with these requirements can result in criminal and civil penalties. To comply with the
	HIPAA security regulations in particular, we must ensure the confidentiality,
</P>
<!-- FIELD: PAGE; SEQUENCE: 19 -->
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 6PT; PADDING-BOTTOM: 12PT; BORDER-BOTTOM: SILVER 4PX SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	18
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage20"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 10PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: LEFT; WIDTH: 100%">
<PAGE>
</PAGE>
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	integrity and availability of all electronic PHI
	(&ldquo;EPHI&rdquo;) that we create, receive, maintain, or transmit. We have some flexibility to fashion our own security measures
	to accomplish these goals. The security regulations strongly emphasize that we must periodically conduct an accurate and thorough
	assessment of the potential risks and vulnerabilities of the confidentiality, integrity and availability of our EPHI and then document
	our response to the various security regulations on the basis of that assessment.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	The privacy, security and breach notification regulations were
	last modified in 2013 as a result of final regulations published pursuant to the Health Information Technology Act (&ldquo;HITECH&rdquo;).
	HITECH requires, among other things, that providers, such as laboratories, notify patients of breaches of unsecured PHI, enter
	into new business associate agreements with existing business associates and revise many of their existing privacy policies. In
	addition, HITECH makes business associates directly liable to the Federal government for compliance with certain aspects of the
	privacy, security and breach notification regulations. As implemented in regulations, a downstream subcontractor of a business
	associate that creates, receives, maintains, or transmits PHI on behalf of the business associate is also itself considered a business
	associate. Under the regulations issued in 2013, health care providers, such as laboratories, that are subject to HIPAA as a Covered
	Entity are vicariously liable for violations of HIPAA based on acts or omissions of their agents, including business associates,
	when the agent is acting within the scope of the agency. Complying with the electronic transaction, privacy, security and breach
	notification rules requires significant effort and expense for virtually all entities that conduct health care transactions electronically
	and handle PHI.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	Medical Regulated Waste
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	We are subject to licensing and regulation under federal, state
	and local laws relating to the handling and disposal of medical specimens, infectious and hazardous waste, as well as to the safety
	and health of laboratory employees. All our laboratories are required to operate in accordance with applicable federal and state
	laws and regulations relating to biohazard disposal of all facilities specimens. We use outside vendors to dispose of such specimens.
	Although we believe that we comply in all respects with such federal, state and local laws, our failure to comply with those laws
	could subject us to denial of the right to conduct business, fines, criminal penalties and/or other enforcement actions.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	Occupational Safety
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	In addition to its comprehensive regulation of safety in the
	workplace, the U.S. Federal Occupational Safety and Health Administration (&ldquo;OSHA&rdquo;) has established extensive requirements
	relating to workplace safety for health care employers, including clinical laboratories, whose workers may be exposed to blood-borne
	pathogens such as HIV and the hepatitis B virus. These regulations, among other things, require work practice controls, protective
	clothing and equipment, training, medical follow-up, vaccinations and other measures designed to minimize exposure to, and transmission
	of, blood-borne pathogens. The Federal Drug Enforcement Administration regulates the use of controlled substances in testing for
	drugs of abuse. We are also subject to OSHA&rsquo;s requirement that employers using hazardous chemicals communicate the properties
	and hazards presented by those chemicals to their employees. We believe that we are in compliance with these OSHA requirements.
	Our failure to comply with those regulations and requirements could subject us to tort liability, civil fines, criminal penalties
	and/or other enforcement actions.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	Other Regulation
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Our business is and will continue to be subject to regulation
	under various state and federal environmental, safety and health laws, including the Occupational Safety and Health Act, the Resource
	Conservation and Recovery Act, and the Atomic Energy Act or their state law analogs. These and other laws govern our use, handling
	and disposal of various biological, chemical and radioactive substances used in our operations and wastes generated by our operations.
	We are required to possess licenses under, or are otherwise subject to federal and state regulations pertaining to, the handling
	and disposal of medical specimens, infectious and hazardous waste and radioactive materials.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	We believe that we are in compliance with applicable environmental,
	safety and health laws in the United States and internationally and that our continual compliance with these laws will not have
	a material adverse effect on our business. All of our laboratories are operated in accordance with applicable federal and state
	laws and regulations relating to hazardous substances and wastes, and we use qualified third-party vendors to dispose of biological
	specimens and other hazardous wastes. Although we believe that we comply in all respects with such federal, state and local laws,
	our failure to comply with those laws could subject us to denial of the right to conduct business, civil fines, criminal penalties
	and/or other enforcement actions. Environmental contamination resulting from spills or disposal of hazardous substances generated
	by our operations, even if caused by a third-party contractor or occurring at a remote location could result in material liability.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	Regulation of Diagnostic Products
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	The diagnostic products that are developed by our collaborators,
	or by us, are likely to be regulated by the FDA as medical devices. Unless an exemption applies, medical devices must receive either
	&ldquo;510(k) clearance&rdquo; or pre-market approval (&ldquo;PMA&rdquo;) from the FDA before marketing them in the United States.
	Both the 510(k) clearance and PMA processes may be costly and time consuming, but the
</P>
<!-- FIELD: PAGE; SEQUENCE: 20 -->
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 6PT; PADDING-BOTTOM: 12PT; BORDER-BOTTOM: SILVER 4PX SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	19
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage21"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 10PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: LEFT; WIDTH: 100%">
<PAGE>
</PAGE>
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	process of obtaining PMA approval is much
	more costly, lengthy and uncertain. We cannot be sure that 510(k) clearance or PMA approval will ever be obtained for any product
	we propose to market.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	The FDA decides whether a device must undergo either the 510(k)
	clearance or PMA approval process based upon statutory criteria. These criteria include the level of risk that the agency perceives
	is associated with the device and a determination whether the product is a type of device that is similar to devices that are already
	legally marketed. Devices deemed to pose relatively less risk are placed in either class I or II, which requires the manufacturer
	to submit a premarket notification requesting 510(k) clearance, unless an exemption applies. In a pre-market notification, the
	applicant must demonstrate that the proposed device is &ldquo;substantially equivalent&rdquo; in intended use and in safety and
	effectiveness to a legally marketed &ldquo;predicate device&rdquo; that is either in class I, class II, or is a &ldquo;pre-amendment&rdquo;
	class III device (i.e., one that was in commercial distribution before May 28, 1976) for which the FDA has not yet called for submission
	of a PMA application.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	After a device receives 510(k) clearance, any modification that
	could significantly affect its safety or effectiveness, or that would constitute a major change in its intended use, requires a
	new 510(k) clearance or could require a PMA approval. The FDA requires each manufacturer to make this determination in the first
	instance, but the FDA can review any such decision. If the FDA disagrees with a manufacturer&rsquo;s decision not to seek a new
	510(k) clearance, the agency may retroactively require the manufacturer to seek 510(k) clearance or PMA approval. The FDA also
	can require the manufacturer to cease marketing and/or recall the modified device until 510(k) clearance or PMA approval is obtained.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Devices deemed by the FDA to pose the greatest risk, such as
	life-sustaining, life-supporting or implantable devices, or deemed not substantially equivalent to a legally marketed class I or
	class II predicate device, or to a preamendment class III device, for which PMAs have not been called, are placed in class III.
	Such devices are required to undergo the PMA approval process in which the manufacturer must provide sufficient valid scientific
	evidence of the safety and effectiveness of the device. A PMA application typically requires the collection of extensive preclinical
	and clinical trial data and also information about the device and its components regarding, among other things, device design,
	manufacturing and labeling. After approval of a PMA, a new PMA or PMA supplement is required in the event of a modification to
	the device, its labeling or its manufacturing process.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Although clinical investigations of most devices are subject
	to the investigational device exemption (&ldquo;IDE&rdquo;) requirements, clinical investigations of certain in vitro diagnostic
	(&ldquo;IVDs&rdquo;) tests are exempt from the IDE requirement provided the testing is non-invasive, does not require an invasive
	sampling procedure that presents a significant risk, does not introduce energy into the subject, and is not used as a diagnostic
	procedure without confirmation by another medically established test or procedure.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	In addition, the IVD must be for use in the laboratory research
	phase of development and not represented as an effective IVD (i.e. labeled for Research Use Only (RUO)) or for use in product testing
	prior to full commercial marketing (i.e. for Investigational Use Only (IUO)). Because RUO and IUO-labeled products are exempt from
	most regulatory requirements it is important that they are not distributed for clinical diagnostics use. Mere placement of an RUO
	or IUO label on an IVD product does not render the device exempt from otherwise applicable regulatory requirements; indeed, FDA
	may determine that the device is intended for use in clinical diagnosis on the basis of other evidence, including how the device
	is marketed. FDA recommends that manufacturers assess the totality of the circumstances surrounding the distribution of their RUO
	and IUO labeled products to ensure that they are not engaging in practices that conflict with their labeling. The FDA expressed
	its intent to exercise heightened enforcement with respect to IUO and RUO devices improperly commercialized prior to receipt of
	FDA clearance or approval.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	We have developed products that we currently distribute in the
	United States on a RUO basis. There can be no assurance that the FDA would agree that our distribution of these products meets
	the requirements for RUO distribution. Furthermore, failure by us or recipients of our RUO products to comply with the regulatory
	limitations on the sale and distribution of RUO devices could result in enforcement action by the FDA, including the imposition
	of restrictions on our distribution of these products.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Although FDA has long asserted it has jurisdiction over laboratory-developed
	tests, the agency has historically exercised discretion enforcement with respect to most such tests and not required laboratories
	that furnish these tests to comply with FDA&rsquo;s regulatory requirements for medical devices. However, on July 31, 2014, the
	FDA issued a 60-day notice to Congress indicating that the FDA intends to issue Draft Guidance on the regulation of laboratory-developed
	test. In the notice, FDA indicates that it intends to end its policy of general enforcement discretion towards laboratory-developed
	test, and proposes the implementation of a risk-based regulatory framework. Under the proposed framework, many laboratory-developed
	tests would be subject to FDA&rsquo;s requirements for medical devices, including registration and listing premarket review, medical
	device reports and quality systems regulations. The implementation of this framework would not begin until after a Final Guidance
	is issued and would occur over a nine year period with those tests that FDA considers to be highest risk falling under FDA&rsquo;s
	review requirements first. The draft guidance was released in late September 2014, and a 120 &ndash; day public comment period
	ended February 2015.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	In so far as the devices that we manufacture or distribute are
	subject to the premarket notification or premarket approval requirements a host of additional regulatory requirements may apply,
	including registration and listing the Quality System Regulation (which requires manufacturers to follow elaborate design, testing,
	control, documentation and other quality assurance procedures), the Medical Device Reporting regulation (which requires that manufacturers
	report to the FDA certain types of adverse events involving their products), labeling regulations, and the FDA&rsquo;s general
	prohibition against promoting products for unapproved or &ldquo;off label&rdquo; uses. Class II devices may also be subject to
	special controls such as performance standards, post market surveillance, patient registries, and
</P>
<!-- FIELD: PAGE; SEQUENCE: 21 -->
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 6PT; PADDING-BOTTOM: 12PT; BORDER-BOTTOM: SILVER 4PX SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	20
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage22"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 10PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: LEFT; WIDTH: 100%">
<PAGE>
</PAGE>
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	FDA guidelines that do not apply
	to class I devices. Unanticipated changes in existing regulatory requirements or adoption of new requirements could hurt our business,
	financial condition and results of operations.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	We are subject to inspection and market surveillance by the
	FDA to determine compliance with regulatory requirements. If the FDA finds that we have failed to comply with applicable requirements,
	the agency can institute a wide variety of enforcement actions, ranging from a public warning letter to more severe sanctions such
	as fines, injunction, civil penalties, recall or seizure of our products, operating restrictions, partial suspension or total shutdown
	of production, refusal of our requests for 510(k) clearance or PMA approval of new products, withdrawal of 510(k) clearance or
	PMA approvals already granted, and criminal prosecution.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	The FDA also has the authority to request repair, replacement
	or refund of the cost of any medical device manufactured or distributed by us. Our failure to comply with applicable requirements
	could lead to an enforcement action that may have an adverse effect on our financial condition and results of operations.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Unanticipated changes in existing regulatory requirements, our
	failure to comply with such requirements or adoption of new requirements could have a material adverse effect on us. We have employees
	to expedite the preparation and filing of documentation necessary for FDA clearances and approvals, patent issuances and licensing
	agreements. We cannot assure you that future clinical diagnostic products developed by us or our collaborators will not be required
	to be reviewed by FDA under the more expensive and time consuming pre-market approval process.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	Regulation of Pharmaceutical Products
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	New drugs and biological drug products are subject to regulation
	under the Federal Food, Drug and Cosmetic Act, and biological products are also regulated under the Public Health Service Act.
	We believe that certain products developed by us or our collaborators will be regulated either as biological products or as new
	drugs. Both statutes and regulations promulgated thereunder govern, among other things, the testing, licensing, manufacturing,
	marketing, distributing, safety, and efficacy requirements, labeling, storage, exporting, record keeping, advertising and other
	promotional practices involving biologics or new drugs, as the case may be. FDA review or approval or other clearances must be
	obtained before clinical testing, and before manufacturing and marketing, of biologics and drugs. At the FDA, the Center for Biological
	Evaluation and Research (&ldquo;CBER&rdquo;) is responsible for the regulation of biological drugs and the Center for Drug Evaluation
	and Research (&ldquo;CDER&rdquo;) is responsible for the regulation of non-biological drugs. Biological drugs are licensed and
	other drugs are approved before commercialization.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Any therapeutics products that we develop will require regulatory
	review before clinical trials, and additional regulatory approval before commercialization. New human gene medicine products as
	well as immune regulation products, as therapeutics, are subject to regulation by the FDA and comparable agencies in other countries.
	The FDA on a case-by-case basis currently reviews each protocol. In addition, the National Institutes of Health (&ldquo;NIH&rdquo;)
	is also involved in the oversight of gene therapies and the FDA has required compliance with certain NIH requirements.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Federal requirements are detailed in Title 21 of the Code of
	Federal Regulations (21 CFR). In addition, the FDA publishes guidance documents with respect to the development of therapeutics
	protocols.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Obtaining FDA approval has historically been a costly and time-consuming
	process. Generally, to gain FDA approval, a developer first must conduct pre-clinical studies in the laboratory evaluating product
	chemistry, formulation and stability and, if appropriate, in animal model systems, to gain preliminary information on safety and
	efficacy.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Pre-clinical safety tests must be conducted by laboratories
	that comply with FDA regulations governing Good Laboratory Practices (GLP). The results of those studies are submitted with information
	characterizing the product and its manufacturing process and controls as a part of an investigational new drug (&ldquo;IND&rdquo;)
	application, which the FDA must review and approve before human clinical trials of an investigational drug can start. The IND application
	includes a detailed description of the clinical investigations to be undertaken in addition to other pertinent information about
	the product, including descriptions of any previous human experience and the company&rsquo;s future plans for studying the drug.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	In order to commercialize our pharmaceutical products, we (as
	the sponsor) file an Investigational New Drug (&ldquo;IND&rdquo;) application with FDA and will be responsible for initiating and
	overseeing the clinical studies to demonstrate the safety and efficacy necessary to obtain FDA marketing approval of any such products.
	For INDs that we sponsor, we will be required to select qualified clinical sites (usually physicians affiliated with medical institutions)
	to supervise the administration of the investigational product. It is the sponsor&rsquo;s responsibility to ensure that the investigations
	are conducted and monitored in accordance with FDA regulations, Good Clinical Practices (GCP) and the general investigational plan
	and protocols contained in the IND. This may be done using in-house trained personnel or an outside contract research organization
	(CRO).
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Each clinical study is also reviewed approved and overseen by
	an Institutional Review Board (IRB). In considering an application to perform a clinical trial, IRB will consider, among other
	things, ethical factors and the safety of human subjects participating in the trial. Clinical trials are normally conducted in
	three phases, although the phases might overlap. Phase I trials, concerned primarily with the safety and tolerance of the drug,
	and its pharmacokinetics (or how it behaves in the body including its absorption and distribution)
</P>
<!-- FIELD: PAGE; SEQUENCE: 22 -->
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 6PT; PADDING-BOTTOM: 12PT; BORDER-BOTTOM: SILVER 4PX SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	21
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage23"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 10PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: LEFT; WIDTH: 100%">
<PAGE>
</PAGE>
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	involve fewer than 100 subjects.
	Phase II trials normally involve a few hundred patients and are designed primarily to demonstrate preliminary effectiveness and
	the most suitable dose or exposure level for treating or diagnosing the disease or condition for which the drug is intended, although
	short-term side effects and risks in people whose health is impaired may also be examined. Phase III trials are expanded, adequate
	and well-controlled clinical trials with larger numbers of patients and are intended to gather the additional information for proper
	dosage and labeling of the drug. Clinical trials may take several years to complete, but the period may vary.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Certain regulations promulgated by the FDA may shorten the time
	periods and reduce the number of patients required to be tested in the case of certain life-threatening diseases, which lack available
	alternative treatments. The FDA receives reports on the progress of each phase of clinical testing, and it may require the modification,
	suspension or termination of clinical trials if an unwarranted risk is presented to patients. Human gene medicine products are
	a new category of therapeutics.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	There can be no assurance regarding the length of the clinical
	trial period, the number of patients that the FDA will require to be enrolled in the clinical trials in order to establish the
	efficacy, safety, purity and/or potency of human gene medicine products, or that the clinical and other data generated will be
	acceptable to the FDA to support marketing approval.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	After completion of clinical trials of a new product, FDA marketing
	approval must be obtained before the product can be sold in the United States. If the product is regulated as a new biologic, CBER
	requires the submission and approval of a Biologics License Application (BLA) before commercial marketing of the biologic product.
	If the product is classified as a new drug, we must file a New Drug Application (&ldquo;NDA&rdquo;) with CDER and receive approval
	before commercial marketing of the drug. The NDA or BLA must include results of product development, pre-clinical studies and clinical
	trials. The testing and approval processes require substantial time and effort and there can be no assurance that any approval
	will be granted on a timely basis, if at all. The median time to obtain new product approvals after submission to the FDA is approximately
	12 months. If questions arise during the FDA review process, approval can take longer. Before completing its review, the FDA may
	seek guidance from an Advisory Panel of outside experts at a public or closed meeting. While the advice of these committees is
	not binding on the FDA, it is often followed. Notwithstanding the submission of relevant data, the FDA might ultimately decide
	that the NDA or BLA does not satisfy its regulatory criteria for approval and, thus, reject the application, refuse to approve
	it, or require additional clinical, preclinical or chemistry studies. Even after FDA regulatory approval or licensure, a marketed
	drug product is subject to continual review by the FDA.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	In addition, if previously unknown problems are discovered or
	we fail to comply with the applicable regulatory requirements, we might be restricted from marketing a product, we might be required
	to withdraw the product from the market, and we might possibly become subject to seizures, injunctions, voluntary recalls, or civil,
	monetary or criminal sanctions. In addition, the FDA may condition marketing approval on the conduct of specific post-marketing
	studies to further evaluate safety and effectiveness.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	For commercialization of our biological or other drug products,
	the manufacturing processes described in our NDA or BLA must receive FDA approval and the manufacturing facility must successfully
	pass an inspection prior to approval or licensure of the product for sale within the United States. The pre-approval inspection
	assesses whether, for example, the facility complies with the FDA&rsquo;s current good manufacturing practices (cGMP) regulations.
	These regulations elaborate testing, control, documentation, personnel, record keeping and other quality assurance procedure requirements
	that must be met.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Once the FDA approves our biological or other drug products
	for marketing, we must continue to comply with the cGMP regulations. The FDA periodically inspects biological and other drug manufacturing
	facilities to ensure compliance with applicable cGMP requirements. Failure to comply with the statutory and regulatory requirements
	subjects the manufacturer to possible legal or regulatory action, such as suspension of manufacturing, seizure of product or voluntary
	recall of a product.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	If a developer obtains designation by the FDA of a biologic
	or other drug as an &ldquo;orphan&rdquo; for a particular use, the developer may request grants from the federal government to
	defray the costs of qualified testing expenses in connection with the development of such drug. Orphan drug designation is possible
	for drugs for rare diseases, including many genetic diseases, which means the drug is for a disease that has a prevalence of less
	than 200,000 patients in the United States. The first applicant who receives an orphan drug designation and who obtains approval
	of a marketing application for such drug acquires the exclusive marketing rights to that drug for that use for a period of seven
	years unless the subsequent drug can be shown to be clinically superior. Accordingly, no other company would be allowed to market
	an identical orphan drug with the same active ingredient for the use approved by the FDA for seven years after the approval.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	Manufacturing and Research Facilities
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Our integrated laboratory and scientific efforts for our three
	segments take place primarily at our two adjacent facilities in Farmingdale, New York. A major part of one facility is utilized
	by Life Science as its global headquarters, and also for research and manufacturing with special handling capabilities and clean
	rooms suitable for our operations. The Life Sciences segment has centered its US logistics, reagent and kit manufacturing at its
	facility in Ann Arbor, Michigan, and has European logistics operations in Lausen, Switzerland. We also contract with qualified
	third-party contractors to manufacture our products in cases where we deem it appropriate, for example, when it is not cost-effective
	to produce a product ourselves or where we seek to leverage the expertise of another manufacturer in a certain area.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 23 -->
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 6PT; PADDING-BOTTOM: 12PT; BORDER-BOTTOM: SILVER 4PX SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	22
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage24"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 10PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: LEFT; WIDTH: 100%">
<PAGE>
</PAGE>
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	Employees
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	As of July 31, 2016, we employed 446 full-time and 43 part-time
	employees. Of the full-time employees, 108 were engaged in research, development, manufacturing, and marketing of research products,
	272 in performing testing, marketing and billing our clinical laboratories services and 66 in finance, information technology,
	administrative and executive functions. Our scientific staff, including 35 individuals with post graduate degrees, possesses a
	wide range of experience and expertise in the areas of recombinant DNA, nucleic acid chemistry, molecular biology and immunology.
	We believe that we have established good relationships with our employees.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	Information Systems
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Information systems are used extensively in virtually all aspects
	of our businesses. In our clinical laboratory business, our information systems are critical with respect to laboratory testing,
	billing, accounts receivable, customer service, logistics, and management of medical data. Our success depends, in part, on the
	continued and uninterrupted performance of our information technology systems. Computer systems are vulnerable to damage from a
	variety of sources, including telecommunications or network failures, malicious human acts and natural disasters.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Moreover, despite network security measures, some of our servers
	are potentially vulnerable to physical or electronic break-ins, computer viruses and similar disruptive problems. We have invested
	heavily in the upgrade of our information and telecommunications systems to improve the quality, efficiency and security of our
	businesses. In addition, to complement our proprietary physician connectivity solution, EnzoDirect we have a web portal version
	which allows physicians to receive laboratory results from any personal computer with a browser and an Internet connection.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Despite the precautionary measures that we have taken to prevent
	unanticipated problems that could affect our information technology systems, sustained or repeated system failures that interrupt
	our ability to process test orders, deliver test results or perform tests in a timely manner could adversely affect our reputation
	and result in a loss of customers and net revenues.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	Quality Assurance
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	We consider the quality of our clinical laboratory tests to
	be of critical importance, and, therefore, we maintain a comprehensive quality assurance program designed to help assure accurate
	and timely test results. In addition to the compulsory external inspections and proficiency programs demanded by the Medicare program
	and other regulatory agencies, our clinical laboratory has in place systems to emphasize and monitor quality assurance.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	In addition to our own internal quality control programs, our
	laboratory participates in numerous externally administered, blind quality surveillance programs, including on-site evaluation
	by the College of American Pathologies (&ldquo;CAP&rdquo;) proficiency testing program and the New York State survey program. The
	blind programs supplement all other quality assurance procedures and give our management the opportunity to review our technical
	and service performance from the client&rsquo;s perspective.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	The CAP accreditation program involves both on-site inspections
	of our laboratory and participation in the CAP&rsquo;s proficiency testing program for all categories in which our laboratory is
	accredited by the CAP. The CAP is an independent nongovernmental organization of board certified pathologists, which offers an
	accreditation program to which laboratories can voluntarily subscribe. A laboratory&rsquo;s receipt of accreditation by the CAP
	satisfies the Medicare requirement for participation in proficiency testing programs administered by an external source. Our clinical
	laboratory facilities are accredited by the CAP.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	FORWARD - LOOKING AND CAUTIONARY STATEMENTS
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	This Annual Report contains &ldquo;forward-looking statements&rdquo;
	as defined in the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact, including,
	without limitation, the statements under &ldquo;Management&rsquo;s Discussion and Analysis of Financial Condition and Results of
	Operations&rdquo; are &ldquo;forward-looking statements.&rdquo; Forward-looking statements may include the words &ldquo;believes,&rdquo;
	&ldquo;expects,&rdquo; &ldquo;plans,&rdquo; &ldquo;intends,&rdquo; &ldquo;anticipates,&rdquo; &ldquo;continues&rdquo; or other
	similar expressions. These statements are based on the Company&rsquo;s current expectations of future events and are subject to
	a number of risks and uncertainties that may cause the Company&rsquo;s actual results to differ materially from those described
	in the forward-looking statements. Should one or more of these risks or uncertainties materialize, or should underlying assumptions
	prove incorrect, actual results may vary materially from those anticipated, estimated or projected. The Company assumes no obligation
	to revise or update any forward-looking statements for any reason, except as required by law.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	The Company files annual, quarterly and current reports, proxy
	statements and other information with the Securities and Exchange Commission (the &ldquo;SEC&rdquo;). These filings are available
	to the public via the Internet at the SEC&rsquo;s website located at http://www.sec.gov. You may also read and copy any document
	the Company files with the SEC at the SEC&rsquo;s public reference room located at 100 F Street, N.E., Washington, D.C. 20549.
	For more information, please call the SEC at 1-800-SEC-0330.
</P>
<!-- FIELD: PAGE; SEQUENCE: 24 -->
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 6PT; PADDING-BOTTOM: 12PT; BORDER-BOTTOM: SILVER 4PX SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	23
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage25"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 10PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: LEFT; WIDTH: 100%">
<PAGE>
</PAGE>
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	The Company&rsquo;s website is located at
<U>
	www.enzo.com.
</U>
	The Company makes available on its website a link to all filings that it makes with the SEC. You may request a copy of the Company&rsquo;s
	filings with the SEC (excluding exhibits) at no cost by writing or telephoning us at the following address or telephone number:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Enzo Biochem, Inc.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	527 Madison Ave.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	New York, New York 10022
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Tel: (212) 583-0100
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Attn: Investor Relations
</P>
</EFX_BUSINESS>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_RISK_FACTORS>
<A NAME="FIS_RISK_FACTORS"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
<A NAME="C86264_10K_HTM_X2_C86264A003">
</A>
	Item 1A.
<U>
	Risk Factors
</U>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
<I>
	Business Risks
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	Our operating results may vary from period to period.
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Our operating results may vary significantly from quarter to
	quarter and from year to year, depending on a variety of factors including:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 3%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&bull;
</FONT>
</TD>
<TD STYLE="WIDTH: 97%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	competitive conditions, including changes in third-party reimbursements;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	health care reform regulations affecting providers and plan sponsors;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	changes in reimbursement policies from third party payers;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	exchange rate fluctuations;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	changes in tax laws, the results of tax audits or the measurement of tax uncertainties;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	the timing of our research and development, sales and marketing expenses;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	the introduction of new products by us or our competitors;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	the success of identifying, acquiring and integrating businesses that complement our product offerings, add new technology or add presence in a market;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	expenses associated with defending our intellectual property portfolio;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	customer demand for our products due to changes in purchasing requirements and research needs;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	general worldwide economic conditions affecting funding of research; and
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	seasonal fluctuations affected by weather and holiday periods.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Consequently, results for any interim period may not necessarily
	be indicative of results in subsequent periods.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	A significant proportion of our sales are to academic centers,
	funded by government grants in our major markets globally.
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Governments around the world have been reviewing long term public
	funding of life science research in response to the problems arising from global financial pressures. As a result, the available
	funds for discretionary purchases from market to market have been capped or reduced based on available National budgets. Reduced
	grants for researchers could impact our business, in the amount, price and type of products bought and used by customers.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	A significant proportion of our sales are to customers in
	pharmaceutical and biotech companies.
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Globally, pharmaceutical companies are challenging internal
	budgets, and the return of investment from their R&amp;D spend. This could impact our business, in the amount, price and type of
	products bought and used by customers.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	Our future success will depend in part upon our ability to
	enhance existing products, develop and introduce new products and realize commercial acceptance of those products, in a rapidly
	changing technological environment.
</B>
</P>
<!-- FIELD: PAGE; SEQUENCE: 25 -->
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 6PT; PADDING-BOTTOM: 12PT; BORDER-BOTTOM: SILVER 4PX SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	24
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage26"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 10PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: LEFT; WIDTH: 100%">
<PAGE>
</PAGE>
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	The market for our products is characterized by rapidly changing
	technology, evolving industry standards and new product introductions, which may make our existing products obsolete. Our future
	success will depend in part upon our ability to enhance existing products, develop and introduce new products, and realize commercial
	acceptance of those products
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	The development of new or enhanced products is a complex and
	uncertain process requiring the accurate anticipation of technological and market trends as well as precise technological execution.
	In addition, the successful development of new products will depend on the development of new technologies. We will be required
	to undertake time-consuming and costly development activities and to seek regulatory approval for these new products. We may experience
	difficulties that could delay or prevent the successful development, introduction and marketing of these new products. Regulatory
	clearance or approval of any new products may not be granted by the FDA, state-wide agency or foreign regulatory authorities on
	a timely basis, or at all, and the new products may not be successfully commercialized.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	We may be unable to identify, acquire and integrate acquisition
	targets.
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Our strategy envisions, if an opportunistic target is identified,
	future growth from acquiring and integrating similar operations and/or product or services lines. There can be no assurance that
	we will be able to identify suitable acquisition candidates and, once identified, to negotiate successfully their acquisition at
	a price or on terms and conditions favorable to us, or to integrate the operations of such acquired businesses with the existing
	operations. In addition, we compete for acquisition candidates with other entities, some of which have greater financial resources
	than ours. Failure to implement successfully our acquisition strategy would limit our potential growth.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	Our inability to carry out certain of our marketing and sales
	plans may make it difficult for us to grow or maintain our business.
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	The Life Sciences segment continues a marketing program designed
	to more directly service its end users, while simultaneously promoting the Enzo Life Science brand, with reference to our acquired
	brands. We will continue to reach out to our customers using our direct field sales force, in-house business team, the on-going
	enhancement of our interactive websites, continued attendance at top industry trade meetings, and publications to customers and
	in leading scientific journals. In addition to our direct sales, we operate worldwide through wholly-owned subsidiaries (in USA,
	Switzerland, Belgium, Germany, and the UK), a branch office in France and a network of third-party distributors in most other significant
	markets. If we are unable to successfully continue these programs, we may be unable to grow and our business could suffer.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	We face significant competition, which could cause us to
	decrease the prices for our products or services or render our products uneconomical or obsolete, any of which could reduce our
	revenues and limit our growth.
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Our competitors in the biotechnology industry in the United
	States and abroad are numerous and include major pharmaceutical, energy, food and chemical companies, as well as specialized genetic
	engineering firms. Many of our large competitors have substantially greater resources than us and have the capability of developing
	products which compete directly with our products. Many of these companies are performing research in the same areas as we are.
	The markets for our products are also subject to competitive risks because markets are highly price competitive. Our competitors
	have competed in the past by lowering prices on certain products.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	The clinical laboratory business is highly fragmented and intensely
	competitive, and we compete with numerous national and local companies. Some of these entities are larger than we are and have
	greater resources than we do. We compete primarily on the basis of the quality of our testing, reporting and information services,
	our reputation in the medical community, the pricing of our services and our ability to employ qualified professionals.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	These competitive conditions could, among other things:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 3%">
<FONT STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	&bull;
</FONT>
</TD>
<TD STYLE="WIDTH: 97%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Require us to reduce our prices to retain market share;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Require us to increase our marketing efforts which could reduce our profit margins;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Increase our cost of labor to attract qualified personnel;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Render our biotechnology products uneconomical or obsolete or;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Reduce our revenue.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	Ethical, legal and social concerns surrounding the use of
	genetic information could reduce demand for our products.
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Genetic testing has raised ethical issues regarding privacy
	and the appropriate uses of the resulting information. For these reasons, governmental authorities may call for limits on or regulation
	of the use of genetic testing or prohibit testing for genetic predisposition
</P>
<!-- FIELD: PAGE; SEQUENCE: 26 -->
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 6PT; PADDING-BOTTOM: 12PT; BORDER-BOTTOM: SILVER 4PX SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	25
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage27"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 10PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: LEFT; WIDTH: 100%">
<PAGE>
</PAGE>
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	to certain conditions, particularly for those that
	have no known cure. Similarly, such concerns may lead individuals to refuse to use genetics tests even if permissible. Any of these
	scenarios could reduce the potential markets for our molecular diagnostic products, which could have a material adverse effect
	on our business, financial condition and results of operations.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	We depend on distributors and contract manufacturers and
	suppliers for materials that could impair our ability to manufacture or distribute our products.
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Our Life Sciences segment manufactures and distributes our own
	brand products and the products of third party manufacturers and suppliers. Distributors also sell our branded products. To the
	extent we are unable to maintain or replace a distributor in a reasonable time period, or on commercially reasonable terms, if
	at all, our operations could be disrupted.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Outside distributors, suppliers and contract manufacturers provide
	key finished goods, components and raw materials used in the sale and manufacture of our products. Although we believe that alternative
	sources for components and raw materials are available, any supply interruption in a limited or sole source component or raw material
	would harm our ability to manufacture our products until a new source of supply is identified and qualified. In addition, an uncorrected
	defect or supplier&rsquo;s variation in a component or raw material, either unknown to us or incompatible with our manufacturing
	process, could harm our ability to manufacture products. We might not be able to find a sufficient alternative supplier in a reasonable
	time period, or on commercially reasonable terms, if at all. If we fail to obtain a supplier for the components of our products,
	our operations could be disrupted.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	We use hazardous materials in our business. Any claims relating
	to improper handling, storage or disposal of these materials could be costly and time-consuming.
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Our manufacturing, clinical laboratory and research and development
	processes involve the storage, use and disposal of hazardous substances, including hazardous chemicals, biological hazardous materials
	and radioactive compounds. We are subject to governmental regulations governing the use, manufacture, storage, handling and disposal
	of materials and waste products. Although we believe that our safety and environmental management practices and procedures for
	handling and disposing of these hazardous materials are in accordance with good industry practice and comply with applicable laws,
	permits, licenses and regulations, the risk of accidental environmental or human contamination or injury from the release or exposure
	of hazardous materials cannot be completely eliminated. In the event of an accident, we could be held liable for any damages that
	result, including environmental clean-up or decontamination costs, and any such liability could exceed the limits of, or fall outside
	the coverage of, our insurance.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	We may not be able to maintain insurance on acceptable terms,
	or at all. We could be required to incur significant costs to comply with current or future environmental and public and workplace
	safety and health laws and regulations.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	We are required to expend significant resources for research
	and development for our products in development and these products may not be developed successfully. Failure to successfully develop
	these products may prevent us from earning a return on our research and development expenditures.
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	The products we are developing are at various stages of development
	and clinical evaluations and may require further technical development and investment to determine whether commercial application
	is practicable. There can be no assurance that our efforts will result in products with valuable commercial applications. Our cash
	requirements may vary materially from current estimates because of results of our research and development programs, competitive
	and technological advances and other factors. In any event, we will require substantial funds to conduct development activities
	and pre-clinical and clinical trials, apply for regulatory approvals and commercialize products, if any, that are developed.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	We do not have any commitments or arrangements to obtain any
	additional financing and there is no assurance that required financing will be available to us on acceptable terms, if at all.
	Even if we spend substantial amounts on research and development, our potential products may not be developed successfully.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	If our product candidates on which we have expended significant
	amounts for research and development are not commercialized, we will not earn a return on our research and development expenditures,
	which may harm our business.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
<I>
	Risks relating to our Intellectual Property and Regulatory
	Approval
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	Protecting our proprietary rights is difficult and costly.
	If we fail to adequately protect or enforce our proprietary rights, we could lose potential revenue from licensing and royalties.
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Our potential revenue and success depends in large part on our
	ability to obtain, maintain and enforce our patents. Our ability to commercialize any product successfully will largely depend
	on our ability to obtain and maintain patents of sufficient scope to prevent
</P>
<!-- FIELD: PAGE; SEQUENCE: 27 -->
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 6PT; PADDING-BOTTOM: 12PT; BORDER-BOTTOM: SILVER 4PX SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	26
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage28"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 10PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: LEFT; WIDTH: 100%">
<PAGE>
</PAGE>
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	third parties from developing similar or competitive
	products. In the absence of patent protection, competitors may impact our business by developing and marketing substantially equivalent
	products and technology.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Patent disputes are frequent and can preclude the commercialization
	of products. We have in the past been, are currently, and may in the future be, involved in material patent litigation, such as
	the matters discussed under &ldquo;Part I - Item 3. Legal Proceedings&rdquo; in this report. Patent protection litigation is time-consuming
	and we have incurred and anticipate continuing to incur significant legal costs. In addition, an adverse decision could force us
	to either obtain third-party licenses at a material cost or cease using the technology or product in dispute.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	We have filed applications for United States and foreign patents
	covering certain aspects of our technology, but there is no assurance that pending patents will issue or as to the degree of protection
	which any issued patent might afford.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	Lawsuits, including patent infringements, in the biotechnology
	industry are not uncommon. If we become involved in any significant litigation, we would suffer as a result of the diversion of
	our management&rsquo;s attention, the expense of litigation and any judgments against us.
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	In addition to intellectual property litigation for infringement,
	other substantial, complex or extended litigation could result in large expenditures by us and distraction of our management. Patent
	litigation is time-consuming and costly in its own right and could subject us to significant liabilities to third parties. In addition,
	an adverse decision could force us to either obtain third-party licenses at a material cost or cease using the technology or product
	in dispute. In addition, lawsuits by employees, stockholders, collaborators or distributors could be very costly and substantially
	disrupt our business. Disputes from time to time with companies or individuals are not uncommon in the biotechnology industry,
	and we cannot assure you that we will always be able to resolve them out of court.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	We also utilize certain unpatented proprietary technology and
	no assurance can be given that others will not independently develop substantially equivalent proprietary technology, that such
	proprietary technology will not be disclosed or that we can meaningfully protect our rights to such proprietary technology.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	Our business is subject to governmental
	laws and regulations. We may be unable to obtain or maintain regulatory approvals for our products, which could reduce our revenue
	or prevent us from earning a return on our research and development expenditures.
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Our research, preclinical development, clinical trials, product
	manufacturing and marketing are subject to regulation by the FDA and similar health authorities in foreign countries. FDA approval
	is required for our products, as well as the manufacturing processes and facilities, if any, used to produce our products that
	may be sold in the United States. The process of obtaining approvals from the FDA is costly, time consuming and often subject to
	unanticipated delays. Even if regulatory approval is granted, such approval may include significant limitations on indicated uses
	for which any products could be marketed. Further, even if such regulatory approvals are obtained, a marketed product and its manufacturer
	are subject to continued review, and later discovery of previously unknown problems may result in restrictions on such product
	or manufacturer, including withdrawal of the product from the market.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	New government regulations in the United States or foreign countries
	also may be established that could delay or prevent regulatory approval of our products under development. Further, because gene
	therapy is a relatively new technology and has not been extensively tested in humans, the regulatory requirements governing gene
	therapy products are uncertain and may be subject to substantial further review by various regulatory authorities in the United
	States and abroad. This uncertainty may result in extensive delays in initiating clinical trials and in the regulatory approval
	process. Our failure to obtain regulatory approval of our proposed products, processes or facilities could have a material adverse
	effect on our business, financial condition and results of operations. The proposed products under development may also be subject
	to certain other federal, state and local government regulations, including, but not limited to, the Federal Food, Drug and Cosmetic
	Act, the Environmental Protection Act, and Occupational Safety and Health Act, and state, local and foreign counterparts to certain
	of such acts.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	In November 2013 the FDA issued a Guidance document entitled
	&ldquo;Distribution of
<I>
	In Vitro
</I>
	Diagnostic Products Labeled for Research Use Only or Investigational Use Only,&rdquo; or
	the RUO Guidance, which highlights the FDA&rsquo;s interpretation that distribution of RUO products with any labeling, advertising
	or promotion that suggests that clinical laboratories can validate the test through their own procedures and subsequently offer
	it for clinical diagnostic use as an LDT is in conflict with RUO status. The RUO Guidance further articulates the FDA&rsquo;s position
	that any assistance offered in performing clinical validation or verification, or similar specialized technical support, to clinical
	laboratories, is in conflict with RUO status. More recently, on October 3, 2014, the FDA announced the availability of a draft
	guidance entitled &ldquo;Framework for Regulatory Oversight of Laboratory-Developed Tests,&rdquo; a risk-based oversight framework
	for LDTs. If the draft guidance is finalized as presently written, such oversight framework includes a premarket review for higher-risk
	LDTs, such as those that have the same intended use as an FDA-approved or cleared companion diagnostic currently on the market,
	as well as other high risk and moderate risk LDTs over time. As a result of the draft guidance, we may be required to seek clearance
	or approval to offer our tests for clinical use earlier than we otherwise might have done. If we engage in any activities that
</P>
<!-- FIELD: PAGE; SEQUENCE: 28 -->
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 6PT; PADDING-BOTTOM: 12PT; BORDER-BOTTOM: SILVER 4PX SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	27
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage29"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 10PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: LEFT; WIDTH: 100%">
<PAGE>
</PAGE>
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	are in conflict with the RUO status held by some of the tests that we sell or intend to sell, we may be subject to immediate, severe
	and broad FDA enforcement action that would adversely affect our ability to continue operations. Accordingly, if the FDA finds
	that we are distributing our RUO products in a manner that is inconsistent with its guidance, we may be forced to stop distribution
	of our RUO tests until we are in compliance, which, would reduce our revenue, increase our costs and adversely affect our business,
	prospects, results of operations and financial condition.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	We cannot be sure that we can obtain necessary regulatory approvals
	on a timely basis, if at all, for any of the products we are developing or manufacturing or that we can maintain necessary regulatory
	approvals for our existing products, and all of the following could have a material adverse effect on our business:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 3%">
<FONT STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	&bull;
</FONT>
</TD>
<TD STYLE="WIDTH: 97%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	significant delays in obtaining or failing to obtain required approvals;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	loss of, or changes to, previously obtained approvals;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	failure to comply with existing or future regulatory requirements and;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	changes to manufacturing processes, manufacturing process standards or Good Manufacturing Practices following approval or changing interpretations of these factors.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	Adverse perception and increased regulatory scrutiny of gene
	medicine and genetic research might limit our ability to conduct our business.
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Ethical, social and legal concerns about gene medicine, genetic
	testing and genetic research could result in additional regulations restricting or prohibiting the technologies we or our collaborators
	may use. Recently, gene medicine studies have come under increasing scrutiny, which has delayed on-going and could delay future
	clinical trials and regulatory approvals. Federal and state agencies, congressional committees and foreign governments have expressed
	interest in further regulating biotechnology. More restrictive regulations or claims that our products are unsafe or pose a hazard
	could prevent us from commercializing any products.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
<I>
	Financial Risks
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	With the exception of 2016, we have experienced significant
	losses in our previous five fiscal years and quarter to quarter over such periods and our losses have resulted in the use of cash
	in operations. If such losses and cash uses continue, the value of your investment could decline significantly.
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Although for fiscal year 2016, we reported net income of $45.3
	million, we incurred net losses of $2.3 million, and $10.0 million for the fiscal years ended July 31, 2015 and 2014, respectively.
	If our revenues do not increase, or if our operating expenses exceed expectations or cannot be reduced, we will continue to suffer
	substantial losses and use cash in operations which could have an adverse effect on our business and adversely affect your investment
	in our Company.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	We may need additional capital to fund growth, which may
	not be available on acceptable terms or at all, and could result in our business plan being limited and our business being harmed.
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Our ability to increase revenue and improve profitability and
	liquidity will depend in part on our ability to grow the Enzo Life Science business with higher margin products and increase our
	market share and continue to grow the Enzo Clinical Lab business with new tests with higher reimbursements and increase our service
	volume which may require significant additional capital that may not be available to us. We may need additional financing due to
	future developments, changes in our business plan or failure of our current business plan to succeed, which could result from increased
	marketing, distribution or research and development costs. Our actual funding requirements could vary materially from our current
	estimates. If additional financing is needed, we may not be able to raise sufficient funds on favourable terms or at all. If we
	issue common stock or securities convertible into common stock in the future, such issuance will result in the then-existing stockholders
	sustaining dilution to their relative proportion of our outstanding equity. If we fail to obtain any necessary financing on a timely
	basis, then our ability to execute our current business plan may be limited, and our business, liquidity and financial condition
	could be harmed.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	We may incur impairment charges on our goodwill and intangibles
	which would reduce our earnings.
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	We are subject to Statement of Financial Accounting Standards
	ASC 350, &ldquo;Intangibles - Goodwill and Other (&ldquo;ASC 350&rdquo;) which requires that goodwill and other intangible assets
	that have an indefinite life be tested at least annually for impairment. Goodwill and other intangible assets with indefinite lives
	must also be tested for impairment between the annual tests if a triggering event occurs that would likely reduce the fair value
	of the asset below its carrying amount.
</P>
<!-- FIELD: PAGE; SEQUENCE: 29 -->
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 6PT; PADDING-BOTTOM: 12PT; BORDER-BOTTOM: SILVER 4PX SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	28
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage30"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 10PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: LEFT; WIDTH: 100%">
<PAGE>
</PAGE>
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	As of July 31, 2016 and 2015, goodwill and intangible assets
	represented approximately 11% and 20%, respectively, of our total assets. If we determine that there has been impairment, our financial
	results for the relevant period would be reduced by the amount of the impairment, net of tax effects, if any. The Company has no
	intangible assets with indefinite lives.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
<I>
	Risks relating to our Clinical Labs segment
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	Our clinical laboratory business is subject to extensive
	government regulation and our loss of any required certifications or licenses could require us to cease operating this part of
	our business, which would reduce our revenue and injure our reputation.
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The clinical
	laboratory industry is subject to significant governmental regulation at the Federal, state and local levels. Under the Clinical
	Laboratory Improvement Act of 1967 and the Clinical Laboratory Improvement Amendments of 1988 (collectively, as amended, &ldquo;CLIA&rdquo;)
	virtually all clinical laboratories, including ours, must be certified by the Federal government. Many clinical laboratories also
	must meet other governmental standards, undergo proficiency testing and are subject to inspection. Certifications or licenses are
	also required by various state and local laws. The failure of our clinical laboratory to obtain or maintain such certifications
	or licenses under these laws could interrupt our ability to operate our clinical laboratory business and injure our reputation.
</FONT>
<FONT STYLE="FONT-FAMILY: INHERIT,SERIF">
	The Protecting Access to Medicare Act (&ldquo;PAMA&rdquo;) of 2014 is impacting
	the clinical laboratory testing industry. Key parts of this legislation include provisions that provide for the establishment of
	an advisory panel and a market-based process to rebase the clinical laboratory fee schedule, developing a new fee schedule and
	limiting reductions in that fee schedule. If this process does not recognize the value that clinical laboratory testing brings
	to the healthcare system, our business can be materially adversely impacted.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	Reimbursements from third-party payers, upon which our clinical
	laboratory business is dependent, are subject to inconsistent rates and coverage and legislative reform that are beyond our control.
	This inconsistency and any reform that decreases coverage and rates could reduce our earnings and harm our business.
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Our clinical laboratory business is primarily dependent upon
	reimbursement from third-party payers, such as Medicaid, Medicare (which principally serves patients 65 and older) and commercial
	insurers. We are subject to variances in reimbursement rates among different third-party payers, as well as constant renegotiation
	of those reimbursement rates. Government and non-government payers have in the past sought, and continue to seek, to reduce and
	limit utilization and reimbursement of healthcare services, including in the area of genetic testing. We also are subject to audit
	by Medicare and the commercial insurers, which can result in the return of payments made to us under these programs. These variances
	in reimbursement rates and audit results could reduce our margins and thus our earnings.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	The health care industry continues to undergo significant change
	as third-party payers&rsquo; increase their efforts to control the cost, utilization and delivery of health care services. In an
	effort to address the problem of increasing health care costs, legislation has been proposed or enacted at both the Federal and
	state levels to regulate health care delivery in general and clinical laboratories in particular. Some of the proposals include
	managed competition, global budgeting and price controls. Changes that decrease reimbursement rates or coverage, or increase administrative
	burdens on billing third-party payers could reduce our revenues and increase our expenses.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Since each payer makes its own decision as to whether to establish
	a policy or enter into a contract to cover our tests, as well as the amount it will reimburse for a test, seeking these approvals
	is a time-consuming and costly process. In addition, the determination by a payer to cover and the amount it will reimburse for
	our tests will likely be made on an indication by indication basis. To date, we have obtained policy-level reimbursement approval
	or contractual reimbursement for some indications for our test from a small number of commercial third-party payers, and have not
	obtained coverage from Medicare or any state Medicaid program. Further, we believe that establishing adequate reimbursement from
	Medicare is an important factor in gaining adoption from healthcare providers. Our claims for reimbursement from commercial payers
	may be denied upon submission, and we must appeal the claims. The appeals process is time consuming and expensive, and may not
	result in payment. In cases where there is not a contracted rate for reimbursement, there is typically a greater co-insurance or
	co-payment requirement from the patient which may result in further delay or decreased likelihood of collection.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	We expect to continue to focus substantial resources on increasing
	adoption of, and coverage and reimbursement for, our current tests and any future tests we may develop. We believe it may take
	several years to achieve coverage and adequate contracted reimbursement with a majority of third-party payers. However, we cannot
	predict whether, under what circumstances, or at what payment levels payers will reimburse for our tests. If we fail to establish
	and maintain broad adoption of, and coverage and reimbursement for, our tests, our ability to generate revenue could be harmed
	and our future prospects and our business could suffer.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	U.S. healthcare reform legislation may result in significant
	change and our business could be adversely impacted if we fail to adapt.
</B>
</P>
<!-- FIELD: PAGE; SEQUENCE: 30 -->
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 6PT; PADDING-BOTTOM: 12PT; BORDER-BOTTOM: SILVER 4PX SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	29
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage31"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 10PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: LEFT; WIDTH: 100%">
<PAGE>
</PAGE>
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Government oversight of and attention to the healthcare industry
	in the United States is significant and increasing. Under the Patient Protections and affordable Care Act, expansion in the pool
	of covered lives may expand the market for clinical diagnostic testing while at the same time, various policies aimed at reducing
	costs or bundling care may reduce the rates paid for such services&rsquo; the net impact of these factors on the market for our
	tests is not clear. In April 2014, Congress passed the Protecting Access to Medicare Act of 2014, which include substantial changes
	to the way in which clinical laboratory services will be paid under Medicare. Beginning in 2017, Medicare payments for clinical
	laboratory services will be paid based upon private payer rates reported by clinical laboratories across the US replacing the current
	system, which is based upon fee schedules derived from historical charges for test from approximately 30 years ago. The impact
	of the new payment system on rates for tests we perform or our customers&rsquo; tests that may use our products is not clear at
	this time.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	The Patient Protection and Affordable Care Act also imposes
	an excise tax on the seller for the sale of certain medical devices in the United States, including those purchased and used by
	laboratories, beginning in 2013. The legislation also establishes the Independent Payment Advisory Board, which will be responsible,
	beginning in 2014, annually to submit proposals aimed at reducing Medicare cost growth while preserving quality. If the projected
	growth in per capita Medicare costs exceeds a specified target level, the IPAB must submit proposals to reduce or eliminate the
	difference. For calendar years 2015 through 2019, the target growth rate is the projected average of the increases in the Consumer
	Price Index and the medical care expenditure category of the Consumer Price Index; for 2020 and thereafter, the target growth rate
	is the rate of increase in gross domestic product per capita plus one percentage point. If it is necessary for the IPAB to submit
	proposals, they will automatically be implemented unless Congress enacts alternative proposals that achieve the same savings targets.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Further, the legislation calls for a Center for Medicare and
	Medicaid Innovation that will examine alternative payment methodologies and conduct demonstration programs. The legislation provides
	for extensive health insurance reforms, including the elimination of pre-existing condition exclusions and other limitations on
	coverage, fixed percentages on medical loss ratios, expansion in Medicaid and other programs, employer mandates, individual mandates,
	creation of state and regional health insurance exchanges, and tax subsidies for individuals to help cover the cost of individual
	insurance coverage. The legislation also permits the establishment of accountable care organizations, a new healthcare delivery
	model. While the ultimate impact of the legislation on the healthcare industry is unknown, it is likely to be extensive and may
	result in significant change. Our failure to adapt to these changes could have a material adverse effect on our business.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	Changes in provider mix, including continued growth in capitated
	managed-cost health care and changes in certain third party provider agreements could have a material adverse impact on the Company&rsquo;s
	net revenues and profitability.
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Certain third party provider companies have adopted national
	and regional programs which include multiple managed-care reimbursement models. If the Company is unable to participate in these
	programs or if the Company would lose a material contract, it could have a material adverse impact on the Company&rsquo;s net revenues
	and profitability.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	The number of individuals covered under managed care contracts
	or other similar arrangements has grown over the past several years and may continue to grow in the future. In addition, Medicare
	and other government healthcare programs may continue to shift to managed care. Entities providing managed care coverage have reduced
	payments for medical services, including clinical laboratory services, in numerous ways such as entering into arrangements under
	which payments to a service provider are capitated, limiting testing to specified procedures, denying payment for services performed
	without prior authorization and refusing to increase fees for specified services. These trends reduce our revenues and limit our
	ability to pass cost increases to our customers. Also, if these or other managed care organizations do not select us as a participating
	provider, we may lose some or all of that business, which could have an adverse effect on our business, financial condition and
	results of operations.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	Because of competitive pressures, impacts of the economy
	on patient traffic at our customers and the complexity and expense of the billing process in our clinical laboratory business,
	we must obtain new customers while maintaining existing customers to grow our business.
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Intense competition in the clinical laboratory business, increasing
	administrative burdens upon the reimbursement process, reduced patient traffic, and reduced coverage and payments by insurers make
	it necessary for us to increase our volume of laboratory services. To do so, we must obtain new customers while retaining existing
	customers.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Our failure to attract new customers or the loss of existing
	customers or a reduction in business from those customers could significantly reduce our revenues and impede our ability to grow.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	Compliance with Medicare administrative policies, including
	those pertaining to certain automated blood chemistry profiles, may reduce the reimbursements we receive.
</B>
</P>
<!-- FIELD: PAGE; SEQUENCE: 31 -->
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 6PT; PADDING-BOTTOM: 12PT; BORDER-BOTTOM: SILVER 4PX SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	30
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage32"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 10PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: LEFT; WIDTH: 100%">
<PAGE>
</PAGE>
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Containment of health care costs, including reimbursement for
	clinical laboratory services, has been a focus of on-going governmental activity. Clinical laboratories must bill Medicare directly
	for the services provided to Medicare beneficiaries and may only collect the amounts permitted under this fee schedule. Reimbursement
	to clinical laboratories under the Medicare Fee Schedule has been steadily declining since its inception. Because a significant
	portion of our costs is fixed, these Medicare reimbursement reductions and changes have a direct adverse effect on our net earnings
	and cash flows.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	The development of new, more cost-effective tests that can
	be performed by our customers or by patients, and the continued internalization of testing by hospitals or physicians, could negatively
	impact our testing volume and revenues.
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	The diagnostic industry is faced with changing technology and
	new product introductions, including technology that enables more convenient or cost-effective testing. Some of our competitors
	also may offer testing to be performed outside of a commercial clinical laboratory, such as point-of-care testing that can be performed
	by physicians in their offices; complex testing that can be performed by hospitals in their own laboratories; and home testing
	that can be carried out without requiring the services of outside providers. Advances in technology also may lead to the need for
	less frequent testing. Further, diagnostic tests approved or cleared by the FDA for home use are automatically deemed to be &ldquo;waived&rdquo;
	tests under CLIA and may be performed by patients in their homes; test kit manufacturers could seek to increase sales to patients
	of such test kits. Development of such technology and its use by our customers would reduce the demand for our laboratory-based
	testing services and negatively impact our revenues.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	Our business could be harmed from the loss or suspension
	of a license or imposition of a fine or penalties under, or future changes in, or changing interpretations of, CLIA or state laboratory
	licensing laws to which we are subject.
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	The clinical laboratory testing industry is subject to extensive
	federal and state regulation, and many of these statutes and regulations have not been interpreted by the courts. The Clinical
	Laboratory Improvement Amendments of 1988, or CLIA, are federal regulatory standards that apply to virtually all clinical laboratories
	(regardless of the location, size or type of laboratory), including those operated by physicians in their offices, by requiring
	that they be certified by the federal government or by a federally approved accreditation agency. CLIA does not pre-empt state
	law, which in some cases may be more stringent than federal law and require additional personnel qualifications, quality control,
	record maintenance and proficiency testing. The sanction for failure to comply with CLIA and state requirements may be suspension,
	revocation or limitation of a laboratory&rsquo;s CLIA certificate, which is necessary to conduct business, as well as significant
	fines and/or criminal penalties. Several states have similar laws and we may be subject to similar penalties.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	We cannot assure that applicable statutes and regulations will
	not be interpreted or applied by a prosecutorial, regulatory or judicial authority in a manner that would adversely affect our
	business. Potential sanctions for violation of these statutes and regulations include significant fines and the suspension or loss
	of various licenses, certificates and authorizations, which could have a material adverse effect on our business. In addition,
	compliance with future legislation could impose additional requirements on us, which may be costly.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	Regulations requiring the use of &ldquo;standard transactions&rdquo;
	for healthcare services may negatively impact our profitability and cash flows.
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	The administrative simplification provisions of the Health Insurance
	Portability and Accountability Act of 1996 and its implementing regulations, or HIPAA, were designed to improve the efficiency
	and effectiveness of the healthcare system by facilitating the electronic exchange of information in certain financial and administrative
	transactions while protecting the privacy and security of the information exchanged. The administrative simplification provisions
	address standards for electronic transactions, security regulations and privacy regulations.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	The HIPAA transaction standards are complex, and subject to
	differences in interpretation by payers. For instance, some payers may interpret the standards to require us to provide certain
	types of information, including demographic information not usually provided to us by physicians. While most of our transactions
	are submitted and/or received in ANSI standard format, inconsistent application of transaction standards by some remaining payers
	or our inability to obtain certain billing information not usually provided to us by physicians could increase our costs and the
	complexity of billing. In addition, new requirements for additional standard transactions, such as claims attachments, could prove
	technically difficult, time-consuming or expensive to implement. We are working closely with our payers to establish acceptable
	protocols for claims submissions and with our industry trade association and an industry coalition to present issues and problems
	as they arise to the appropriate regulators and standards setting organizations.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	Our business could be adversely impacted by CMS&rsquo; adoption
	of the new coding set for diagnoses.
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	CMS has adopted a new coding set for diagnosis, commonly known
	as ICD-10, which significantly expands the coding set for diagnoses. The new coding set was required to be implemented by October
	1, 2015. We must adequately implement the new coding set. In addition, physicians may fail to provide appropriate codes for desired
	tests; historically, delays in billing have resulted in increased costs and decreased collection of payment.
</P>
<!-- FIELD: PAGE; SEQUENCE: 32 -->
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 6PT; PADDING-BOTTOM: 12PT; BORDER-BOTTOM: SILVER 4PX SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	31
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage33"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 10PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: LEFT; WIDTH: 100%">
<PAGE>
</PAGE>
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	Compliance with the HIPAA security, privacy and breach notification
	regulations and privacy regulations may increase our costs.
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	The HIPAA privacy and security and breach notification regulations
	establish comprehensive federal standards with respect to the uses and disclosures PHI by Covered Entities. These regulations were
	recently amended by the Health Information Technology for Economic and Clinical Health Act and its implementing regulations, or
	HITECH, to, among other things directly apply to business associates (i.e., individuals or entities who create, receive, maintain
	or transmit PHI on behalf of a Covered Entity in performing functions or activities regulated by HIPAA or who perform certain services,
	other than treatment, on behalf of Covered Entities and receive PHI in order to perform such services) with regard to certain requirements.
	The regulations also specify that business associates include subcontractors that create, receive, maintain or transmit PHI on
	behalf of a business associate. The regulations establish a complex regulatory framework on a variety of subjects, including:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 3%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 3%">
<FONT STYLE="FONT: 10PT WINGDINGS">
	&#167;
</FONT>
</TD>
<TD STYLE="WIDTH: 94%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	the circumstances under which uses and disclosures of PHI are permitted or required without a specific authorization by the patient, including but not limited to treatment purposes, activities to obtain payments for our services, and our healthcare operations activities;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT WINGDINGS">
	&#167;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	a patient&rsquo;s rights to access, amend and receive an accounting of certain disclosures of PHI;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT WINGDINGS">
	&#167;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	requirements to notify individuals if there is a breach of their PHI;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT WINGDINGS">
	&#167;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	the requirements for business associates and the terms of business associate agreements;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT WINGDINGS">
	&#167;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	the content of notices of privacy practices for protected health information and;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT WINGDINGS">
	&#167;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	administrative, technical and physical safeguards required of entities that use or receive PHI.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	We have implemented practices to meet the requirements of the
	HIPAA privacy, security and breach notification regulations, and updated these practices to comply with HITECH. HIPAA establishes
	a &ldquo;floor&rdquo; and does not supersede state laws that are more stringent. Therefore, we are required to comply with federal
	privacy security and breach notification regulations and varying state privacy, security and breach notification laws and regulations.
	In addition, for healthcare data transfers from other countries relating to citizens of those countries, we must comply with the
	laws of those other countries. The federal privacy regulations restrict our ability to use or disclose patient-identifiable laboratory
	data, without patient authorization, for purposes other than payment, treatment, healthcare operations and certain other specified
	disclosures such as public health and governmental oversight of the health care industry. The privacy, security and breach notification
	regulations provide for significant fines and other penalties for wrongful use or disclosure of PHI, including potential civil
	and criminal fines and penalties. Although the HIPAA statute and regulations do not expressly provide for a private right of damages,
	we also could incur damages under state laws to private parties for the wrongful use or disclosure of confidential health information
	or other private personal information.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Compliance with all of the HIPAA regulations, including standard
	transactions, requires on-going resources from all healthcare organizations, not just clinical laboratories. While we believe our
	total costs to comply with HIPAA will not be material to our operations or cash flows, new standard transactions and additional
	customer requirements resulting from different interpretations of the current regulations could impose additional costs on us.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	FDA regulation of laboratory-developed tests, analyte specific
	reagents, or genetic testing could lead to increased costs and delays in introducing new genetic tests.
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	The FDA has regulatory responsibility over instruments, test
	kits, reagents and other devices used to perform diagnostic testing by clinical laboratories. In the past, the FDA has claimed
	regulatory authority over laboratory-developed tests, but has exercised enforcement discretion in not regulating tests performed
	by high complexity CLIA-certified laboratories. However, on July 31, 2014, the FDA issued a 60-day notice to Congress indicating
	that the FDA intends to issue Draft Guidance on the regulation of laboratory-developed tests. In the notice, FDA indicates that
	it intends to end its policy of general enforcement discretion towards laboratory-developed tests, and proposes the implementation
	of a risk-based regulatory framework. Under the proposed framework many laboratory-developed tests would be subject to FDA&rsquo;s
	regulations for medical devices, including registrations and listing premarket review, medical device reports, and quality systems
	regulations. The implementation of this framework would not begin until after a Final Guidance is issued and would occur over a
	nine year period with those tests that FDA considers to be highest risk falling under FDA&rsquo;s review requirements first. On
	September 30, 2014, the FDA issued draft guidelines and announced a 120 day public comment period on its proposal.
</P>
<!-- FIELD: PAGE; SEQUENCE: 33 -->
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 6PT; PADDING-BOTTOM: 12PT; BORDER-BOTTOM: SILVER 4PX SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	32
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage34"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 10PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: LEFT; WIDTH: 100%">
<PAGE>
</PAGE>
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	In December 2000, the HHS Secretary&rsquo;s Advisory Committee
	on Genetic Testing recommended that the FDA be the lead federal agency to regulate genetic testing. In late 2002, a new HHS Secretary&rsquo;s
	Advisory Committee on Genetics, Health and Society, or SACGHS, was appointed to replace the prior Advisory Committee. Ultimately,
	SACGHS decided that it would continue to monitor the progress of the federal agencies in the oversight of genetic technologies,
	but it did not believe that further action was warranted. In the meantime, the FDA is considering revising its regulations on analyte
	specific reagents, which are used in laboratory-developed tests, including laboratory-developed genetic testing. We cannot predict
	whether FDA regulation &ndash; including premarket review requirements &ndash; will apply to the laboratory-developed tests that
	we perform or the tests in which our customers may use our products. FDA interest in or actual regulation of laboratory-developed
	tests or increased regulation of the various medical devices used in laboratory-developed testing could lead to increased regulatory
	burdens and increased costs and delays in introducing new tests, including genetic tests and decreased demand for our products.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	In the past, the clinical laboratory industry has received negative
	publicity. This publicity has led to increased legislation, regulation, and review of industry practices. These factors may adversely
	affect our ability to market our services, require us to change our services and increase the regulatory burdens under which we
	operate, further increasing the costs of doing business and adversely affecting our operating results. If we experience a significant
	disruption in our information technology systems, including our website, or if we fail to implement new systems and software successfully,
	our business could be adversely affected.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	We are subject to federal and state healthcare fraud and
	abuse and other laws and regulations and could face substantial penalties if we are unable to fully comply with such laws.
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	As a provider of clinical laboratory testing services, we are
	subject to extensive and frequently changing federal, state and local laws and regulations governing various aspects of our business.
	For example, we are subject to healthcare fraud and abuse regulation and enforcement by both the federal government and the states
	in which we conduct our business. These healthcare laws and regulations include, for example:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 3%">
</TD>
<TD STYLE="WIDTH: 3%">
<FONT STYLE="FONT-FAMILY: WINGDINGS">
	&#167;
</FONT>
</TD>
<TD STYLE="WIDTH: 94%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	the federal Anti-Kickback Law, which constrains our marketing practices,
	educational programs, pricing policies, and relationships with healthcare providers or other entities, including third-party laboratories,
	by prohibiting, among other things, persons or entities from soliciting, receiving, offering or providing remuneration, directly
	or indirectly, in return for or to induce either the referral of an individual for, or the purchase, lease order or recommendation
	of, any good, facility, item or services for which payment may be made, in whole or in part, under a federal healthcare program
	such as the Medicare and Medicaid programs;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 3%">
</TD>
<TD STYLE="WIDTH: 3%">
<FONT STYLE="FONT-FAMILY: WINGDINGS">
	&#167;
</FONT>
</TD>
<TD STYLE="WIDTH: 94%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	federal civil and criminal false claims laws and civil monetary penalty
	laws, which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims
	for payment from Medicare, Medicaid or other third-party payers that are false or fraudulent, and which may apply to entities like
	us to the extent that our interactions with customers may affect their billing or coding practices;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 3%">
</TD>
<TD STYLE="WIDTH: 3%">
<FONT STYLE="FONT-FAMILY: WINGDINGS">
	&#167;
</FONT>
</TD>
<TD STYLE="WIDTH: 94%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	the federal Health Insurance Portability and Accountability Act of
	1996, as amended, or HIPAA, which imposes certain requirements relating to the privacy, security and transmission of individually
	identifiable health information, and also established federal crimes for knowingly and willfully executing a scheme to defraud
	any healthcare benefit program or making false statements in connection with the delivery of or payment for healthcare benefits,
	items or services, and which imposed certain requirements relating to privacy, security, and transmission of individually identifiable
	health information;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 3%">
</TD>
<TD STYLE="WIDTH: 3%">
<FONT STYLE="FONT-FAMILY: WINGDINGS">
	&#167;
</FONT>
</TD>
<TD STYLE="WIDTH: 94%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	the federal physician self-referral law, commonly known as the Stark
	Law, which prohibits a physician from making a referral to an entity for certain designated health services reimbursed by Medicare
	or Medicaid if the physician (or a member of the physician&rsquo;s family) has a financial relationship with the entity, and which
	also prohibits the submission of any claims for reimbursement for designated health services furnished pursuant to a prohibited
	referral;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 3%">
</TD>
<TD STYLE="WIDTH: 3%">
<FONT STYLE="FONT-FAMILY: WINGDINGS">
	&#167;
</FONT>
</TD>
<TD STYLE="WIDTH: 94%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	the federal Physician Payment Sunshine Act, and its implementing regulations,
	which requires manufacturers of certain drugs, devices, biologics and medical supplies for which payment is available under Medicare,
	Medicaid or the Children&rsquo;s Health Insurance Program (with certain exceptions) to report annually to the United States Department
	of Health and Human Services information related to payments or other transfers of value made to physicians (defined to include
	doctors, dentists, optometrists, podiatrists and chiropractors) and teaching hospitals, as well as ownership and investment interests
	held by physicians and their immediate family members;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 3%">
</TD>
<TD STYLE="WIDTH: 3%">
<FONT STYLE="FONT-FAMILY: WINGDINGS">
	&#167;
</FONT>
</TD>
<TD STYLE="WIDTH: 94%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	federal consumer protection and unfair competition laws, which broadly
	regulate marketplace activities and activities that potentially harm consumers; and
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 3%">
</TD>
<TD STYLE="WIDTH: 3%">
<FONT STYLE="FONT-FAMILY: WINGDINGS">
	&#167;
</FONT>
</TD>
<TD STYLE="WIDTH: 94%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	state law equivalents of each of the above federal laws, such as anti-kickback
	and false claims laws, which may apply to items or services reimbursed by any third-party payer, including commercial insurers
	and state laws governing the privacy and security of health information in certain circumstances, many of which differ from each
	other in significant ways, with differing effects.
</FONT>
</TD>
</TR>
</TABLE>
<!-- FIELD: PAGE; SEQUENCE: 34 -->
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 6PT; PADDING-BOTTOM: 12PT; BORDER-BOTTOM: SILVER 4PX SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	33
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage35"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 10PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: LEFT; WIDTH: 100%">
<PAGE>
</PAGE>
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	We are unable to predict what additional federal or state legislation
	or regulatory initiatives may be enacted in the future regarding our business or the healthcare industry in general, or what effect
	such legislation or regulations may have on us. Federal or state governments may impose additional restrictions or adopt interpretations
	of existing laws that could have an adverse effect on us.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	We incur significant costs in complying with these laws and
	regulations. Because of the breadth of these laws and the narrowness of available statutory and regulatory exemptions, it is possible
	that some of our business activities could be subject to challenge under one or more of such laws. If our operations, or our sales
	techniques or product placement strategies, are found to be in violation of, or to encourage or assist the violation by third parties
	of, any of the laws described above or any other governmental regulations that apply to us, or if we fail to maintain, renew or
	obtain necessary permits, licenses and approvals related to our in-house laboratory, we may be subject to penalties, including
	civil and criminal penalties, damages, fines, exclusion from the Medicare and Medicaid programs, disgorgement, contractual damages,
	reputational harm, diminished profits and future earnings, suspension or revocation of certifications or licenses that are required
	to operate our business, injunctions and other associated remedies, the curtailment or restructuring of our operations, denial
	or withdrawal of product clearances, or private &ldquo;qui tam&rdquo; actions brought by individual whistleblowers in the name
	of the government, any of which could have an adverse effect on our business. If we or others determine that any of our existing
	customer relationships do not comply with applicable laws and regulations, either due to changes in such laws and regulations or
	evolving interpretations of such laws and regulations, we may be required to renegotiate or terminate such relationships. Any penalties,
	damages, fines, exclusions, curtailment or restructuring of our operations could adversely affect our ability to operate our business
	and our financial results. The risk of our being found in violation of these laws is increased by the fact that many of these laws
	are broad and their provisions are open to a variety of interpretations. Any action against us for violation of these laws, even
	if we successfully defend against it, could cause us to incur significant legal expenses and divert our management&rsquo;s attention
	from the operation of our business.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
<I>
	Other risks relating to our business
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	If we fail to maintain or monitor our information systems
	our businesses could be adversely affected.
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	We depend on information systems throughout our Company to control
	our Life Science manufacturing, inventory, distribution and website and the Clinical Lab processes for: processing specimens, managing
	inventory, processing test results and submitting claims, collecting from insurers and patients, responding to inquiries, contributing
	to our overall internal control processes, maintaining records of our property, plant and equipment, and recording and paying amounts
	due vendors and other creditors. If we were to experience a prolonged disruption in our information systems that involve interactions
	with customers and suppliers, it could result in the loss of sales and customers and/or increased costs, which could adversely
	affect our business.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	Cyber security risks and the failure
	to maintain the confidentiality, integrity, and availability of our computer hardware, software, and Internet applications and
	related tools and functions could result in damage to the Company&rsquo;s reputation and/or subject the Company to costs, fines,
	or lawsuits.
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	The integrity and protection of our own data, and that of its
	customers and employees, is critical to the Company&rsquo;s business. The regulatory environment governing information, security
	and privacy laws is increasingly demanding and continues to evolve. Maintaining compliance with applicable security and privacy
	regulations may increase the Company&rsquo;s operating costs and/or adversely impact the Company&rsquo;s ability to market its
	products and services to customers. Although the Company&rsquo;s computer and communications hardware is protected through physical
	and software safeguards, it is still vulnerable to fire, storm, flood, power loss, earthquakes, telecommunications failures, physical
	or software break-ins, software viruses, and similar events. These events could lead to the unauthorized access, disclosure and
	use of non-public information. The techniques used by criminal elements to attack computer systems are sophisticated, change frequently
	and may originate from less regulated and remote areas of the world. As a result, the Company may not be able to address these
	techniques proactively or implement adequate preventative measures. If the Company&rsquo;s computer systems are compromised, it
	could be subject to fines, damages, litigation, and enforcement actions, customers could curtail or cease using its applications,
	and the Company could lose trade secrets, the occurrence of which could harm its business.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	If we fail to attract and retain key personnel, including
	our senior management, our business could be adversely affected.
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Most of our products and services are highly technical in nature.
	In general, only highly qualified and trained scientists and technician personnel have the necessary skills to develop proprietary
	technological products and market our products, support our research and development programs and provide our Clinical Lab services.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	In addition, some of our manufacturing, quality control, safety
	and compliance, information technology and e-commerce related positions are highly technical as well. Further, our sales personnel
	highly trained and are important to retaining and growing our businesses. Our success depends in large part upon our ability to
	identify, hire, retain and motivate highly skilled professionals.
</P>
<!-- FIELD: PAGE; SEQUENCE: 35 -->
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 6PT; PADDING-BOTTOM: 12PT; BORDER-BOTTOM: SILVER 4PX SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	34
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage36"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 10PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: LEFT; WIDTH: 100%">
<PAGE>
</PAGE>
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	We face intense competition for these professionals from our
	competitors, customers, marketing partners and other companies throughout the industries in which we compete. Since our inception
	we have successfully recruited and hired qualified key employees. Any failure on our part to hire, train, and retain a sufficient
	number of qualified professionals would seriously damage our business.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	We depend heavily on the services of our senior management.
	We believe that our future success depends on the continued services of such management. Our business may be harmed by the loss
	of a significant number of our senior management in a short period of time.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	The insurance we purchase to cover our potential business
	risk may be inadequate.
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Although we believe that our present insurance coverage is sufficient
	to cover our current estimated exposures, we cannot assure that we will not incur losses or liabilities in excess of our policy
	limits. In addition, although we believe that will be able to continue to obtain adequate coverage, we cannot assure that we will
	be able to do so at acceptable costs.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
<I>
	Risks relating to our international operations
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	Foreign currency exchange rate fluctuations may adversely
	affect our business.
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Since we operate as a multinational corporation that sells and
	sources products in many different countries, changes in exchange rates could in the future, adversely affect our cash flows and
	results of operations.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Furthermore, reported sales and purchases made in non-U.S. currencies
	by our international businesses, when translated into U.S. dollars for financial reporting purposes, fluctuate due to exchange
	rate movement. Due to the number of currencies involved, the variability of currency exposures and the potential volatility of
	currency exchange rates, we cannot predict the effect of exchange rate fluctuations on future sales and operating results.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	We are subject to economic, political and other risks associated
	with our significant international business, which could adversely affect our financial results.
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	We operate internationally primarily through wholly-owned subsidiaries
	located in North America and Europe. Revenues outside the United States were approximately 9% of total revenues in fiscal 2016.
	Our sales and earnings could be adversely affected by a variety of factors resulting from our international operations, including
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 3%">
<FONT STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	&bull;
</FONT>
</TD>
<TD STYLE="WIDTH: 97%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	future fluctuations in exchange rates;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	complex regulatory requirements and changes in those requirements;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	trade protection measures and import or export licensing requirements;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	multiple jurisdictions and differing tax laws, as well as changes in those laws;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	restrictions on our ability to repatriate investments and earnings from foreign operations;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	changes in the political or economic conditions in a country or region, particularly in developing or emerging markets;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	changes in shipping costs; and
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	difficulties in collecting on accounts receivable.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	If any of these risks materialize, we could face substantial
	increases in costs, the reduction of profit and the inability to do business.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	As we expand our commercialization activities outside of
	the United States, we will be subject to an increased risk of inadvertently conducting activities in a manner that violates the
	U.S. Foreign Corrupt Practices Act and similar laws. If that occurs, we may be subject to civil or criminal penalties which could
	have a material adverse effect on our business, financial condition, results of operations and growth prospects.
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	We are subject to the U.S. Foreign Corrupt Practices Act (&ldquo;FCPA&rdquo;),
	which prohibits corporations and individuals from paying, offering to pay, or authorizing the payment of anything of value to any
	foreign government official, government staff member, political party, or political candidate in an attempt to obtain or retain
	business or to otherwise influence a person working in an official
</P>
<!-- FIELD: PAGE; SEQUENCE: 36 -->
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 6PT; PADDING-BOTTOM: 12PT; BORDER-BOTTOM: SILVER 4PX SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	35
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage37"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 10PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: LEFT; WIDTH: 100%">
<PAGE>
</PAGE>
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	capacity. We are also subject to the UK Anti-Bribery Act, which
	prohibits both domestic and international bribery, as well as bribery across both public and private sectors.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	In the course of establishing and expanding our commercial operations
	and seeking regulatory approvals outside of the United States, we will need to establish and expand business relationships with
	various third parties and we will interact more frequently with foreign officials, including regulatory authorities. Expanded programs
	to maintain compliance with such laws will be costly and may not be effective. Any interactions with any such parties or individuals
	where compensation is provided that are found to be in violation of such laws could result in substantial fines and penalties and
	could materially harm our business. Furthermore, any finding of a violation under one country&rsquo;s laws may increase the likelihood
	that we will be prosecuted and be found to have violated another country&rsquo;s laws. If our business practices outside the United
	States are found to be in violation of the FCPA, UK Anti-Bribery Act or other similar law, we may be subject to significant civil
	and criminal penalties which could have a material adverse effect on our financial condition and results of operations.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
<I>
	Risks Relating to our Common Stock
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	Our stock price has been volatile, which could result in
	substantial losses for investors.
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Our common stock is quoted on the New York Stock Exchange, and
	there has been historical volatility in the market price of our common stock. The trading price of our common stock has been, and
	is likely to continue to be, subject to significant fluctuations due to a variety of factors, including:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 3%">
<FONT STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	&bull;
</FONT>
</TD>
<TD STYLE="WIDTH: 97%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	fluctuations in our quarterly operating and earnings per share results;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	the gain or loss of significant contracts;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	the carrying value of our goodwill and intangible assets;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	loss of key personnel;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	announcements of technological innovations or new products by us or our competitors;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	delays in the development and introduction of new products;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	legislative or regulatory changes;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	general trends in the industries we operate;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	recommendations and/or changes in estimates by equity and market research analysts;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	biological or medical discoveries;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	disputes and/or developments concerning intellectual property, including patents and litigation matters;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	public concern as to the safety of new technologies;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	sales of common stock of existing holders;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	securities class action or other litigation;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	developments in our relationships with current or future customers and suppliers and;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	general economic conditions, both in the United States and worldwide.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	In addition, the stock market in general has experienced extreme
	price and volume fluctuations that have affected the market price of our common stock, as well as the stock of many companies in
	our industries. Often, price fluctuations are unrelated to operating performance of the specific companies whose stock is affected.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	In the past, following periods of volatility in the market price
	of a company&rsquo;s stock, securities class action litigation has occurred against the issuing company. If we were subject to
	this type of litigation in the future, we could incur substantial costs and a diversion
</P>
<!-- FIELD: PAGE; SEQUENCE: 37 -->
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 6PT; PADDING-BOTTOM: 12PT; BORDER-BOTTOM: SILVER 4PX SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	36
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage38"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 10PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: LEFT; WIDTH: 100%">
<PAGE>
</PAGE>
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	of our management&rsquo;s attention and
	resources, each of which could have a material adverse effect on our revenue and earnings. Any adverse determination in this type
	of litigation could also subject us to significant liabilities.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	Because we do not intend to pay cash dividends on our common
	stock, an investor in our common stock will benefit only if it appreciates in value.
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	We currently intend to retain our retained earnings and future
	earnings, if any, to finance the expansion of our business and do not expect to pay any cash dividends on our common stock in the
	foreseeable future. As a result, the success of an investment in our common stock will depend entirely upon any future appreciation.
	There is no guarantee that our common stock will appreciate in value or even maintain the price at which investors purchased their
	shares.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	It may be difficult for a third party to acquire us, which
	could inhibit stockholders from realizing a premium on their stock price.
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	We are subject to the New York anti-takeover laws regulating
	corporate takeovers. These anti-takeover laws prohibit certain business combinations between a New York corporation and any &ldquo;interested
	shareholder&rdquo; (generally, the beneficial owner of 20% or more of the corporation&rsquo;s voting shares) for five years following
	the time that the shareholder became an interested shareholder, unless the corporation&rsquo;s board of directors approved the
	transaction prior to the interested shareholder becoming interested.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Our certificate of incorporation, as amended, and by-laws contain
	provisions that could have the effect of delaying, deferring or preventing a change in control of us that stockholders may consider
	favorable or beneficial. These provisions could discourage proxy contests and make it more difficult for stockholders to elect
	directors and take other corporate actions. These provisions could also limit the price that investors might be willing to pay
	in the future for shares of our common stock. These provisions include:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 3%">
<FONT STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	&bull;
</FONT>
</TD>
<TD STYLE="WIDTH: 97%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	a staggered board of directors, so that it would take three successive annual meetings to replace all directors; and
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	advance notice requirements for the submission by stockholders of nominations for election to the board of directors and for proposing matters that can be acted upon by stockholders at a meeting.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	Future sales of shares of our common stock or the issuance
	of securities senior to our common stock could adversely affect the trading price of our common stock and our ability to raise
	funds in new equity offerings.
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	We are not restricted from issuing additional common stock,
	preferred stock or securities convertible into or exchangeable for common stock. Future sales of a substantial number of our shares
	of common stock or equity-related securities in the public market or privately, or the perception that such sales could occur,
	could adversely affect prevailing trading prices of our common stock, and could impair our ability to raise capital through future
	offerings of equity or equity-related securities. No prediction can be made as to the effect, if any, that future sales of shares
	of common stock or the availability of shares of common stock for future sale will have on the trading price of our common stock.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
<I>
	Risk relating to our debt
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	Our use of leverage may expose us to substantial risks, including
	interest rate risk.
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	As of July 31, 2016 and 2015, we had $1.6 million and $3.0 million,
	respectively, in borrowings under our Revolving Loan and Security Agreement (&ldquo;credit agreement&rdquo;), which expires December
	7, 2016. In addition, we may incur additional indebtedness in the future. Accordingly, we are exposed to the typical risks associated
	with the use of leverage. Increased leverage makes it more difficult for us to withstand adverse economic conditions or business
	plan variances, to take advantage of new business opportunities, or to make necessary capital expenditures. The existing credit
	agreement contains restrictive covenant restrictions that limit our ability to conduct our business, including restrictions on
	our ability to incur additional indebtedness. Our ability to maintain our compliance with these covenants is dependent on our financial
	performance, which is influenced by a number of factors. Violation of any of these covenants would result in an event of default
	under the credit agreement. Upon the occurrence of an event of default that is not cured or waived, the lender would have the ability
	to accelerate the repayment of all amounts then outstanding under the credit agreement. In the event of a default, and during the
	continuance of an event of default under the credit agreement, we would no longer have the right to borrow additional funds under
	the credit agreement. Under these circumstances, we may not be able to pay our debt or borrow sufficient funds to refinance it
	on terms that are acceptable to us or at all.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Our credit agreement requires the payment of interest based
	on 3 month LIBOR plus a fixed rate. Fluctuations in this variable interest rate could negatively impact our financial results.
</P>
<!-- FIELD: PAGE; SEQUENCE: 38 -->
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 6PT; PADDING-BOTTOM: 12PT; BORDER-BOTTOM: SILVER 4PX SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	37
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage39"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 10PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: LEFT; WIDTH: 100%">
<PAGE>
</PAGE>
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	In addition, there can be no assurance that we can extend or
	negotiate an update to the Revolving Loan under favorable condition and satisfactory terms upon expiration in December 2016.
</P>
</EFX_RISK_FACTORS>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_UNRESOLVED_STAFF_COMMENTS>
<A NAME="FIS_UNRESOLVED_STAFF_COMMENTS"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<A NAME="C86264_10K_HTM_X2_C86264A004">
</A>
	Item 1B.
<U>
	Unresolved Staff Comments
</U>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	None
</P>
</EFX_UNRESOLVED_STAFF_COMMENTS>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_PROPERTIES>
<A NAME="FIS_PROPERTIES"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Item 2.
<U>
<A NAME="C86264_10K_HTM_X2_C86264A005">
</A>
	Properties
</U>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	The following are the principal facilities of the Company:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_5"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-LEFT: 10PT; TEXT-INDENT: -10PT; WIDTH: 15%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; WIDTH: 2%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; WIDTH: 37%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; WIDTH: 2%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; WIDTH: 20%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; WIDTH: 2%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; WIDTH: 10%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Leased /
</B>
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; WIDTH: 2%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; WIDTH: 10%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Square
</B>
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="PADDING-LEFT: 10PT; TEXT-INDENT: -10PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Location
</B>
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Primary use
</B>
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Segments
</B>
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	owned
</B>
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	footage
</B>
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="PADDING-LEFT: 10PT; TEXT-INDENT: -10PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: RGB(229,255,255)">
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-LEFT: 10PT; TEXT-INDENT: -10PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Farmingdale, NY
</FONT>
<BR>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	(Note1)
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Clinical laboratory and research
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Clinical Labs
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Leased
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	43,000
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-LEFT: 10PT; TEXT-INDENT: -10PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-LEFT: 10PT; TEXT-INDENT: -10PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Farmingdale, NY
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Manufacturing, research, sales and administrative office
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Life Sciences, Therapeutics
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Owned
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	22,000
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-LEFT: 10PT; TEXT-INDENT: -10PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: RGB(229,255,255)">
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-LEFT: 10PT; TEXT-INDENT: -10PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	New York, NY
</FONT>
<BR>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	(Note 2)
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Corporate headquarters
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Other
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Leased
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	11,300
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-LEFT: 10PT; TEXT-INDENT: -10PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-LEFT: 10PT; TEXT-INDENT: -10PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Lausen, Switzerland
</FONT>
<BR>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	(Note 3)
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Operational headquarters in Europe, including sales and distribution
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Life Sciences
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Leased
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	9,626
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-LEFT: 10PT; TEXT-INDENT: -10PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: RGB(229,255,255)">
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-LEFT: 10PT; TEXT-INDENT: -10PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Ann Arbor, Michigan
</FONT>
<BR>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	(Note 4)
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Manufacturing, research, and distribution
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Life Sciences
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Leased
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	26,820
</FONT>
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Note 1 - On October 9, 2015, this lease was amended and extended
	through March 31, 2027.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Note 2 - In February 2010, the lease, which includes 4,100 square
	feet under a sublease rental agreement through December 31, 2017, was extended through May 2020.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Note 3 - In July 2016, the lease was automatically
	extended through December 2018.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Note 4 - In March 2009 the lease was amended and extended through
	May 2021.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	We believe the current facilities are suitable and adequate
	for the Company&rsquo;s current operating needs for its clinical laboratories, life science and therapeutics segments and that
	the production capacity in various locations is sufficient to manage product requirements.
</P>
<!-- FIELD: PAGE; SEQUENCE: 39 -->
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 6PT; PADDING-BOTTOM: 12PT; BORDER-BOTTOM: SILVER 4PX SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	38
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
</EFX_PROPERTIES>
<A NAME="eolPage40"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 10PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: LEFT; WIDTH: 100%">
<PAGE>
</PAGE>
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<EFX_LEGAL_PROCEEDINGS>
<A NAME="FIS_LEGAL_PROCEEDINGS"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Item 3.
<U>
<A NAME="C86264_10K_HTM_X2_C86264A006">
</A>
	Legal Proceedings
</U>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	On June 7, 2004, the Company and Enzo Life Sciences, Inc.,
	filed suit in the United States District Court for the District of Connecticut against Applera Corporation and its wholly-owned
	subsidiary Tropix, Inc., which became Life Technologies, Inc. and was acquired by Thermo Fisher Scientific, Inc. (NYSE:TMO) on
	February 3, 2014. The complaint alleged infringement of six patents relating to DNA sequencing systems, labeled nucleotide products,
	and other technology. Yale University is the owner of four of the patents and the Company is the exclusive licensee. These four
	patents are commonly referred to as the &ldquo;Ward&rdquo; patents. On November 12, 2012, a jury in New Haven found that one of
	these patents (United States Patent No. 5,449,667) was infringed and not proven invalid. The jury awarded $48.5 million for this
	infringement. On January 6, 2014, the judge awarded prejudgment interest of approximately $12.5 million and additional post-interest
	on the full amount was also be awarded starting November 7, 2012 until the total award is satisfied. The final award to the Company
	could have been reduced or subject to possible claims from third parties. On March 16, 2015, the Court of Appeals for the Federal
	Circuit vacated that judgment in a decision remanding the matter to the district court for further proceedings. On February 22,
	2016, the Connecticut District Court granted Applera&rsquo;s motion for summary judgment of non-infringement. The Company appealed
	that decision. There can be no assurance that the Company will be successful in this litigation. Even if the Company is not successful,
	management does not believe that there will be a significant adverse monetary impact on the Company.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	As of August 1, 2014 the Company was engaged in litigation in
	the United States District Court for the Southern District of New York against Roche Diagnostic GmbH and its related company Roche
	Molecular Systems, Inc. (&ldquo;Roche&rdquo;), as declaratory judgment defendant. This case was commenced in May 2004. Roche seeks
	a declaratory judgment of non-breach of contract and patent invalidity against the Company. Roche has also asserted tort claims
	against the Company. The Company has asserted breach of contract and patent infringement causes of action against Roche. There
	has been extensive discovery in the case. In 2011, Roche moved for summary judgment of non-infringement regarding the Company&rsquo;s
	patent claims. In 2012, the motion was granted in part and denied in part. In December 2012, Roche moved for summary judgment on
	the Company&rsquo;s non-patent claims. Additional discovery was taken and the Company responded to the motions in May 2013. On
	December 6, 2013, the Court granted in part and denied in part Roche&rsquo;s summary judgment motion. On October 22, 2014, the
	Court ordered that damages discovery concerning the Company&rsquo;s remaining contract and patent claims and Roche&rsquo;s claims
	should be completed by January 30, 2015, and expert discovery should be completed following the Court&rsquo;s not-yet-issued claim
	construction ruling concerning the Company&rsquo;s patent infringement claim against Roche. Roche dropped its tort claims during
	damages discovery. On April 28, 2015, the Court heard oral argument on claim construction issues. On May 8, 2015, Roche and the
	Company jointly moved the Court to extend the schedule for damages discovery until May 29, 2015, and the Court granted that motion. The parties
	are waiting for the Court&rsquo;s ruling on claim construction. The Company and Enzo Life Sciences intend to vigorously press their remaining claims and contest the claims against them.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	In 2012, the Company received a Subpoena Duces Tecum (the &ldquo;Subpoena&rdquo;)
	from the Department of Health and Human Services, Office of Inspector General (&ldquo;OIG&rdquo;). The Subpoena was issued as part
	of an investigation being conducted by the US Attorney&rsquo;s Office for the Eastern District of New York in conjunction with
	the OIG. While a number of potential issues were raised initially by the government, the investigation came to focus primarily
	on an alleged failure to collect diagnosis codes from physicians who ordered tests through Enzo Clinical Labs. The time period
	initially covered by the investigation was from 2004 through 2011. In response to the Subpoena, the Company cooperated with the
	government. On September 22, 2014, the Company and the U.S. Department of Justice reached a settlement agreement to resolve this
	matter, in substantive form as disclosed in the Company&rsquo;s fiscal quarter ended April 30, 2014. During the quarter ended April,
	30, 2014, the Company recorded a charge of $2.0 million in the statement of operations under legal settlements, net within the
	Clinical Labs segment. The settlement amount will be paid with interest over a five-year period. The final settlement covers the time period 2004-2014. During the three months ended January 31,
	2016, the Company accrued an additional $1.5 million, due to the Company&rsquo;s achievement of certain financial milestones. As
	of July 31, 2016, the total liability for this settlement is $1.2 million, of which $0.4 million is included in other current liabilities
	and $0.8 million included in other liabilities.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	On June 20, 2014, the Company, as plaintiff finalized and
	executed a settlement agreement with PerkinElmer, Inc., and PerkinElmer Health Sciences, Inc. (formerly known as PerkinElmer
	Life Sciences, Inc.) (together, &ldquo;PerkinElmer&rdquo;), with respect to an action between the Company and PerkinElmer
	before the U.S. District Court, Southern District of New York, Case No 03-CV-3817. PerkinElmer paid $7.0 million in escrow
	pursuant to the agreement because of a former attorney&rsquo;s charging lien for fees allegedly owed for past services
	rendered to the Company. On December
	3, 2015, the Company entered into a Settlement Agreement with the former attorney pursuant to which the Company and the
	former attorney resolved their respective claims against each other. As of July 31, 2016, the Company received a total of
	approximately $7.0 million from the escrow referred to above in accordance with the terms of the Settlement Agreement. This
	settlement is included in the statement of operations under Legal settlements, net within the Life Science segment.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 40 -->
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 6PT; PADDING-BOTTOM: 12PT; BORDER-BOTTOM: SILVER 4PX SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	39
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage41"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 10PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: LEFT; WIDTH: 100%">
<PAGE>
</PAGE>
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	On July 2, 2015, the Company as Plaintiff executed
	a settlement agreement with Luminex Corporation with respect to an action between the Company and Abbott Laboratories
	and Abbott Molecular, Inc. (Defendants) and Luminex Corporation (Intervening Defendant) before the United States District
	Court for the District of Delaware for alleged patent infringement. Luminex paid the Company a total of $7.1 million
	as consideration for this agreement and the dismissal of the litigation against Luminex. The case against the Abbott
	defendants continues. The parties have not begun summary judgement briefing because the court has not set a briefing
	schedule. The court also has not set a trial date.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	On July 20, 2015, the Company as a Plaintiff finalized and executed
	a settlement agreement with Siemens Healthcare Diagnostics Inc. (&ldquo;Siemens&rdquo;) to settle a patent litigation lawsuit before
	the U.S. District Court for the District of Delaware in the amount of $6.7 million, net. Under terms of the agreement, Siemens
	will also pay the Company additional royalties of $1.0 million per annum on sales of its molecular products manufactured and/or
	sold in the United States during the its fiscal years 2015 through 2019 if sales of such products exceed a contractual amount.
	The net settlement amount was included in other receivables in the consolidated balance sheet as of July 31, 2015 and was received
	in August 2015.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	On October 9, 2015, the Company reached and finalized a settlement
	with Affymetrix, Inc. in the amount of $6.8 million, net in a patent infringement action brought by the Company. On January 4,
	2016, the Company reached and finalized a settlement agreement with Agilent Technologies, Inc. in the amount of $6.1 million, net
	in a patent infringement action brought by the Company. Both cases were originally brought by the Company in the United States
	District Court for the District of Delaware. The settlements are included in the statement of operations under Legal settlements,
	net within the Life Science segment.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	On May 16, 2016, the Company reached and finalized
	a settlement with Life Technologies Corporation in the amount of $24.3 million, net in an infringement action brought by
	the Company regarding its US Patents No. 6,992,180 and 7,064,197. On July 1, 2016, the Company reached and finalized a
	settlement with Illumina, Inc., in the amount of $14.5 million, net in an infringement action brought by the Company regarding
	US Patent No. 7,064,197. These cases were originally brought by the Company in the United States District Court for the
	District of Delaware. The settlements are included in the statement of operations under Legal settlements, net within the
	Life Science segment.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="BACKGROUND-COLOR: WHITE">
	As of July 31, 2016, there
	are six pending cases originally brought by the Company in the United States District Court for the District of Delaware alleging
	patent infringements against various companies.
</FONT>
	There can be no assurance that the Company will be successful in these litigations.
	Even if the Company is not successful, management does not believe that there will be a significant adverse monetary impact on
	the Company.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	The Company is party to other claims, legal actions, complaints,
	and contractual disputes that arise in the ordinary course of business. The Company believes that any liability that may ultimately
	result from the resolution of these matters will not, individually or in the aggregate, have a material adverse effect on its financial
	position or results of operations
</P>
</EFX_LEGAL_PROCEEDINGS>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_MINE_SAFETY_DISCLOSURE>
<A NAME="FIS_MINE_SAFETY_DISCLOSURE"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<A NAME="C86264_10K_HTM_X2_C86264A007">
</A>
	Item 4.
<U>
	Mine Safety Disclosures
</U>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Not Applicable
</P>
<!-- FIELD: PAGE; SEQUENCE: 41 -->
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 6PT; PADDING-BOTTOM: 12PT; BORDER-BOTTOM: SILVER 4PX SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	40
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
</EFX_MINE_SAFETY_DISCLOSURE>
</EFX_PART_I>
<A NAME="eolPage42"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 10PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: LEFT; WIDTH: 100%">
<PAGE>
</PAGE>
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<EFX_PART_II>
<A NAME="FIS_PART_II"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; BORDER-BOTTOM: BLACK 1PX SOLID">
<B>
<A NAME="C86264_10K_HTM_X2_C86264A008">
</A>
	Part II
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_MARKET>
<A NAME="FIS_MARKET"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<A NAME="C86264_10K_HTM_X2_C86264A009">
</A>
	Item 5.
<U>
	Market for Registrant&rsquo;s Common Equity, Related
	Stockholder Matters and Issuer Purchases of Equity Securities
</U>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	The common stock of the Company is traded on the New York Stock
	Exchange (Symbol: ENZ). The following table sets forth the high and low price of the Company&rsquo;s common stock for the periods
	indicated as reported on the New York Stock Exchange.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_6"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 80%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	2016 Fiscal Year (August 1, 2015 to July 31, 2016):
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="PADDING-BOTTOM: 1PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	High
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Low
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255)">
<TD STYLE="WIDTH: 72%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	1st Quarter
</FONT>
</TD>
<TD STYLE="WIDTH: 2%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</FONT>
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	4.01
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 2%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</FONT>
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	2.79
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	2nd Quarter
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	4.95
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	3.82
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255)">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	3rd Quarter
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	5.07
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	4.06
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	4th Quarter
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	6.97
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	4.81
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_7"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 80%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	2015 Fiscal Year (August 1, 2014 to July 31, 2015):
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	High
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Low
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255)">
<TD STYLE="WIDTH: 72%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	1st Quarter
</FONT>
</TD>
<TD STYLE="WIDTH: 2%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</FONT>
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	6.08
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 2%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</FONT>
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	4.55
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	2nd Quarter
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	5.27
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	3.13
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255)">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	3rd Quarter
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	3.43
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	2.57
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	4th Quarter
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	3.25
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	2.43
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	As of September 30, 2016, the Company had approximately 710
	stockholders of record of its common stock.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	The Company has not paid a cash dividend on its common stock
	and intends to continue a policy of retaining earnings to finance and build its operations. Accordingly, the Company does not anticipate
	the payment of cash dividends to holders of common stock in the foreseeable future.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	Performance Graph
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	The graph below compares the five-year cumulative shareholder
	total return based upon an initial $100 investment (assuming the reinvestment of dividends) for Enzo Biochem, Inc. shares of Common
	Stock with the comparable return for the New York Stock Exchange Market Value Index and two peer issuer indices selected on an
	industry basis. The two peer group indices include: (i) 147 biotechnology companies engaged in the research and development of
	diagnostics substances and (ii) 18 companies engaged in the medical laboratories business. All of the indices include only companies
	whose common stock has been registered under Section 12 of the Security Exchange Act of 1934 for at least the time frame set forth
	in the graph.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	The total shareholder returns depicted in the graph are not
	necessarily indicative of future performance. The Performance Graph and related disclosure shall not be incorporated by reference
	in any filing by the Company under the Securities Act of 1933 of the Securities Act of 1934, except to the extent that the Company
	specifically incorporates the graph and such disclosure by reference.
</P>
<!-- FIELD: PAGE; SEQUENCE: 42 -->
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 6PT; PADDING-BOTTOM: 12PT; BORDER-BOTTOM: SILVER 4PX SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	41
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage43"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 10PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: LEFT; WIDTH: 100%">
<PAGE>
</PAGE>
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	COMPARISON OF 5-YEAR CUMULATIVE TOTAL
<BR>
	RETURN AMONG ENZO BIOCHEM, INC.,
<BR>
	NYSE MARKET INDEX, MORNINGSTAR DIAGNOSTIC AND RESEARCH
<BR>
	INDEX AND MEDICAL LABORATORIES INDEX
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<IMG SRC="http://content.edgar-online.com/edgar_conv_img/2016/10/13/0000930413-16-008464_X2_C86264A001.JPG" ALT="">
</P>
<P STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_8"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	ASSUMES $100 INVESTED ON AUGUST 1, 2011
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	ASSUMES DIVIDEND REINVESTED
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	COMPARISON OF CUMULATIVE TOTAL RETURN OF
	ONE OR MORE
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	COMPANIES, PEER GROUPS, INDUSTRY INDEXES
	AND/OR BROAD MARKETS
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	7/31/2011
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	7/31/2012
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	7/31/2013
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	7/31/2014
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	7/31/2015
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	7/31/2016
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255)">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Company/Market/Peer Group
</B>
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="WIDTH: 40%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Enzo Biochem, Inc.
</FONT>
</TD>
<TD STYLE="WIDTH: 2%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 8%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	100.00
</FONT>
</TD>
<TD STYLE="WIDTH: 2%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 8%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	39.06
</FONT>
</TD>
<TD STYLE="WIDTH: 2%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 8%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	56.77
</FONT>
</TD>
<TD STYLE="WIDTH: 2%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 8%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	125.00
</FONT>
</TD>
<TD STYLE="WIDTH: 2%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 8%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	78.13
</FONT>
</TD>
<TD STYLE="WIDTH: 2%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 8%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	175.00
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255)">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	NYSE Composite Index
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	100.00
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	100.17
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	125.19
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	144.08
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	149.81
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	152.72
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Morningstar Diagnostic &amp; Research
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	100.00
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	95.95
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	128.59
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	154.73
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	184.89
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	199.35
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255)">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	SIC 8071 - Medical Laboratories
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	100.00
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	100.29
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	112.20
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	115.38
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	127.53
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	142.46
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Medical Laboratories + Enzo Biochem Inc.
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	100.00
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	99.86
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	111.81
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	115.49
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	127.17
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	142.74
</FONT>
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<!-- FIELD: PAGE; SEQUENCE: 43 -->
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 6PT; PADDING-BOTTOM: 12PT; BORDER-BOTTOM: SILVER 4PX SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	42
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
</EFX_MARKET>
<A NAME="eolPage44"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 10PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: LEFT; WIDTH: 100%">
<PAGE>
</PAGE>
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<EFX_FINANCIAL_DATA>
<A NAME="FIS_FINANCIAL_DATA"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<A NAME="C86264_10K_HTM_X2_C86264A010">
</A>
	Item 6.
<U>
	Selected Financial Data
</U>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	The following table, which is derived from the audited consolidated
	financial statements of the Company for the fiscal years 2012 through 2016 should be read together with the discussion in &ldquo;Management&rsquo;s
	Discussion and Analysis of Financial Condition and Results of Operations&rdquo; and the Company&rsquo;s consolidated financial
	statements and notes to those statements included elsewhere in this Annual Report on Form 10-K.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_9"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="18" STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: CENTER; FONT-SIZE: 12PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	For the fiscal year ended July 31,
</B>
</FONT>
<BR>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	(In thousands, except per share amounts)
</B>
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Operating Results
</B>
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	2016
</B>
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	2015
</B>
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	2014
</B>
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	2013
</B>
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-INDENT: 19.8PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	2012
</B>
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255)">
<TD STYLE="WIDTH: 40%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Revenues
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</FONT>
</TD>
<TD STYLE="WIDTH: 9%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	102,773
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</FONT>
</TD>
<TD STYLE="WIDTH: 9%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	97,599
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</FONT>
</TD>
<TD STYLE="WIDTH: 9%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	95,947
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</FONT>
</TD>
<TD STYLE="WIDTH: 9%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	93,707
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</FONT>
</TD>
<TD STYLE="WIDTH: 9%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	103,083
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Impairment charges (1)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&mdash;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&mdash;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&mdash;
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&mdash;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	(24,540
</FONT>
</TD>
<TD>
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255)">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Operating income (loss)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	47,003
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	(1,206
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	(10,180
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	(18,890
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	(40,479
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Net income (loss) (2)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	45,286
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	(2,285
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	(9,977
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	(18,237
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	(39,269
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255)">
<TD STYLE="PADDING-LEFT: 8.65PT; TEXT-INDENT: -8.65PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Basic net income (loss) per common share:
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	0.98
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	(0.05
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	)
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	(0.23
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	)
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	(0.46
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	)
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	(1.01
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="PADDING-LEFT: 8.65PT; TEXT-INDENT: -8.65PT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-LEFT: 8.65PT; TEXT-INDENT: -8.65PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Diluted net income (loss) per common share:
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	0.97
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	(0.05
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	(0.23
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	(0.46
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	(1.01
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="PADDING-LEFT: 8.65PT; TEXT-INDENT: -8.65PT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="18" STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	July 31,
</B>
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 12PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Financial Position (in thousands)
</B>
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	2016
</B>
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	2015
</B>
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	2014
</B>
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	2013
</B>
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	2012
</B>
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255)">
<TD STYLE="WIDTH: 40%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Working capital
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</FONT>
</TD>
<TD STYLE="WIDTH: 9%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	70,829
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</FONT>
</TD>
<TD STYLE="WIDTH: 9%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	22,528
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</FONT>
</TD>
<TD STYLE="WIDTH: 9%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	15,771
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</FONT>
</TD>
<TD STYLE="WIDTH: 9%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	8,704
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</FONT>
</TD>
<TD STYLE="WIDTH: 9%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	21,412
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Total assets (1)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	111,821
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	68,394
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	64,411
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	58,958
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	69,123
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255)">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Stockholders&rsquo; equity (1)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	89,554
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	42,606
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	36,950
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	34,132
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	49,101
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	Notes to Selected Financial Data:
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 3%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	(1)
</FONT>
</TD>
<TD STYLE="WIDTH: 97%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	In the fourth quarter of fiscal 2012, the Company recorded an impairment charge on goodwill and indefinite lived intangible assets.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 3%">
<FONT STYLE="FONT-SIZE: 10PT">
	(2)
</FONT>
</TD>
<TD STYLE="WIDTH: 97%">
<FONT STYLE="FONT-SIZE: 10PT">
	In the fiscal year 2016, the Company recorded legal settlements, net
	of approximately $57.3 million.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 44 -->
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 6PT; PADDING-BOTTOM: 12PT; BORDER-BOTTOM: SILVER 4PX SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	43
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
</EFX_FINANCIAL_DATA>
<A NAME="eolPage45"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 10PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: LEFT; WIDTH: 100%">
<PAGE>
</PAGE>
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<EFX_MANAGEMENTS_DISCUSSION>
<A NAME="FIS_MANAGEMENTS_DISCUSSION"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-SIZE: 10PT">
	Item 7.
<U>
<A NAME="C86264_10K_HTM_X2_C86264A011">
</A>
	Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operations
</U>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	See in this Form 10-K for the fiscal year ended July 31, 2016
	Part 1. Item 1.
<I>
	Business
</I>
	, for Forward Looking Cautionary Statements.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	The Company&rsquo;s Enzo Clinical Labs and Enzo Life Sciences
	reporting units, as described below, are affected by different US and global economic conditions which are included in Item 1A,
	Risk Factors.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	We are comprised of three operating companies that have evolved
	out of our core competence: the use of nucleic acids as informational molecules and the use of compounds for immune modulation.
	These wholly-owned operating companies and the foreign subsidiaries of Enzo Life Sciences conduct their operations through three
	reportable segments. Below are brief descriptions of each of the three operating segments (see Note 15 in the Notes to Consolidated
	Financial Statements):
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
<U>
	Enzo Clinical Labs
</U>
</B>
	is a regional clinical laboratory
	serving the greater New York and New Jersey medical communities. The Company believes having clinical diagnostic services allows
	us to capitalize first hand on our extensive advanced molecular and cytogenetic capabilities and the broader trends in predictive
	and personalized diagnostics. We offer a menu of routine and esoteric clinical laboratory tests or procedures used in general patient
	care by physicians to establish or support a diagnosis, monitor treatment or medication, or search for an otherwise undiagnosed
	condition. We operate a full-service clinical laboratory in Farmingdale, New York, a network of over 30 patient service centers
	throughout greater New York and New Jersey, a free-standing &ldquo;STAT&rdquo; or rapid response laboratory in New York City, and
	a full-service phlebotomy and an in-house logistics department. Payments for clinical laboratory testing services are made by the
	Medicare program, healthcare insurers and patients.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	The Clinical Lab reporting unit is impacted by various risk
	factors, including among others, reduced reimbursements from third party payers for testing performed and from recent health care
	legislation. Despite the growth we have experienced, there can be no assurance future growth can be achieved. The introduction
	of new molecular and esoteric tests is expected to increase our revenue per test and could offset impacts from the above factors.
	The Company anticipates improved profitability with increased service volume. Clinical Labs experienced year over year growth in
	fiscal 2016 and 2015 of 12% and 8% respectively.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
<U>
	Enzo Life Sciences
</U>
</B>
	manufactures, develops and
	markets products and tools to life sciences, drug development and clinical research customers world-wide and has amassed a large
	patent and technology portfolio. Enzo Life Sciences, Inc. is a recognized leader in labelling and detection technologies across
	research and diagnostic markets. Our strong portfolio of proteins, antibodies, peptides, small molecules, labelling probes, dyes
	and kits provides life science researchers tools for target identification/validation, high content analysis, gene expression analysis,
	nucleic acid detection, protein biochemistry and detection, and cellular analysis. We are internationally recognized and acknowledged
	as a leader in manufacturing, in-licensing, and commercialization of over 9,000 of our own products and in addition distribute
	over 40,000 products made by over 40 other original manufacturers. Our strategic focus is directed to innovative high quality research
	reagents and kits in the primary key research areas of genomics, cellular analysis, small molecule chemistry, protein homeostasis,
	epigenetics, immunoassays, and assay development. The segment is an established source for a comprehensive panel of products to
	scientific experts in the fields of cancer, cardiovascular disease, neurological disorders, diabetes and obesity, endocrine disorders,
	infectious and autoimmune disease, hepatotoxicity and renal injury.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
<U>
	Enzo Therapeutics
</U>
</B>
	is a biopharmaceutical venture
	that has developed multiple novel approaches in the areas of gastrointestinal, infectious, ophthalmic and metabolic diseases, many
	of which are derived from the pioneering work of Enzo Life Sciences. The Company has focused its efforts on developing treatment
	regimens for diseases and conditions in which current treatment options are ineffective, costly, and/or cause unwanted side effects.
	This focus has generated a clinical and preclinical pipeline, as well as more than 115 patents and patent applications.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	The following table summarizes the sources of revenues for the
	fiscal years ended July 31, 2016, 2015 and 2014 (in $000&rsquo;s and percentages):
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_10"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="RIGHT" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 90%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="6" STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	2016
</B>
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="6" STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	2015
</B>
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="6" STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	2014
</B>
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255)">
<TD STYLE="WIDTH: 40%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Clinical laboratory services
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</FONT>
</TD>
<TD STYLE="WIDTH: 7%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	70,915
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 7%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	69
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	%
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</FONT>
</TD>
<TD STYLE="WIDTH: 7%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	63,414
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 7%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	65
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	%
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</FONT>
</TD>
<TD STYLE="WIDTH: 7%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	58,689
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 7%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	61
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	%
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Product revenues
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	30,337
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	30
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	31,690
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	32
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	32,850
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	34
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255)">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Royalty and license fee income
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	1,521
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	1
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	2,495
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	3
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	4,408
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	5
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-BOTTOM: 3PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Total
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	102,773
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX; BORDER-BOTTOM: BLACK 3PX DOUBLE">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	100
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	%
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	97,599
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX; BORDER-BOTTOM: BLACK 3PX DOUBLE">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	100
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	%
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	95,947
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX; BORDER-BOTTOM: BLACK 3PX DOUBLE">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	100
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	%
</FONT>
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<BR STYLE="CLEAR: BOTH">
<!-- FIELD: PAGE; SEQUENCE: 45 -->
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 6PT; PADDING-BOTTOM: 12PT; BORDER-BOTTOM: SILVER 4PX SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	44
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage46"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 10PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: LEFT; WIDTH: 100%">
<PAGE>
</PAGE>
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<EFX_RESULTS_OF_OPERATIONS>
<A NAME="FIS_RESULTS_OF_OPERATIONS"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PX SOLID">
<B>
<I>
	Results
	of Operations
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
<I>
	Fiscal year ended July 31, 2016 compared
	to July 31, 2015
<BR>
	(in 000s)
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD COLSPAN="17">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<U>
	Comparative Financial Data for the Fiscal Years Ended July 31,
</U>
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<EFX_UNIDENTIFIED_TABLE>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-ALIGN: CENTER">
<A NAME="FIS_UNIDENTIFIED_TABLE_11"></A>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD COLSPAN="2" STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	2016
</B>
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD COLSPAN="2" STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	2015
</B>
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD COLSPAN="2" STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Increase
</B>
</FONT>
<BR>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	(Decrease)
</B>
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD COLSPAN="2" STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	% Change
</B>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	&nbsp;
</B>
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255)">
<TD STYLE="PADDING-LEFT: 11PT; WIDTH: 42%; TEXT-INDENT: -11PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Revenues:
</FONT>
</TD>
<TD STYLE="WIDTH: 3%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 3%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 3%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 3%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 8%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-LEFT: 11PT; TEXT-INDENT: -11PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Clinical laboratory services
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	70,915
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	63,414
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	7,501
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	12
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255)">
<TD STYLE="PADDING-LEFT: 11PT; TEXT-INDENT: -11PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Product revenues
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	30,337
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	31,690
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	(1,353
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	(4
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-LEFT: 11PT; TEXT-INDENT: -11PT; PADDING-BOTTOM: 1PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Royalty and license fee income
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	1,521
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	2,495
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	(974
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	)
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-BOTTOM: 1PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	(39
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255)">
<TD STYLE="PADDING-LEFT: 11PT; TEXT-INDENT: -11PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Total revenues
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	102,773
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	97,599
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	5,174
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	5
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="PADDING-LEFT: 11PT; TEXT-INDENT: -11PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-LEFT: 11PT; TEXT-INDENT: -11PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Operating costs, expenses and legal settlements, net:
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255)">
<TD STYLE="PADDING-LEFT: 11PT; TEXT-INDENT: -11PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Cost of clinical laboratory services
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	42,859
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	39,589
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	3,270
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	8
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-LEFT: 11PT; TEXT-INDENT: -11PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Cost of product revenues
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	14,331
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	15,183
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	(852
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	(6
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255)">
<TD STYLE="PADDING-LEFT: 11PT; TEXT-INDENT: -11PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Research and development
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	3,524
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	3,350
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	174
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	5
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-LEFT: 11PT; TEXT-INDENT: -11PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Selling, general, and administrative
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	43,586
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	41,069
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	2,517
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	6
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255)">
<TD STYLE="PADDING-LEFT: 11PT; TEXT-INDENT: -11PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Provision for uncollectible accounts receivable
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	2,336
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	2,284
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	52
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	2
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-LEFT: 11PT; TEXT-INDENT: -11PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Legal fee expense
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	6,384
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	8,788
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	(2,404
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	(27
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255)">
<TD STYLE="PADDING-LEFT: 11PT; TEXT-INDENT: -11PT; PADDING-BOTTOM: 1PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Legal settlements, net
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	(57,250
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	)
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	(11,458
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	)
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	(45,792
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	)
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-BOTTOM: 1PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	**
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-LEFT: 11PT; TEXT-INDENT: -11PT; PADDING-BOTTOM: 1PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Total costs, expenses and legal settlements, net
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	55,770
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	98,805
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	(43,035
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	)
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-BOTTOM: 1PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	(44
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="PADDING-LEFT: 11PT; TEXT-INDENT: -11PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255)">
<TD STYLE="PADDING-LEFT: 11PT; TEXT-INDENT: -11PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Operating income (loss)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	47,003
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	(1,206
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	48,209
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	**
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="PADDING-LEFT: 11PT; TEXT-INDENT: -11PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-LEFT: 11PT; TEXT-INDENT: -11PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Other income (expense):
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255)">
<TD STYLE="PADDING-LEFT: 11PT; TEXT-INDENT: -11PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Interest
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	(136
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	(245
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	109
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	44
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-LEFT: 11PT; TEXT-INDENT: -11PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Other
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	122
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	95
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	27
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	28
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255)">
<TD STYLE="PADDING-LEFT: 11PT; TEXT-INDENT: -11PT; PADDING-BOTTOM: 1PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Foreign currency loss
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	(474
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	)
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	(936
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	)
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	462
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-BOTTOM: 1PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	49
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-LEFT: 11PT; TEXT-INDENT: -11PT; PADDING-BOTTOM: 3PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Income (loss) before income taxes
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	46,515
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	(2,292
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	)
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	48,807
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-BOTTOM: 3PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	**
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 3PX">
	&nbsp;
</TD>
</TR>
</EFX_UNIDENTIFIED_TABLE>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	** not meaningful
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	Consolidated Results:
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	The &ldquo;2016 period&rdquo; and the &ldquo;2015 period&rdquo;
	refer to the fiscal year ended July 31, 2016 and 2015, respectively.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Clinical laboratory services revenues for the 2016 period were
	$70.9 million compared to $63.4 million in the 2015 period, an increase of $7.5 million or 12%. The increase is attributed to molecular
	testing volume and higher value account acquisitions which were offset in part by attrition and a decline in routine test volume.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Product revenues for the 2016 period were $30.3 million compared
	to $31.7 million in the 2015 period, a decrease of $1.4 million or 4%. The decrease was due to a decline in product sales of $0.8
	million in the United States and foreign markets and the negative impact of $0.6 million from translating revenues denominated
	in the euro, pound sterling and Swiss franc which depreciated on average versus the US dollar during the 2016 period compared to
	the 2015 period. Revenues decreased due to lower order volume and were also negatively impacted by pricing due to competition and
	lower research funding, especially in academia.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Royalty and license fee income during the 2016 period was $1.5
	million compared to $2.5 million in the 2015 period a decrease of $1.0 million or 39%. Royalties are primarily earned from the
	reported sales of Qiagen products subject to a license agreement. Qiagen is experiencing declines in its US sales of HPV products
	which in turn reduced our royalty income. There are no direct expenses relating to royalty and licensing income.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	The cost of clinical laboratory services during the 2016 period
	was $42.9 million as compared to $39.6 million in the 2015 period, an increase of $3.3 million or 8% primarily due to the increase
	in clinical laboratory services revenue for molecular testing of 76%.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	The cost of product revenues during the 2016 period was $14.3
	million compared to $15.2 million in the 2015 period, a decrease of $0.9 million or 6% due to lower sales. The gross profit margin
	was 53% in the 2016 period and 52% in the 2015 period due to a favorable mix of products sold.
</P>
<!-- FIELD: PAGE; SEQUENCE: 46 -->
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 6PT; PADDING-BOTTOM: 12PT; BORDER-BOTTOM: SILVER 4PX SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	45
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage47"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 10PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: LEFT; WIDTH: 100%">
<PAGE>
</PAGE>
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Research and development expenses were approximately $3.5 million
	and $3.3 million during the 2016 and 2015 periods, respectively, an increase of $0.2 million. The expense for the Life Sciences
	segment increased $0.1 million primarily due to patent procurement costs. The expense for the Therapeutics segment increased $0.1
	million compared to the 2015 period due to the impact of an adjustment made in the 2015 period which decreased an obligation for
	clinical trial activity.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Selling, general and administrative expenses were approximately
	$43.6 million during the 2016 period versus $41.1 million during the 2015 period, an increase of $2.5 million or 6%. The Clinical
	Lab segment selling, general and administrative increased $2.2 million due to increases in sales commissions and compensation and
	administrative function salaries in support of greater molecular testing volume, increases in collection and bank expenses, and
	building and depreciation expense. The Life Sciences segment selling, general and administrative declined approximately $0.4 million
	due to declines in payroll and facilities expense. Other segment selling, general and administrative increased $0.7 million due
	to an increase of $1.1 million for contested proxy expenses relating to our annual stockholders&rsquo; meeting which took place
	in January 2016, partially offset by decreases of $0.3 million for professional fees and $0.1 million of payroll related expenses.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	The provision for uncollectible accounts receivable, primarily
	related to the Clinical Labs segment, was approximately $2.3 million for both the 2016 and 2015 periods. As a percent of Clinical
	laboratory services, the provision for uncollectible accounts receivable relating to the Clinical Labs segment in the 2016 and
	2015 periods was 3.3% and 3.8%, respectively. The decrease is primarily due to enhanced collection procedures for self-pay patient
	receivables.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Legal fee expense was $6.4 million during the 2016 period compared
	to $8.8 million in the 2015 period, a decrease of $2.4 million or 27% due to the timing of legal activity fees and related costs
	associated with on-going patent litigation where the Company is plaintiff. Legal fee expense in the 2016 period includes $0.4 million
	for contested proxy costs relating to our annual stockholders meeting which took place in January 2016.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Legal settlements, net was $57.3 million in the 2016 period
	versus $11.5 million in the 2015 period, an increase of $45.8 million. During the 2016 period the Company as plaintiff finalized
	and executed settlement agreements with Affymetrix, Inc., Agilent Technologies, Inc., Life Technologies Corporation, and Illumina
	Inc. relating to patent infringement claims and collected proceeds held in escrow relating to the PerkinElmer, Inc. and Molecular
	Probes, Inc. settlements, all totalling $58.8 million of net proceeds. The Company also recorded an additional charge of $1.5 million
	relating to the settlement with the U.S. Department of Justice, due to the achievement of certain financial milestones. See Note
	14 Contingencies.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Interest expense was $0.1 million during the 2016 versus $0.2
	million in the 2015 periods. During the 2015 period there were some additional fees relating to the credit agreement, which was
	entered into in 2013.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	During the 2016 and the 2015 periods, the foreign currency loss
	was $0.5 million and $0.9 million, respectively, a favorable change of $0.4 million. The Company has loans and receivables with
	its foreign subsidiaries which may be denominated in US dollars or a foreign currency. When re-measuring these amounts into the
	respective entities&rsquo; functional currency, the Company recognizes a loss if those foreign currencies, including the Swiss
	Franc, British pound and Euro depreciate relative to the US dollar and a gain if those foreign currencies appreciate relative to
	the US dollar, year over year.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	As compared to the US dollar at the end of the 2016 period versus
	the start of the 2016 period, the Euro appreciated approximately 2%, the Swiss franc was unchanged, and the British pound depreciated
	15%. As compared to the US dollar at the end of the 2015 period versus the start of the 2015 period, these currencies had all depreciated
	between 6% and 18%.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	Segment Results:
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
<U>
	Clinical Labs
</U>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	The Clinical Labs segment&rsquo;s operating income before taxes
	was $1.1 million for 2016 period as compared to $0.5 million in the 2015 period. The 2016 period includes an additional $1.5 million
	charge for the legal settlement with the U.S. Department of Justice, due to the achievement of certain financial milestones. Revenue
	from laboratory services for the 2016 period were $70.9 million compared to $63.4 million in the 2015 period. The increase of $7.5
	million is attributed to increased molecular testing volume and higher value account acquisitions, which were offset in part by
	attrition and a decline in routine test volume. Cost of sales during the 2016 period was $42.9 million as compared to $39.6 million
	in the 2015 period, an increase of $3.3 million due to higher molecular testing service revenues. Clinical Lab gross profit margin
	was 40% in the 2016 period and 38% in the 2015 period. As a percentage of revenues, the provision for uncollectable accounts declined
	to 3.3% versus 3.8% in the 2015 period and is due to enhanced collection procedures for self-pay patient receivables.
</P>
<!-- FIELD: PAGE; SEQUENCE: 47 -->
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 6PT; PADDING-BOTTOM: 12PT; BORDER-BOTTOM: SILVER 4PX SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	46
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage48"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 10PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: LEFT; WIDTH: 100%">
<PAGE>
</PAGE>
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
<U>
	Life Sciences
</U>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	The Life Sciences segment&rsquo;s operating income before
	taxes was $61.4 million for the 2016 period as compared to $15.0 million for the 2015 period, an improvement of $46.4
	million. The 2016 period includes $58.8 million for patent litigation settlements previously described and $11.5 million in
	the 2015 period. Product revenues decreased $1.4 million or 4% in the 2016 period due to declines in product sales of $0.8
	million in the United States and foreign markets and the negative impact of $0.6 million from translating revenues
	denominated in the euro, pound sterling and Swiss franc which depreciated on average versus the US dollar during the 2016
	period compared to the 2015 period. Revenues decreased due to lower order volume and were negatively impacted by pricing due
	to competition and lower research funding, especially in academia. The segment&rsquo;s gross profit was $17.5 million in the
	2016 period, as compared $19.0 million in the 2015 period, a decrease of $1.5 million primarily due to lower royalty and
	license fee income of $1.0 million and a gross margin decrease of $0.5 million on lower product revenues. Due to
	significantly smaller depreciation of foreign currencies versus the US dollar, in particular the British pound and Euro at
	the end of the 2016 period versus the start of the 2016 period, the foreign currency loss was $0.5 million compared to a loss
	of $0.9 million in the 2015 period, a favorable change of $0.4 million in the 2016 period.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
<U>
	Therapeutics
</U>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Therapeutics segment&rsquo;s operating loss before income taxes
	was approximately $0.8 and $0.7 million in the 2016 and 2015 periods, respectively.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
<U>
	Other
</U>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	The Other segment&rsquo;s operating loss before taxes for the
	2016 period was approximately $15.2 million as compared to $16.9 million for the 2015 period, a decrease of $1.7 million. During
	the 2016 period, legal fee expense associated with on-going patent litigation declined $2.8 million, professional fees declined
	$0.3 million, and salary related expenses declined $0.1 million. These declines were partially offset by $1.5 million of consulting
	and legal fee expenses relating to contested proxy costs for our annual stockholders&rsquo; meeting which took place in January
	2016.
</P>
<!-- FIELD: PAGE; SEQUENCE: 48 -->
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 6PT; PADDING-BOTTOM: 12PT; BORDER-BOTTOM: SILVER 4PX SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	47
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage49"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 10PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: LEFT; WIDTH: 100%">
<PAGE>
</PAGE>
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_12"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PX SOLID">
<B>
<I>
	Results
	of Operations
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
<I>
	Fiscal year ended July 31, 2015 compared
	to July 31, 2014
<BR>
	(in 000s)
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD COLSPAN="17">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<U>
	Comparative Financial Data for the Fiscal Years Ended July 31,
</U>
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD COLSPAN="2" STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	2015
</B>
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD COLSPAN="2" STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	2014
</B>
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD COLSPAN="2" STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Increase
</B>
</FONT>
<BR>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	(Decrease)
</B>
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD COLSPAN="2" STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	% Change
</B>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	&nbsp;
</B>
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255)">
<TD STYLE="PADDING-LEFT: 11PT; WIDTH: 42%; TEXT-INDENT: -11PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Revenues:
</FONT>
</TD>
<TD STYLE="WIDTH: 3%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 3%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 3%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 3%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 8%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-LEFT: 11PT; TEXT-INDENT: -11PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Clinical laboratory services
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	63,414
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	58,689
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	4,725
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	8
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255)">
<TD STYLE="PADDING-LEFT: 11PT; TEXT-INDENT: -11PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Product revenues
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	31,690
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	32,850
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	(1,160
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	(4
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-LEFT: 11PT; TEXT-INDENT: -11PT; PADDING-BOTTOM: 1PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Royalty and license fee income
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	2,495
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	4,408
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	(1,913
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	)
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-BOTTOM: 1PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;&nbsp;&nbsp;(43
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255)">
<TD STYLE="PADDING-LEFT: 11PT; TEXT-INDENT: -11PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Total revenues
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	97,599
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	95,947
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	1,652
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	2
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="PADDING-LEFT: 11PT; TEXT-INDENT: -11PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-LEFT: 11PT; TEXT-INDENT: -11PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Operating costs, expenses and legal settlements, net:
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255)">
<TD STYLE="PADDING-LEFT: 11PT; TEXT-INDENT: -11PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Cost of clinical laboratory services
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	39,589
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	38,948
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	641
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	2
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-LEFT: 11PT; TEXT-INDENT: -11PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Cost of product revenues
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	15,183
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	15,320
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	(137
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	(1
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255)">
<TD STYLE="PADDING-LEFT: 11PT; TEXT-INDENT: -11PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Research and development
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	3,350
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	3,141
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	209
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	7
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-LEFT: 11PT; TEXT-INDENT: -11PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Selling, general, and administrative
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	41,069
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	41,801
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	(732
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	(2
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255)">
<TD STYLE="PADDING-LEFT: 11PT; TEXT-INDENT: -11PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Provision for uncollectible accounts receivable
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	2,284
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	3,063
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	(779
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	(25
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-LEFT: 11PT; TEXT-INDENT: -11PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Legal fee expense
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	8,788
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	6,954
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	1,834
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	26
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255)">
<TD STYLE="PADDING-LEFT: 11PT; TEXT-INDENT: -11PT; PADDING-BOTTOM: 1PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Legal settlements, net
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	(11,458
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	)
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	(3,100
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	)
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	(8,358
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	)
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-BOTTOM: 1PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	**
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-LEFT: 11PT; TEXT-INDENT: -11PT; PADDING-BOTTOM: 1PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Total costs, expenses and legal settlements, net
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	98,805
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	106,127
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	(7,322
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	)
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-BOTTOM: 1PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	(7
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="PADDING-LEFT: 11PT; TEXT-INDENT: -11PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255)">
<TD STYLE="PADDING-LEFT: 11PT; TEXT-INDENT: -11PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Operating loss
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	(1,206)
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	(10,180
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	(8,974)
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	88
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="PADDING-LEFT: 11PT; TEXT-INDENT: -11PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-LEFT: 11PT; TEXT-INDENT: -11PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Other income (expense):
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255)">
<TD STYLE="PADDING-LEFT: 11PT; TEXT-INDENT: -11PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Interest
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	(245
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	(208
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	37
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	(18
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-LEFT: 11PT; TEXT-INDENT: -11PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Other
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	95
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	194
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	99
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	51
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255)">
<TD STYLE="PADDING-LEFT: 11PT; TEXT-INDENT: -11PT; PADDING-BOTTOM: 1PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Foreign currency (loss) gain
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	(936
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	)
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	289
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	1,225
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-BOTTOM: 1PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	**
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-LEFT: 11PT; TEXT-INDENT: -11PT; PADDING-BOTTOM: 3PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Loss before income taxes
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	(2,292
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	)
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	(9,905
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	)
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	(7,613
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-BOTTOM: 3PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	(77
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 3PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	)
</FONT>
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	** not meaningful
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	Consolidated Results:
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	The &ldquo;2015 period&rdquo; and the &ldquo;2014 period&rdquo;
	refer to the fiscal year ended July 31, 2015 and 2014, respectively.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Clinical laboratory services revenues for the 2015 period were
	$63.4 million compared to $58.7 million, an increase of $4.7 million or 8%. The increase in revenue from fiscal year 2014 to 2015
	is mainly attributed to an increase in molecular testing related to volume and the increase in the average gross charge per accession.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Product revenues for the 2015 period were $31.7 million compared
	to $32.9 million in the 2014 period, a decrease of $1.2 million or 4%. The decrease was due to the negative impact of translating
	revenues denominated in the euro, pound sterling and Swiss franc which depreciated versus the US dollar in the 2015 period compared
	to the 2014 period ($0.9 million) and declines in sales of non-proprietary products ($0.3 million), primarily in markets other
	than the US.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Royalty and license fee income during the 2015 period was $2.5
	million compared to $4.4 million in the 2014 period a decrease of $1.9 million or 43%. Royalties are primarily earned from the
	reported sales of Qiagen products subject to a license agreement. Qiagen has experienced declines in its US sales of HPV products
	which in turn reduces our royalty income. There are no direct expenses relating to royalty and licensing income.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	The cost of clinical laboratory services during the 2015 period
	was $39.6 million as compared to $38.9 million in the 2014 period, an increase of $0.6 million or 2%.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	The cost of product revenues during the 2015 period was $15.2
	million compared to $15.3 million in the 2014 period, a decrease of $0.1 million or 1%. The gross profit margin was 52% in the
	2015 period versus 53% in the 2014 period.
</P>
<!-- FIELD: PAGE; SEQUENCE: 49 -->
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 6PT; PADDING-BOTTOM: 12PT; BORDER-BOTTOM: SILVER 4PX SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	48
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage50"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 10PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: LEFT; WIDTH: 100%">
<PAGE>
</PAGE>
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Research and development expenses were approximately $3.4 million
	during the 2015 period, compared to $3.1 million in the 2014 period, an increase of $0.2 million or 7%. The increase was attributed
	to an increase in payroll and material costs related to product development for the Life Sciences segment.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Selling, general and administrative expenses were approximately
	$41.1 million during the 2015 period and $41.8 million during the 2014 period, a decrease of $0.7 million or 2%. For the Enzo Life
	Sciences segment, selling, general and administrative decreased $1.2 million due to the positive effects from the business realignments
	occurring in fiscal 2014 resulting in lower compensation related costs and lower facility costs. Other segment selling, general
	and administrative increased $0.3 million, primarily due to compensation related costs and professional and other fees. The Clinical
	Lab segment selling, general and administrative increased $0.2 million primarily due to increases in compensation related expenses.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	The provision for uncollectible accounts receivable, primarily
	related to the Clinical Labs segment, was $2.3 million for the 2015 period as compared to $3.1 million in the 2014 period, a decrease
	of $0.8 million or 25%. The decrease is primarily due to improved collection procedures at the Clinical Labs.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Legal fee expense was $8.8 million during the 2015 period compared
	to $7.0 million in the 2014 period, an increase of $1.8 million or 26% primarily due to increased legal fees and related costs
	associated with on-going patent litigation.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 2.2PT 0PT 0">
	Legal settlements, net was $(11.5) million in the
	2015 period and $(3.1) in the 2014 period. During the 2015 period the Company as plaintiff finalized and executed settlement agreements
	with Luminex Corporation ($4.9 million, net), Siemens Healthcare Diagnostics ($6.4 million, net), and Molecular Probes ($0.2 million).
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 2.2PT 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 2.2PT 0PT 0">
	During the 2014 period the Company as plaintiff finalized
	and executed a settlement agreement with Affymetrix, Inc. in the amount of $5.1 million. Also during the 2014 period, the Company
	reached a final agreement on the principal terms of a settlement with the U.S. Department of Justice relating to their investigation
	of an alleged failure to collect diagnosis codes from physicians who ordered tests through Enzo Clinical Labs. As a result, the
	Company recorded a charge of $2.0 million.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 2.2PT 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Interest expense was $0.2 million during the 2015 and 2014 periods
	due to interest incurred on the credit agreement entered into in 2013.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	During the 2015 and the 2014 periods, the (loss) gain on foreign
	currency transactions was $(0.9) million and $0.3 million, respectively, an unfavorable change of $1.2 million. The Company has
	loans and receivables with its foreign subsidiaries which may be denominated in US dollars or a foreign currency. When re-measuring
	these amounts into the respective entities&rsquo; functional currency, the Company recognizes a loss if those foreign currencies,
	including the Swiss Franc, British pound and Euro depreciate relative to the US dollar during the period and a gain if those foreign
	currencies appreciate relative to the US dollar. During the 2015 period, those currencies depreciated between 6.4% and 18.3% relative
	to the US dollar. During the 2014 period, those currencies appreciated relative to the US dollar.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	Segment Results:
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
<U>
	Clinical Labs
</U>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	The Clinical Labs segment&rsquo;s income (loss) before taxes
	was $0.5 million for 2015 period as compared to a loss of $(6.6) million in the 2014 period, an improvement year over year of $7.1
	million. The 2014 period loss includes a $2.0 million charge for a legal settlement with the U.S. Department of Justice. Revenue
	from laboratory services for the 2015 period were $63.4 million compared to $58.7 in the 2014 period. The increase of $4.7 million
	is mainly attributed to an increase in molecular testing related to volume and the increase in the average gross charge per accession.
	Cost of sales during the 2015 period was $39.6 million as compared to $38.9 million in the 2014 period, an increase of $0.6 million.
	Clinical Lab gross profit margin was 38% in the 2015 period and 34% in the 2014 period. The provision for uncollectable accounts
	was $2.4 million as compared to $3.1 million; the decrease is primarily due to continued process review and improvement.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
<U>
	Life Sciences
</U>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	The Life Sciences segment&rsquo;s income before taxes was $15.0
	million for the 2015 period as compared to $10.8 million for the 2014 period, an improvement of $4.2 million over fiscal 2014.
	The 2015 and 2014 periods include $11.5 and $5.1 million, respectively for patent litigation settlement agreements previously described.
	Product revenues decreased $1.2 million or 4% in the 2015 period due to the negative impact of translating revenues denominated
	in foreign currencies into the US dollar ($0.9 million) and by declines in sales of non-proprietary products ($0.3 million), primarily
	in markets other than the US. The segment&rsquo;s gross profit was $19.0 million in the 2015 period, as compared $21.9 million
	in the 2014 period, a decrease of $2.9 million primarily due to a decrease in royalty and license fee income of $1.9 million and
	a gross margin decrease of $1.0 million on lower product revenues. The segment&rsquo;s other
</P>
<!-- FIELD: PAGE; SEQUENCE: 50 -->
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 6PT; PADDING-BOTTOM: 12PT; BORDER-BOTTOM: SILVER 4PX SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	49
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage51"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 10PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: LEFT; WIDTH: 100%">
<PAGE>
</PAGE>
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	operating expenses, excluding legal
	and legal settlements, net, decreased approximately $1.0 million during the 2015 period due to cost reductions from headcount realignments
	and continued centralization of activities, particularly relating to selling, general and administrative. Due to the depreciation
	of foreign currencies versus the US dollar, including the Swiss Franc, British pound and Euro during the 2015 period, the foreign
	currency loss was $0.9 million compared to a $0.3 million gain in the 2014 period, resulting in an unfavorable change of $1.2 million
	in the 2015 period.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
<U>
	Therapeutics
</U>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Therapeutics loss before income taxes was approximately $0.7
	million for the 2015 period as compared to $0.8 million in 2014 period due to lower activity
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
<U>
	Other
</U>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	The Other loss before taxes for the 2015 period was approximately
	$17.0 million as compared to $13.4 million for the 2014 period, an increase of $3.6 million primarily from the increase in legal
	fee expense and related costs associated with on-going patent litigation.
</P>
</EFX_RESULTS_OF_OPERATIONS>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_LIQUIDITY_CAPITAL>
<A NAME="FIS_LIQUIDITY_CAPITAL"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	Liquidity and Capital Resources
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	At July 31, 2016, the Company had cash and cash equivalents
	of $67.8 million of which $0.5 million was in foreign accounts, as compared to cash and cash equivalents of $18.1 million, of which
	$0.5 million was in foreign accounts at July 31, 2015. It is the Company&rsquo;s current intent to permanently reinvest these funds
	outside of the United States, and its current plans do not demonstrate a need to repatriate them to fund its United States operations.
	The Company had working capital of $70.8 million at July 31, 2016 compared to $22.5 million at July 31, 2015. The increase in working
	capital of $48.3 million was primarily due to the recognition of $45.3 million in net income for the fiscal year ended July 31,
	2016.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Net cash provided by operating activities in fiscal 2016 was
	approximately $53.1 million as compared to net cash used in operating activities of $3.7 million in fiscal 2015, an increase of
	approximately $56.8 million. The increase in net cash provided by operating activities in the 2016 period versus the 2015 period
	was primarily due to an increase in net income of $47.6 million, and a net change in operating assets and liabilities of $9.3 million.
	Net cash used in operating activities in fiscal 2015 was approximately $3.7 million as compared to $1.7 million in fiscal 2014,
	an increase of approximately $2.0 million. The increase in net cash used in operating activities in the 2015 period versus the
	2014 period was primarily due to a net change in operating assets and liabilities of $9.5 million, which includes the increase
	in other receivables of $6.7 million for the settlement agreement with Siemens Healthcare Diagnostics Inc., and a decrease in non-cash
	charges of $0.2 million, partially offset by the change in the net loss of $7.7 million.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Net cash used
	in investing activities in fiscal 2016 was approximately $1.5 million as compared to $1.8 million in the year ago period, a decrease
	of $0.3 million. The decrease in the 2016 period is primarily due to decreased capital expenditures.
</FONT>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Net
	cash used in investing activities in fiscal 2015 was approximately $1.8 million as compared to $0.8 million in the year ago period,
	an increase of $1.0 million. The increase in the 2015 period is primarily due to increased capital expenditures.
</FONT>
</P>
<P STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Net cash used in financing activities in fiscal 2016 was approximately
	$1.9 million as compared to cash provided by financing activities of $6.2 million in fiscal 2015. The decrease of $8.2 million
	was due to the decrease in proceeds from the issuance of common stock of $6.7 million and increased net payments under the Credit
	Agreement of $1.5 million. Net cash provided by financing activities in fiscal 2015 was approximately $6.2 million as compared
	to $10.9 million in fiscal 2014. The decrease of $4.7 million was due to the decrease in proceeds from the issuance of common stock
	of $4.9 million partially offset by a decrease of $0.3 million in net payments under the Credit Agreement and Installment loans
	and capital leases.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	On June 7,
	2013, the Company entered into a secured Revolving Loan and Security Agreement (the &ldquo;Credit Agreement&rdquo;) among the Company
	and certain of its subsidiaries, with Enzo Therapeutics as a guarantor, and
</FONT>
	MidCap Financial Services, LLC (formerly
<FONT STYLE="COLOR: #1F497D">
</FONT>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Healthcare Finance Group, LLC). The Credit Agreement, which expires
	in December 2016, provides for borrowings against eligible US receivables, as defined, of the Clinical Labs and Life Sciences segments
	up to $8.0 million at defined eligibility percentages and provides for additional borrowings of $4.0 million for increased eligible
	assets. At July 31, 2016, 2015 and 2014, the borrowings under the Credit Agreement related to the Clinical Labs and Life Sciences
	receivables aggregated $1.6, $3.0 and $3.0 million, respectively, with an additional availability of $6.2 million as of July 31,
	2016. As of July 31, 2013, the Company received a waiver from the Lender for non-compliance with a financial covenant and the lender
	modified various financial covenants relating to fiscal 2014. As of July 31, 2016 and 2015, the Company has been in compliance
	with the modified financial covenants. See Note 7 to the Consolidated Financial Statements for a further description of the Credit
	Agreement&rsquo;s terms and financial covenants.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	The Company continued to review all operating units to further
	reduce annual operating expenditures in fiscal 2016. While revenues and operating results at the Clinical Labs segment improved,
	revenues for the Life Sciences segment declined versus fiscal 2016. If revenues continue to decline, the segment may be required
	to record impairments of its intangible assets, which last occurred in fiscal 2012. The Company believes that its current cash
	and cash equivalents level, utilization of the Controlled Equity Offering program
</P>
<!-- FIELD: PAGE; SEQUENCE: 51 -->
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 6PT; PADDING-BOTTOM: 12PT; BORDER-BOTTOM: SILVER 4PX SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	50
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage52"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 10PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: LEFT; WIDTH: 100%">
<PAGE>
</PAGE>
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	disclosed in Note 10 to the financial statements,
	which has resulted in net proceeds of $6.7 million and $11.5 million during the fiscal year ended July 31, 2015 and 2014, respectively,
	and none during 2016, and available borrowings under the aforementioned Revolving Loan and Security Agreement disclosed in Note
	7 to the financial statements are sufficient for its foreseeable liquidity and capital resource needs over the next twelve (12)
	months, although there can be no assurance that future events will not alter such view. Although there can be no assurances, in
	the event additional capital is required, the Company believes it has the ability to raise additional funds through equity offerings
	or other sources of funds. Our liquidity plans are subject to a number of risks and uncertainties, including those described in
	the Item 1A. &ldquo;Risk Factors&rdquo; section of this Form 10-K for the year ended July 31, 2016, some of which are outside our
	control. Macroeconomic conditions could limit our ability to successfully execute our business plans and therefore adversely affect
	our liquidity plans.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
<I>
	Effect of New Accounting Pronouncements
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	In May 2014, the Financial Accounting Standards Board (&ldquo;FASB&rdquo;)
	issued Accounting Standard Update (&ldquo;ASU&rdquo;) No. 2014-09,
<I>
	Revenue from Contracts with Customers: Topic 606
</I>
	. ASU
	2014-09 amends the guidance for revenue recognition to replace numerous, industry-specific requirements and converges areas under
	this topic with those of the International Financial Reporting Standards. ASU 2014-09 implements a five-step process for customer
	contract revenue recognition that focuses on transfer of control, as opposed to transfer of risk and rewards. The amendment also
	requires enhanced disclosures regarding the nature, amount, timing and uncertainty of revenues and cash flows from contracts with
	customers. Other major provisions include the capitalization and amortization of certain contract costs, ensuring the time value
	of money is considered in the transaction price, and allowing estimates of variable consideration to be recognized before contingencies
	are resolved in certain circumstances. As of July 9, 2015, the FASB decided to delay the effective date of the new revenue standard
	by one year. The amendments in ASU 2014-09 are effective for reporting periods beginning after December 15, 2017, (the fiscal year
	ending July 31, 2019 for the Company) and early adoption is permitted for reporting periods beginning after December 15, 2016.
	Entities can transition to the standard either retrospectively or as a cumulative-effect adjustment as of the date of adoption.
	We are currently assessing the impact the adoption of ASU 2014-09 will have on the Company&rsquo;s combined consolidated financial
	statements.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	In August 2014, the FASB issued ASU No. 2014-15,
<I>
	Disclosure
	of Uncertainties about an Entity&rsquo;s Ability to Continue as a Going Concern
</I>
	. ASU 2014-15 will explicitly require management
	to assess an entity&rsquo;s ability to continue as a going concern, and to provide related footnote disclosure in certain circumstances.
	The new standard will be effective for all entities in the first annual period ending after December 15, 2016. Earlier adoption
	is permitted. We do not expect the adoption of this update to have a material impact on our consolidated financial statements.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	In January 2015, the FASB issued ASU No. 2015-01,
<I>
	Income
	Statement Extraordinary and Unusual Items.
</I>
	The ASU eliminates the concept of extraordinary items from U.S. GAAP as part of
	its simplification initiative. The ASU does not affect disclosure guidance for events or transactions that are unusual in nature
	or infrequent in their occurrence. The update applies to all entities for fiscal years, and interim periods within those fiscal
	years, beginning after December 15, 2015. The adoption of this update will not have any impact on our consolidated financial statements.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	In February 2015, the FASB issued ASU No. 2015-02,
<I>
	Consolidation:
	Amendments to the Consolidation Analysis.
</I>
	The amendments in the update affect reporting entities that are required to evaluate
	whether they should consolidate certain legal entities. All legal entities are subject to reevaluation under the revised consolidation
	model. The amendments in the Update are effective for public business entities for fiscal years, and for interim periods within
	those fiscal years, beginning after December 15, 2015. For all other entities, the effective date for fiscal years beginning after
	December 15, 2016, and for interim periods within fiscal years beginning after December 15, 2017. Early adoption is permitted.
	The adoption of this update will not have any impact on our consolidated financial statements.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	In April 2015, the FASB issued ASU No. 2015-03
<I>
	Interest &ndash;
	Imputation of Interest.
</I>
	The ASU was issued as part of the Simplification Initiatives, to simplify presentation of debt issuance
	costs. The amendments in the update require that debt issuance costs related to a recognized debt liability be presented in the
	balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts. The recognition
	and measurement guidance for debt issuance costs are not affected by the amendments in this update. For public business entities,
	the amendments in the update are effective for financial statements issued for fiscal years beginning after December 15, 2015,
	and interim periods within those fiscal years. Early adoption of the amendments in this update is permitted for financial statements
	that have not been previously issued. We do not expect the adoption of this update to have a material impact on our consolidated
	financial statements.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	In July 2015, the FASB issued ASU No. 2015-11,
<I>
	Simplifying
	the Measurement of Inventory (Topic 330).
</I>
	ASU 2015-11 changes the measurement principle for inventory from the lower of cost
	or market to lower of cost or net realizable value. The new standard is effective for our fiscal years and interim periods beginning
	after December 15, 2016. We do not expect the adoption of this update to have a material impact on our consolidated financial statements.
</P>
<!-- FIELD: PAGE; SEQUENCE: 52 -->
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 6PT; PADDING-BOTTOM: 12PT; BORDER-BOTTOM: SILVER 4PX SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	51
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage53"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 10PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: LEFT; WIDTH: 100%">
<PAGE>
</PAGE>
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	In February 2016, the FASB issued Accounting Standards Update
	(&ldquo;ASU&rdquo;) No. 2016-02 &ndash;
<I>
	Leases (Topic 842)
</I>
	. The new standard establishes a right-of-use (ROU) model that
	requires a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months.
	Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the
	income statement. The new standard is effective for fiscal years beginning after December 15, 2018, including interim periods within
	those fiscal years. A modified retrospective transition approach is required for lessees for capital and operating leases existing
	at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain
	practical expedients available. While we are evaluating the impact of adopting the new standard on our consolidated financial statements,
	we expect that upon adoption we will recognize ROU assets and lease liabilities in amounts that could be material.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	In March 2016, the FASB issued ASU 2016-09,
<I>
	&ldquo;Improvements
	to Employee Share-Based Payment Accounting,&rdquo;
</I>
	which requires all excess tax benefits or deficiencies to be recognized
	as income tax expense or benefit in the income statement. In addition, excess tax benefits should be classified along with other
	income tax cash flows as an operating activity in the statement of cash flows. Application of the standard is required for the
	annual and interim periods beginning after December 15, 2016. Early adoption is permitted. We are currently evaluating the impact
	of this new standard on our consolidated financial statements.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	In June 2016, the FASB issued ASU no. 2016-13,
<I>
	&ldquo;Financial
	Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments.&rdquo;
</I>
	ASU 2016-13 introduces
	a new forward-looking &ldquo;expected loss&rdquo; approach, to estimate credit losses on most financial assets and certain other
	instruments, including trade receivables. The estimate of expected credit losses will require entities to incorporate considerations
	of historical information, current information and reasonable and supportable forecasts. This ASU also expands the disclosure requirements
	to enable users of financial statements to understand the entity&rsquo;s assumptions, models and methods for estimating expected
	credit losses. ASU 2016-13 is effective for the Company&rsquo;s fiscal year ending July 31, 2021, and the guidance is to be applied
	using the modified-retrospective approach. The Company is currently evaluating the potential impact of adopting this guidance on
	our consolidated financial statements.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
<I>
	Contractual Obligations
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	The Company has entered into various real estate and equipment
	operating leases and has employment agreements with certain executive officers. The real estate lease for the Company&rsquo;s Farmingdale
	Clinical Lab and Research facility is with a related party. See Item 2, Properties, and Note 13 to the Consolidated Financial Statements
	for a further description of these various leases.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	The following is a summary of future payments under the Company&rsquo;s
	contractual obligations as of July 31, 2016:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_13"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	&nbsp;Payments Due by Period
</B>
	(In thousands)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD COLSPAN="2" STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Total
</B>
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD COLSPAN="2" STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Less than
</B>
</FONT>
<BR>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	1 year
</B>
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD COLSPAN="2" STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	1-3 years
</B>
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD COLSPAN="2" STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	4-5 years
</B>
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD COLSPAN="2" STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	More than 5
</B>
</FONT>
<BR>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	&nbsp;&nbsp;years
</B>
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	&nbsp;
</B>
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	&nbsp;
</B>
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255)">
<TD STYLE="WIDTH: 38%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Operating lease obligations
</FONT>
</TD>
<TD STYLE="WIDTH: 3%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</FONT>
</TD>
<TD STYLE="WIDTH: 9%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	36,933
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</FONT>
</TD>
<TD STYLE="WIDTH: 9%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	7,256
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</FONT>
</TD>
<TD STYLE="WIDTH: 9%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	13,211
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</FONT>
</TD>
<TD STYLE="WIDTH: 9%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	6,404
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</FONT>
</TD>
<TD STYLE="WIDTH: 9%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	10,062
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Current and long term debt obligations
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	3,098
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	2,193
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	905
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&mdash;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&mdash;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255)">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Employment agreements
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	2,271
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	1,048
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	1,223
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&mdash;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&mdash;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Capital lease obligations
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	1,312
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	307
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	557
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	448
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&mdash;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255)">
<TD STYLE="PADDING-BOTTOM: 3PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Total
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	43,614
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	10,804
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	15,896
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	6,852
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	10,062
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Management is not aware of any material claims, disputes or
	settled matters concerning third-party reimbursements that would have a material effect on our financial statements.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	Off-Balance Sheet Arrangements
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	The Company does not have any &ldquo;off-balance sheet arrangements&rdquo;
	as such term is defined in Item 303(a) (4) of Regulation S-K.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	Critical Accounting Policies
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<I>
<U>
	General
</U>
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	The Company&rsquo;s discussion and analysis of its financial
	condition and results of operations are based upon Enzo Biochem, Inc.&rsquo;s consolidated financial statements, which have been
	prepared in accordance with accounting principles generally accepted in the United States. The preparation of these financial statements
	requires the Company to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses.
	These estimates and judgments also affect related disclosure of contingent assets and liabilities.
</P>
<!-- FIELD: PAGE; SEQUENCE: 53 -->
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 6PT; PADDING-BOTTOM: 12PT; BORDER-BOTTOM: SILVER 4PX SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	52
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage54"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 10PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: LEFT; WIDTH: 100%">
<PAGE>
</PAGE>
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	On an on-going basis, we evaluate our estimates, including those
	related to contractual expense, allowance for uncollectible accounts, inventory, intangible assets and income taxes. The Company
	bases its estimates on experience and on various other assumptions that are believed to be reasonable under the circumstances,
	the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily
	apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<I>
<U>
	Product revenues
</U>
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Revenues from product sales are recognized when the products
	are shipped and title transfers, the sales price is fixed or determinable and collectability is reasonably assured.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<I>
<U>
	Royalties
</U>
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Royalty revenues are recorded in the period earned. Royalties
	received in advance of being earned are recorded as deferred revenues.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<I>
<U>
	Revenues - Clinical laboratory services
</U>
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Revenues from the Clinical Labs segment are recognized upon
	completion of the testing process for a specific patient and reported to the ordering physician. These revenues and the associated
	accounts receivable are based on gross amounts billed or billable for services rendered, net of a contractual adjustment, which
	is the difference between amounts billed to payers and the expected approved reimbursable settlements from such payers.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	The following table represents the Clinical Labs segment&rsquo;s
	net revenues and percentages by revenue category (in thousands):
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_14"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="PADDING-RIGHT: -0.4PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD COLSPAN="6" STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Year ended July 31,
</B>
</FONT>
<BR>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	2016
</B>
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD COLSPAN="6" STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Year ended July 31,
</B>
</FONT>
<BR>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	2015
</B>
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD COLSPAN="6" STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Year ended July 31,
</B>
</FONT>
<BR>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	2014
</B>
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; PADDING-RIGHT: -0.4PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Category
</B>
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD COLSPAN="2" STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Revenue
</B>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD COLSPAN="2" STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	%
</B>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD COLSPAN="2" STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Revenue
</B>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD COLSPAN="2" STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	%
</B>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD COLSPAN="2" STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Revenue
</B>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD COLSPAN="2" STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	%
</B>
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	&nbsp;
</B>
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255)">
<TD STYLE="WIDTH: 27%; PADDING-RIGHT: -0.4PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Third-party payers
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</FONT>
</TD>
<TD STYLE="WIDTH: 9%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	40,211
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 9%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	57
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</FONT>
</TD>
<TD STYLE="WIDTH: 9%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	35,631
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 9%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	56
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</FONT>
</TD>
<TD STYLE="WIDTH: 9%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	29,509
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 9%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	50
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-RIGHT: -0.4PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Medicare
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	11,392
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	16
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	11,981
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	19
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	12,815
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	22
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255)">
<TD STYLE="PADDING-RIGHT: -0.4PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Patient self-pay
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	14,744
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	21
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	11,028
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	17
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	11,204
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	19
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-RIGHT: -0.4PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	HMO&rsquo;s
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	4,568
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	6
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	4,774
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	8
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	5,161
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	9
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255)">
<TD STYLE="PADDING-RIGHT: -0.4PT; PADDING-BOTTOM: 3PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Total
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	70,915
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	100
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	%
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	63,414
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	100
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	%
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	58,689
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	100
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	%
</FONT>
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	The Company provides services to certain patients covered by
	various third-party payers, including the Federal Medicare program. Laws and regulations governing Medicare are complex and subject
	to interpretation for which action for noncompliance includes fines, penalties and exclusion from the Medicare programs. See Item
	3. Legal Proceedings.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Other than the Medicare program, one provider whose programs
	are included in the &ldquo;Third-party payers&rdquo; and &ldquo;Health Maintenance Organizations&rdquo; (&ldquo;HMO&rsquo;s&rdquo;)
	categories represent approximately 30%, 28% and 25% of the Clinical Labs segment net revenue for the years ended July 31, 2016,
	2015 and 2014 respectively.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<I>
	Contractual Adjustment
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	The Company&rsquo;s estimate of contractual adjustment is based
	on significant assumptions and judgments, such as its interpretation of payer reimbursement policies, and bears the risk of change.
	The estimation process is based on the experience of amounts approved as reimbursable and ultimately settled by payers, versus
	the corresponding gross amount billed to the respective payers. The contractual adjustment is an estimate that reduces gross revenue
	based on gross billing rates to amounts expected to be approved and reimbursed. Gross billings are based on a standard fee schedule
	we set for all third party payers, including Medicare, health maintenance organizations (&ldquo;HMO&rsquo;s&rdquo;) and managed
	care. The Company adjusts the contractual adjustment estimate quarterly, based on its evaluation of current and historical settlement
	experience with payers, industry reimbursement trends, and other relevant factors. The other relevant factors that affect our contractual
	adjustment include the monthly and quarterly review of: 1) current gross billings and receivables and reimbursement by payer, 2)
	current changes in third party arrangements and 3) the growth of in-network provider arrangements and managed care plans specific
	to our Company.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Our clinical laboratory business is primarily dependent upon
	reimbursement from third-party payers, such as Medicare (which principally serves patients 65 and older) and insurers. We are subject
	to variances in reimbursement rates among different third-party payers, as well as constant changes of reimbursement rates. Changes
	that decrease reimbursement rates or coverage would negatively
</P>
<!-- FIELD: PAGE; SEQUENCE: 54 -->
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 6PT; PADDING-BOTTOM: 12PT; BORDER-BOTTOM: SILVER 4PX SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	53
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage55"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 10PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: LEFT; WIDTH: 100%">
<PAGE>
</PAGE>
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	impact our revenues. The number of individuals covered under managed
	care contracts or other similar arrangements has grown over the past several years and may continue to grow in the future. In addition,
	Medicare and other government healthcare programs continue to shift to managed care. These trends will continue to reduce our revenues.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	During the years ended July 31, 2016, 2015 and 2014, the contractual
	adjustment percentages, determined using current and historical reimbursement statistics, were approximately 84%, 85% and 86%,
	respectively, of gross billings. The Company believes a decline in reimbursement rates or a shift to managed care, or similar arrangements
	may be offset by the positive impact of an increase in the number of tests we perform. However, there can be no assurance that
	we can increase the number of tests we perform or that if we do increase the number of tests we perform, that we can maintain that
	higher number of tests performed, or that an increase in the number of tests we perform would result in increased revenue.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	The Company estimates (by using a sensitivity analysis) that
	each 1% point change in the contractual adjustment percentage could result in a change in clinical laboratory services revenues
	of approximately $4.5 million, $4.3 million, and $4.1 million, for the years ended July 31, 2016, 2015, and 2014, respectively,
	and a change in the net accounts receivable of approximately $0.6 million as of each of July 31, 2016 and $0.5 million as of July
	31, 2015 and 2014.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Our clinical laboratory financial billing system records gross
	billings using a standard fee schedule for all payers and does not record contractual adjustment by payer at the time of billing.
	Therefore, we are unable to quantify the effect of contractual adjustment recorded during the current period that relate to revenue
	recorded in a previous period. However, we can reasonably estimate our monthly contractual adjustment to revenue on a timely basis
	based on our quarterly review process, which includes:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 3%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&bull;
</FONT>
</TD>
<TD STYLE="WIDTH: 97%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	an analysis of industry reimbursement trends;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 12PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	an evaluation of third-party reimbursement rates changes and changes in reimbursement arrangements with third-party payers;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 12PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	a rolling monthly analysis of current and historical claim settlement and reimbursement experience statistics with payers;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 12PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	an analysis of current gross billings and receivables by payer.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<I>
<U>
	Accounts Receivable and Allowance for Doubtful Accounts
</U>
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Accounts receivable are reported at realizable value, net of
	allowances for doubtful accounts, which is estimated and recorded in the period of the related revenue.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	The following is a table of the Company&rsquo;s net accounts
	receivable by segment. The Clinical Labs segment&rsquo;s net receivables are detailed by billing category and as a percent to its
	total net receivables. As of July 31, 2016 and 2015, approximately 71% and 68% respectively, of the Company&rsquo;s net accounts
	receivable relates to its Clinical Labs business, which operates in the New York and New Jersey medical communities. The Life Sciences
	segment&rsquo;s accounts receivable, of which $1.2 million or 28% and $1.1 million or 28% represents foreign receivables as of
	July 31, 2016 and 2015 respectively, includes royalty receivables of $0.5 million and $0.1 million, respectively, from Qiagen Corporation.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<U>
	Net accounts receivable (in thousands)
</U>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_15"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD COLSPAN="6" STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	July 31, 2016
</B>
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD COLSPAN="6" STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	July 31, 2015
</B>
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	&nbsp;
</B>
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD COLSPAN="2" STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Total Amount
</B>
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD COLSPAN="2" STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	%
</B>
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD COLSPAN="2" STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Total Amount
</B>
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD COLSPAN="2" STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	%
</B>
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	&nbsp;
</B>
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255)">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Clinical Labs (by billing category)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="WIDTH: 40%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Third party payers
</FONT>
</TD>
<TD STYLE="WIDTH: 2%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</FONT>
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	6,868
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 2%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	67
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 2%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</FONT>
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	3,595
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 2%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	44
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255)">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Patient self-pay
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	1,676
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	16
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	3,213
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	39
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Medicare
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	1,486
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	14
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	1,081
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	13
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255)">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	HMO&rsquo;s
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	334
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	3
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	305
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	4
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-BOTTOM: 3PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Total Clinical Labs
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-BOTTOM: 3PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	10,364
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	100
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	%
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-BOTTOM: 3PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	8,194
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	100
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	%
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255)">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Total Life Sciences
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	4,228
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	3,915
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-BOTTOM: 3PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Total accounts receivable &ndash; net
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	14,592
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-BOTTOM: 3PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	12,109
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-BOTTOM: 3PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Changes in the Company&rsquo;s allowance for doubtful accounts
	are as follows:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_16"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD COLSPAN="2" STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	July 31, 2016
</B>
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD COLSPAN="2" STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	July 31, 2015
</B>
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	&nbsp;
</B>
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255)">
<TD STYLE="WIDTH: 70%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Beginning balance
</FONT>
</TD>
<TD STYLE="WIDTH: 2%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</FONT>
</TD>
<TD STYLE="WIDTH: 11%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	1,786
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 2%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</FONT>
</TD>
<TD STYLE="WIDTH: 11%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	2,142
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Provision for doubtful accounts
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	2,336
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	2,284
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255)">
<TD STYLE="PADDING-BOTTOM: 1PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Write-offs, net
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	(605
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	)
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	(2,640
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-BOTTOM: 3PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Ending balance
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	3,517
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	1,786
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 55 -->
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 6PT; PADDING-BOTTOM: 12PT; BORDER-BOTTOM: SILVER 4PX SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	54
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage56"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 10PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: LEFT; WIDTH: 100%">
<PAGE>
</PAGE>
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	For the Clinical Labs segment, the allowance for doubtful accounts
	represents amounts that the Company does not expect to collect after the Company has exhausted its collection procedures. The Company
	estimates its allowance for doubtful accounts in the period the related services are billed and reduces the allowance in future
	accounting periods based on write-offs during those periods. It bases the estimate for the allowance on the evaluation of historical
	experience of accounts going to collections and the net amounts not received. Accounts going to collection include the balances,
	after receipt of the approved settlements from third party payers, for the insufficient diagnosis information received from the
	ordering physician which result in denials of payment, and our estimate of the uncollected portion of receivables from self-payers,
	including deductibles and copayments, which are subject to credit risk and patients&rsquo; ability to pay. As of July 31, 2016
	and 2015, the Company recategorizes to collections customers whose accounts receivable have been outstanding more than 210 days.
	The Company fully reserves through its contractual allowances amounts that have not been written off because the payer&rsquo;s
	filing date deadline has not occurred or the collection process has not been exhausted. The Company&rsquo;s collection experience
	on Medicare receivables beyond 210 days has been insignificant. The Company adjusts the historical collection analysis for recoveries,
	if any, on an on-going basis.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	The Company&rsquo;s ability to collect outstanding receivables
	from third party payers is critical to its operating performance and cash flows. The primary collection risk lies with uninsured
	patients or patients for whom primary insurance has paid but a patient portion remains outstanding. The Company also assesses the
	current state of its billing functions in order to identify any known collection or reimbursement issues in order to assess the
	impact, if any, on the allowance estimates, which involves judgment. The Company believes that the collectability of its receivables
	is directly linked to the quality of its billing processes, most notably, those related to obtaining the accurate patient information
	in order to bill effectively for the services provided. Should circumstances change (e.g. shift in payer mix, decline in economic
	conditions or deterioration in aging of receivables), our estimates of net realizable value of receivables could be reduced by
	a material amount.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Billing for laboratory services is complicated because of many
	factors, especially: the differences between our standard gross fee schedule for all payers and the reimbursement rates of the
	various payers we deal with, disparity of coverage and information requirements among the various payers, and disputes with payers
	as to which party is responsible for reimbursement.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	The allowance for doubtful accounts as a percentage of total
	accounts receivable at July 31, 2016 and 2015 was 19.4% and 12.9% respectively. During fiscal 2016 a higher allowance was required
	due to the volume increase in genetic testing.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	The following table indicates the Clinical Labs aged gross receivables
	by payer group (in thousands), which is prior to adjustment to gross receivables for: 1) contractual adjustment, 2) fully reserved
	balances not yet written off, and 3) other revenue adjustments.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_17"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
<B>
	As of July 31, 2016
</B>
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD COLSPAN="2" STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Total
</B>
</FONT>
<BR>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Amount
</B>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	%
</B>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD COLSPAN="2" STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Third Party Payers Amount
</B>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	%
</B>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD COLSPAN="2" STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Medicare Amount
</B>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	%
</B>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD COLSPAN="2" STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Self-pay
</B>
</FONT>
<BR>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Amount
</B>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	%
</B>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD COLSPAN="2" STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	HMO&rsquo;s
</B>
</FONT>
<BR>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Amount
</B>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	%
</B>
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	&nbsp;
</B>
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255)">
<TD STYLE="WIDTH: 31%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	1-30 days
</FONT>
</TD>
<TD STYLE="WIDTH: 3%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</FONT>
</TD>
<TD STYLE="WIDTH: 6%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	29,091
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 2%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	49
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</FONT>
</TD>
<TD STYLE="WIDTH: 6%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	18,020
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 2%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	43
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</FONT>
</TD>
<TD STYLE="WIDTH: 7%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	4,945
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 2%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	72
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</FONT>
</TD>
<TD STYLE="WIDTH: 6%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	3,138
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 2%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	41
</FONT>
</TD>
<TD STYLE="WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</FONT>
</TD>
<TD STYLE="WIDTH: 6%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	2,988
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 2%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	98
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	31-60 days
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	9,081
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	15
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	6,176
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	15
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	625
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	9
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	2,253
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	29
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	27
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	1
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255)">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	61-90 days
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	6,364
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	11
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	3,947
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	9
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	402
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	6
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	1,987
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	26
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	28
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	1
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	91-120 days
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	4,025
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	7
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	3,339
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	8
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	354
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	5
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	325
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	4
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	7
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&mdash;
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255)">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	121-150 days
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	3,546
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	5
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	3,279
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	7
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	261
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	4
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	1
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&mdash;
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	5
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&mdash;
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-BOTTOM: 1PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Greater than 150 days*
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	7,666
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	13
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	7,427
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	18
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	292
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	4
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	(57
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&mdash;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	4
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&mdash;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255)">
<TD STYLE="PADDING-BOTTOM: 3PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Totals
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	59,773
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-BOTTOM: 3PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	100
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	%
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	42,188
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-BOTTOM: 3PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	100
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	%
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	6,879
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-BOTTOM: 3PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	100
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	%
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	7,647
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-BOTTOM: 3PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	100
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	%
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	3,059
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-BOTTOM: 3PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	100
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	%
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
</TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	As of July 31, 2015
</B>
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD COLSPAN="2" STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Total
</B>
</FONT>
<BR>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Amount
</B>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	%
</B>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD COLSPAN="2" STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Third Party Payers
</B>
</FONT>
<BR>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Amount
</B>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	%
</B>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD COLSPAN="2" STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Medicare
</B>
</FONT>
<BR>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Amount
</B>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	%
</B>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD COLSPAN="2" STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Self-pay
</B>
</FONT>
<BR>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Amount
</B>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	%
</B>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD COLSPAN="2" STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	HMO&rsquo;s
</B>
</FONT>
<BR>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Amount
</B>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	%
</B>
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	&nbsp;
</B>
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255)">
<TD STYLE="WIDTH: 31%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	1-30 days
</FONT>
</TD>
<TD STYLE="WIDTH: 3%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</FONT>
</TD>
<TD STYLE="WIDTH: 6%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	28,157
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 2%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	53
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</FONT>
</TD>
<TD STYLE="WIDTH: 6%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	17,527
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 2%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	50
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</FONT>
</TD>
<TD STYLE="WIDTH: 7%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	4,048
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 2%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	52
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</FONT>
</TD>
<TD STYLE="WIDTH: 6%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	2,991
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 2%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	47
</FONT>
</TD>
<TD STYLE="WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</FONT>
</TD>
<TD STYLE="WIDTH: 6%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	3,591
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 2%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	95
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	31-60 days
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	6,650
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	13
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	4,109
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	12
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	802
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	10
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	1,718
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	27
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	21
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	1
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255)">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	61-90 days
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	4,191
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	8
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	2,313
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	7
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	578
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	7
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	1,276
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	20
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	24
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	1
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	91-120 days
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	3,651
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	7
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	2,534
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	7
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	604
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	8
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	474
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	7
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	39
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	1
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255)">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	121-150 days
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	2,856
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	5
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	2,426
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	7
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	399
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	5
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	(3
</FONT>
</TD>
<TD>
	)
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&mdash;
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	34
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	1
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-BOTTOM: 1PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Greater than 150 days**
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	7,187
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	14
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	5,878
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	17
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	1,329
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	18
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	(40
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	(1
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	20
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	1
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255)">
<TD STYLE="PADDING-BOTTOM: 3PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Totals
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	52,692
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-BOTTOM: 3PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	100
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	%
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	34,787
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-BOTTOM: 3PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	100
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	%
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	7,760
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-BOTTOM: 3PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	100
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	%
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	6,416
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-BOTTOM: 3PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	100
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	%
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	3,729
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-BOTTOM: 3PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	100
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	%
</FONT>
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	* Total includes $3,115 fully reserved over 210 days as of July
	31, 2016.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	** Total includes $4,072 fully reserved over 210 days as of
	July 31, 2015.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 56 -->
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 6PT; PADDING-BOTTOM: 12PT; BORDER-BOTTOM: SILVER 4PX SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	55
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage57"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 10PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: LEFT; WIDTH: 100%">
<PAGE>
</PAGE>
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<I>
	Income Taxes
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	The Company accounts for income taxes under the liability method
	of accounting for income taxes. Under the liability method, deferred tax assets and liabilities are recognized for the future tax
	consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and
	their respective tax bases. The liability method requires that any tax benefits recognized for net operating loss carry forwards
	and other items be reduced by a valuation allowance where it is not more likely than not the benefits will be realized in the foreseeable
	future. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years
	in which those temporary differences are expected to be recovered or settled. Under the liability method, the effect on deferred
	tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. It
	is the Company&rsquo;s policy to provide for uncertain tax positions, if any, and the related interest and penalties based upon
	management&rsquo;s assessment of whether a tax benefit is more likely than not to be sustained upon examination by tax authorities.
	To the extent the Company prevails in matters for which a liability for an unrecognized tax benefit is established or is required
	to pay amounts in excess of the liability, the Company&rsquo;s effective tax rate in a given financial statement period may be
	affected.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<I>
	Inventory
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	The Company values inventory at the lower of cost (first-in,
	first-out) or market. Work-in-process and finished goods inventories consist of material, labor, and manufacturing overhead. Write
	downs of inventories to market value are based on a review of inventory quantities on hand and estimated sales forecasts based
	on sales history and anticipated future demand. Unanticipated changes in demand could have a significant impact on the value of
	our inventory and require additional write downs of inventory which would impact our results of operations.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<I>
	Goodwill and Intangible Assets
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Goodwill represents the excess of the cost of an acquisition
	over the fair value of the net assets acquired. Intangible assets (exclusive of patents), arose primarily from acquisitions, and
	primarily consist of customer relationships, trademarks, licenses, and website and database content. Finite-lived intangible assets
	are amortized according to their estimated useful lives, which range from 4 to 15 years. Patents represent capitalized legal costs
	incurred in pursuing patent applications. When such applications result in an issued patent, the related capitalized costs are
	amortized over a ten year period or the life of the patent, whichever is shorter, using the straight-line method. The Company reviews
	its issued patents and pending patent applications, and if it determines to abandon a patent application or that an issued patent
	no longer has economic value, the unamortized balance in deferred patent costs relating to that patent is immediately expensed.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	The Company tests goodwill and long-lived assets annually as
	of the first day of the fourth quarter, or more frequently if indicators of potential impairment exist. In assessing goodwill and
	long-lived assets for impairment, the Company has the option to first perform a qualitative assessment to determine whether the
	existence of events or circumstances leads to a determination that it is more likely than not that the fair value of a reporting
	unit is less than its carrying amount. If the Company determines that it is not more likely that not that the fair value of a reporting
	unit is less than its carrying amount, the Company is not required to perform any additional tests in assessing goodwill and long-lived
	assets for impairment. However, if the Company concludes otherwise or elects not to perform the qualitative assessment, then it
	is required to perform the first step of a two-step quantitative impairment review process. The first step of the quantitative
	impairment test requires the identification of the reporting units and comparison of the fair value of each of these reporting
	units to their respective carrying value. If the carrying value of the reporting unit is less than its fair value, no impairment
	exists and the second step is not performed. If the carrying value of the reporting unit is higher than its fair value, the second
	step must be performed to compute the amount of the goodwill impairment, if any. In the second step, the impairment is computed
	by comparing the implied fair value of the reporting unit goodwill with the carrying amount of that goodwill. If the carrying amount
	of the reporting unit goodwill exceeds the implied fair value of that goodwill, an impairment loss is recognized for the excess
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	During fiscal years 2016, 2015 and 2014, there was no impairment
	of Goodwill or Long-lived Assets.
</P>
</EFX_LIQUIDITY_CAPITAL>
</EFX_MANAGEMENTS_DISCUSSION>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_MARKET_RISK>
<A NAME="FIS_MARKET_RISK"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<A NAME="C86264_10K_HTM_X2_C86264A012">
</A>
	Item 7A.
<U>
	Quantitative and Qualitative Disclosures About Market
	Risk
</U>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	We are exposed to market risk from changes in foreign currency
	exchange rates resulting from activities in foreign locations (See Item 1A. Risk Factors and Note 2 in the Notes to Consolidated
	Financial Statements) that could impact our results of operations and financial position. We do not currently engage in any hedging
	or market risk management tools.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<I>
	Foreign Currency Exchange Rate Risk
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	The financial reporting of our non-U.S. subsidiaries is denominated
	in currencies other than the U.S. dollar. Since the functional currency of our non-U.S. subsidiaries is the local currency, foreign
	currency translation adjustments are accumulated as a component of accumulated other comprehensive income in stockholders&rsquo;
	equity. Assuming a hypothetical decline of 10% in the exchange rates of
</P>
<!-- FIELD: PAGE; SEQUENCE: 57 -->
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 6PT; PADDING-BOTTOM: 12PT; BORDER-BOTTOM: SILVER 4PX SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	56
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage58"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 10PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: LEFT; WIDTH: 100%">
<PAGE>
</PAGE>
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	foreign currencies against the U.S. dollar at July 31,
	2016, our assets and liabilities would decrease by $0.5 million and $0.1 million, respectively, and our net sales and net earnings
	(loss) would decrease by $0.9 million and $0.2 million, respectively, on an annual basis.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	We also maintain intercompany balances and loans receivable
	with subsidiaries with different local currencies. These amounts are at risk of foreign exchange losses if exchange rates fluctuate.
	Assuming a hypothetical increase of 10% in the exchange rates of foreign currencies against the U.S. dollar at July 31, 2016, our
	pre-tax earnings (loss) would be unfavorably impacted by approximately $1.1 million on an annual basis.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<I>
	Interest Rate Risk
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	We are exposed to interest rate risk with our variable rate
	Credit Agreement which bears interest at the three month LIBOR with a floor of 1.25% plus 4% per annum. A 300 basis point change
	in the LIBOR rate would impact our interest expense by $0.1 million. As of July 31, 2016, we have fixed interest rate financing
	on transportation and equipment leases.
</P>
</EFX_MARKET_RISK>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_FINANCIAL_STATEMENTS>
<A NAME="FIS_FINANCIAL_STATEMENTS"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<A NAME="C86264_10K_HTM_X2_C86264A013">
</A>
	Item 8.
<U>
	Financial Statements and Supplementary Data
</U>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	The response to this item is submitted in a separate section
	of this report. See Item 15(a) (1) and (2)
</P>
</EFX_FINANCIAL_STATEMENTS>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_ACCOUNTING_CHANGES>
<A NAME="FIS_ACCOUNTING_CHANGES"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<A NAME="C86264_10K_HTM_X2_C86264A014">
</A>
	Item 9.
<U>
	Changes in and Disagreements with Accountants on
	Accounting and Financial Disclosure
</U>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	None.
</P>
</EFX_ACCOUNTING_CHANGES>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_CONTROL_AND_PROCEDURES>
<A NAME="FIS_CONTROL_AND_PROCEDURES"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<A NAME="C86264_10K_HTM_X2_C86264A015">
</A>
	Item 9A.
<U>
	Controls and Procedures
</U>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	Evaluation of Disclosure Controls and Procedures
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	As required by Rule 13a-15(e) of the Securities Exchange Act
	of 1934, as amended (the &ldquo;Exchange Act&rdquo;), we conducted an evaluation of the effectiveness of the design and operation
	of our disclosure controls and procedures as of July 31, 2016. This evaluation was carried out under the supervision and with participation
	of our Chief Executive Officer and Chief Financial Officer. There are inherent limitations to the effectiveness of any system of
	disclosure controls and procedures. Therefore, effective disclosure controls and procedures can only provide reasonable assurance
	of achieving their control objectives.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Based upon our evaluation, our Chief Executive Officer and Chief
	Financial Officer concluded that our disclosure controls and procedures are effective at that reasonable assurance level as of
	July 31, 2016, and that information required to be disclosed in the reports that we file under the Exchange Act is recorded, processed,
	summarized and reported in a timely manner and is accumulated and communicated to management, including our Chief Executive Officer
	and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	Changes in Internal Control over Financial Reporting
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	There was no change in our internal control over financial reporting
	during the fourth quarter ended July 31, 2016 that has materially affected, or is reasonably likely to materially affect, our internal
	control over financial reporting.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	Management&rsquo;s Annual Report on Internal Control over
	Financial Reporting
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Our management is responsible for establishing and maintaining
	adequate internal control over financial reporting, as such term is defined in Rules 13a-15(f) under the Exchange Act.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Our internal control over financial reporting is a process designed
	to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for
	external purposes in accordance with generally accepted accounting principles and includes those policies and procedures that:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 3%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&bull;
</FONT>
</TD>
<TD STYLE="WIDTH: 97%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of our assets;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&bull;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that our receipts and expenditures are being made only in accordance with authorizations of management and our directors; and
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN: 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 58 -->
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 6PT; PADDING-BOTTOM: 12PT; BORDER-BOTTOM: SILVER 4PX SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	57
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage59"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 10PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: LEFT; WIDTH: 100%">
<PAGE>
</PAGE>
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 3%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&bull;
</FONT>
</TD>
<TD STYLE="WIDTH: 97%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	provide reasonable assurance regarding prevention and timely detection of unauthorized acquisition, use or disposition of our assets that could have a material effect on our financial statements.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Internal control systems, no matter how well designed, have
	inherent limitations. Therefore, even those systems that are determined to be effective provide only reasonable assurance with
	respect to financial statement preparation and presentation. Also, projections of any evaluation of effectiveness to future periods
	are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance
	with the policies or procedures may deteriorate.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Management assessed the effectiveness of our internal control
	over financial reporting based on criteria for effective internal control over financial reporting described in the 2013 Internal
	Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). Based on its
	assessment, management concluded that we maintained effective internal control over financial reporting as of July 31, 2016.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	EisnerAmper LLP, our independent registered public accounting
	firm, has audited the effectiveness of the Company&rsquo;s internal control over financial reporting as of July 31, 2016, as stated
	in their report, which is included herein.
</P>
<!-- FIELD: PAGE; SEQUENCE: 59 -->
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 6PT; PADDING-BOTTOM: 12PT; BORDER-BOTTOM: SILVER 4PX SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	58
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
</EFX_CONTROL_AND_PROCEDURES>
<A NAME="eolPage60"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 10PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: LEFT; WIDTH: 100%">
<PAGE>
</PAGE>
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<EFX_AUDITORS_OPINION>
<A NAME="FIS_AUDITORS_OPINION"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	Report of Independent Registered Public
	Accounting Firm
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	The Board of Directors and Stockholders
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	Enzo Biochem, Inc.
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	We have audited Enzo Biochem, Inc. and
	subsidiaries&rsquo; (the &ldquo;Company&rdquo;) internal control over financial reporting as of July 31, 2016, based on criteria
	established in the 2013
<I>
	Internal Control-Integrated Framework
</I>
	issued by the Committee of Sponsoring Organizations of the
	Treadway Commission (&ldquo;COSO&rdquo;). The Company&rsquo;s management is responsible for maintaining effective internal control
	over financial reporting and for its assessment of the effectiveness of internal control over financial reporting, included in
	the accompanying Management&rsquo;s Annual Report on Internal Control over Financial Reporting. Our responsibility is to express
	an opinion on the Company&rsquo;s internal control over financial reporting based on our audit.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	We conducted our audit in accordance with
	the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform
	the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all
	material respects. Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk
	that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on
	the assessed risk. Our audit also included performing such other procedures as we considered necessary in the circumstances. We
	believe that our audit provides a reasonable basis for our opinion.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	A company&rsquo;s internal control over
	financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and
	the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company&rsquo;s
	internal control over financial reporting includes those policies and procedures that (i) pertain to the maintenance of records
	that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (ii)
	provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance
	with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance
	with authorizations of management and directors of the company; and (iii) provide reasonable assurance regarding prevention or
	timely detection of unauthorized acquisition, use, or disposition of the company&rsquo;s assets that could have a material effect
	on the financial statements.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Because of its inherent limitations, internal
	control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness
	to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree
	of compliance with the policies or procedures may deteriorate.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	In our opinion, Enzo Biochem, Inc. and
	subsidiaries maintained, in all material respects, effective internal control over financial reporting as of July 31, 2016, based
	on criteria established in the 2013
<I>
	Internal Control-Integrated Framework
</I>
	issued by COSO.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	We also have audited, in accordance with
	the standards of the Public Company Accounting Oversight Board (United States), the consolidated balance sheets of Enzo Biochem,
	Inc. and subsidiaries as of July 31, 2016 and 2015, and the related consolidated statements of operations, comprehensive income
	(loss), stockholders&rsquo; equity, and cash flows for each of the years in the three-year period ended July 31, 2016, and our
	report dated October 13, 2016 expressed an unqualified opinion thereon.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	/s/ EisnerAmper LLP
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	New York, New York
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	October 13, 2016
</P>
<!-- FIELD: PAGE; SEQUENCE: 60 -->
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 6PT; PADDING-BOTTOM: 12PT; BORDER-BOTTOM: SILVER 4PX SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	59
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
</EFX_AUDITORS_OPINION>
<A NAME="eolPage61"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 10PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: LEFT; WIDTH: 100%">
<PAGE>
</PAGE>
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<EFX_OTHER_INFORMATION>
<A NAME="FIS_OTHER_INFORMATION"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<A NAME="C86264_10K_HTM_X2_C86264A016">
</A>
	Item 9B.
<U>
	Other Information
</U>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	None
</P>
</EFX_OTHER_INFORMATION>
</EFX_PART_II>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_PART_III>
<A NAME="FIS_PART_III"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
<A NAME="C86264_10K_HTM_X2_C86264A017">
</A>
	PART III
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_DIRECTORS_AND_OFFICERS>
<A NAME="FIS_DIRECTORS_AND_OFFICERS"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<A NAME="C86264_10K_HTM_X2_C86264A018">
</A>
	Item 10.
<U>
	Directors, Executive Officers and Corporate Governance
</U>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	The information required under this item will be set forth in
	the Company&rsquo;s proxy statement to be filed with the Securities and Exchange Commission on or before November 28, 2016 and
	is incorporated herein by reference.
</P>
</EFX_DIRECTORS_AND_OFFICERS>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_COMPENSATION>
<A NAME="FIS_COMPENSATION"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<A NAME="C86264_10K_HTM_X2_C86264A019">
</A>
	Item 11.
<U>
	Executive Compensation
</U>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	The information required under this item will be set forth in
	the Company&rsquo;s proxy statement to be filed with the Securities and Exchange Commission on or before November 28, 2016 and
	is incorporated herein by reference.
</P>
</EFX_COMPENSATION>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_SECURITY_OWNERS>
<A NAME="FIS_SECURITY_OWNERS"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<A NAME="C86264_10K_HTM_X2_C86264A020">
</A>
	Item 12.
<U>
	Security Ownership of Certain Beneficial Owners
	and Management and Related Stockholder Matters
</U>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	The information required under this item will be set forth in
	the Company&rsquo;s proxy statement to be filed with the Securities and Exchange Commission on or before November 28, 2016 and
	is incorporated herein by reference.
</P>
</EFX_SECURITY_OWNERS>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_OFFICER_TRANSACTIONS>
<A NAME="FIS_OFFICER_TRANSACTIONS"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<A NAME="C86264_10K_HTM_X2_C86264A021">
</A>
	Item 13.
<U>
	Certain Relationships and Related Transactions,
	and Director Independence
</U>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	The information required under this item will be set forth in
	the Company&rsquo;s proxy statement to be filed with the Securities and Exchange Commission on or before November 28, 2016 and
	is incorporated herein by reference.
</P>
</EFX_OFFICER_TRANSACTIONS>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_ACCOUNTANT_FEES>
<A NAME="FIS_ACCOUNTANT_FEES"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<A NAME="C86264_10K_HTM_X2_C86264A022">
</A>
	Item 14.
<U>
	Principal Accountant Fees and Services
</U>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	The information required under this item will be set forth in
	the Company&rsquo;s proxy statement expected to be filed with the Securities and Exchange Commission on or before November 28,
	2016 and is incorporated herein by reference.
</P>
</EFX_ACCOUNTANT_FEES>
</EFX_PART_III>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_PART_IV>
<A NAME="FIS_PART_IV"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<A NAME="C86264_10K_HTM_X2_C86264A023">
</A>
<B>
	PART IV
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_EXHIBITS>
<A NAME="FIS_EXHIBITS"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<A NAME="C86264_10K_HTM_X2_C86264A024">
</A>
	Item 15.
<U>
	Exhibits, Financial Statement Schedules
</U>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 8%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 3%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	(a)
</FONT>
</TD>
<TD STYLE="WIDTH: 3%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	(1)
</FONT>
</TD>
<TD STYLE="WIDTH: 86%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Consolidated Financial Statements
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Consolidated Balance Sheets - July 31, 2016 and 2015
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Consolidated Statements of Operations - Years ended July 31, 2016, 2015 and 2014
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Consolidated Statements of Comprehensive Income (Loss) - Years ended July 31, 2016, 2015 and 2014
</FONT>
<BR>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Consolidated Statements of Stockholders&rsquo; Equity - Years ended July 31, 2016, 2015 and 2014
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Consolidated Statements of Cash Flows - Years ended July 31, 2016, 2015 and 2014
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Notes to Consolidated Financial Statements
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	(2)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Financial Statement Schedule
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Schedule II - Valuation and Qualifying Accounts
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	All other schedules have been omitted because the required information
	is included in the consolidated financial statements or the notes thereto or because they are not required.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 8%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 3%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 3%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	(3)
</FONT>
</TD>
<TD STYLE="WIDTH: 86%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Exhibits
</FONT>
</TD>
</TR>
</TABLE>
<!-- FIELD: PAGE; SEQUENCE: 61 -->
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 6PT; PADDING-BOTTOM: 12PT; BORDER-BOTTOM: SILVER 4PX SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	60
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage62"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 10PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: LEFT; WIDTH: 100%">
<PAGE>
</PAGE>
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	The following documents are filed as Exhibits to this Annual
	Report on Form 10-K:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_18"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 9%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Exhibit
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 2%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 89%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	No.
</B>
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Description
</B>
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	3(a)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Certificate of Incorporation (1)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	3(b)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Certificate of Incorporation, as amended on March 17, 1980. (1)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	3(c)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Certificate of Amendment of the Certificate of Incorporation as amended on June 16, 1981. (2)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	3(d)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Certificate of Amendment to the Certificate of Incorporation as of July 22, 1988. (3)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	3(e)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Amended and restated Bylaws. (4)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	10(a)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	1994 Stock Option Plan. (5)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	10 (b)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	1999 Stock Option Plan. (6)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	10 (c)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	2005 Equity Compensation Incentive Plan (7)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	10 (d)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	2011 Incentive Plan (8)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	10 (e)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Lease agreement with Pari Management (9)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	10 (f)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Settlement and Release Agreement between the Company and Sigma Aldrich (10)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	10 (g)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Stock Purchase Agreement By and Among Enzo Life Sciences, Inc., Axxora Life Sciences Inc., and the Stock holders, Option holders and Warrant holders (12)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	10 (h)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Stock Asset Purchase Agreement By and Among Buyer Parties and Seller Parties with respect to the Biomol International and affiliate acquisition (13)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	10 (i)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Asset Purchase Agreement By and Among Enzo Life Sciences, Acquisition, Inc. and Assay Designs, Inc.(14)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	10 (j)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Amended and Restated Employment Agreement with Elazar Rabbani (15)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	10 (k)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Amended and Restated Employment Agreement with Barry Weiner (15)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	10 (l)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Controlled Equity Offering Sales Agreement with Cantor Fitzgerald &amp; Co,, as sales agent (16)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	10 (m)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Revolving Loan and Security Agreement among the Enzo Biochem, Inc., Enzo Clinical Labs, Inc., Enzo Life Sciences, Inc., Axxora, LLC and Enzo Realty, LLC as borrowers, and Enzo Therapeutics, Inc. as a guarantor, and Healthcare Finance Group, LLC as Lender (17)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	10 (n)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Settlement and Release Agreement between the Company and Affymetrix (18)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	10 (o)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Settlement and Release Agreement between the Company and PerkinElmer (19)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	10 (p)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Settlement and Release Agreement between the Company and U.S. Department of Justice (20)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	10 (q)
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Settlement and Release Agreement between the Company and Luminex
	Corporation (21)
</P>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	10 (r)
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Settlement and Release Agreement between the Company and Siemens
	Healthcare Diagnostics Inc. (22)
</P>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	10 (s)
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	Amendment of Lease with Pari Management (23)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	10 (t)
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	Settlement and Release Agreement between the Company and Affymetrix
	(24)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	10 (u)*
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Settlement and Release Agreement between the Company
	and Illumina, Inc. (25)
</P>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	14 (a)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Code of Ethics (11)
</FONT>
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN: 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 62 -->
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 6PT; PADDING-BOTTOM: 12PT; BORDER-BOTTOM: SILVER 4PX SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	61
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage63"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 10PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: LEFT; WIDTH: 100%">
<PAGE>
</PAGE>
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_19"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 9%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	21*
</FONT>
</TD>
<TD STYLE="WIDTH: 2%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 89%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	List of subsidiaries of the Company
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	23.1*
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Consent of Independent Registered Public Accounting Firm
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	31 (a)*
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Certification of CEO Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 9%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	31 (b)*
</FONT>
</TD>
<TD STYLE="WIDTH: 2%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 89%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Certification of CFO Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	32 (a)*
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Certification of CEO Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	32 (b)*
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Certification of CFO Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	101. INS**
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	XBRL Instance Document
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	101. SCH**
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	XBRL Taxonomy Extension Schema Document
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	101. CAL**
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	XBRL Taxonomy Extension Calculation Linkbase Document
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	101.DEF**
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	XBRL Taxonomy Extension Definitions Linkbase Document
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	101.LAB**
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	XBRL Taxonomy Extension Label Linkbase Document
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	101.PRE**
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	XBRL Taxonomy Extension Presentation Linkbase Document
</FONT>
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<!-- FIELD: PAGE; SEQUENCE: 63 -->
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 6PT; PADDING-BOTTOM: 12PT; BORDER-BOTTOM: SILVER 4PX SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	62
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage64"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 10PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: LEFT; WIDTH: 100%">
<PAGE>
</PAGE>
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 8%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 2%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 90%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Notes to exhibits
</B>
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	*
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Filed herewith
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	**
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	XBRL (Extensible Business Reporting Language) information is being furnished and not filed for purposes of Sections 11 and 12 of the Securities Act of 1933 and Section 18 of the Securities Exchange Act of 1934.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	(1)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	The exhibits were filed as exhibits to the Company&rsquo;s Registration Statement on Form S-18 (File No. 2-67359) and are incorporated herein by reference.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	(2)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	This exhibit was filed as an exhibit to the Company&rsquo;s Annual Report on Form 10-K for the year ended July 31, 1981 and is incorporated herein by reference.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	(3)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	This exhibit was filed with the Company&rsquo;s Annual Report on Form 10-K for the year ended July 31, 1989 and is incorporated herein by reference.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	(4)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	This exhibit was filed with the Company&rsquo;s Current Report on Form 8-K May 8, 2008 and is incorporated herein by reference.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	(5)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	This exhibit was filed with the Company&rsquo;s Annual Report on Form 10-K for the year ended July 31, 1995 and is incorporated herein by reference.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	(6)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	This exhibit was filed with the Company&rsquo;s Registration Statement on Form S-8 (333-87153) and is incorporated herein by reference.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	(7)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	This exhibit was filed as an exhibit to the Company&rsquo;s Proxy Statement of Schedule 14A filed on January 19, 2006 and is incorporated herein by reference.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	(8)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	This exhibit was filed as appendix B to the Company&rsquo;s Definitive Proxy Statement on Schedule 14A, which was filed with the Securities and Exchange Commission on November 16, 2010 and is incorporated herein by reference.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	(9)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	This exhibit was filed with the Company&rsquo;s Annual Report on Form 10-K for the year ended July 31, 2005 and is incorporated herein by reference.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	(10)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	This exhibit was filed with the Company&rsquo;s Current Report on Form 8-K on September 21, 2006 and is incorporated herein by reference.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	(11)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	This exhibit was filed with the Company&rsquo;s Annual Report on Form 10-K for the year ended July 31, 2003 and is incorporated here by reference.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	(12)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	This exhibit was filed with the Company&rsquo;s Current Report on Form 8-K May 30, 2007 and is incorporated herein by reference.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	(13)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	This exhibit was filed with the Company&rsquo;s Current Report on Form 8-K May 8, 2008 and is incorporated herein by reference.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	(14)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	This exhibit was filed with the Company&rsquo;s Current Report on Form 8-K March 13, 2009 and is incorporated herein by reference.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	(15)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	This exhibit was filed with the Company&rsquo;s Annual Report on Form 10-K for the year ended July 31, 2010 and is incorporated herein by reference.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	(16)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	This exhibit was filed with the Company&rsquo;s Current Report on Form 8-K on March 28, 2013 and incorporated herein by reference.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	(17)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	This exhibit was filed with the Company&rsquo;s Current Report on Form 10-K for the year ended July 31, 2013 and incorporated herein by reference.
</FONT>
</TD>
</TR>
</TABLE>
<!-- FIELD: PAGE; SEQUENCE: 64 -->
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 6PT; PADDING-BOTTOM: 12PT; BORDER-BOTTOM: SILVER 4PX SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	63
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage65"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 10PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: LEFT; WIDTH: 100%">
<PAGE>
</PAGE>
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 8%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	(18)
</FONT>
</TD>
<TD STYLE="WIDTH: 2%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 90%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	This exhibit was filed with the Company&rsquo;s Current Report on Form 8-K on April 24, 2014 and incorporated herein by reference.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	(19)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	This exhibit was filed with the Company&rsquo;s Current Report on Form 8-K on June 23, 2014 and incorporated herein by reference.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	(20)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	This exhibit was filed with the Company&rsquo;s Current Report on Form 10-K for the year ended July 31, 2014 and is incorporated herein by reference.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	(21)
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	This exhibit was filed with the Company&rsquo;s Current Report
	on Form 8-K on July 7, 2015 and incorporated herein by reference.
</P>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	(22)
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	This exhibit was filed with the Company&rsquo;s Current Report
	on Form 8-K on July 22, 2015 and incorporated herein by reference.
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	(23)
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	This exhibit was filed with the Company&rsquo;s Annual Report
	on Form 10-K for the year ended July 31, 2015 and is incorporated herein by reference.
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	(24)
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	This exhibit was filed with the Company&rsquo;s Current Report
	on Form 8-K on October 13, 2015 and incorporated herein by reference.
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	(25)
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	This exhibit is being filed with the Company&rsquo;s
	Annual Report on Form 10-K for the year ended July 31, 2016.
</P>
</TD>
</TR>
</TABLE>
</EFX_EXHIBITS>
</EFX_PART_IV>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_SIGNATURES>
<A NAME="FIS_SIGNATURES"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<U>
	SIGNATURES
</U>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Pursuant to the requirements of Section 13 or 15(d) of the Securities
	Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly
	authorized.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	ENZO BIOCHEM, INC.
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="WIDTH: 25%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 40%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 2%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 23%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 10%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Date: October 13, 2016
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	By:&nbsp;&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	/s/ Elazar Rabbani Ph.D.
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Chairman of the Board
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Pursuant to the requirements of the Securities Exchange Act
	of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the
	dates indicated.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 73%; BORDER-BOTTOM: BLACK 1PX SOLID">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	By: /s/ Elazar Rabbani Ph.D.
</FONT>
</TD>
<TD STYLE="WIDTH: 3%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 17%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	October 13, 2016
</FONT>
</TD>
<TD STYLE="WIDTH: 7%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Elazar Rabbani,
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Chairman of Board of Directors and Secretary
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	(Principal Executive Officer)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	By: /s/ Barry W. Weiner
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	October 13, 2016
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Barry W. Weiner,
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	President, Chief Financial Officer, Principal Accounting Officer, Treasurer and Director
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	By: /s/ Bernard L. Kasten MD
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	October 13, 2016
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Bernard Kasten, Director
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	By: /s/ Gregory M. Bortz
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	October 13, 2016
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Gregory M. Bortz, Director
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	By: /s/ Dov Perlysky
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	October 13, 2016
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Dov Perlysky, Director
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
</TABLE>
<!-- FIELD: PAGE; SEQUENCE: 65 -->
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 6PT; PADDING-BOTTOM: 12PT; BORDER-BOTTOM: SILVER 4PX SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	64
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage66"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 10PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: LEFT; WIDTH: 100%">
<PAGE>
</PAGE>
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	FORM 10-K, ITEM 15(a) (1) and (2)
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 17.3PT; TEXT-INDENT: -8.65PT">
	ENZO BIOCHEM, INC.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 17.3PT; TEXT-INDENT: -8.65PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<A NAME="C86264_10K_HTM_X2_C86264A025">
</A>
<A NAME="C86264_10K_HTM_X2_C86264B001">
</A>
	LIST OF CONSOLIDATED FINANCIAL STATEMENTS
	AND
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	FINANCIAL STATEMENT SCHEDULE
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	The following consolidated financial statements and financial
	statement schedule of Enzo Biochem, Inc. are included in Item 15(a):
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_20"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 94%">
<A HREF="#C86264_10K_HTM_X2_C86264B001">
	List of Consolidated Financial Statements and Financial
	Statements Schedule
</A>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; WIDTH: 5%; TEXT-ALIGN: RIGHT">
	F-1
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP">
<A HREF="#C86264_10K_HTM_X2_C86264B002">
	Report of Independent Registered Public Accounting Firm
</A>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT">
	F-2
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP">
<A HREF="#C86264_10K_HTM_X2_C86264B003">
	Consolidated Balance Sheets - July 31, 2016 and 2015
</A>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT">
	F-3
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP">
<A HREF="#C86264_10K_HTM_X2_C86264B004">
	Consolidated Statements of Operations - Years ended July 31, 2016, 2015 and 2014
</A>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT">
	F-4
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP">
<A HREF="#C86264_10K_HTM_X2_C86264B005">
	Consolidated Statements of Comprehensive Income (Loss) - Years ended July 31, 2016, 2015 and 2014
</A>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT">
	F-5
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP">
<A HREF="#C86264_10K_HTM_X2_C86264B006">
	Consolidated Statements of Stockholders&rsquo; Equity - Years ended July 31, 2016, 2015 and 2014
</A>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT">
	F-6
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP">
<A HREF="#C86264_10K_HTM_X2_C86264B007">
	Consolidated Statements of Cash Flows - Years ended July 31, 2016, 2015 and 2014
</A>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT">
	F-7
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP">
<A HREF="#C86264_10K_HTM_X2_C86264B008">
	Notes to Consolidated Financial Statements
</A>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT">
	F-8
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP">
<A HREF="#C86264_10K_HTM_X2_C86264B009">
	Schedule II - Valuation and Qualifying Accounts - Years ended July 31, 2016, 2015 and 2014
</A>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT">
	S-1
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	All other schedules for which provision is made in the applicable
	accounting regulation of the Securities and Exchange Commission are not required under the related instructions or are inapplicable,
	and therefore have been omitted.
</P>
<!-- FIELD: PAGE; SEQUENCE: 1 -->
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 6PT; PADDING-BOTTOM: 12PT; BORDER-BOTTOM: SILVER 4PX SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	1
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
</EFX_SIGNATURES>
<A NAME="eolPage67"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 10PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: LEFT; WIDTH: 100%">
<PAGE>
</PAGE>
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<EFX_AUDITORS_OPINION>
<A NAME="FIS_AUDITORS_OPINION_2"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
<A NAME="C86264_10K_HTM_X2_C86264B002">
</A>
<A NAME="C86264_10K_HTM_X2_C86264A026">
</A>
	Report of Independent Registered Public
	Accounting Firm
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	The Board of Directors and Stockholders of Enzo Biochem,
	Inc.
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	We have audited the accompanying consolidated
	balance sheets of Enzo Biochem, Inc. and subsidiaries (the &ldquo;Company&rdquo;) as of July 31, 2016 and 2015, and the related
	consolidated statements of operations, comprehensive income (loss), stockholders&rsquo; equity, and cash flows for each of the
	years in the three-year period ended July 31, 2016. The financial statements are the responsibility of the Company&rsquo;s management.
	Our responsibility is to express an opinion on these financial statements based on our audits.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	We conducted our audits in accordance with
	the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform
	the audits to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes
	examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes
	assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial
	statement presentation. We believe that our audits provide a reasonable basis for our opinion.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	In our opinion, the financial statements
	referred to above present fairly, in all material respects, the consolidated financial position of Enzo Biochem, Inc. and subsidiaries
	as of July 31, 2016 and 2015, and the consolidated results of their operations and their cash flows for each of the years in the
	three-year period ended July 31, 2016 in conformity with accounting principles generally accepted in the United States of America.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	We also have audited, in accordance with
	the standards of the Public Company Accounting Oversight Board (United States), Enzo Biochem, Inc. and subsidiaries&rsquo; internal
	control over financial reporting as of July 31, 2016, based on criteria established in the 2013
<I>
	Internal Control-Integrated
	Framework
</I>
	issued by the Committee of Sponsoring Organizations of the Treadway Commission (&ldquo;COSO&rdquo;), and our report
	dated October 13, 2016 expressed an unqualified opinion thereon.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	In connection with our audits of the consolidated
	financial statements referred to above, we also audited Schedule II - Valuation and Qualifying Accounts for each of the years in
	the three-year period ended July 31, 2016. In our opinion, this financial schedule, when considered in relation to the consolidated
	financial statements taken as a whole, presents fairly, in all material respects, the information stated therein.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	/s/ EisnerAmper LLP
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	New York, New York
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	October 13, 2016
</P>
<!-- FIELD: PAGE; SEQUENCE: 2 -->
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 6PT; PADDING-BOTTOM: 12PT; BORDER-BOTTOM: SILVER 4PX SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	2
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
</EFX_AUDITORS_OPINION>
<A NAME="eolPage68"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 10PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: LEFT; WIDTH: 100%">
<PAGE>
</PAGE>
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<EFX_BALANCE_SHEET>
<A NAME="FIS_BALANCE_SHEET"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
<A NAME="C86264_10K_HTM_X2_C86264A027">
</A>
<A NAME="C86264_10K_HTM_X2_C86264B003">
</A>
	ENZO BIOCHEM, INC.
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	CONSOLIDATED BALANCE SHEETS
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	(in thousands, except share and per share
	data)
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="PADDING-LEFT: 10PT; TEXT-INDENT: -10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PX SOLID">
	July 31,
<BR>
	2016
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PX SOLID">
	July 31,
<BR>
	2015
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="PADDING-LEFT: 10PT; TEXT-INDENT: -10PT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255)">
<TD STYLE="PADDING-LEFT: 10PT; TEXT-INDENT: -10PT">
	ASSETS
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT; TEXT-INDENT: -10PT">
	Current assets:
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255)">
<TD STYLE="WIDTH: 70%; TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT; TEXT-INDENT: -10PT">
	Cash and cash equivalents
</TD>
<TD STYLE="WIDTH: 3%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	67,777
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 3%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	18,109
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT; TEXT-INDENT: -10PT">
	Accounts receivable, net of allowance for doubtful accounts of $3,517 in 2016 and $1,786 in 2015
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	14,592
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	12,109
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT; TEXT-INDENT: -10PT">
	Other receivables
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	6,650
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-LEFT: 10PT; TEXT-INDENT: -10PT">
	Inventories
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	6,971
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	7,396
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PX; PADDING-LEFT: 10PT; TEXT-INDENT: -10PT">
	Prepaid expenses
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
	2,057
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
	2,222
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="PADDING-LEFT: 10PT; TEXT-INDENT: -10PT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT; TEXT-INDENT: -10PT">
	Total current assets
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	91,397
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	46,486
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="PADDING-LEFT: 10PT; TEXT-INDENT: -10PT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT; TEXT-INDENT: -10PT">
	Property, plant, and equipment, net
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	8,214
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	7,948
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-LEFT: 10PT; TEXT-INDENT: -10PT">
	Goodwill
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	7,452
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	7,452
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT; TEXT-INDENT: -10PT">
	Intangible assets, net
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	4,422
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	6,155
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-BOTTOM: 1PX; PADDING-LEFT: 10PT; TEXT-INDENT: -10PT">
	Other
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
	336
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
	353
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="PADDING-LEFT: 10PT; TEXT-INDENT: -10PT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 3PX; PADDING-LEFT: 10PT; TEXT-INDENT: -10PT">
	Total assets
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; TEXT-ALIGN: RIGHT">
	111,821
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; TEXT-ALIGN: RIGHT">
	68,394
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="PADDING-LEFT: 10PT; TEXT-INDENT: -10PT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT; TEXT-INDENT: -10PT">
	LIABILITIES AND STOCKHOLDERS&rsquo; EQUITY
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="PADDING-LEFT: 10PT; TEXT-INDENT: -10PT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT; TEXT-INDENT: -10PT">
	Current liabilities:
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT; TEXT-INDENT: -10PT">
	Loan payable
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,557
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	3,013
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT; TEXT-INDENT: -10PT">
	Accounts payable - trade
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	9,857
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	8,762
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT; TEXT-INDENT: -10PT">
	Accrued liabilities
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	8,211
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	11,297
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PX; PADDING-LEFT: 10PT; TEXT-INDENT: -10PT">
	Other current liabilities
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
	943
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
	886
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="PADDING-LEFT: 10PT; TEXT-INDENT: -10PT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT; TEXT-INDENT: -10PT">
	Total current liabilities
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	20,568
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	23,958
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="PADDING-LEFT: 10PT; TEXT-INDENT: -10PT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT; TEXT-INDENT: -10PT">
	Deferred taxes
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	37
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PX; PADDING-LEFT: 10PT; TEXT-INDENT: -10PT">
	Other liabilities
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
	1,699
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
	1,793
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="PADDING-LEFT: 10PT; TEXT-INDENT: -10PT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PX; PADDING-LEFT: 10PT; TEXT-INDENT: -10PT">
	Total liabilities
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
	22,267
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
	25,788
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="PADDING-LEFT: 10PT; TEXT-INDENT: -10PT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT; TEXT-INDENT: -10PT">
	Commitments and contingencies
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="PADDING-LEFT: 10PT; TEXT-INDENT: -10PT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT; TEXT-INDENT: -10PT">
	Stockholders&rsquo; equity:
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT; TEXT-INDENT: -10PT">
	Preferred Stock, $.01 par value; authorized 25,000,000 shares; no shares issued or outstanding
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255)">
<TD STYLE="PADDING-LEFT: 10PT; TEXT-INDENT: -10PT">
	Common Stock, $.01 par value; authorized 75,000,000 shares; shares issued and outstanding: 46,267,619 at July 31, 2016
	and 46,062,065 at July 31, 2015
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	463
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	461
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT; TEXT-INDENT: -10PT">
	Additional paid-in capital
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	326,288
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	324,966
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT; TEXT-INDENT: -10PT">
	Accumulated deficit
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(239,396
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(284,682
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PX; PADDING-LEFT: 10PT; TEXT-INDENT: -10PT">
	Accumulated other comprehensive income
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
	2,199
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
	1,861
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="PADDING-LEFT: 10PT; TEXT-INDENT: -10PT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PX; PADDING-LEFT: 10PT; TEXT-INDENT: -10PT">
	Total stockholders&rsquo; equity
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
	89,554
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
	42,606
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="PADDING-LEFT: 10PT; TEXT-INDENT: -10PT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 3PX; PADDING-LEFT: 10PT; TEXT-INDENT: -10PT">
	Total liabilities and stockholders&rsquo; equity
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; TEXT-ALIGN: RIGHT">
	111,821
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; TEXT-ALIGN: RIGHT">
	68,394
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_BALANCE_SHEET>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	The accompanying notes are an integral part
	of these consolidated financial statements
</P>
<!-- FIELD: PAGE; SEQUENCE: 3 -->
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 6PT; PADDING-BOTTOM: 12PT; BORDER-BOTTOM: SILVER 4PX SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	3
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage69"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 10PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: LEFT; WIDTH: 100%">
<PAGE>
</PAGE>
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<EFX_INCOME_STATEMENT>
<A NAME="FIS_INCOME_STATEMENT"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
<A NAME="C86264_10K_HTM_X2_C86264B004">
</A>
<A NAME="C86264_10K_HTM_X2_C86264A028">
</A>
	ENZO BIOCHEM, INC.
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	CONSOLIDATED STATEMENTS OF OPERATIONS
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	(in thousands, except per share data)
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="PADDING-LEFT: 10PT; TEXT-INDENT: -10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD COLSPAN="10" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PX SOLID">
	Years ended July 31,
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="PADDING-LEFT: 10PT; TEXT-INDENT: -10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PX SOLID">
	2016
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PX SOLID">
	2015
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PX SOLID">
	2014
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255)">
<TD STYLE="PADDING-LEFT: 10PT; TEXT-INDENT: -10PT">
	Revenues:
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="WIDTH: 55%; TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT; TEXT-INDENT: -10PT">
	Clinical laboratory services
</TD>
<TD STYLE="WIDTH: 3%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	70,915
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 3%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	63,414
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 3%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	58,689
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT; TEXT-INDENT: -10PT">
	Product revenues
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	30,337
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	31,690
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	32,850
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PX; PADDING-LEFT: 10PT; TEXT-INDENT: -10PT">
	Royalty and license fee income
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
	1,521
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
	2,495
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
	4,408
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PX; PADDING-LEFT: 10PT; TEXT-INDENT: -10PT">
	Total revenues
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
	102,773
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
	97,599
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
	95,947
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="PADDING-LEFT: 10PT; TEXT-INDENT: -10PT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT; TEXT-INDENT: -10PT">
	Operating costs, expenses and legal settlements, net:
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT; TEXT-INDENT: -10PT">
	Cost of clinical laboratory services
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	42,859
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	39,589
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	38,948
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT; TEXT-INDENT: -10PT">
	Cost of product revenues
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	14,331
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	15,183
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	15,320
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT; TEXT-INDENT: -10PT">
	Research and development
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	3,524
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	3,350
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	3,141
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT; TEXT-INDENT: -10PT">
	Selling, general, and administrative
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	43,586
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	41,069
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	41,801
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT; TEXT-INDENT: -10PT">
	Provision for uncollectible accounts receivable
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2,336
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2,284
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	3,063
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT; TEXT-INDENT: -10PT">
	Legal fee expense
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	6,384
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	8,788
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	6,954
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PX; PADDING-LEFT: 10PT; TEXT-INDENT: -10PT">
	Legal settlements, net
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
	(57,250
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
	(11,458
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
	(3,100
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PX; PADDING-LEFT: 10PT; TEXT-INDENT: -10PT">
	Total costs, expenses and legal settlements, net
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
	55,770
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
	98,805
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
	106,127
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="PADDING-LEFT: 10PT; TEXT-INDENT: -10PT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT; TEXT-INDENT: -10PT">
	Operating income (loss)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	47,003
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(1,206
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(10,180
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="PADDING-LEFT: 10PT; TEXT-INDENT: -10PT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT; TEXT-INDENT: -10PT">
	Other income (expense):
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255)">
<TD STYLE="PADDING-LEFT: 10PT; TEXT-INDENT: -10PT">
	Interest
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(136
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(245
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(208
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-LEFT: 10PT; TEXT-INDENT: -10PT">
	Other
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	122
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	95
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	194
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PX; PADDING-LEFT: 10PT; TEXT-INDENT: -10PT">
	Foreign exchange (loss) gain
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
	(474
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
	(936
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
	289
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="PADDING-LEFT: 10PT; TEXT-INDENT: -10PT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT; TEXT-INDENT: -10PT">
	Income (loss) before income taxes
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	46,515
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(2,292
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(9,905
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PX; PADDING-LEFT: 10PT; TEXT-INDENT: -10PT">
	Benefit (provision) for income taxes
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
	(1,229
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
	7
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
	(72
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="PADDING-LEFT: 10PT; TEXT-INDENT: -10PT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 3PX; PADDING-LEFT: 10PT; TEXT-INDENT: -10PT">
	Net income (loss)
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; TEXT-ALIGN: RIGHT">
	45,286
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; TEXT-ALIGN: RIGHT">
	(2,285
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; TEXT-ALIGN: RIGHT">
	(9,977
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="PADDING-LEFT: 10PT; TEXT-INDENT: -10PT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT; TEXT-INDENT: -10PT">
	Net income (loss) per common share:
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-BOTTOM: 3PX; PADDING-LEFT: 10PT; TEXT-INDENT: -10PT">
	Basic
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; TEXT-ALIGN: RIGHT">
	0.98
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; TEXT-ALIGN: RIGHT">
	(0.05
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; TEXT-ALIGN: RIGHT">
	(0.23
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255)">
<TD STYLE="PADDING-BOTTOM: 3PX; PADDING-LEFT: 10PT; TEXT-INDENT: -10PT">
	Diluted
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; TEXT-ALIGN: RIGHT">
	0.97
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; TEXT-ALIGN: RIGHT">
	(0.05
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; TEXT-ALIGN: RIGHT">
	(0.23
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="PADDING-LEFT: 10PT; TEXT-INDENT: -10PT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-LEFT: 10PT; TEXT-INDENT: -10PT">
	Weighted average common shares outstanding:
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255)">
<TD STYLE="PADDING-BOTTOM: 3PX; PADDING-LEFT: 10PT; TEXT-INDENT: -10PT">
	Basic
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; TEXT-ALIGN: RIGHT">
	46,153
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; TEXT-ALIGN: RIGHT">
	45,355
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; TEXT-ALIGN: RIGHT">
	42,561
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-BOTTOM: 3PX; PADDING-LEFT: 10PT; TEXT-INDENT: -10PT">
	Diluted
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; TEXT-ALIGN: RIGHT">
	46,602
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; TEXT-ALIGN: RIGHT">
	45,355
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; TEXT-ALIGN: RIGHT">
	42,561
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_INCOME_STATEMENT>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	The accompanying notes are an integral part
	of these consolidated financial statements
</P>
<!-- FIELD: PAGE; SEQUENCE: 4 -->
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 6PT; PADDING-BOTTOM: 12PT; BORDER-BOTTOM: SILVER 4PX SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	4
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage70"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 10PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: LEFT; WIDTH: 100%">
<PAGE>
</PAGE>
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_21"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
<A NAME="C86264_10K_HTM_X2_C86264A029">
</A>
<A NAME="C86264_10K_HTM_X2_C86264B005">
</A>
	ENZO BIOCHEM, INC.
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	CONSOLIDATED STATEMENTS OF COMPREHENSIVE
	INCOME (LOSS)
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	(in thousands)
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="PADDING-LEFT: 10PT; TEXT-INDENT: -10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD COLSPAN="10" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PX SOLID">
	Years Ended July 31,
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="PADDING-LEFT: 10PT; TEXT-INDENT: -10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PX SOLID">
	2016
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PX SOLID">
	2015
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PX SOLID">
	2014
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255)">
<TD STYLE="WIDTH: 55%; TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT; TEXT-INDENT: -10PT">
	Net income (loss)
</TD>
<TD STYLE="WIDTH: 3%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	45,286
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 3%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	(2,285
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="WIDTH: 3%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	(9,977
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT; TEXT-INDENT: -10PT">
	Other comprehensive income (loss):
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PX; PADDING-LEFT: 10PT; TEXT-INDENT: -10PT">
	Foreign currency translation adjustments
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
	338
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
	(117
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
	(114
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 3PX; PADDING-LEFT: 10PT; TEXT-INDENT: -10PT">
	Comprehensive income (loss)
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; TEXT-ALIGN: RIGHT">
	45,624
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; TEXT-ALIGN: RIGHT">
	(2,168
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; TEXT-ALIGN: RIGHT">
	(10,091
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	The accompanying notes are an integral part
	of these consolidated financial statements.
</P>
<!-- FIELD: PAGE; SEQUENCE: 5 -->
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 6PT; PADDING-BOTTOM: 12PT; BORDER-BOTTOM: SILVER 4PX SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	5
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage71"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 10PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: LEFT; WIDTH: 100%">
<PAGE>
</PAGE>
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<EFX_STOCKHOLDERS_EQUITY>
<A NAME="FIS_STOCKHOLDERS_EQUITY"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
<A NAME="C86264_10K_HTM_X2_C86264B006">
</A>
<A NAME="C86264_10K_HTM_X2_C86264A030">
</A>
	ENZO BIOCHEM, INC.
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	CONSOLIDATED STATEMENTS OF STOCKHOLDERS&rsquo;
	EQUITY
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	Years ended July 31, 2016, 2015, and
	2014
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	(in thousands, except share data)
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="PADDING-LEFT: 10PT; TEXT-INDENT: -10PT; PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; FONT-STYLE: ITALIC; PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; FONT-STYLE: ITALIC; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PX SOLID">
	Common
<BR>
	Stock
<BR>
	Shares
<BR>
	Issued
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT-WEIGHT: BOLD; FONT-STYLE: ITALIC">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; BORDER-BOTTOM: BLACK 1PX SOLID">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PX SOLID">
	Common
<BR>
	Stock
<BR>
	Amount
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; BORDER-BOTTOM: BLACK 1PX SOLID">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PX SOLID">
	Additional
<BR>
	Paid-in
<BR>
	Capital
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; BORDER-BOTTOM: BLACK 1PX SOLID">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PX SOLID">
	Accumulated
<BR>
	Deficit
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; BORDER-BOTTOM: BLACK 1PX SOLID">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PX SOLID">
	Accumulated
<BR>
	Other
<BR>
	Comprehensive
<BR>
	Income
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; BORDER-BOTTOM: BLACK 1PX SOLID">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PX SOLID">
	Total
<BR>
	Stockholders&rsquo;
<BR>
	Equity
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="PADDING-LEFT: 10PT; TEXT-INDENT: -10PT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255)">
<TD STYLE="WIDTH: 38%; FONT-WEIGHT: BOLD; PADDING-LEFT: 10PT; TEXT-INDENT: -10PT">
	Balance at July 31, 2013
</TD>
<TD STYLE="WIDTH: 2%; FONT-STYLE: ITALIC">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-STYLE: ITALIC; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 6%; FONT-STYLE: ITALIC; TEXT-ALIGN: RIGHT">
	40,569,393
</TD>
<TD STYLE="WIDTH: 1%; FONT-STYLE: ITALIC; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 6%; TEXT-ALIGN: RIGHT">
	406
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 6%; TEXT-ALIGN: RIGHT">
	304,288
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 6%; TEXT-ALIGN: RIGHT">
	(272,420
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 6%; TEXT-ALIGN: RIGHT">
	1,858
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 8%; TEXT-ALIGN: RIGHT">
	34,132
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT; TEXT-INDENT: -10PT">
	Net (loss) for the year ended July 31, 2014
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(9,977
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(9,977
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT; TEXT-INDENT: -10PT">
	Vesting of restricted stock
</TD>
<TD STYLE="FONT-STYLE: ITALIC">
	&nbsp;
</TD>
<TD STYLE="FONT-STYLE: ITALIC; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-STYLE: ITALIC; TEXT-ALIGN: RIGHT">
	82,968
</TD>
<TD STYLE="FONT-STYLE: ITALIC; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT; TEXT-INDENT: -10PT">
	Share-based compensation charges
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	594
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	594
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT; TEXT-INDENT: -10PT">
	Net proceeds from Issuance of common stock (net of expenses of $357)
</TD>
<TD STYLE="FONT-STYLE: ITALIC">
	&nbsp;
</TD>
<TD STYLE="FONT-STYLE: ITALIC; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-STYLE: ITALIC; TEXT-ALIGN: RIGHT">
	3,421,176
</TD>
<TD STYLE="FONT-STYLE: ITALIC; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	34
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	11,508
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	11,542
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT; TEXT-INDENT: -10PT">
	Issuance of options in lieu of payment of &nbsp;cash bonuses
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	136
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	136
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT; TEXT-INDENT: -10PT">
	Issuance of common stock for employee 401(k) plan match
</TD>
<TD STYLE="FONT-STYLE: ITALIC">
	&nbsp;
</TD>
<TD STYLE="FONT-STYLE: ITALIC; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-STYLE: ITALIC; TEXT-ALIGN: RIGHT">
	165,646
</TD>
<TD STYLE="FONT-STYLE: ITALIC; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	634
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	636
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PX; PADDING-LEFT: 10PT; TEXT-INDENT: -10PT">
	Foreign currency translation adjustments
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
	(114
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
	(114
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255)">
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-LEFT: 10PT; TEXT-INDENT: -10PT">
	Balance at July 31, 2014
</TD>
<TD STYLE="FONT-STYLE: ITALIC">
	&nbsp;
</TD>
<TD STYLE="FONT-STYLE: ITALIC; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-STYLE: ITALIC; TEXT-ALIGN: RIGHT">
	44,239,183
</TD>
<TD STYLE="FONT-STYLE: ITALIC; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	443
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	317,160
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(282,397
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,744
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	36,950
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT; TEXT-INDENT: -10PT">
	Net (loss) for the year ended July 31, 2015
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(2,285
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(2,285
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT; TEXT-INDENT: -10PT">
	Vesting of restricted stock
</TD>
<TD STYLE="FONT-STYLE: ITALIC">
	&nbsp;
</TD>
<TD STYLE="FONT-STYLE: ITALIC; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-STYLE: ITALIC; TEXT-ALIGN: RIGHT">
	19,418
</TD>
<TD STYLE="FONT-STYLE: ITALIC; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT; TEXT-INDENT: -10PT">
	Share-based compensation charges
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	429
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	429
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT; TEXT-INDENT: -10PT">
	Net proceeds from Issuance of common stock (net of expenses of $207)
</TD>
<TD STYLE="FONT-STYLE: ITALIC">
	&nbsp;
</TD>
<TD STYLE="FONT-STYLE: ITALIC; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-STYLE: ITALIC; TEXT-ALIGN: RIGHT">
	1,588,480
</TD>
<TD STYLE="FONT-STYLE: ITALIC; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	16
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	6,672
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	6,688
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT; TEXT-INDENT: -10PT">
	Issuance of options in lieu of payment of &nbsp;cash bonuses
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	45
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	45
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT; TEXT-INDENT: -10PT">
	Issuance of common stock for employee 401(k) plan match
</TD>
<TD STYLE="FONT-STYLE: ITALIC">
	&nbsp;
</TD>
<TD STYLE="FONT-STYLE: ITALIC; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-STYLE: ITALIC; TEXT-ALIGN: RIGHT">
	214,984
</TD>
<TD STYLE="FONT-STYLE: ITALIC; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	660
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	662
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PX; PADDING-LEFT: 10PT; TEXT-INDENT: -10PT">
	Foreign currency translation adjustments
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
	117
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
	117
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255)">
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-LEFT: 10PT; TEXT-INDENT: -10PT">
	Balance at July 31, 2015
</TD>
<TD STYLE="FONT-STYLE: ITALIC">
	&nbsp;
</TD>
<TD STYLE="FONT-STYLE: ITALIC; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-STYLE: ITALIC; TEXT-ALIGN: RIGHT">
	46,062,065
</TD>
<TD STYLE="FONT-STYLE: ITALIC; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	461
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	324,966
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(284,682
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,861
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	42,606
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT; TEXT-INDENT: -10PT">
	Net income for the year ended July 31, 2016
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	45,286
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	45,286
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT; TEXT-INDENT: -10PT">
	Vesting of restricted stock
</TD>
<TD STYLE="FONT-STYLE: ITALIC">
	&nbsp;
</TD>
<TD STYLE="FONT-STYLE: ITALIC; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-STYLE: ITALIC; TEXT-ALIGN: RIGHT">
	11,500
</TD>
<TD STYLE="FONT-STYLE: ITALIC; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT; TEXT-INDENT: -10PT">
	Share-based compensation charges
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	525
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	525
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT; TEXT-INDENT: -10PT">
	Issuance of common stock for employee 401(k) plan match
</TD>
<TD STYLE="FONT-STYLE: ITALIC">
	&nbsp;
</TD>
<TD STYLE="FONT-STYLE: ITALIC; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-STYLE: ITALIC; TEXT-ALIGN: RIGHT">
	160,352
</TD>
<TD STYLE="FONT-STYLE: ITALIC; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	707
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	709
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-LEFT: 10PT; TEXT-INDENT: -10PT">
	Exercise of stock options
</TD>
<TD STYLE="FONT-STYLE: ITALIC">
	&nbsp;
</TD>
<TD STYLE="FONT-STYLE: ITALIC; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-STYLE: ITALIC; TEXT-ALIGN: RIGHT">
	33,702
</TD>
<TD STYLE="FONT-STYLE: ITALIC; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	90
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	90
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT; TEXT-INDENT: -10PT; PADDING-BOTTOM: 1PX">
	Foreign currency translation adjustments
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PX SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PX SOLID">
	&mdash;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PX SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PX SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PX SOLID">
	&mdash;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PX SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PX SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PX SOLID">
	&mdash;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PX SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PX SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PX SOLID">
	&mdash;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PX SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PX SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PX SOLID">
	338
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PX SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PX SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PX SOLID">
	338
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PX SOLID">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PX; PADDING-LEFT: 10PT; TEXT-INDENT: -10PT">
	Balance at July 31, 2016
</TD>
<TD STYLE="FONT-STYLE: ITALIC; PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT-STYLE: ITALIC; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT-STYLE: ITALIC; TEXT-ALIGN: RIGHT">
	46,267,619
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT-STYLE: ITALIC; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
	463
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
	326,288
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
	(239,396
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
	2,199
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
	89,554
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_STOCKHOLDERS_EQUITY>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&#9;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	The accompanying notes are an integral part
	of these consolidated financial statements
</P>
<!-- FIELD: PAGE; SEQUENCE: 6 -->
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 6PT; PADDING-BOTTOM: 12PT; BORDER-BOTTOM: SILVER 4PX SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	6
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage72"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 10PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: LEFT; WIDTH: 100%">
<PAGE>
</PAGE>
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<EFX_CASH_FLOW>
<A NAME="FIS_CASH_FLOW"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
<A NAME="C86264_10K_HTM_X2_C86264A031">
</A>
<A NAME="C86264_10K_HTM_X2_C86264B007">
</A>
	ENZO BIOCHEM, INC.
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	CONSOLIDATED STATEMENTS OF CASH FLOWS
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	(in thousands)
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD COLSPAN="10" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PX SOLID">
	Years ended July 31,
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PX SOLID">
	2016
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PX SOLID">
	2015
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PX SOLID">
	2014
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Cash flows from operating activities:
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="WIDTH: 55%; TEXT-ALIGN: LEFT">
	Net income (loss)
</TD>
<TD STYLE="WIDTH: 3%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	45,286
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 3%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	(2,285
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="WIDTH: 3%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	(9,977
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Depreciation and amortization of property, plant and equipment
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2,163
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2,019
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2,131
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Amortization of intangible assets
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,677
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,770
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,840
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Provision for uncollectible accounts receivable
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2,336
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2,284
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	3,063
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Deferred income tax benefit
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(60
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(104
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(18
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Share-based compensation charges
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	525
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	429
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	594
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Share-based 401(k) employer match expense
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	709
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	662
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	636
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Foreign exchange loss (gain)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	357
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	664
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(304
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Changes in operating assets and liabilities:
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Accounts receivable
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(4,791
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(2,003
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(3,224
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Other receivables - settlements
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	6,650
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(6,650
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
	Inventories
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	466
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,151
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	159
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Prepaid expenses
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	169
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(108
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	336
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Accounts payable - trade
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,103
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	394
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(226
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PX">
	Accrued liabilities, other current liabilities and other liabilities
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
	(3,464
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
	(1,923
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
	3,293
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PX">
	Total adjustments
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
	7,840
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
	(1,415
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
	8,280
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PX">
	Net cash provided by (used in) operating activities
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
	53,126
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
	(3,700
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
	(1,697
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Cash flows from investing activities:
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Capital expenditures
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(1,530
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(1,783
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(838
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PX">
	Decrease in security deposits and other
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
	18
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
	31
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
	5
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PX">
	Net cash used in investing activities
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
	(1,512
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
	(1,752
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
	(833
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Cash flows from financing activities:
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Net proceeds from issuance of common stock
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	6,688
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	11,542
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Proceeds from borrowings under Credit Agreement
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	89,880
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	88,632
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	78,814
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Repayments under Credit Agreement
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(91,336
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(88,632
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(79,065
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Installment loan payments
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(565
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(463
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(374
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PX">
	Proceeds from exercise of stock options
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
	90
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PX">
	Net cash (used in) provided by financing activities
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
	(1,931
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
	6,225
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
	10,917
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PX">
	Effect of exchange rate changes on cash and cash equivalents
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
	(15
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
	(119
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
	61
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Increase in cash and cash equivalents
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	49,668
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	654
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	8,448
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PX">
	Cash and cash equivalents - beginning of year
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
	18,109
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
	17,455
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
	9,007
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 3PX">
	Cash and cash equivalents - end of year
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; TEXT-ALIGN: RIGHT">
	67,777
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; TEXT-ALIGN: RIGHT">
	18,109
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; TEXT-ALIGN: RIGHT">
	17,455
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_CASH_FLOW>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	The accompanying notes are an integral part
	of these consolidated financial statements
</P>
<!-- FIELD: PAGE; SEQUENCE: 7 -->
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 6PT; PADDING-BOTTOM: 12PT; BORDER-BOTTOM: SILVER 4PX SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	7
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage73"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 10PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: LEFT; WIDTH: 100%">
<PAGE>
</PAGE>
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<A NAME="C86264_10K_HTM_X2_C86264B008">
</A>
<A NAME="C86264_10K_HTM_X2_C86264A032">
</A>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	ENZO BIOCHEM, INC.
</B>
</FONT>
</P>
<EFX_NOTES_TO_FINANCIAL_STATEMENT>
<A NAME="FIS_NOTES_TO_FINANCIAL_STATEMENT"></A>
<P STYLE="MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	NOTES TO CONSOLIDATED FINANCIAL
	STATEMENTS
</B>
</FONT>
</P>
<P STYLE="MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	July 31, 2016
</B>
</FONT>
</P>
<P STYLE="MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	(Dollars in thousands except
	share data)
</B>
</FONT>
</P>
<P STYLE="MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN: 0PT 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Note 1 - Summary of significant accounting
	policies
</B>
</FONT>
</P>
<P STYLE="MARGIN: 0PT 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN: 0PT 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Nature of business
</FONT>
</P>
<P STYLE="MARGIN: 0PT 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN: 0PT 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Enzo Biochem, Inc. (the &#8220;Company&#8221;)
	is an integrated life science and biotechnology company engaged in research, development, manufacturing and marketing of diagnostic
	and research products based on genetic engineering, biotechnology and molecular biology. These products are designed for the diagnosis
	of and/or screening for infectious diseases, cancers, genetic defects and other medically pertinent diagnostic information and
	are distributed in the United States and internationally. The Company is conducting research and development activities in the
	development of therapeutic products based on the Company&#8217;s technology platform of genetic modulation and immune modulation.
	The Company also operates a clinical laboratory that offers and provides molecular and esoteric diagnostic medical testing services
	in the New York and New Jersey medical communities. The Company operates in three segments (see Note 15).
</FONT>
</P>
<P STYLE="MARGIN: 0PT 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN: 0PT 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<I>
	Principles of consolidation
</I>
</FONT>
</P>
<P STYLE="MARGIN: 0PT 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN: 0PT 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	The accompanying consolidated financial statements
	have been prepared in conformity with accounting principles generally accepted in the United States (&#8220;U.S. GAAP&#8221;)
	and include the accounts of the Company and its wholly-owned subsidiaries, Enzo Clinical Labs, Inc., Enzo Life Sciences, Inc.
	(and its wholly-owned foreign subsidiaries), Enzo Therapeutics, Inc. and Enzo Realty LLC (&#8220;Realty&#8221;). All intercompany
	transactions and balances have been eliminated.
</FONT>
</P>
<P STYLE="MARGIN: 0PT 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN: 0PT 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<I>
	Use of Estimates
</I>
</FONT>
</P>
<P STYLE="MARGIN: 0PT 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN: 0PT 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	The preparation of financial statements in conformity
	with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements
	and accompanying footnotes. Actual results could differ from those estimates.
</FONT>
</P>
<P STYLE="MARGIN: 0PT 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN: 0PT 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<I>
	Foreign Currency Translation/Transactions
</I>
</FONT>
</P>
<P STYLE="MARGIN: 0PT 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN: 0PT 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	The Company has determined that the functional
	currency for its foreign subsidiaries is the local currency. For financial reporting purposes, assets and liabilities denominated
	in foreign currencies are translated at current exchange rates and profit and loss accounts are translated at weighted average
	exchange rates. Resulting translation gains and losses are included as a separate component of stockholders&#8217; equity as accumulated
	other comprehensive income or loss. Gains or losses resulting from transactions entered into in other than the functional currency
	are recorded as foreign exchange gains and losses in the consolidated statements of operations.
</FONT>
</P>
<P STYLE="MARGIN: 0PT 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN: 0PT 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<I>
	Cash and cash equivalents
</I>
</FONT>
</P>
<P STYLE="MARGIN: 0PT 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN: 0PT 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Cash and cash equivalents consist of demand deposits
	with banks and highly liquid money market funds. At July 31, 2016 and 2015, the Company had cash and cash equivalents in foreign
	bank accounts of $0.5 million.
</FONT>
</P>
<P STYLE="MARGIN: 0PT 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN: 0PT 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<I>
	Fair Values of Financial Instruments
</I>
</FONT>
</P>
<P STYLE="MARGIN: 0PT 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN: 0PT 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	The recorded amounts of the Company&#8217;s cash
	and equivalents, receivables, loan payable, accounts payable and accrued liabilities approximate their fair values principally
	because of the short-term nature of these items.
</FONT>
</P>
<P STYLE="MARGIN: 0PT 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN: 0PT 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<I>
	Concentration of credit risk
</I>
</FONT>
</P>
<P STYLE="MARGIN: 0PT 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN: 0PT 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Financial instruments that potentially subject
	the Company to concentrations of credit risk primarily consist of cash and cash equivalents and accounts receivable.
</FONT>
</P>
<P STYLE="MARGIN: 0PT 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN: 0PT 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	The Company believes the fair value of the aforementioned
	financial instruments approximates the cost due to the immediate or short-term nature of these items.
</FONT>
</P>
<P STYLE="MARGIN: 0PT 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN: 0PT 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Concentration of credit risk with respect to the
	Company&#8217;s Life Sciences segment is mitigated by the diversity of the Company&#8217;s clients and their dispersion across
	many different geographic regions. To reduce risk, the Company routinely assesses the financial strength of these customers and,
	consequently, believes that its accounts receivable credit exposure with respect to these customers is limited.
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 1; OPTIONS: NEWSECTION; VALUE: 8 -->
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 6PT; PADDING-BOTTOM: 12PT; BORDER-BOTTOM: SILVER 4PX SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	8
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage74"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 10PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: LEFT; WIDTH: 100%">
<PAGE>
</PAGE>
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	ENZO BIOCHEM, INC.
</B>
</FONT>
</P>
<P STYLE="MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	NOTES TO CONSOLIDATED FINANCIAL
	STATEMENTS
</B>
</FONT>
</P>
<P STYLE="MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	July 31, 2016
</B>
</FONT>
</P>
<P STYLE="MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	(Dollars in thousands except
	share data)
</B>
</FONT>
</P>
<P STYLE="MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN: 0PT 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	The Company believes that the concentration of
	credit risk with respect to the Clinical Labs accounts receivable is mitigated by the diversity of third party payers that insure
	individuals. To reduce risk, the Company routinely assesses the financial strength of these payers and, consequently, believes
	that its accounts receivable credit risk exposure, with respect to these payers, is limited. While the Company also has receivables
	due from the Federal Medicare program, the Company does not believe that these receivables represent a credit risk since the Medicare
	program is funded by the federal government and payment is primarily dependent on our submitting the appropriate documentation.
</FONT>
</P>
<P STYLE="MARGIN: 0PT 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN: 0PT 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<I>
	Accrual for Self-Funded Medical
</I>
</FONT>
</P>
<P STYLE="MARGIN: 0PT 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN: 0PT 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Accruals for self-funded medical insurance are
	determined based on a number of assumptions and factors, including historical payment trends, claims history and current estimates.
	These estimated liabilities are not discounted. If actual trends differ from these estimates, the financial results could be impacted.
</FONT>
</P>
<P STYLE="MARGIN: 0PT 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN: 0PT 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<I>
	Revenue Recognition - Product revenues
</I>
</FONT>
</P>
<P STYLE="MARGIN: 0PT 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN: 0PT 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Revenues from product sales are recognized when
	the products are shipped and title transfers, the sales price is fixed or determinable and collectability is reasonably assured.
</FONT>
</P>
<P STYLE="MARGIN: 0PT 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN: 0PT 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<I>
	Royalties
</I>
</FONT>
</P>
<P STYLE="MARGIN: 0PT 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN: 0PT 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Royalty revenues are recorded in the period earned.
	Royalties received in advance of being earned are recorded as deferred revenues.
</FONT>
</P>
<P STYLE="MARGIN: 0PT 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN: 0PT 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<I>
	Clinical laboratory services
</I>
</FONT>
</P>
<P STYLE="MARGIN: 0PT 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN: 0PT 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Revenues from the Clinical Labs segment are recognized
	upon completion of the testing process for a specific patient and reported to the ordering physician. These revenues and the associated
	accounts receivable are based on gross amounts billed or billable for services rendered, net of a contractual adjustment, which
	is the difference between amounts billed to payers and the expected reimbursable settlements from such payers.
</FONT>
</P>
<P STYLE="MARGIN: 0PT 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN: 0PT 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	The following table summarizes the Clinical Lab
	segment&#8217;s net revenues and revenue percentages by revenue category:
</FONT>
</P>
<P STYLE="MARGIN: 0PT 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_22"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="23" STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Years Ended July 31,
</B>
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="PADDING-BOTTOM: 1PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="6" STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PX SOLID">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	2016
</B>
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="6" STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PX SOLID">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	2015
</B>
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="6" STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PX SOLID">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	2014
</B>
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Revenue category
</B>
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PX SOLID">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Amount
</B>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PX SOLID">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	%
</B>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PX SOLID">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Amount
</B>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PX SOLID">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	%
</B>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PX SOLID">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Amount
</B>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PX SOLID">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	%
</B>
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255)">
<TD STYLE="WIDTH: 34%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Third-party payers
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</FONT>
</TD>
<TD STYLE="WIDTH: 7%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	40,211
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 8%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	57
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</FONT>
</TD>
<TD STYLE="WIDTH: 8%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	35,631
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 8%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	56
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</FONT>
</TD>
<TD STYLE="WIDTH: 8%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;&nbsp;29,509
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 8%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	50
</FONT>
</TD>
<TD STYLE="WIDTH: 2%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Patient self-pay
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	14,744
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	21
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	11,028
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	17
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	11,204
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	19
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255)">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Medicare
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	11,392
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	16
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	11,981
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	19
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	12,815
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	22
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-BOTTOM: 1PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	HMO&#8217;s
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PX SOLID">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	4,568
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; BORDER-BOTTOM: BLACK 1PX SOLID">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PX SOLID">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	6
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PX SOLID">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	4,774
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; BORDER-BOTTOM: BLACK 1PX SOLID">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PX SOLID">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	8
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PX SOLID">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	5,161
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; BORDER-BOTTOM: BLACK 1PX SOLID">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PX SOLID">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	9
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255)">
<TD STYLE="PADDING-BOTTOM: 3PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Total
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 3PX DOUBLE">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	70,915
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX; BORDER-BOTTOM: BLACK 3PX DOUBLE">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 3PX DOUBLE">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	100
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	%
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 3PX DOUBLE">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	63,414
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX; BORDER-BOTTOM: BLACK 3PX DOUBLE">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 3PX DOUBLE">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	100
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	%
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 3PX DOUBLE">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	58,689
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX; BORDER-BOTTOM: BLACK 3PX DOUBLE">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 3PX DOUBLE">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	100
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	%
</FONT>
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN: 0PT 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN: 0PT 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	The Company provides services to certain patients
	covered by various third-party payers, including the Federal Medicare program. Laws and regulations governing Medicare are complex
	and subject to interpretation for which action for noncompliance includes fines, penalties and exclusion from the Medicare programs
	(See Note 14).
</FONT>
</P>
<P STYLE="MARGIN: 0PT 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Other than the Medicare program, one provider
	whose programs are included in the &#8220;Third-party payers&#8221; and &#8220;Health Maintenance Organizations&#8221; (&#8220;HMO&#8217;s&#8221;)
	categories represent approximately 30%, 28% and 25% of the Clinical Labs segment net revenue for the years ended July 31, 2016,
	2015 and 2014 respectively.
</P>
<!-- FIELD: PAGE; SEQUENCE: 2; VALUE: 8 -->
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 6PT; PADDING-BOTTOM: 12PT; BORDER-BOTTOM: SILVER 4PX SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	9
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage75"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 10PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: LEFT; WIDTH: 100%">
<PAGE>
</PAGE>
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	ENZO BIOCHEM, INC.
</B>
</FONT>
</P>
<P STYLE="MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	NOTES TO CONSOLIDATED FINANCIAL
	STATEMENTS
</B>
</FONT>
</P>
<P STYLE="MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	July 31, 2016
</B>
</FONT>
</P>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	(Dollars
	in thousands except share data)
</B>
</FONT>
</P>
<P STYLE="MARGIN: 0PT 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN: 0PT 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<I>
	Contractual Adjustment
</I>
</FONT>
</P>
<P STYLE="MARGIN: 0PT 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN: 0PT 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	The Company&#8217;s estimate of contractual adjustment
	is based on significant assumptions and judgments, such as its interpretation of payer reimbursement policies, and bears the risk
	of change. The estimation process is based on the experience of amounts approved as reimbursable and ultimately settled by payers,
	versus the corresponding gross amount billed to the respective payers. The contractual adjustment is an estimate that reduces
	gross revenue based on gross billing rates to amounts expected to be approved and reimbursed. Gross billings are based on a standard
	fee schedule the Company sets for all third-party payers, including Medicare, HMO&#8217;s and managed care providers. The Company
	adjusts the contractual adjustment estimate quarterly, based on its evaluation of current and historical settlement experience
	with payers, industry reimbursement trends, and other relevant factors which include the monthly and quarterly review of: 1) current
	gross billings and receivables and reimbursement by payer, 2) current changes in third party arrangements and 3) the growth of
	in-network provider arrangements and managed care plans specific to our Company.
</FONT>
</P>
<P STYLE="MARGIN: 0PT 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN: 0PT 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	During the years ended July 31, 2016, 2015 and
	2014, the contractual adjustment percentages, determined using current and historical reimbursement statistics, were approximately
	84%, 85% and 86%, respectively, of gross billings.
</FONT>
</P>
<P STYLE="MARGIN: 0PT 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN: 0PT 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<I>
	Accounts Receivable and Allowance for Doubtful
	Accounts
</I>
</FONT>
</P>
<P STYLE="MARGIN: 0PT 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN: 0PT 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Accounts receivable are reported at realizable
	value, net of allowances for doubtful accounts, which is estimated and recorded in the period of the related revenue.
</FONT>
</P>
<P STYLE="MARGIN: 0PT 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN: 0PT 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	For the Clinical Labs segment, the allowance for
	doubtful accounts represents amounts that the Company does not expect to collect after the Company has exhausted its collection
	procedures. The Company estimates its allowance for doubtful accounts in the period the related services are billed and reduces
	the allowance in future accounting periods based on write-offs during those periods. It bases the estimate for the allowance on
	the evaluation of historical experience of accounts going to collections and the net amounts not received. Accounts going to collection
	include the balances, after receipt of the approved settlements from third party payers, for the insufficient diagnosis information
	received from the ordering physician which result in denials of payment, and our estimate of the uncollected portion of receivables
	from self-payers, including deductibles and copayments, which are subject to credit risk and patients&#8217; ability to pay. As
	of July 31, 2016 and 2015, the Company recategorizes to collections customers whose accounts receivable have been outstanding
	more than 210 days. The Company fully reserves through its contractual allowances amounts that have not been written off because
	the payer&#8217;s filing date deadline has not occurred or the collection process has not been exhausted. The Company&#8217;s
	collection experience on Medicare receivables beyond 210 days has been insignificant. The Company adjusts the historical collection
	analysis for recoveries, if any, on an on-going basis.
</FONT>
</P>
<P STYLE="MARGIN: 0PT 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN: 0PT 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	As of July 31, 2016 and 2015, the Company determined
	an allowance for doubtful accounts for customers whose accounts receivable have been outstanding less than 210 days and either
	fully reserved (principally Medicare) or wrote off 100% of accounts receivable over 210 days, as it determined based on historical
	trends that these accounts were unlikely to be collected. Amounts fully reserved have not been written off because the payer&#8217;s
	filing date deadline has not occurred or the collection process has not been exhausted. The Company adjusts the historical collection
	analysis for recoveries, if any, on an on-going basis.
</FONT>
</P>
<P STYLE="MARGIN: 0PT 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN: 0PT 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	The Company&#8217;s ability to collect outstanding
	receivables from third-party payers is critical to its operating performance and cash flows. The primary collection risk lies
	with uninsured patients or patients for whom primary insurance has paid but a patient portion remains outstanding. The Company
	also assesses the current state of its billing functions in order to identify any known collection issues and to assess the impact,
	if any, on the allowance estimates which involves judgment. The Company believes that the collectability of its receivables is
	directly linked to the quality of its billing processes, most notably, those related to obtaining the correct information in order
	to bill effectively for the services provided. Should circumstances change (e.g. shift in payer mix, decline in economic conditions
	or deterioration in aging of receivables), our estimates of net realizable value of receivables could be reduced by a material
	amount.
</FONT>
</P>
<P STYLE="MARGIN: 0PT 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN: 0PT 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	The allowance for doubtful accounts as a percentage
	of total accounts receivable at July 31, 2016 and 2015 was 19.4% and 12.9% respectively. During fiscal 2016 a higher allowance
	was required due to the volume increase in genetic testing.
</FONT>
</P>
<P STYLE="MARGIN: 0PT 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN: 0PT 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	The Clinical Labs segment&#8217;s net receivables
	are detailed by billing category and as a percent to its total net receivables. At July 31, 2016 and 2015, approximately 71% and
	68%, respectively, of the Company&#8217;s net accounts receivable relates to its Clinical Labs business, which operates in the
	New York and New Jersey medical communities.
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 3; VALUE: 8 -->
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 6PT; PADDING-BOTTOM: 12PT; BORDER-BOTTOM: SILVER 4PX SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	10
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage76"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 10PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: LEFT; WIDTH: 100%">
<PAGE>
</PAGE>
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	ENZO
	BIOCHEM, INC.
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	NOTES
	TO CONSOLIDATED FINANCIAL STATEMENTS
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	July
	31, 2016
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	(Dollars
	in thousands except share data)
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	The
	Life Sciences segment&#8217;s accounts receivable includes royalties receivable of $0.5 million and $0.1 million, as of July 31,
	2016 and 2015, respectively, due from QIAGEN Gaithersburg Inc. (&#8220;Qiagen&#8221;) (see Note 12).
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	The
	following is a table of the Company&#8217;s net accounts receivable by segment.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_23"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT CAMBRIA, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="PADDING-BOTTOM: 1PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="6" STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PX SOLID">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	July
	31, 2016
</B>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; PADDING-BOTTOM: 1PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; PADDING-BOTTOM: 1PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="6" STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PX SOLID">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	July
	31, 2015
</B>
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Net accounts receivable
	by segment
</B>
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PX SOLID">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Amount
</B>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PX SOLID">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	%
</B>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PX SOLID">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Amount
</B>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PX SOLID">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	%
</B>
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255)">
<TD STYLE="WIDTH: 52%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Clinical Labs (by billing category)
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 9%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 9%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 9%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 9%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Third party payers
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	6,868
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	67
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	3,595
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	44
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255)">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Patient self-pay
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	1,676
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	16
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	3,213
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	39
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Medicare
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	1,486
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	14
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	1,081
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	13
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255)">
<TD STYLE="PADDING-BOTTOM: 1PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	HMO&#8217;s
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PX SOLID">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	334
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; BORDER-BOTTOM: BLACK 1PX SOLID">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PX SOLID">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	3
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PX SOLID">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	305
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; BORDER-BOTTOM: BLACK 1PX SOLID">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PX SOLID">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	4
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Total Clinical Labs
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 3PX DOUBLE">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	10,364
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 3PX DOUBLE">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	100
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	%
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 3PX DOUBLE">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	8,194
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 3PX DOUBLE">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	100
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	%
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255)">
<TD STYLE="PADDING-BOTTOM: 1PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Total Life Sciences
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PX SOLID">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	4,228
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-BOTTOM: 1PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PX SOLID">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	3,915
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-BOTTOM: 1PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-BOTTOM: 3PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Total accounts receivable &#8211; net
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 3PX DOUBLE">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	14,592
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-BOTTOM: 3PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 3PX DOUBLE">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	12,109
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-BOTTOM: 3PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Changes
	in the Company&#8217;s allowance for doubtful accounts are as follows:
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_24"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT CAMBRIA, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="PADDING-BOTTOM: 1PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PX SOLID">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	July
	31, 2016
</B>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-BOTTOM: 1PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-BOTTOM: 1PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PX SOLID">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	July
	31, 2015
</B>
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255)">
<TD STYLE="WIDTH: 72%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Beginning balance
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</FONT>
</TD>
<TD STYLE="WIDTH: 11%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	1,786
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</FONT>
</TD>
<TD STYLE="WIDTH: 11%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	2,142
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Provision for doubtful accounts
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	2,336
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	2,284
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255)">
<TD STYLE="PADDING-BOTTOM: 1PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Write-offs
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PX SOLID">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	(605
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	)
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PX SOLID">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	(2,640
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-BOTTOM: 3PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Ending balance
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 3PX DOUBLE">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	3,517
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 3PX DOUBLE">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	1,786
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<I>
	Inventories
</I>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	The
	Company values inventory at the lower of cost (first-in, first-out) or market. Work-in-process and finished goods inventories
	consist of material, labor, and manufacturing overhead. Write downs of inventories to market value are based on a review of inventory
	quantities on hand and estimated sales forecasts based on sales history and anticipated future demand. Unanticipated changes in
	demand could have a significant impact on the value of our inventory and require additional write downs of inventory which would
	impact our results of operations.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<I>
	Property,
	plant and equipment
</I>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Property,
	plant and equipment is stated at cost, and depreciated on the straight-line basis over the estimated useful lives of the various
	asset classes as follows: building and building improvements: 15-30 years, and laboratory machinery and equipment and office furniture
	and computer equipment which range from 3-10 years. Leasehold improvements are amortized over the term of the related leases or
	estimated useful lives of the assets, whichever is shorter.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<I>
	Goodwill
	and Intangible Assets
</I>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Goodwill
	represents the excess of the cost of an acquisition over the fair value of the net assets acquired.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Intangible
	assets (exclusive of patents), arose primarily from acquisitions, and primarily consist of customer relationships, trademarks,
	licenses, and website and database content. Finite-lived intangible assets are amortized according to their estimated useful lives,
	which range from 4 to 15 years. Indefinite-lived intangibles are not amortized and are evaluated each reporting period to determine
	whether events and circumstances continue to support their having an indefinite life. Indefinite-lived intangibles found
	to no longer have an indefinite life are evaluated for impairment and are then amortized over their remaining useful life as finite-lived
	intangible assets. Patents represent capitalized legal costs incurred in pursuing patent applications. When such applications
	result in an issued patent, the related capitalized costs are amortized over a ten year period or the life of the patent, whichever
	is shorter, using the straight-line method.
</P>
<!-- FIELD: PAGE; SEQUENCE: 4; VALUE: 8 -->
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 6PT; PADDING-BOTTOM: 12PT; BORDER-BOTTOM: SILVER 4PX SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	11
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage77"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 10PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: LEFT; WIDTH: 100%">
<PAGE>
</PAGE>
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	ENZO
	BIOCHEM, INC.
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	NOTES
	TO CONSOLIDATED FINANCIAL STATEMENTS
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	July
	31, 2016
</B>
</FONT>
</P>
<P STYLE="FONT: 9PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	(Dollars
	in thousands except share data)
</B>
</FONT>
</P>
<P STYLE="FONT: 9PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	The
	Company reviews its issued patents and pending patent applications, and if it determines to abandon a patent application or that
	an issued patent no longer has economic value, the unamortized balance in deferred patent costs relating to that patent is immediately
	expensed.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<I>
	Impairment
	testing for Goodwill and Long-Lived Assets
</I>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	The
	Company tests goodwill annually as of the first day of the fourth quarter, or more frequently if indicators of potential impairment
	exist. In assessing goodwill for impairment, the Company has the option to first perform a qualitative assessment to determine
	whether the existence of events or circumstances leads to a determination that it is more likely than not that the fair value
	of a reporting unit is less than its carrying amount. If the Company determines that it is not more likely than not that the fair
	value of a reporting unit is less than its carrying amount, the Company is not required to perform any additional tests in assessing
	goodwill for impairment. If the Company concludes otherwise or elects not to perform the qualitative assessment, then it is required
	to perform the first step of a two-step quantitative impairment review process. The first step of the quantitative impairment
	test requires the identification of the reporting units and comparison of the fair value of each of these reporting units to their
	respective carrying value. If the carrying value of the reporting unit is less than its fair value, no impairment exists and the
	second step is not performed. If the carrying value of the reporting unit is higher than its fair value, the second step must
	be performed to compute the amount of the goodwill impairment, if any. In the second step, the impairment is computed by comparing
	the implied fair value of the reporting unit goodwill with the carrying amount of that goodwill. If the carrying amount of the
	reporting unit goodwill exceeds the implied fair value of that goodwill, an impairment loss is recognized for the excess. The
	Company performed a qualitative assessment in 2016, 2015, and 2014 and concluded there were no goodwill impairments.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	The
	Company reviews the recoverability of the carrying value of long-lived assets (including intangible assets with finite lives)
	for impairment annually as of the first day of the fourth quarter, or more frequently if indicators of potential impairment exist.
	Should indicators of impairment exist, the carrying values of the assets are evaluated in relation to the operating performance
	and future undiscounted cash flows of the underlying business. The net book value of an asset is adjusted to fair value if its
	expected future undiscounted cash flow is less than its book value. There were no long-lived asset impairments in 2016, 2015 or
	2014.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<I>
	Comprehensive
	income (loss)
</I>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Comprehensive
	income (loss) consists of the Company&#8217;s consolidated net income (loss) and foreign currency translation adjustments. Foreign
	currency translation adjustments included in comprehensive income (loss) were not tax effected as investments in international
	affiliates are deemed to be permanent. Accumulated other comprehensive income is a separate component of stockholders&#8217; equity
	and consists of the cumulative foreign currency translation adjustments.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<I>
	Shipping
	and Handling Costs
</I>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Shipping
	and handling costs associated with the distribution of finished goods to customers are recorded in cost of goods sold.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<I>
	Research
	and Development
</I>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Research
	and development costs are charged to expense as incurred.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<I>
	Advertising
</I>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	All
	costs associated with advertising are expensed as incurred. Advertising expense, included in selling, general and administrative
	expense, approximated $601, $556 and $440 for the years ended July 31, 2016, 2015 and 2014, respectively.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<I>
	Income
	Taxes
</I>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	The
	Company accounts for income taxes under the liability method of accounting for income taxes. Under the liability method, deferred
	tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement
	carrying amounts of existing assets and liabilities and their respective tax bases. The liability method requires that any tax
	benefits recognized for net operating loss carry forwards and other items be reduced by a valuation allowance when it is more
	likely
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 5; VALUE: 8 -->
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 6PT; PADDING-BOTTOM: 12PT; BORDER-BOTTOM: SILVER 4PX SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	12
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage78"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 10PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: LEFT; WIDTH: 100%">
<PAGE>
</PAGE>
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	ENZO
	BIOCHEM, INC.
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	NOTES
	TO CONSOLIDATED FINANCIAL STATEMENTS
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	July
	31, 2016
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	(Dollars
	in thousands except share data)
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	than
	not that the benefits may not be realized. Deferred tax assets and liabilities are measured using enacted tax rates expected to
	apply to taxable income in the years in which those temporary differences are expected to be recovered or settled.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Under
	the liability method, the effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the
	period that includes the enactment date.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	It is
	the Company&#8217;s policy to provide for uncertain tax positions and the related interest and penalties based upon management&#8217;s
	assessment of whether a tax benefit is more likely than not to be sustained upon examination by tax authorities. At July 31, 2016,
	the Company believes it has appropriately accounted for any unrecognized tax benefits. To the extent the Company prevails in matters
	for which a liability for an unrecognized tax benefit is established or is required to pay amounts in excess of the liability,
	the Company&#8217;s effective tax rate in a given financial statement period may be affected.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<I>
	Segment
	Reporting
</I>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	The
	Company separately reports information about each operating segment that engages in business activities from which the segment
	may earn revenues and incur expenses, whose separate operating results are regularly reviewed by the chief operating decision
	maker regarding allocation of resources and performance assessment and which exceed specific quantitative thresholds related to
	revenue and profit or loss. The Company&#8217;s operating activities are reported in three segments (see Note 15).
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<I>
	Net
	income (loss) per share
</I>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Basic
	net income (loss) per share represents net income (loss) divided by the weighted average number of common shares outstanding during
	the period. The dilutive effect of potential common shares, consisting of outstanding stock options and unvested restricted stock,
	is determined using the treasury stock method. For fiscal 2016, approximately 449,000 weighted average stock options were included
	in the calculation of diluted weighted average shares outstanding. Diluted weighted average shares outstanding for fiscal 2015
	and 2014 do not include the potential common shares from stock options and unvested restricted stock because to do so would have
	been antidilutive and as such is the same as basic weighted average shares outstanding for 2015 and 2014. The number of potential
	common shares (&#8220;in the money options&#8221;) and unvested restricted stock excluded from the calculation of diluted weighted
	average shares outstanding for the years ended July 31, 2015, and 2014 was 403,000, and 1,016,000, respectively.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	For
	the years ended July 31, 2016, 2015 and 2014, the effect of approximately 282,000, 977,000 and 182,000 respectively, of outstanding
	&#8220;out of the money&#8221; options to purchase common shares were excluded from the calculation of diluted weighted average
	shares outstanding because their effect would be anti-dilutive. The following table sets forth the computation of basic and diluted
	net loss per share for the years ended July 31:
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_25"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT CAMBRIA, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="PADDING-BOTTOM: 1PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PX SOLID">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	2016
</B>
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PX SOLID">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	2015
</B>
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PX SOLID">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	2014
</B>
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255)">
<TD STYLE="WIDTH: 58%; PADDING-BOTTOM: 3PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Net income (loss)
</FONT>
</TD>
<TD STYLE="WIDTH: 2%; PADDING-BOTTOM: 3PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 3PX DOUBLE">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</FONT>
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 3PX DOUBLE">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	45,286
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; PADDING-BOTTOM: 3PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 2%; PADDING-BOTTOM: 3PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 3PX DOUBLE">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</FONT>
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 3PX DOUBLE">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	(2,285
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; PADDING-BOTTOM: 3PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	)
</FONT>
</TD>
<TD STYLE="WIDTH: 2%; PADDING-BOTTOM: 3PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 3PX DOUBLE">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</FONT>
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 3PX DOUBLE">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	(9,977
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; PADDING-BOTTOM: 3PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="PADDING-BOTTOM: 1PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Weighted-average common shares outstanding - basic
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PX SOLID">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	46,153
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PX SOLID">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	45,355
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PX SOLID">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	42,561
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255)">
<TD STYLE="PADDING-BOTTOM: 1PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Add: effect of dilutive stock options and restricted stock
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PX SOLID">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	449
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PX SOLID">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&#8212;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PX SOLID">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&#8212;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="PADDING-BOTTOM: 3PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Weighted-average common shares outstanding - diluted
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 3PX DOUBLE">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	46,602
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 3PX DOUBLE">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	45,355
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 3PX DOUBLE">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	42,561
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255)">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Net income (loss) per share &#8211; basic
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	0.98
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 2.05PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	(0.05
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 2.05PT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	(0.23
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Net income (loss) per share &#8211; diluted
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	0.97
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	(0.05
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	(0.23
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	)
</FONT>
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<I>
	&nbsp;
</I>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<I>
	Share-Based
	Compensation
</I>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	The
	Company records compensation expense associated with stock options and restricted stock based upon the fair value of stock based
	awards as measured at the grant date. The Company determines the award values of stock options using the Black Scholes option
	pricing model.
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 6; VALUE: 8 -->
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 6PT; PADDING-BOTTOM: 12PT; BORDER-BOTTOM: SILVER 4PX SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	13
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage79"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 10PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: LEFT; WIDTH: 100%">
<PAGE>
</PAGE>
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	ENZO
	BIOCHEM, INC.
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	NOTES
	TO CONSOLIDATED FINANCIAL STATEMENTS
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	July
	31, 2016
</B>
</FONT>
</P>
<P STYLE="FONT: 9PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	(Dollars
	in thousands except share data
</B>
</FONT>
</P>
<P STYLE="FONT: 9PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	The
	expense is recorded by amortizing the fair values on a straight-line basis over the vesting period, adjusted for forfeitures.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	For
	the years ended July 31, 2016, 2015 and 2014, share-based compensation expense relating to the fair value of stock options, restricted
	shares and restricted stock units was approximately $525, $429, and $594, respectively (see Note 10). No excess tax benefits were
	recognized for the year ended July 31, 2016, 2015 and 2014.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	The
	following table sets forth the amount of expense related to share-based payment arrangements included in specific line items in
	the accompanying statement of operations for the years ended July 31:
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_26"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT CAMBRIA, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="PADDING-BOTTOM: 1PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PX SOLID">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	2016
</B>
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PX SOLID">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	2015
</B>
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PX SOLID">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	2014
</B>
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255)">
<TD STYLE="WIDTH: 58%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Cost of clinical laboratory services
</FONT>
</TD>
<TD STYLE="WIDTH: 2%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</FONT>
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	6
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 2%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</FONT>
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	5
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 2%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</FONT>
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	9
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Research and development
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&#8212;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	2
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	1
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255)">
<TD STYLE="PADDING-BOTTOM: 1PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Selling, general and administrative
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PX SOLID">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	519
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PX SOLID">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	422
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PX SOLID">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	584
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-BOTTOM: 3PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 3PX DOUBLE">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	525
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 3PX DOUBLE">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	429
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 3PX DOUBLE">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	594
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	As of
	July 31, 2016, there was $810 of total unrecognized compensation cost related to non-vested share-based payment arrangements granted
	under the Company&#8217;s incentive stock plans, which will be recognized over a weighted average remaining life of approximately
	sixteen months.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<I>
	Effect
	of new accounting pronouncements
</I>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	In May
	2014, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standard Update (&#8220;ASU&#8221;) No.
	2014-09,
<I>
	Revenue from Contracts with Customers: Topic 606
</I>
	. ASU 2014-09 amends the guidance for revenue recognition to replace
	numerous, industry-specific requirements and converges areas under this topic with those of the International Financial Reporting
	Standards. ASU 2014-09 implements a five-step process for customer contract revenue recognition that focuses on transfer of control,
	as opposed to transfer of risk and rewards. The amendment also requires enhanced disclosures regarding the nature, amount, timing
	and uncertainty of revenues and cash flows from contracts with customers. Other major provisions include the capitalization and
	amortization of certain contract costs, ensuring the time value of money is considered in the transaction price, and allowing
	estimates of variable consideration to be recognized before contingencies are resolved in certain circumstances. As of July 9,
	2015, the FASB decided to delay the effective date of the new revenue standard by one year. The amendments in ASU 2014-09 are
	effective for reporting periods beginning after December 15, 2017, (the fiscal year ending July 31, 2019 for the Company) and
	early adoption is permitted for reporting periods beginning after December 15, 2016. Entities can transition to the standard either
	retrospectively or as a cumulative-effect adjustment as of the date of adoption. We are currently assessing the impact the adoption
	of ASU 2014-09 will have on the Company&#8217;s combined consolidated financial statements.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	In August
	2014, the FASB issued ASU No. 2014-15,
<I>
	Disclosure of Uncertainties about an Entity&#8217;s Ability to Continue as a Going Concern
</I>
	.
	ASU 2014-15 will explicitly require management to assess an entity&#8217;s ability to continue as a going concern, and to provide
	related footnote disclosure in certain circumstances. The new standard will be effective for all entities in the first annual
	period ending after December 15, 2016. Earlier adoption is permitted. We do not expect the adoption of this update to have a material
	impact on our consolidated financial statements.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	In January
	2015, the FASB issued ASU No. 2015-01,
<I>
	Income Statement Extraordinary and Unusual Items.
</I>
	The ASU eliminates the concept
	of extraordinary items from U.S. GAAP as part of its simplification initiative. The ASU does not affect disclosure guidance for
	events or transactions that are unusual in nature or infrequent in their occurrence. The update applies to all entities for fiscal
	years, and interim periods within those fiscal years, beginning after December 15, 2015. The adoption of this update will not
	have any impact on our consolidated financial statements.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	In February
	2015, the FASB issued ASU No. 2015-02,
<I>
	Consolidation: Amendments to the Consolidation Analysis.
</I>
	The amendments in the update
	affect reporting entities that are required to evaluate whether they should consolidate certain legal entities. All legal entities
	are subject to reevaluation under the revised consolidation model. The amendments in the Update are effective for public business
	entities for fiscal years, and for interim periods within those fiscal years, beginning after December 15, 2015. For all other
	entities, the effective date for fiscal years beginning after December 15, 2016, and for interim periods within fiscal years beginning
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 7; VALUE: 8 -->
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 6PT; PADDING-BOTTOM: 12PT; BORDER-BOTTOM: SILVER 4PX SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	14
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage80"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 10PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: LEFT; WIDTH: 100%">
<PAGE>
</PAGE>
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	ENZO BIOCHEM, INC.
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	July 31, 2016
</B>
</P>
<P STYLE="FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	(Dollars in thousands except share data
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	after December 15, 2017. Early adoption is permitted. The adoption
	of this update will not have any impact on our consolidated financial statements.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	In April 2015, the FASB issued ASU No. 2015-03
<I>
	Interest &ndash;
	Imputation of Interest.
</I>
	The ASU was issued as part of the Simplification Initiatives, to simplify presentation of debt issuance
	costs. The amendments in the update require that debt issuance costs related to a recognized debt liability be presented in the
	balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts. The recognition
	and measurement guidance for debt issuance costs are not affected by the amendments in this update. For public business entities,
	the amendments in the update are effective for financial statements issued for fiscal years beginning after December 15, 2015,
	and interim periods within those fiscal years. Early adoption of the amendments in this update is permitted for financial statements
	that have not been previously issued. We do not expect the adoption of this update to have a material impact on our consolidated
	financial statements.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	In July 2015, the FASB issued ASU No. 2015-11,
<I>
	Simplifying the
	Measurement of Inventory (Topic 330).
</I>
	ASU 2015-11 changes the measurement principle for inventory from the lower of cost
	or market to lower of cost or net realizable value. The new standard is effective for our fiscal years and interim periods beginning
	after December 15, 2016. We do not expect the adoption of this update to have a material impact on our consolidated financial statements.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	In February 2016, the FASB issued Accounting Standards Update (&ldquo;ASU&rdquo;)
	No. 2016-02 &ndash;
<I>
	Leases (Topic 842)
</I>
	. The new standard establishes a right-of-use (ROU) model that requires a lessee to
	record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months. Leases will be classified
	as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. The new
	standard is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years.
	A modified retrospective transition approach is required for lessees for capital and operating leases existing at, or entered into
	after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients
	available. While we are evaluating the impact of adopting the new standard on our consolidated financial statements, we expect
	that upon adoption we will recognize ROU assets and lease liabilities in amounts that could be material.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	In March 2016, the FASB issued ASU 2016-09,
<I>
	&ldquo;Improvements
	to Employee Share-Based Payment Accounting,&rdquo;
</I>
	which requires all excess tax benefits or deficiencies to be recognized
	as income tax expense or benefit in the income statement. In addition, excess tax benefits should be classified along with other
	income tax cash flows as an operating activity in the statement of cash flows. Application of the standard is required for the
	annual and interim periods beginning after December 15, 2016. Early adoption is permitted. We are currently evaluating the impact
	of this new standard on our consolidated financial statements.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	In June 2016, the FASB issued ASU no. 2016-13,
<I>
	&ldquo;Financial
	Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments.&rdquo;
</I>
	ASU 2016-13 introduces
	a new forward-looking &ldquo;expected loss&rdquo; approach, to estimate credit losses on most financial assets and certain other
	instruments, including trade receivables. The estimate of expected credit losses will require entities to incorporate considerations
	of historical information, current information and reasonable and supportable forecasts. This ASU also expands the disclosure requirements
	to enable users of financial statements to understand the entity&rsquo;s assumptions, models and methods for estimating expected
	credit losses. ASU 2016-13 is effective for the Company&rsquo;s fiscal year ending July 31, 2021, and the guidance is to be applied
	using the modified-retrospective approach. The Company is currently evaluating the potential impact of adopting this guidance on
	our consolidated financial statements.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	Note 2 - Goodwill and intangible assets
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	Goodwill
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	The Company&rsquo;s net carrying amount of goodwill is in the Clinical
	Labs segment as of July 31, 2016 and 2015 is $7,452.
</P>
<!-- FIELD: PAGE; SEQUENCE: 1; OPTIONS: NEWSECTION; VALUE: 15 -->
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 6PT; PADDING-BOTTOM: 12PT; BORDER-BOTTOM: SILVER 4PX SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	15
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage81"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 10PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: LEFT; WIDTH: 100%">
<PAGE>
</PAGE>
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0">
<B>
	ENZO BIOCHEM, INC.
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0">
<B>
	NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0">
<B>
	July 31, 2016
</B>
</P>
<P STYLE="FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0">
<B>
	(Dollars in thousands
	except share data)
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	Intangible assets
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	The Company&rsquo;s change in the net carrying amount of intangible
	assets, all in the Life Sciences segment is as follows:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_27"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PX SOLID">
	Gross
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PX SOLID">
	Accumulated
<BR>
	Amortization
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PX SOLID">
	Net
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255)">
<TD>
	July 31, 2014
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	28,478
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(20,370
</TD>
<TD>
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	8,108
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="WIDTH: 52%; TEXT-ALIGN: LEFT">
	Amortization expense&#9;
</TD>
<TD STYLE="WIDTH: 3%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 11%; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 3%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 11%; TEXT-ALIGN: RIGHT">
	(1,770
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="WIDTH: 3%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 11%; TEXT-ALIGN: RIGHT">
	(1,770
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PX">
	Foreign currency translation&#9;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
	(640
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
	457
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
	(183
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
	July 31, 2015&#9;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	27,838
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(21,683
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	6,155
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Amortization expense&#9;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(1,677
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(1,677
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PX">
	Foreign currency translation&#9;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
	(188
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
	132
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
	(56
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255)">
<TD STYLE="PADDING-BOTTOM: 3PX">
	July 31, 2016&#9;
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; TEXT-ALIGN: RIGHT">
	27,650
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; TEXT-ALIGN: RIGHT">
	(23,228
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; TEXT-ALIGN: RIGHT">
	4,422
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	Intangible assets, all finite-lived, consist of the following:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_28"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD COLSPAN="10" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PX SOLID">
	July 31, 2016
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD COLSPAN="10" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PX SOLID">
	July 31, 2015
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PX SOLID">
	Gross
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PX SOLID">
	Accumulated
<BR>
	Amortization
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PX SOLID">
	Net
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PX SOLID">
	Gross
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PX SOLID">
	Accumulated
<BR>
	Amortization
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PX SOLID">
	Net
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255)">
<TD STYLE="WIDTH: 40%; TEXT-INDENT: -10PT; PADDING-LEFT: 10PT">
	Patents&#9;
</TD>
<TD STYLE="WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 6%; TEXT-ALIGN: RIGHT">
	11,027
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 6%; TEXT-ALIGN: RIGHT">
	(10,905
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 6%; TEXT-ALIGN: RIGHT">
	122
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 6%; TEXT-ALIGN: RIGHT">
	11,028
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 6%; TEXT-ALIGN: RIGHT">
	(10,871
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 6%; TEXT-ALIGN: RIGHT">
	157
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -10PT; PADDING-LEFT: 10PT">
	Customer relationships&#9;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	12,122
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(8,331
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	3,791
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	12,243
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(7,398
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	4,845
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255)">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -10PT; PADDING-LEFT: 10PT">
	Website and acquired content&#9;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,011
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(1,011
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,020
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(1,020
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -10PT; PADDING-LEFT: 10PT">
	Licensed technology and other&#9;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	485
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(437
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	48
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	518
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(441
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	77
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255)">
<TD STYLE="PADDING-BOTTOM: 1PX; TEXT-INDENT: -10PT; PADDING-LEFT: 10PT">
	Trademarks&#9;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
	3,005
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
	(2,544
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
	461
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
	3,029
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
	(1,953
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
	1,076
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-BOTTOM: 3PX; TEXT-INDENT: -10PT; PADDING-LEFT: 10PT">
	Total&#9;
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; TEXT-ALIGN: RIGHT">
	27,650
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; TEXT-ALIGN: RIGHT">
	(23,228
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; TEXT-ALIGN: RIGHT">
	4,422
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; TEXT-ALIGN: RIGHT">
	27,838
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; TEXT-ALIGN: RIGHT">
	(21,683
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; TEXT-ALIGN: RIGHT">
	6,155
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	At July 31, 2016 information with respect to the intangibles acquired
	is as follows:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_29"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: RIGHT">
<B>
	Useful life
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: RIGHT">
<B>
	assigned
</B>
</P>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: RIGHT">
<B>
	Weighted average
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: RIGHT">
<B>
	remaining useful life
</B>
</P>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255)">
<TD STYLE="WIDTH: 60%; TEXT-ALIGN: LEFT">
	Customer relationships&#9;
</TD>
<TD STYLE="WIDTH: 3%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	8-15 years
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 3%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	4 years
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
	Trademarks&#9;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	5 years
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	1 years
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Other intangibles&#9;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	10 years
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	3 years
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	At July 31, 2016, the weighted average remaining useful life of
	intangible assets was approximately three years.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	Estimated amortization expense related to these
	finite-lived intangible assets for the five succeeding fiscal years ending July 31 is as follows:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_30"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 80%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255)">
<TD STYLE="WIDTH: 89%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	2017&#9;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</FONT>
</TD>
<TD STYLE="WIDTH: 8%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	1,508
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	2018&#9;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	1,141
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255)">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	2019&#9;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	827
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	2020&#9;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	512
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255)">
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	2021&#9;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	283
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	Amortization expense for the years ended July 31, 2016, 2015, and
	2014 was $1,677, $1,770, and $1,840, respectively.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	Note 3 - Supplemental disclosure for statement of cash flows
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 36PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	In the years ended July 31, 2016, 2015, and 2014, income taxes paid
	by the Company approximated $279, $115, and $44 respectively
<B>
	.
</B>
</P>
<!-- FIELD: PAGE; SEQUENCE: 2; VALUE: 15 -->
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 6PT; PADDING-BOTTOM: 12PT; BORDER-BOTTOM: SILVER 4PX SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	16
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage82"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 10PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: LEFT; WIDTH: 100%">
<PAGE>
</PAGE>
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0">
<B>
	ENZO BIOCHEM, INC.
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0">
<B>
	NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0">
<B>
	July 31, 2016
</B>
</P>
<P STYLE="FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0">
<B>
	(Dollars in thousands
	except share data)
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	In the years ended July 31, 2016, 2015, and 2014, interest paid
	by the Company approximated $121, $206, and $208 respectively.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 36PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	During fiscal 2016, 2015 and 2014, the Company financed $95, $346
	and
<FONT STYLE="COLOR: BLACK">
	$392
</FONT>
	, respectively, in machinery and transportation equipment under installment loans.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 36PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	During fiscal 2016 and 2015, the Company entered into capital lease
	agreements for machinery and equipment with a cost basis of $1,280 and $155, respectively. During fiscal 2014, the Company did
	not enter into any capital lease agreements.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	During fiscal 2015 and 2014, the Company recorded $45 and $136,
	respectively, in additional paid in capital and reduced accrued liabilities by the same amount for options issued in lieu of cash
	payment of certain incentive compensation awards. There were no such transactions recorded during fiscal 2016.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	During fiscal 2016, 2015 and 2014, the Company issued shares of
	common stock in connection with its share-based 401(k) employer match and recorded expense in the amount of $709, $663 and $636,
	respectively.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_31"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	Note 4 - Inventories
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 36PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	Inventories consisted of the following at July 31:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PX SOLID">
	2016
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PX SOLID">
	2015
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255)">
<TD STYLE="WIDTH: 70%; TEXT-ALIGN: LEFT">
	Raw materials&#9;
</TD>
<TD STYLE="WIDTH: 3%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	951
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 3%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	1,013
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Work in process&#9;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,755
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2,002
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PX">
	Finished products&#9;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
	4,265
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
	4,381
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-BOTTOM: 3PX">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; TEXT-ALIGN: RIGHT">
	6,971
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; TEXT-ALIGN: RIGHT">
	7,396
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_32"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	Note 5 - Property, plant, and equipment
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 36PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	At July 31, 2016 and 2015 property, plant, and equipment consist
	of:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PX SOLID">
	2016
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PX SOLID">
	2015
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255)">
<TD STYLE="WIDTH: 70%; TEXT-ALIGN: LEFT">
	Building and building improvements&#9;
</TD>
<TD STYLE="WIDTH: 3%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	4,915
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 3%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	4,854
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Machinery and equipment (includes asset under capital lease - see Note 9)&#9;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	7,479
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	7,397
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Office furniture and computer equipment&#9;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	19,765
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	18,289
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PX">
	Leasehold improvements&#9;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
	5,172
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
	4,958
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255)">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	37,331
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	35,498
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PX">
	Accumulated depreciation and amortization&#9;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
	(29,829
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
	(28,262
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255)">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	7,502
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	7,236
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PX">
	Land and land improvements&#9;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
	712
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
	712
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255)">
<TD STYLE="PADDING-BOTTOM: 3PX">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; TEXT-ALIGN: RIGHT">
	8,214
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; TEXT-ALIGN: RIGHT">
	7,948
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_33"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 0">
<B>
	Note 6 - Income taxes
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 36PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	The benefit (provision) for income taxes for fiscal years ended
	July 31 is as follows:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 36PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PX SOLID">
	2016
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PX SOLID">
	2015
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PX SOLID">
	2014
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Current (provision) benefit:
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="WIDTH: 55%">
	Federal&#9;
</TD>
<TD STYLE="WIDTH: 3%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	(968
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="WIDTH: 3%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 3%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	State and local&#9;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(276
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(72
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(68
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
	Foreign&#9;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(45
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(25
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(22
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PX">
	Deferred benefit&#9;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
	60
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
	104
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
	18
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 3PX">
	Benefit (provision) for income taxes&#9;
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; TEXT-ALIGN: RIGHT">
	(1,229
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; TEXT-ALIGN: RIGHT">
	7
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; TEXT-ALIGN: RIGHT">
	(72
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	Deferred tax assets and liabilities arise from temporary differences
	between the tax basis of assets and liabilities and their reported amounts in the financial statements. The components of deferred
	tax assets (liabilities) as of July 31 are as follows:
</P>
<!-- FIELD: PAGE; SEQUENCE: 3; VALUE: 15 -->
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 6PT; PADDING-BOTTOM: 12PT; BORDER-BOTTOM: SILVER 4PX SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	17
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage83"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 10PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: LEFT; WIDTH: 100%">
<PAGE>
</PAGE>
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_34"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	ENZO BIOCHEM, INC.
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	July 31, 2016
</B>
</P>
<P STYLE="FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0">
<B>
	(Dollars in thousands
	except share data)
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 36PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 80%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PX SOLID">
	2016
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PX SOLID">
	2015
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Deferred tax assets:
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="WIDTH: 70%; TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT">
	Federal tax carryforward losses&#9;
</TD>
<TD STYLE="WIDTH: 3%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	18,964
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 3%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	35,411
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT">
	Provision for uncollectible accounts receivable&#9;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,406
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	685
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT">
	State and local tax carry forward losses&#9;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2,757
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2,661
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT">
	Accrued royalties&#9;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	146
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	144
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT">
	Stock compensation&#9;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	616
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	99
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255)">
<TD STYLE="PADDING-LEFT: 10PT">
	Depreciation&#9;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	769
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	618
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT">
	Research and development and other tax credit carryforwards&#9;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2,152
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,134
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT">
	Foreign tax carryforward losses&#9;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2,046
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,476
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-LEFT: 10PT">
	Intangibles&#9;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2,915
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2,951
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255)">
<TD STYLE="PADDING-LEFT: 10PT">
	Inventory&#9;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2,477
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2,558
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT">
	Accrued expenses&#9;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,321
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2,627
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT">
	Unrealized foreign exchange&#9;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	100
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	98
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PX; PADDING-LEFT: 10PT">
	Other, net&#9;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
	63
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
	18
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PX">
	Deferred tax assets&#9;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
	35,732
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
	50,480
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Deferred tax liabilities:
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT">
	Deferred patent costs&#9;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(152
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT">
	Prepaid expenses&#9;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(820
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(676
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PX; PADDING-LEFT: 10PT">
	Other, net&#9;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
	(31
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PX">
	Deferred tax liabilities&#9;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
	(820
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
	(859
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Net deferred tax assets before valuation allowance&#9;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	34,912
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	49,621
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PX">
	Less: valuation allowance&#9;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
	(34,912
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
	(49,658
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 3PX">
	Net deferred tax liabilities&#9;
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; TEXT-ALIGN: RIGHT">
	(37
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	Net deferred tax liabilities are included in the consolidated balance
	sheets as of July 31 as follows:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_35"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PX SOLID">
	2016
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PX SOLID">
	2015
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Deferred taxes:
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
	Current&#9;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255)">
<TD STYLE="WIDTH: 70%; PADDING-BOTTOM: 1PX">
	Non-current&#9;
</TD>
<TD STYLE="WIDTH: 3%; PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 10%; BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="WIDTH: 1%; PADDING-BOTTOM: 1PX; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 3%; PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 10%; BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
	37
</TD>
<TD STYLE="WIDTH: 1%; PADDING-BOTTOM: 1PX; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-BOTTOM: 3PX">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; TEXT-ALIGN: RIGHT">
	37
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT">
	The Company recorded a valuation
	allowance during the years ended July 31, 2016 and 2015 equal to domestic and certain foreign net deferred tax assets. The
	Company believes that the valuation allowance is necessary as it is not more likely than not that the deferred tax assets
	will be realized in the foreseeable future based on positive and negative evidence available at this time. This conclusion
	was reached because of uncertainties relating to future taxable income, in terms of both its timing and its sufficiency,
	which would enable the Company to realize the deferred tax assets. For fiscal year 2016 and 2015 the change in the valuation
	allowance was $14.7 million and $0.2 million, respectively.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	As of July 31, 2016, the Company had U.S. federal net operating
	loss carryforwards of approximately $55.0 million. The U.S. federal tax loss carryforwards, if not fully utilized, expire between
	2030 and 2035. Utilization is dependent on generating sufficient taxable income prior to expiration of the tax loss carryforwards.
	In addition, the Company has research and development tax credit carryforwards of approximately $1.0 million which expire between
	2025 and 2036. As of July 31, 2016, the Company had foreign loss carryforwards of approximately $7.9 million.
</P>
<P STYLE="FONT: 9PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	The components of income (loss) before income taxes consisted of
	the following for the years ended July 31:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 36PT">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_36"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PX SOLID">
	2016
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PX SOLID">
	2015
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PX SOLID">
	2014
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255)">
<TD STYLE="WIDTH: 55%; TEXT-ALIGN: LEFT">
	United States operations&#9;
</TD>
<TD STYLE="WIDTH: 3%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	48,847
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 3%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	(615
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="WIDTH: 3%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	(8,702
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PX">
	International operations&#9;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
	(2,332
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
	(1,677
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
	(1,203
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 3PX">
	Income (loss) before taxes&#9;
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; TEXT-ALIGN: RIGHT">
	46,515
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; TEXT-ALIGN: RIGHT">
	(2,292
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; TEXT-ALIGN: RIGHT">
	(9,905
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<!-- FIELD: PAGE; SEQUENCE: 4; VALUE: 15 -->
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 6PT; PADDING-BOTTOM: 12PT; BORDER-BOTTOM: SILVER 4PX SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	18
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage84"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 10PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: LEFT; WIDTH: 100%">
<PAGE>
</PAGE>
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	ENZO BIOCHEM, INC.
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	July 31, 2016
</B>
</P>
<P STYLE="FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0">
<B>
	(Dollars in thousands
	except share data)
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 36PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	The (provision) benefit for income taxes was at rates different
	from U.S. federal statutory rates for the following reasons for the years ended July 31:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 36PT">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_37"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="PADDING-LEFT: 10PT; TEXT-INDENT: -10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PX SOLID">
	2016
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PX SOLID">
	2015
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PX SOLID">
	2014
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255)">
<TD STYLE="WIDTH: 55%; TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT; TEXT-INDENT: -10PT">
	Federal statutory rate&#9;
</TD>
<TD STYLE="WIDTH: 3%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	(34.0
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	)%
</TD>
<TD STYLE="WIDTH: 3%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	34.0
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	%
</TD>
<TD STYLE="WIDTH: 3%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	34.0
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	%
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT; TEXT-INDENT: -10PT">
	Penalties and other expenses not deductible for income tax return purposes&#9;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(1.1
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(18.6
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(6.6
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT; TEXT-INDENT: -10PT">
	State income taxes, net of benefit of federal tax deduction&#9;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(0.4
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(0.5
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	0.2
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT; TEXT-INDENT: -10PT">
	Change in valuation allowance&#9;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	32.9
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(15.2
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(16.5
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT; TEXT-INDENT: -10PT">
	State tax law change&#9;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(12.3
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-BOTTOM: 1PX; PADDING-LEFT: 10PT; TEXT-INDENT: -10PT">
	Other&#9;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
	0.6
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
	0.5
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255)">
<TD STYLE="PADDING-BOTTOM: 3PX; PADDING-LEFT: 10PT; TEXT-INDENT: -10PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; TEXT-ALIGN: RIGHT">
	(2.6
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX; TEXT-ALIGN: LEFT">
	)%
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; TEXT-ALIGN: RIGHT">
	0.3
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX; TEXT-ALIGN: LEFT">
	%
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; TEXT-ALIGN: RIGHT">
	(0.7
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX; TEXT-ALIGN: LEFT">
	)%
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 36PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	U.S. federal income taxes have not been provided on approximately
	$101 of undistributed earnings at the Company&rsquo;s foreign subsidiaries at July 31, 2016, because it is the Company&rsquo;s
	intent to keep the earnings reinvested. As of July 31, 2016, the Company has no liabilities for uncertain tax positions. It is
	the Company&rsquo;s policy to record interest and penalties as a component of tax expense. The Company files income tax returns
	in the U.S. Federal jurisdiction, various U.S. state jurisdictions and several foreign jurisdictions.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	Note 7 - Loan Payable
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 36PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	On June 7, 2013, the Company entered into a secured Revolving Loan
	and Security Agreement (the &ldquo;Credit Agreement&rdquo;) among the Company and certain of its subsidiaries, with Enzo Therapeutics
	as a guarantor, and MidCap Financial LLC. (formerly Healthcare Finance Group, LLC). The Credit Agreement, which expires in December
	2016, provides for borrowings against eligible US receivables, as defined, of the Clinical Lab and Life Science segments up to
	$8.0 million at defined eligibility percentages and provides for additional borrowings of $4.0 million for increased eligible assets.
	Debt issuance costs of $281 are being amortized over the life of the Credit Agreement. The balance of unamortized debt issuance
	cost was $28 and $111 at July 31, 2016 and 2015, respectively, and is included in prepaid expenses. If the amount of borrowings
	outstanding under the revolving credit facility exceeds the borrowing base then in effect, or the Lender requires a reserve, the
	Company will be required to repay such borrowings in an amount sufficient to eliminate such excess. Interest on advances, payable
	monthly, is based on the three month LIBOR rate, with a floor of 1.25% plus an applicable margin of 4.0%. The nominal interest
	rate for both years ended July 31, 2016 and 2015 was 5.25%. In the event of any default, the interest rate may be increased 3.0%
	over the current rate. The facility also carries a non-utilization fee of 0.50% per annum, payable monthly, on the unused portion
	of the credit line. The effective interest rate for the credit agreement was 11.4%, 10.5% and 10.6% for the fiscal years ended
	July 31, 2016, 2015 and 2014, respectively. The Credit Agreement requires a minimum borrowing of $2.0 million. At July 31, 2016
	and 2015, the borrowings under the Credit Agreement related to the Clinical Labs and Life Sciences receivables aggregated $1.6
	and $3.0 million, respectively, with an additional availability of $6.2 million at July 31, 2016.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	The Company&rsquo;s obligations under the Credit Agreement are
	secured by primarily all the unencumbered U.S. assets of the Company, excluding buildings and intellectual property which the
	Lender has a negative pledge, and the capital stock of subsidiaries. The Credit Agreement includes customary affirmative and negative
	covenants and events of default and requires maximum levels of cash usage and minimum levels of liquidity, as defined, and provides
	for increased liquidity levels if operating results are not achieved. Negative covenants include among others, limitations on
	additional debt, liens, loans or investments, distributions, asset sales and affiliate transactions. Events of default include
	non-payment of principal and interest on debt outstanding, non-performance of covenants, material change in business, breach of
	representations, bankruptcy and insolvency, material judgments and changes in control. As of July 31, 2016 and 2015, the Company
	is in compliance with the financial covenants.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	The Credit Agreement includes customary affirmative and negative
	covenants and events of default. The terms of the debt covenants include:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 18PT">
</TD>
<TD STYLE="WIDTH: 18PT">
<FONT STYLE="FONT: 10PT COURIER NEW, COURIER, MONOSPACE">
	o
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	The minimum balance the Company must borrow at any time is $2.0 million.
	In the event the Company&rsquo;s loan balance is less than $2.0 million, it will be charged interest on $2.0 million. At July 31,
	2016, the loan balance was approximately $1.6 million. Loan balance of less than $2.0 million is not a non-compliance event.
</FONT>
</TD>
</TR>
</TABLE>
<!-- FIELD: PAGE; SEQUENCE: 5; VALUE: 15 -->
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 6PT; PADDING-BOTTOM: 12PT; BORDER-BOTTOM: SILVER 4PX SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	19
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage85"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 10PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: LEFT; WIDTH: 100%">
<PAGE>
</PAGE>
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	ENZO BIOCHEM, INC.
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	NOTES TO CONSOLIDATED
	FINANCIAL STATEMENTS
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	July 31, 2016
</B>
</P>
<P STYLE="FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: CENTER">
<B>
	(Dollars in thousands except share data)
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 18PT">
</TD>
<TD STYLE="WIDTH: 18PT">
<FONT STYLE="FONT: 10PT COURIER NEW, COURIER, MONOSPACE">
	o
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	The Company must maintain a Minimum Liquidity, as defined in the Credit
	Agreement, of not less than $3.0 million. At July 31, 2016, the Company&rsquo;s Minimum Liquidity was $11.2 million.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 18PT">
</TD>
<TD STYLE="WIDTH: 18PT">
<FONT STYLE="FONT: 10PT COURIER NEW, COURIER, MONOSPACE">
	o
</FONT>
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	The quarterly Cash Burn, as defined in the Credit Agreement, must be
	greater than zero. During the three months ended July 31, 2016, the Cash Burn was positive in the amount of $1.3 million.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	Based on its current level of Minimum Liquidity and Cash Burn, the
	Company believes it will continue to be in compliance with the financial covenants in future periods; however there are no assurances
	of such compliance. Based on our ability to comply with financial covenants in the past, our ability to obtain covenant waivers
	previously, and our expected future performance, we believe we would be able to cure a non-compliance event and obtain a Lender
	waiver. The Company currently believes that the Lender would be willing to negotiate and provide waivers to the Company in the
	event of non-compliance with covenants, although there can be no assurances. In addition, the Company believes the effects of non-compliance
	with the covenants would not have a material effect on our financial condition and liquidity due to cash provided by operating
	cash flows and funds available under the Company&rsquo;s Controlled Equity Offering program.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_38"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	Note 8 - Accrued Liabilities, Other Current Liabilities and Other
	Liabilities
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 36PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	At July 31 accrued liabilities consist of:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PX SOLID">
	2016
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PX SOLID">
	2015
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255)">
<TD STYLE="WIDTH: 70%; TEXT-ALIGN: LEFT">
	Payroll, benefits, severance and commissions&#9;
</TD>
<TD STYLE="WIDTH: 3%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	3,956
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 3%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	3,907
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
	Legal&#9;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	954
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	4,183
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	Professional fees&#9;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	503
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	678
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Research and development&#9;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	300
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	300
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255)">
<TD STYLE="PADDING-BOTTOM: 1PX">
	Other&#9;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
	2,498
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
	2,229
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-BOTTOM: 3PX">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; TEXT-ALIGN: RIGHT">
	8,211
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; TEXT-ALIGN: RIGHT">
	11,297
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<I>
	&nbsp;
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<I>
	Self-Insured Medical Plan
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 36PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	The Company self-funds medical insurance coverage for certain of
	its U.S. based employees. The risk to the Company is believed to be limited through the use of individual and aggregate stop loss
	insurance. As of July 31, 2016 and 2015, the Company has established a reserve of $0.3 million, which is included in accrued liabilities,
	for claims that have been reported but not paid and incurred but not reported. The reserve is based upon the Company&rsquo;s historical
	payment trends, claim history and current estimates.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_39"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
<B>
	Note 9 - Other liabilities
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-INDENT: 36PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	At July 31 Other liabilities consist of:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PX SOLID">
	2016
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PX SOLID">
	2015
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255)">
<TD STYLE="WIDTH: 70%; TEXT-ALIGN: LEFT">
	Accrued legal settlement &ndash; see Note 14&#9;
</TD>
<TD STYLE="WIDTH: 3%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	800
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 3%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	1,220
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Capital lease obligation&#9;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	794
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	210
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PX">
	Installment loans&#9;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
	105
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
	363
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-BOTTOM: 3PX">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; TEXT-ALIGN: RIGHT">
	1,699
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; TEXT-ALIGN: RIGHT">
	1,793
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	The capital lease obligation and Installment loans are for machinery
	and equipment used in the Clinical Labs segment. Amortization of the assets recorded under the capital lease is included in depreciation
	expense. At July 31, 2016, the accumulated amortization on the capital lease was $271 and the imputed interest rate ranges from
	4.3% to 9.5%.
</P>
<!-- FIELD: PAGE; SEQUENCE: 6; VALUE: 15 -->
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 6PT; PADDING-BOTTOM: 12PT; BORDER-BOTTOM: SILVER 4PX SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	20
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage86"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 10PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: LEFT; WIDTH: 100%">
<PAGE>
</PAGE>
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	ENZO BIOCHEM, INC.
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	July 31, 2016
</B>
</P>
<P STYLE="FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	(Dollars in thousands except share data)
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	Future minimum lease and loan payments are as follows:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_40"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PX SOLID">
	Capital lease
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PX SOLID">
	Installment
<BR>
	loans
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255)">
<TD STYLE="WIDTH: 70%; TEXT-ALIGN: LEFT">
	2017
</TD>
<TD STYLE="WIDTH: 3%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	307
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 3%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
	236
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	2018
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	299
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	97
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
	2019
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	258
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	9
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	2020
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	250
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PX">
	2021
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PX SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PX SOLID">
	198
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PX SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PX SOLID">
	&mdash;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT">
	Total payments
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,312
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	342
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PX">
	Less: interest
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PX SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PX SOLID">
	(211
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PX">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PX SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PX SOLID">
	(1
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PX">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PX">
	Total net of interest
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PX SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PX SOLID">
	1,101
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PX SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PX SOLID">
	341
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PX">
	Less: current portion
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PX SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PX SOLID">
	(307
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PX">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PX SOLID">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PX SOLID">
	(236
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PX">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 3PX">
	Other liabilities - net
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 3PX DOUBLE">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 3PX DOUBLE">
	794
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 3PX">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 3PX DOUBLE">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 3PX DOUBLE">
	105
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 3PX">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	The weighted average interest rate on our short term borrowings
	during fiscal 2016 and 2015 was 8.0% and 2.7%, respectively.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	Note 10 - Stockholders&rsquo; equity
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
<I>
	Controlled Equity Offering
</I>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	On March 28, 2013, the Company entered into a Controlled Equity
	Offering
<SUP>
	SM
</SUP>
	Sales Agreement (the &ldquo;Sales Agreement&rdquo;) with Cantor Fitzgerald &amp; Co., as sales agent (&ldquo;Cantor&rdquo;).
	Under the Sales Agreement, the Company may offer and sell, from time to time, through Cantor, shares of the Company&rsquo;s common
	stock, par value $0.01 per share (the &ldquo;Common Stock&rdquo;), having an aggregate offering price of up to $20.0 million (the
	&ldquo;Shares&rdquo;). The Company pays Cantor a commission of 3.0% of the aggregate gross proceeds received under the Sale Agreement.
	The Company is not obligated to make any sales of the Shares under the Sales Agreement. The offering of Shares pursuant to the
	Sales Agreement will terminate upon the earlier of (a) the sale of all of the Shares subject to the Sales Agreement or (b) the
	termination of the Sales Agreement by Cantor or the Company, as permitted therein. The Shares were initially issued pursuant to
	the Company&rsquo;s &ldquo;shelf&rdquo; Registration Statement which was declared effective on August 5, 2010 and the prospectus
	supplement, dated March 28, 2013, and under a &ldquo;shelf&rdquo; registration statement and prospectus supplement dated August
	1, 2013 declared effective August 13, 2013.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	On December 31, 2014, the Sales Agreement was amended in order
	for the Company to offer and sell, through Cantor, acting as agent, additional shares of Common Stock having an aggregate offering
	price of $20.0 million.&nbsp; In connection with the amendment to the Sales Agreement, the Company also filed with the SEC a prospectus
	supplement dated December 31, 2014.&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Most recently with respect to the Sales Agreement, the Company
	filed a &ldquo;shelf&rdquo; registration and prospectus supplement dated September 1, 2016 and is waiting for it to be declared
	effective by the Securities and Exchange Commission.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	For the year ended July 31, 2016, the Company did not sell any
	shares of common stock under the Sales Agreement. For the year ended July 31, 2015, the Company sold an aggregate of 1,588,480
	shares of common stock under the Sales Agreement at an average price of $4.34 per share and received proceeds of approximately
	$6.7 million, net of expenses of $207.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<I>
	Common stock
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	In fiscal 2016, the Company issued 160,352 shares of common
	stock for its employees&rsquo; 401(k) matching contributions obligation. The Company recorded an expense of $709 for the match
	representing the fair value of the shares at the date of issuance.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	In fiscal 2015, the Company issued 214,984 shares of common
	for its employees&rsquo; 401(k) matching contributions obligation. The Company recorded an expense of $662 for the match, representing
	the fair value of the shares at the date of issuance.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	In fiscal 2014, the Company issued 165,646 shares of common
	for its employees&rsquo; 401(k) matching contributions obligation. The Company recorded an expense of $636 for the match, representing
	the fair value of the shares at the date of issuance.
</P>
<!-- FIELD: PAGE; SEQUENCE: 1; OPTIONS: NEWSECTION; VALUE: 21 -->
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 6PT; PADDING-BOTTOM: 12PT; BORDER-BOTTOM: SILVER 4PX SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	21
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage87"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 10PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: LEFT; WIDTH: 100%">
<PAGE>
</PAGE>
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	ENZO BIOCHEM, INC.
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	July 31, 2016
</B>
</P>
<P STYLE="FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0">
<B>
	(Dollars in thousands
	except share data)
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<I>
	Incentive stock plans
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	The Company has an incentive stock option and restricted
	(non-vested) stock award plan (the &ldquo;2005 Plan&rdquo;), under which the Company could grant options and restricted stock
	(non-vested) awards for up to 1,000,000 common shares under the 2005 Plan. No additional awards may be granted under the 2005
	Plan. On January 14, 2011, the Company&rsquo;s stockholders approved the adoption of the 2011 Incentive Plan (the &ldquo;2011
	Plan&rdquo;) which provides for the issuance of equity awards, including among others, options, restricted stock and
	restricted stock units for up to 3,000,000 Common Shares. The exercise price of options granted under the 2011 Plan, and
	consistent with other Plans, is equal to or greater than fair market value of the Common Stock on the date of grant. Unless
	terminated earlier by the Board of Directors, the 2011 Plan will terminate at the earliest of; (a) such time as no shares of
	Common Stock remain available for issuance under the 2011 Plan or (b) tenth anniversary of the effective date of the 2011
	Plan. Awards outstanding upon expiration of the 2011 Plan shall remain in effect until they have been exercised, terminated,
	or have expired. As of July 31, 2016, there were approximately 818,000 shares available for grant under the 2011 Plan.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	The Company estimates the fair value of each stock option award
	on the measurement date using a Black-Scholes option pricing model. The fair value of awards is amortized to expense on a straight
	line basis over the requisite service period. The Company expenses restricted stock awards based on vesting requirements, primarily
	time elapsed.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Options granted pursuant to the plans may be either incentive
	stock options or non-statutory options The 2011 Plan provides for the issuance of stock options, restricted stock and restricted
	stock unit awards which generally vest over a two to four year period. A summary of the activity pursuant to the Company&rsquo;s
	stock option plans for the years ended July 31, 2016, 2015, and 2014 is as follows:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_41"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD COLSPAN="6" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PX SOLID">
	2016
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD COLSPAN="6" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PX SOLID">
	2015
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD COLSPAN="6" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PX SOLID">
	2014
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PX SOLID">
	Options
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PX SOLID">
	Weighted -
<BR>
	Average
<BR>
	Exercise
<BR>
	Price
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PX SOLID">
	Options
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PX SOLID">
	Weighted -
<BR>
	Average
<BR>
	Exercise
<BR>
	Price
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PX SOLID">
	Options
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PX SOLID">
	Weighted -
<BR>
	Average
<BR>
	Exercise
<BR>
	Price
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255)">
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: LEFT; TEXT-INDENT: -11PT; PADDING-LEFT: 11PT">
	Outstanding at beginning of year&#9;
</TD>
<TD STYLE="WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 6%; TEXT-ALIGN: RIGHT">
	1,358,104
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 8%; TEXT-ALIGN: RIGHT">
	3.04
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 6%; TEXT-ALIGN: RIGHT">
	1,155,910
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 8%; TEXT-ALIGN: RIGHT">
	5.03
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 6%; TEXT-ALIGN: RIGHT">
	726,645
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 8%; TEXT-ALIGN: RIGHT">
	10.39
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -11PT; PADDING-LEFT: 11PT">
	New Grants &#9;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	490,473
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	4.48
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	383,873
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	3.55
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	665,117
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2.77
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255)">
<TD STYLE="TEXT-INDENT: -11PT; PADDING-LEFT: 11PT">
	Exercised
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(33,702
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2.81
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-BOTTOM: 1PX; TEXT-INDENT: -11PT; PADDING-LEFT: 11PT">
	Expired &#9;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
	(6,000
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; TEXT-ALIGN: RIGHT">
	3.61
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
	(181,679
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; TEXT-ALIGN: RIGHT">
	16.84
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
	(236,852
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; TEXT-ALIGN: RIGHT">
	15.80
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 3PX; TEXT-INDENT: -11PT; PADDING-LEFT: 11PT">
	Outstanding at end of year &#9;
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; TEXT-ALIGN: RIGHT">
	1,808,875
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX; TEXT-ALIGN: RIGHT">
	3.43
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; TEXT-ALIGN: RIGHT">
	1,358,104
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX; TEXT-ALIGN: RIGHT">
	3.04
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; TEXT-ALIGN: RIGHT">
	1,155,910
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX; TEXT-ALIGN: RIGHT">
	5.03
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 3PX; TEXT-INDENT: -11PT; PADDING-LEFT: 11PT">
	Exercisable at end of year &#9;
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; TEXT-ALIGN: RIGHT">
	1,094,794
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX; TEXT-ALIGN: RIGHT">
	2.95
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; TEXT-ALIGN: RIGHT">
	782,688
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX; TEXT-ALIGN: RIGHT">
	2.88
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; TEXT-ALIGN: RIGHT">
	399,262
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX; TEXT-ALIGN: RIGHT">
	7.66
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255)">
<TD STYLE="PADDING-BOTTOM: 3PX; TEXT-INDENT: -11PT; PADDING-LEFT: 11PT">
	Weighted average fair value of options granted during year &#9;
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; TEXT-ALIGN: RIGHT">
	1.58
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; TEXT-ALIGN: RIGHT">
	1.36
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; TEXT-ALIGN: RIGHT">
	0.90
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	The intrinsic value of stock option awards that vested during
	the fiscal year represents the value of the Company&rsquo;s closing stock price on the last trading day of the fiscal year in excess
	of the exercise price multiplied by the number of options that vested. Total intrinsic value of options that vested and were exercisable
	during the fiscal years ended July 31, 2016, 2015, and 2014 was $4,399, $97 and $425, respectively. The intrinsic value of options
	outstanding at July 31, 2016, 2015, and 2014 was $6,451, $154 and $1,915, respectively. The intrinsic value of the options exercised
	in fiscal 2016 was $64.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	On January 6, 2016, the Company awarded 189,873 options to the
	board of directors with an exercise price of $4.66 and a five-year term, which vest annually over two years. The fair value of
	the options granted was $1.65 per share. The assumption used to fair value these options were as follow: expected life of 3.25
	years, expected volatility 48.6%, a risk free interest rate of 1.31% and no dividend yield. As of July 31, 2016 none of these options
	were vested.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	On March 14, 2016, the Company awarded 110,000 options to senior
	officers with an exercise price of $4.35 and a five-year term, which vest annually over two years. The fair value of the options
	granted was $1.46 per share. The assumption used to fair value these options were as follow: expected life of 3.25 years, expected
	volatility 46.13%, a risk free interest rate of 1.19% and no dividend yield. As of July 31, 2016 none of these options were vested.
</P>
<!-- FIELD: PAGE; SEQUENCE: 2; VALUE: 21 -->
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 6PT; PADDING-BOTTOM: 12PT; BORDER-BOTTOM: SILVER 4PX SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	22
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage88"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 10PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: LEFT; WIDTH: 100%">
<PAGE>
</PAGE>
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	ENZO BIOCHEM, INC.
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	July 31, 2016
</B>
</P>
<P STYLE="FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0">
<B>
	(Dollars in thousands
	except share data)
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	On March 14, 2016, the Company also awarded 188,600 options
	to senior management and employees with an exercise price of $4.35 and a five-year term, which vest annually over three years.
	The fair value of the options granted was $1.57 per share. The assumption used to fair value these options were as follow: expected
	life of 3.5 years, expected volatility 48.14%, a risk free interest rate of 1.24% and no dividend yield. As of July 31, 2016 none
	of these options were vested.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	On June 16, 2016, the Company awarded 2,000 options to an employee
	with an exercise price of $5.61 per share and a five-year term, which vest annually over two years. The fair value of the options
	granted was $1.88 per share. The assumption used to fair value these options were as follows: expected life of 3.25 years, expected
	volatility 46.64%, a risk free interest rate of 0.846% and no dividend yield. As of July 31, 2016 none of these options were vested.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	On January 21, 2015, the Company awarded 293,373 options to
	two senior officers and the board of directors with an exercise price of $3.40 and a five-year term, which vest annually over
	two years. The fair value of the options granted was $1.27 per share. The assumptions used to fair value these option awards were
	as follows: expected life of 3.25 years, expected volatility 52.25%, a risk free interest rate of 0.93% and no dividend yield.
	As of July 31, 2016, approximately 146,687 of these options were vested. Further on January 21, 2015, the Company awarded 40,000
	options to executive officers with an exercise price of $3.40 and a five-year term, which vest annually over three years. The
	fair value of the options granted was $1.39 per share. The assumptions used to fair value these option awards were as follows:
	expected life of 3.5 years, expected volatility 55.63%, a risk free interest rate of 1.00% and no dividend yield. As of July 31,
	2016, approximately 11,667 of these options were vested and 5,000 were forfeited.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	On December 10, 2014, the Company awarded 50,500 options to
	employees with an exercise price of $4.66 and a five-year term, which vest annually over three years. The fair value of the options
	granted was $1.894 per share. The assumption used to fair value these option awards were as follows: expected life of 3.5 years,
	expected volatility 55.16%, a risk free interest rate of 1.15% and no dividend yield. As of July 31, 2016 approximately 15,167
	of these options were vested.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	On February 3, 2014, the Company awarded 20,000 options to an
	executive officer with an exercise price of $2.75 and a five year term, which vest annually over three years. The fair value of
	the options granted was $1.11 per share. The assumptions used to fair value this option award were as follows: expected life of
	3.5 years, expected volatility 55.07%, risk free interest rate of 0.84% and no dividend yield. As of July 31, 2016, approximately
	13,333 of these options were vested.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	On January 17, 2014, the Company awarded 267,797 options to
	two senior officers and the board of directors with an exercise price of $2.70 and a five year-term, which vest annually over two
	years. The fair value of the options granted was $1.05 per share. The assumptions used to fair value these option awards were as
	follows: expected life of 3.25 years, expected volatility 54.78%, a risk free interest rate of 0.90% and no dividend yield. As
	of July 31, 2016, all of these options were fully vested. Further on January 17, 2014, the Company awarded 95,729 options to executive
	officers with an exercise price of $2.70 and a five-year term, which vest annually over three years. The fair value of the options
	granted was $1.10 per share. The assumptions used to fair value these option awards were as follows: expected life of 3.5 years,
	expected volatility 55.45%, a risk free interest rate of 1.00% and no dividend yield. As of July 31, 2016, approximately 57,200
	of these options were vested, including approximately 42,000 which became fully vested upon termination and 12,000 were forfeited.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	On November 26, 2013, the Company awarded 271,591 options to
	two senior officers with an exercise price of $3.00 and a four-year term, which vest over one year. The award satisfies $0.2 million
	of their fiscal 2013 incentive compensation award liability in lieu of cash. The fair value of the options granted was $0.66 per
	share. The assumptions used to fair value these option awards were as follows: expected life of 2.5 years, expected volatility
	54.79%, risk free interest rate of 0.42% and no dividend yield. As of July 31, 2016, all of these options were vested.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	The following table summarizes information for stock options
	outstanding at July 31, 2016:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_42"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD COLSPAN="10" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PX SOLID">
	Options outstanding and exercisable
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: BOLD; BORDER-BOTTOM: BLACK 1PX SOLID">
	Range of Exercise prices
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PX SOLID">
	Shares
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PX SOLID">
	Weighted-Average
<BR>
	Remaining Contractual
<BR>
	Life in Years
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PX SOLID">
	Weighted-Average
<BR>
	Exercise Price
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255)">
<TD STYLE="WIDTH: 41%; TEXT-INDENT: -10PT; PADDING-LEFT: 10PT">
	$2.53 &ndash; $4.00
</TD>
<TD STYLE="WIDTH: 3%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 11%; TEXT-ALIGN: RIGHT">
	1,272,903
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 3%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 20%; TEXT-ALIGN: RIGHT">
	1.05
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 3%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 13%; TEXT-ALIGN: RIGHT">
	2.99
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-BOTTOM: 1PX; TEXT-INDENT: -10PT; PADDING-LEFT: 10PT">
	$4.01 &ndash; $5.61
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
	535,972
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; TEXT-ALIGN: RIGHT">
	0.56
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; TEXT-ALIGN: RIGHT">
	4.49
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255)">
<TD STYLE="TEXT-ALIGN: RIGHT; PADDING-BOTTOM: 3PX; TEXT-INDENT: -10PT; PADDING-LEFT: 10PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; TEXT-ALIGN: RIGHT">
	1,808,875
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 36PT">
</P>
<!-- FIELD: PAGE; SEQUENCE: 3; VALUE: 21 -->
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 6PT; PADDING-BOTTOM: 12PT; BORDER-BOTTOM: SILVER 4PX SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	23
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage89"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 10PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: LEFT; WIDTH: 100%">
<PAGE>
</PAGE>
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0">
<B>
	ENZO BIOCHEM, INC.
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	July 31, 2016
</B>
</P>
<P STYLE="FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0">
<B>
	(Dollars in thousands
	except share data)
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<I>
	Restricted Stock Awards
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	During fiscal 2016, 2015 and 2014, the compensation committee
	of the Company&rsquo;s board of directors approved grants of restricted stock and restricted stock unit awards (the &ldquo;Awards&rdquo;)
	to certain officers and certain employees under the 2011 or 2005 Plans. The Awards vest upon the recipient&rsquo;s continued employment
	service rateably over either two, three or four years. Share-based compensation expense is based on the fair value of the award
	as measured on the grant date and is recorded over the vesting period on a straight-line basis. The Awards will be forfeited if
	the recipient ceases to be employed by the Company, as defined in the Plans&rsquo; terms. The Awards settle in shares of the Company&rsquo;s
	common stock on a one-for-one basis.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	The following table summarizes the activity pursuant to restricted
	stock awards for the years ended July 31,
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_43"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD COLSPAN="6" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PX SOLID">
	2016
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD COLSPAN="6" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PX SOLID">
	2015
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD COLSPAN="6" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PX SOLID">
	2014
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PX SOLID">
	Awards
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PX SOLID">
	Weighted -
<BR>
	Average
<BR>
	Award Price
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PX SOLID">
	Awards
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PX SOLID">
	Weighted -
<BR>
	Average
<BR>
	Award Price
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PX SOLID">
	Awards
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PX SOLID">
	Weighted -
<BR>
	Average
<BR>
	Award Price
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255)">
<TD STYLE="WIDTH: 31%; TEXT-ALIGN: LEFT; TEXT-INDENT: -10PT; PADDING-LEFT: 10PT">
	Outstanding at beginning of year
</TD>
<TD STYLE="WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 6%; TEXT-ALIGN: RIGHT">
	21,501
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 9%; TEXT-ALIGN: RIGHT">
	8.84
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 6%; TEXT-ALIGN: RIGHT">
	42,502
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 9%; TEXT-ALIGN: RIGHT">
	5.74
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 6%; TEXT-ALIGN: RIGHT">
	125,133
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 9%; TEXT-ALIGN: RIGHT">
	3.45
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-INDENT: -10PT; PADDING-LEFT: 10PT">
	Awarded
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	4,250
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	4.75
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	11,500
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	4.77
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255)">
<TD STYLE="TEXT-INDENT: -10PT; PADDING-LEFT: 10PT">
	Vested
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(11,500
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(2.83
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(19,418
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(2.83
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(82,971
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	(2.70
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-BOTTOM: 1PX; TEXT-INDENT: -10PT; PADDING-LEFT: 10PT">
	Forfeited
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
	(1,500
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; TEXT-ALIGN: RIGHT">
	(2.86
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
	(5,833
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; TEXT-ALIGN: RIGHT">
	(3.22
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
	(11,160
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; TEXT-ALIGN: RIGHT">
	(1.70
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 3PX; TEXT-INDENT: -10PT; PADDING-LEFT: 10PT">
	Outstanding (non-vested) at end of year
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; TEXT-ALIGN: RIGHT">
	8,501
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX; TEXT-ALIGN: RIGHT">
	4.13
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; TEXT-ALIGN: RIGHT">
	21,501
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX; TEXT-ALIGN: RIGHT">
	8.84
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; TEXT-ALIGN: RIGHT">
	42,502
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX; TEXT-ALIGN: RIGHT">
	5.74
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-BOTTOM: 3PX; TEXT-INDENT: -10PT; PADDING-LEFT: 10PT">
	Weighted average market value of awards granted during year
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; TEXT-ALIGN: RIGHT">
	4.75
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; TEXT-ALIGN: RIGHT">
	4.77
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	The fair value of the awards that vested during the years ended
	July 31, 2016, 2015 and 2014 was $46, $79 and $253, respectively.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	Note 11 - Employee benefit plan
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	The Company has a qualified Salary Reduction Profit Sharing
	Plan (the &ldquo;Plan&rdquo;) for eligible U.S. employees under Section 401(k) of the Internal Revenue Code. The Plan provides
	for voluntary employee contributions through salary reduction and voluntary employer contributions at the discretion of the Company.
	For the years ended July 31, 2016, 2015, and 2014, the Company authorized employer matched contributions of 50% of the employees&rsquo;
	contribution up to 10% of the employees&rsquo; compensation, payable in Enzo Biochem, Inc. common stock. The share-based 401(k)
	employer matched contribution was approximately $709, $662, and $636 in fiscal years 2016, 2015, and 2014, respectively. As of
	July 31, 2016, 2015 and 2014 the Company accrued a total of $413, $387 and $372 in 401(K) matching contributions within the Accrued
	liabilities account.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	The Company&rsquo;s Swiss operations provide a pension plan
	named the Enzo Life Sciences (ELS) AG Vertrag - Nr. 2/401144, (the &ldquo;Swiss Plan&rdquo;) under the Swiss government&rsquo;s
	social security system for Swiss employees. The current required minimum saving contribution is 13% for employees over age 25 and
	minimum annual investment return is 1.25%. Employees are required to contribute based on a formula and the Company&rsquo;s Swiss
	operations make contributions of at least 50% of the employee contribution. The status of the Swiss Plan, which is substantially
	funded as of December 31, 2015, the latest plan year end, is as follows:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_44"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PX">
	As of December 31,
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PX SOLID">
	2015
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PX SOLID">
	2014
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PX SOLID">
	2013
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255)">
<TD STYLE="WIDTH: 46%; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PX; TEXT-INDENT: -10PT; PADDING-LEFT: 10PT">
	Total Assets
</TD>
<TD STYLE="WIDTH: 3%; PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 9%; BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
	2,149
</TD>
<TD STYLE="WIDTH: 1%; PADDING-BOTTOM: 1PX; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 3%; PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 9%; BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
	2,132
</TD>
<TD STYLE="WIDTH: 1%; PADDING-BOTTOM: 1PX; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 3%; PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 9%; BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
	2,531
</TD>
<TD STYLE="WIDTH: 1%; PADDING-BOTTOM: 1PX; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="PADDING-BOTTOM: 1PX; TEXT-INDENT: -10PT; PADDING-LEFT: 10PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PX; TEXT-INDENT: -10PT; PADDING-LEFT: 10PT">
	Accumulated Benefit Obligation
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
	2,397
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
	2,421
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
	2,697
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255)">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -10PT; PADDING-LEFT: 10PT">
	Funded status
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	90
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	88
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	94
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	%
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-INDENT: -10PT; PADDING-LEFT: 10PT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PX; TEXT-INDENT: -10PT; PADDING-LEFT: 10PT">
	Fiscal Year ended July 31,
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	2015
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	2014
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	2013
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-INDENT: -10PT; PADDING-LEFT: 10PT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="PADDING-BOTTOM: 1PX; TEXT-INDENT: -10PT; PADDING-LEFT: 10PT">
	Contributions
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
	224
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
	279
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
	467
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
</P>
<!-- FIELD: PAGE; SEQUENCE: 4; VALUE: 21 -->
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 6PT; PADDING-BOTTOM: 12PT; BORDER-BOTTOM: SILVER 4PX SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	24
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage90"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 10PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: LEFT; WIDTH: 100%">
<PAGE>
</PAGE>
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	ENZO BIOCHEM, INC.
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	July 31, 2016
</B>
</P>
<P STYLE="FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0">
<B>
	(Dollars in thousands
	except share data)
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	The Swiss Plan&rsquo;s contract expires December 31, 2019 and
	currently the Company has no plans to change the current funding or plan design. No events have occurred that would impact the
	Swiss Plan status.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	Note 12 - Royalty and other income
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	The Company has a license agreement with Qiagen that began in
	2005, whereby the Company earns quarterly running royalties on the net sales of Qiagen products subject to the license until the
	expiration of the patent on April 24, 2018. During the years ended July 31, 2016, 2015 and 2014, the Company recorded royalty income
	under the agreement of approximately $1,521, $2,495 and $4,408 respectively, which is included in the Life Sciences segment.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	Note 13 - Commitments
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<I>
	Leases
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	The Company leases equipment, office and laboratory space under
	several non-cancellable operating leases that expire between September 2015 and May 2023. Certain leases include renewal options
	and rent escalation clauses. An entity owned by certain executive officers/directors of the Company owns the building that the
	Company leases as its main facility for clinical laboratory operations and certain research operations. In March 2005, the Company
	amended and extended the lease for 12 years. In addition to the minimum annual rentals of space, the lease is subject to annual
	increases, based on the consumer price index. Annual increases are limited to 3% per year. Rent expense for this lease, inclusive
	of real estate taxes, approximated $1,704, $1,623(net of real estate tax abatement received of $61) and $1,649 during fiscal years
	2016, 2015 and 2014, respectively. Total rent expense incurred by the Company during fiscal 2016, 2015 and 2014 for all its facilities
	was approximately $4,572, $4,504 and $4,488, respectively.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Minimum future annual rentals under all non-cancellable operating
	leases, net of sublease rental income of $323, as of July 31, 2016, are as follows:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_45"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BORDER-COLLAPSE: COLLAPSE; WIDTH: 40%">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	Years ended July 31,
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255)">
<TD STYLE="WIDTH: 50%; TEXT-ALIGN: RIGHT">
	2017
</TD>
<TD STYLE="WIDTH: 2%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 15%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 2%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 29%; TEXT-ALIGN: RIGHT">
	7,256
</TD>
<TD STYLE="WIDTH: 2%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: RIGHT">
	2018
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	7,003
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255)">
<TD STYLE="TEXT-ALIGN: RIGHT">
	2019
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	6,208
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: RIGHT">
	2020
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	4,244
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255)">
<TD STYLE="TEXT-ALIGN: RIGHT">
	2021
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2,160
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-BOTTOM: 1PX; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Thereafter
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
	10,062
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255)">
<TD STYLE="PADDING-BOTTOM: 3PX; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; TEXT-ALIGN: RIGHT">
	36,933
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<I>
	Employment Agreements
</I>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	The Company has employment agreements with certain officers
	that are cancellable at any time but provide for severance pay in the event an officer is terminated by the Company without cause,
	as defined in the agreements. Unless cancelled earlier or with notice as defined, the agreement automatically renews for two years.
	Aggregate minimum compensation commitments, exclusive of any severance provisions as of July 31, 2016 is $2,271.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	Note 14 &ndash; Contingencies
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	On June 7, 2004, the Company and Enzo Life Sciences, Inc., filed
	suit in the United States District Court for the District of Connecticut against Applera Corporation and its wholly-owned subsidiary
	Tropix, Inc., which became Life Technologies, Inc. and was acquired by Thermo Fisher Scientific, Inc. (NYSE:TMO) on February 3,
	2014.&nbsp;The complaint alleged infringement of six patents relating to DNA sequencing systems, labeled nucleotide products, and
	other technology. Yale University is the owner of four of the patents and the Company is the exclusive licensee. These four patents
	are commonly referred to as the &ldquo;Ward&rdquo; patents. On November 12, 2012, a jury in New Haven found that one of these patents
	(United States Patent No. 5,449,667) was infringed and not proven invalid. The jury awarded $48.5 million for this infringement.
	On January 6, 2014, the judge awarded prejudgment interest of approximately $12.5 million and additional post-interest on the full
	amount was also awarded starting November 7, 2012 until the total award is satisfied. The final award to the Company
	could have been reduced or subject to possible claims from third parties.
</P>
<!-- FIELD: PAGE; SEQUENCE: 5; VALUE: 21 -->
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 6PT; PADDING-BOTTOM: 12PT; BORDER-BOTTOM: SILVER 4PX SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	25
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage91"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 10PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: LEFT; WIDTH: 100%">
<PAGE>
</PAGE>
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	ENZO BIOCHEM, INC.
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	July 31, 2016
</B>
</P>
<P STYLE="FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0">
<B>
	(Dollars in thousands
	except share data)
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	On March 16, 2015, the Court of Appeals for the Federal Circuit
	vacated that judgment in a decision remanding the matter to the district court for further proceedings.&nbsp; On February 22, 2016,
	the Connecticut District Court granted Applera&rsquo;s motion for summary judgment of non-infringement.&nbsp; The Company appealed
	that decision. There can be no assurance that the Company will be successful in this litigation. Even if the Company is not successful,
	management does not believe that there will be a significant adverse monetary impact on the Company.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	As of August 1, 2014 the Company was engaged in
	litigation in the United States District Court for the Southern District of New York against Roche Diagnostic GmbH and its
	related company Roche Molecular Systems, Inc. (&ldquo;Roche&rdquo;), as declaratory judgment defendant. This case was
	commenced in May 2004. Roche seeks a declaratory judgment of non-breach of contract and patent invalidity against the
	Company. Roche has also asserted tort claims against the Company. The Company has asserted breach of contract and patent
	infringement causes of action against Roche. There has been extensive discovery in the case. In 2011, Roche moved for summary
	judgment of non-infringement regarding the Company&rsquo;s patent claims. In 2012, the motion was granted in part and denied
	in part. In December 2012, Roche moved for summary judgment on the Company&rsquo;s non-patent claims. Additional discovery
	was taken and the Company responded to the motions in May 2013. On December 6, 2013, the Court granted in part and denied in
	part Roche&rsquo;s summary judgment motion. On October 22, 2014, the Court ordered that damages discovery concerning the
	Company&rsquo;s remaining contract and patent claims and Roche&rsquo;s claims should be completed by January 30, 2015, and
	expert discovery should be completed following the Court&rsquo;s not-yet-issued claim construction ruling concerning the
	Company&rsquo;s patent infringement claim against Roche. Roche dropped its tort claims during damages discovery. On April 28,
	2015, the Court heard oral argument on claim construction issues. On May 8, 2015, Roche and the Company jointly moved the
	Court to extend the schedule for damages discovery until May 29, 2015, and the Court granted that motion. The parties
	are waiting for the Court&rsquo;s ruling on claim construction. The Company and Enzo Life Sciences intend to vigorously press their remaining claims and contest the claims against them.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	In 2012, the Company received a Subpoena Duces Tecum (the &ldquo;Subpoena&rdquo;)
	from the Department of Health and Human Services, Office of Inspector General (&ldquo;OIG&rdquo;). The Subpoena was issued as part
	of an investigation being conducted by the US Attorney&rsquo;s Office for the Eastern District of New York in conjunction with
	the OIG. While a number of potential issues were raised initially by the government, the investigation came to focus primarily
	on an alleged failure to collect diagnosis codes from physicians who ordered tests through Enzo Clinical Labs. The time period
	initially covered by the investigation was from 2004 through 2011. In response to the Subpoena, the Company cooperated with the
	government. On September 22, 2014, the Company and the U.S. Department of Justice reached a settlement agreement to resolve this
	matter, in substantive form as disclosed in the Company&rsquo;s fiscal quarter ended April 30, 2014. During the quarter ended April,
	30, 2014, the Company recorded a charge of $2.0 million in the statement of operations under legal settlements, net within the
	Clinical Labs segment. The settlement amount will be paid with interest over a five-year period. The final settlement covers the time period 2004-2014. During the three months ended January 31,
	2016, the Company accrued an additional $1.5 million, due to the Company&rsquo;s achievement of certain financial milestones. As
	of July 31, 2016, the total liability for this settlement is $1.2 million, of which $0.4 million is included in other current liabilities
	and $0.8 million included in other liabilities.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	On June 20, 2014, the Company, as plaintiff finalized and
	executed a settlement agreement with PerkinElmer, Inc., and PerkinElmer Health Sciences, Inc. (formerly known as PerkinElmer
	Life Sciences, Inc.) (together, &ldquo;PerkinElmer&rdquo;), with respect to an action between the Company and PerkinElmer
	before the U.S. District Court, Southern District of New York, Case No 03-CV-3817. PerkinElmer paid $7.0 million in escrow
	pursuant to the agreement because of a former attorney&rsquo;s charging lien for fees allegedly owed for past services
	rendered to the Company. On December
	3, 2015, the Company entered into a Settlement Agreement with the former attorney pursuant to which the Company and the
	former attorney resolved their respective claims against each other. As of July 31, 2016, the Company received a total of
	approximately $7.0 million from the escrow referred to above in accordance with the terms of the Settlement Agreement. This
	settlement is included in the statement of operations under Legal settlements, net within the Life Science segment.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	On July 2, 2015, the Company as Plaintiff executed a settlement
	agreement with Luminex Corporation with respect to an action between the Company and Abbott Laboratories and Abbott Molecular,
	Inc. (Defendants) and Luminex Corporation (Intervening Defendant) before the United States District Court for the District of Delaware
	for alleged patent infringement. Luminex paid the Company a total of $7.1 million as consideration for this agreement and the dismissal
	of the litigation against Luminex. The case against the Abbott
	defendants continues. The parties have not begun summary judgement briefing because the court has not set a briefing
	schedule. The court also has not set a trial date.
</P>
<!-- FIELD: PAGE; SEQUENCE: 6; VALUE: 21 -->
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 6PT; PADDING-BOTTOM: 12PT; BORDER-BOTTOM: SILVER 4PX SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	26
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage92"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 10PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: LEFT; WIDTH: 100%">
<PAGE>
</PAGE>
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	ENZO BIOCHEM, INC.
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	July 31, 2016
</B>
</P>
<P STYLE="FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0">
<B>
	(Dollars in thousands
	except share data)
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	On July 20, 2015, the Company as a Plaintiff finalized and executed
	a settlement agreement with Siemens Healthcare Diagnostics Inc. (&ldquo;Siemens&rdquo;) to settle a patent litigation lawsuit before
	the U.S. District Court for the District of Delaware in the amount of $6.7 million, net. Under terms of the agreement, Siemens
	will also pay the Company additional royalties of $1.0 million per annum on sales of its molecular products manufactured and/or
	sold in the United States during the its fiscal years 2015 through 2019 if sales of such products exceed a contractual amount.
	The net settlement amount was included in other receivables in the consolidated balance sheet as of July 31, 2015 and was received
	in August 2015.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	On October 9, 2015, the Company reached and finalized a settlement
	with Affymetrix, Inc. in the amount of $6.8 million, net in a patent infringement action brought by the Company. On January 4,
	2016, the Company reached and finalized a settlement agreement with Agilent Technologies, Inc. in the amount of $6.1 million, net
	in a patent infringement action brought by the Company. Both cases were originally brought by the Company in the United States
	District Court for the District of Delaware. The settlements are included in the statement of operations under Legal settlements,
	net within the Life Science segment.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	On May 16, 2016, the Company reached and finalized a
	settlement with Life Technologies Corporation in the amount of $24.3 million, net in an infringement action brought by the
	Company regarding its US Patents No. 6,992,180 and 7,064,197. On July 1, 2016, the Company reached and finalized a settlement
	with Illumina, Inc., in the amount of $14.5 million, net in an infringement action brought by the Company regarding US Patent
	No. 7,064,197. These cases were originally brought by the Company in the United States District Court for the District of
	Delaware. The settlements are included in the statement of operations under Legal settlements, net within the Life Science
	segment.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="BACKGROUND-COLOR: WHITE">
	As of July 31, 2016, there
	are six pending cases originally brought by the Company in the United States District Court for the District of Delaware alleging
	patent infringements against various companies.
</FONT>
	There can be no assurance that the Company will be successful in these litigations.
	Even if the Company is not successful, management does not believe that there will be a significant adverse monetary impact on
	the Company.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	The Company is party to other claims, legal actions, complaints,
	and contractual disputes that arise in the ordinary course of business. The Company believes that any liability that may ultimately
	result from the resolution of these matters will not, individually or in the aggregate, have a material adverse effect on its financial
	position or results of operations.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<B>
	Note 15 - Segment reporting
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	The Company has three reportable segments: Life Sciences, Clinical
	Labs and Therapeutics. The Company&rsquo;s Life Sciences segment develops, manufactures, and markets products to research and pharmaceutical
	customers. The Clinical Labs segment provides diagnostic services to the health care community. The Company&rsquo;s Therapeutics
	segment conducts research and development activities for therapeutic drug candidates. The Company evaluates segment performance
	based on segment income (loss) before taxes. Costs excluded from segment income (loss) before taxes and reported as &ldquo;Other&rdquo;
	consist of corporate general and administrative costs which are not allocable to the three reportable segments.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Legal fee expense incurred to defend the Company&rsquo;s intellectual
	property, which may result in settlements recognized in another segment and other general corporate matters are considered a component
	of the Other segment. Legal fee expense specific to other segments&rsquo; activities have been allocated to those segments.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Legal settlements, net, represent activities for which royalties
	would have been received in the Company&rsquo;s Life Sciences segment and expenses related to an investigation within the Clinical
	Labs segment.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	Management of the Company assesses assets on a consolidated
	basis only and therefore, assets by reportable segment have not been included in the reportable segments below. The accounting
	policies of the reportable segments are the same as those described in the summary of significant accounting policies.
</P>
<!-- FIELD: PAGE; SEQUENCE: 7; VALUE: 21 -->
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 6PT; PADDING-BOTTOM: 12PT; BORDER-BOTTOM: SILVER 4PX SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	27
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage93"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 10PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: LEFT; WIDTH: 100%">
<PAGE>
</PAGE>
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="MARGIN: 0; TEXT-ALIGN: CENTER; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	ENZO BIOCHEM, INC.
</B>
<BR>
<B>
	NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
</B>
<BR>
<B>
	July 31, 2016
</B>
</P>
<P STYLE="MARGIN: 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0; FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	(Dollars in thousands
	except share data)
</B>
</P>
<P STYLE="MARGIN: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<P STYLE="MARGIN: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	The following financial information represents the operating results
	of the reportable segments of the Company:
</P>
<P STYLE="MARGIN: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<EFX_INCOME_STATEMENT>
<A NAME="FIS_INCOME_STATEMENT_2"></A>
<P STYLE="MARGIN: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Year ended July 31, 2016
</B>
</P>
<P STYLE="MARGIN: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	Clinical
<BR>
	Labs
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	Life
<BR>
	Sciences
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	Therapeutics
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	Other
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	Consolidated
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255); FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Revenues:
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="WIDTH: 35%; COLOR: BLACK; TEXT-ALIGN: LEFT; TEXT-INDENT: -10PT; PADDING-LEFT: 10PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Clinical
	laboratory services
</TD>
<TD STYLE="WIDTH: 2%; COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</TD>
<TD STYLE="WIDTH: 9%; COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	70,915
</TD>
<TD STYLE="WIDTH: 1%; COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 2%; COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 9%; COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&mdash;
</TD>
<TD STYLE="WIDTH: 1%; COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 2%; COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 9%; COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&mdash;
</TD>
<TD STYLE="WIDTH: 1%; COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 2%; COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 9%; COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&mdash;
</TD>
<TD STYLE="WIDTH: 1%; COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 2%; COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</TD>
<TD STYLE="WIDTH: 9%; COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	70,915
</TD>
<TD STYLE="WIDTH: 1%; COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255); FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; TEXT-INDENT: -10PT; PADDING-LEFT: 10PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Product
	revenues
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&mdash;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	30,337
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&mdash;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&mdash;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	30,337
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PX; TEXT-INDENT: -10PT; PADDING-LEFT: 10PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Royalty
	and license fee income
</TD>
<TD STYLE="COLOR: BLACK; PADDING-BOTTOM: 1PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; PADDING-BOTTOM: 1PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	1,521
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; PADDING-BOTTOM: 1PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; PADDING-BOTTOM: 1PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; PADDING-BOTTOM: 1PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	1,521
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255); FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PX; TEXT-INDENT: -10PT; PADDING-LEFT: 10PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Total
	revenues
</TD>
<TD STYLE="COLOR: BLACK; PADDING-BOTTOM: 1PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	70,915
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; PADDING-BOTTOM: 1PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	31,858
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; PADDING-BOTTOM: 1PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; PADDING-BOTTOM: 1PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; PADDING-BOTTOM: 1PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	102,773
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="TEXT-INDENT: -10PT; PADDING-LEFT: 10PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: ITALIC 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: ITALIC 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: ITALIC 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT: ITALIC 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; TEXT-INDENT: -10PT; PADDING-LEFT: 10PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Operating
	costs, expenses and legal settlements, net:
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255); FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; TEXT-INDENT: -10PT; PADDING-LEFT: 10PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Cost
	of clinical laboratory services
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	42,859
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&mdash;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&mdash;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&mdash;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	42,859
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; TEXT-INDENT: -10PT; PADDING-LEFT: 10PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Cost
	of product revenues
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&mdash;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	14,331
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&mdash;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&mdash;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	14,331
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255); FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; TEXT-INDENT: -10PT; PADDING-LEFT: 10PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Research
	and development
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&mdash;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	2,720
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	804
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&mdash;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	3,524
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; TEXT-INDENT: -10PT; PADDING-LEFT: 10PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Selling,
	general and administrative
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	22,882
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	11,761
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&mdash;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	8,943
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	43,586
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255); FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; TEXT-INDENT: -10PT; PADDING-LEFT: 10PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Provision
	for uncollectible accounts receivable
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	2,375
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	(39
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	)
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&mdash;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&mdash;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	2,336
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; TEXT-INDENT: -10PT; PADDING-LEFT: 10PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Legal
	fee expense
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	134
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	11
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&mdash;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	6,239
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	6,384
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255); FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PX; TEXT-INDENT: -10PT; PADDING-LEFT: 10PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Legal
	settlements, net
</TD>
<TD STYLE="COLOR: BLACK; PADDING-BOTTOM: 1PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	1,500
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; PADDING-BOTTOM: 1PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	(58,750
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	)
</TD>
<TD STYLE="COLOR: BLACK; PADDING-BOTTOM: 1PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; PADDING-BOTTOM: 1PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; PADDING-BOTTOM: 1PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	(57,250
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PX; TEXT-INDENT: -10PT; PADDING-LEFT: 10PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Total
	costs, expenses and legal settlements, net
</TD>
<TD STYLE="COLOR: BLACK; PADDING-BOTTOM: 1PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	69,750
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; PADDING-BOTTOM: 1PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	(29,966
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	)
</TD>
<TD STYLE="COLOR: BLACK; PADDING-BOTTOM: 1PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	804
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; PADDING-BOTTOM: 1PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	15,182
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; PADDING-BOTTOM: 1PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	55,770
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="TEXT-INDENT: -10PT; PADDING-LEFT: 10PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255); FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; TEXT-INDENT: -10PT; PADDING-LEFT: 10PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Operating
	income (loss)
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	1,165
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	61,824
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	(804
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	)
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	(15,182
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	)
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	47,003
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="TEXT-INDENT: -10PT; PADDING-LEFT: 10PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; TEXT-INDENT: -10PT; PADDING-LEFT: 10PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Other
	income (expense)
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255); FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="COLOR: BLACK; TEXT-INDENT: -10PT; PADDING-LEFT: 10PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Interest
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	(105
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	)
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	47
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&mdash;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	(78
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	)
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	(136
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="COLOR: BLACK; TEXT-INDENT: -10PT; PADDING-LEFT: 10PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Other
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	10
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	38
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&mdash;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	74
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	122
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255); FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PX; TEXT-INDENT: -10PT; PADDING-LEFT: 10PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Foreign
	exchange gain
</TD>
<TD STYLE="COLOR: BLACK; PADDING-BOTTOM: 1PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; PADDING-BOTTOM: 1PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	(474
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	)
</TD>
<TD STYLE="COLOR: BLACK; PADDING-BOTTOM: 1PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; PADDING-BOTTOM: 1PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; PADDING-BOTTOM: 1PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	(474
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="TEXT-INDENT: -10PT; PADDING-LEFT: 10PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 3PX; TEXT-INDENT: -10PT; PADDING-LEFT: 10PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Income
	(loss) before taxes
</TD>
<TD STYLE="COLOR: BLACK; PADDING-BOTTOM: 3PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	1,070
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX; COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; PADDING-BOTTOM: 3PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	61,435
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX; COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; PADDING-BOTTOM: 3PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	(804
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX; COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	)
</TD>
<TD STYLE="COLOR: BLACK; PADDING-BOTTOM: 3PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	(15,186
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX; COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	)
</TD>
<TD STYLE="COLOR: BLACK; PADDING-BOTTOM: 3PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	46,515
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX; COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="TEXT-INDENT: -10PT; PADDING-LEFT: 10PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255); FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 3PX; TEXT-INDENT: -10PT; PADDING-LEFT: 10PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Depreciation
	and amortization included above
</TD>
<TD STYLE="COLOR: BLACK; PADDING-BOTTOM: 3PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	1,676
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX; COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; PADDING-BOTTOM: 3PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	2,091
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX; COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; PADDING-BOTTOM: 3PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX; COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; PADDING-BOTTOM: 3PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	73
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX; COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; PADDING-BOTTOM: 3PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	3,840
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX; COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="TEXT-INDENT: -10PT; PADDING-LEFT: 10PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; TEXT-INDENT: -10PT; PADDING-LEFT: 10PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Share-based
	compensation included in above:
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255); FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; TEXT-INDENT: -10PT; PADDING-LEFT: 10PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Cost
	of clinical laboratory services
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	6
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&mdash;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&mdash;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&mdash;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	6
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PX; TEXT-INDENT: -10PT; PADDING-LEFT: 10PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Selling,
	general and administrative
</TD>
<TD STYLE="COLOR: BLACK; PADDING-BOTTOM: 1PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	51
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; PADDING-BOTTOM: 1PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	30
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; PADDING-BOTTOM: 1PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; PADDING-BOTTOM: 1PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	438
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; PADDING-BOTTOM: 1PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	519
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255); FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="COLOR: BLACK; PADDING-BOTTOM: 3PX; TEXT-INDENT: -10PT; PADDING-LEFT: 10PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Total
</TD>
<TD STYLE="COLOR: BLACK; PADDING-BOTTOM: 3PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	57
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX; COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; PADDING-BOTTOM: 3PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	30
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX; COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; PADDING-BOTTOM: 3PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX; COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; PADDING-BOTTOM: 3PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	438
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX; COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; PADDING-BOTTOM: 3PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	525
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX; COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="TEXT-INDENT: -10PT; PADDING-LEFT: 10PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 3PX; TEXT-INDENT: -10PT; PADDING-LEFT: 10PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Capital
	expenditures
</TD>
<TD STYLE="COLOR: BLACK; PADDING-BOTTOM: 3PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	1,216
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX; COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; PADDING-BOTTOM: 3PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	314
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX; COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; PADDING-BOTTOM: 3PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX; COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; PADDING-BOTTOM: 3PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX; COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; PADDING-BOTTOM: 3PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	1,530
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX; COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_INCOME_STATEMENT>
<!-- FIELD: PAGE; SEQUENCE: 1; OPTIONS: NEWSECTION; VALUE: 28 -->
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 6PT; PADDING-BOTTOM: 10PT; BORDER-BOTTOM: SILVER 4PX SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	28
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage94"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 10PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: LEFT; WIDTH: 100%">
<PAGE>
</PAGE>
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="MARGIN: 0; TEXT-ALIGN: CENTER; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	ENZO BIOCHEM, INC.
</B>
<BR>
<B>
	NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
</B>
<BR>
<B>
	July 31, 2016
</B>
</P>
<P STYLE="MARGIN: 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0; FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	(Dollars in thousands except
	share data)
</B>
</P>
<P STYLE="MARGIN: 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0.5IN; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<P STYLE="MARGIN: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	The following financial information represents the operating results
	of the reportable segments of the Company:
</P>
<P STYLE="MARGIN: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<EFX_INCOME_STATEMENT>
<A NAME="FIS_INCOME_STATEMENT_3"></A>
<P STYLE="MARGIN: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Year ended July 31, 2015
</B>
</P>
<P STYLE="MARGIN: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="PADDING-LEFT: 10PT; TEXT-INDENT: -10PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	Clinical
<BR>
	Labs
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	Life
<BR>
	Sciences
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	Therapeutics
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	Other
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	Consolidated
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255); FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="COLOR: BLACK; PADDING-LEFT: 10PT; TEXT-INDENT: -10PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Revenues:
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="WIDTH: 35%; COLOR: BLACK; TEXT-ALIGN: LEFT; TEXT-INDENT: -10PT; PADDING-LEFT: 10PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Clinical
	laboratory services
</TD>
<TD STYLE="WIDTH: 2%; COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</TD>
<TD STYLE="WIDTH: 9%; COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	63,414
</TD>
<TD STYLE="WIDTH: 1%; COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 2%; COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 9%; COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&mdash;
</TD>
<TD STYLE="WIDTH: 1%; COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 2%; COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 9%; COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&mdash;
</TD>
<TD STYLE="WIDTH: 1%; COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 2%; COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 9%; COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&mdash;
</TD>
<TD STYLE="WIDTH: 1%; COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 2%; COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</TD>
<TD STYLE="WIDTH: 9%; COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	63,414
</TD>
<TD STYLE="WIDTH: 1%; COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255); FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; TEXT-INDENT: -10PT; PADDING-LEFT: 10PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Product
	revenues
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&mdash;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	31,690
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&mdash;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&mdash;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	31,690
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PX; TEXT-INDENT: -10PT; PADDING-LEFT: 10PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Royalty
	and license fee income
</TD>
<TD STYLE="COLOR: BLACK; PADDING-BOTTOM: 1PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; PADDING-BOTTOM: 1PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	2,495
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; PADDING-BOTTOM: 1PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; PADDING-BOTTOM: 1PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; PADDING-BOTTOM: 1PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	2,495
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255); FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PX; TEXT-INDENT: -10PT; PADDING-LEFT: 10PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Total
	revenues
</TD>
<TD STYLE="COLOR: BLACK; PADDING-BOTTOM: 1PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	63,414
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; PADDING-BOTTOM: 1PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	34,185
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; PADDING-BOTTOM: 1PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; PADDING-BOTTOM: 1PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; PADDING-BOTTOM: 1PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	97,599
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="PADDING-LEFT: 10PT; TEXT-INDENT: -10PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; TEXT-INDENT: -10PT; PADDING-LEFT: 10PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Operating
	costs, expenses and legal settlements, net:
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255); FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; TEXT-INDENT: -10PT; PADDING-LEFT: 10PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Cost
	of clinical laboratory services
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	39,589
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&mdash;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&mdash;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&mdash;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	39,589
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; TEXT-INDENT: -10PT; PADDING-LEFT: 10PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Cost
	of product revenues
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&mdash;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	15,183
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&mdash;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&mdash;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	15,183
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255); FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; TEXT-INDENT: -10PT; PADDING-LEFT: 10PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Research
	and development
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&mdash;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	2,608
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	742
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&mdash;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	3,350
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; TEXT-INDENT: -10PT; PADDING-LEFT: 10PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Selling,
	general and administrative
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	20,666
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	12,168
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&mdash;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	8,235
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	41,069
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255); FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; TEXT-INDENT: -10PT; PADDING-LEFT: 10PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Provision
	for uncollectible accounts receivable
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	2,418
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	(134
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	)
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&mdash;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&mdash;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	2,284
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; TEXT-INDENT: -10PT; PADDING-LEFT: 10PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Legal
	fee expense
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	196
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	(67
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	)
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&mdash;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	8,659
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	8,788
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255); FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PX; TEXT-INDENT: -10PT; PADDING-LEFT: 10PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Legal
	settlements, net
</TD>
<TD STYLE="COLOR: BLACK; PADDING-BOTTOM: 1PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; PADDING-BOTTOM: 1PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	(11,458
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	)
</TD>
<TD STYLE="COLOR: BLACK; PADDING-BOTTOM: 1PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; PADDING-BOTTOM: 1PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; PADDING-BOTTOM: 1PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	(11,458
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PX; TEXT-INDENT: -10PT; PADDING-LEFT: 10PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Total
	costs, expenses and legal settlements, net
</TD>
<TD STYLE="COLOR: BLACK; PADDING-BOTTOM: 1PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	62,869
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; PADDING-BOTTOM: 1PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	18,300
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; PADDING-BOTTOM: 1PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	742
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; PADDING-BOTTOM: 1PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	16,894
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; PADDING-BOTTOM: 1PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	98,805
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="PADDING-LEFT: 10PT; TEXT-INDENT: -10PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255); FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; TEXT-INDENT: -10PT; PADDING-LEFT: 10PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Operating
	income (loss)
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	545
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	15,885
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	(742
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	)
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	(16,894
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	)
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	(1,206
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="PADDING-LEFT: 10PT; TEXT-INDENT: -10PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; TEXT-INDENT: -10PT; PADDING-LEFT: 10PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Other
	income (expense)
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255); FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="COLOR: BLACK; TEXT-INDENT: -10PT; PADDING-LEFT: 10PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Interest
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	(86
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	)
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	10
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&mdash;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	(169
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	)
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	(245
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="COLOR: BLACK; TEXT-INDENT: -10PT; PADDING-LEFT: 10PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Other
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	28
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	9
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&mdash;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	58
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	95
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255); FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PX; TEXT-INDENT: -10PT; PADDING-LEFT: 10PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Foreign
	exchange gain
</TD>
<TD STYLE="COLOR: BLACK; PADDING-BOTTOM: 1PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; PADDING-BOTTOM: 1PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	(936
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	)
</TD>
<TD STYLE="COLOR: BLACK; PADDING-BOTTOM: 1PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; PADDING-BOTTOM: 1PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; PADDING-BOTTOM: 1PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	(936
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="PADDING-LEFT: 10PT; TEXT-INDENT: -10PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 3PX; TEXT-INDENT: -10PT; PADDING-LEFT: 10PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Income
	(loss) before taxes
</TD>
<TD STYLE="COLOR: BLACK; PADDING-BOTTOM: 3PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	487
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX; COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; PADDING-BOTTOM: 3PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	14,968
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX; COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; PADDING-BOTTOM: 3PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	(742
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX; COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	)
</TD>
<TD STYLE="COLOR: BLACK; PADDING-BOTTOM: 3PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	(17,005
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX; COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	)
</TD>
<TD STYLE="COLOR: BLACK; PADDING-BOTTOM: 3PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	(2,292
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX; COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="PADDING-LEFT: 10PT; TEXT-INDENT: -10PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255); FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 3PX; TEXT-INDENT: -10PT; PADDING-LEFT: 10PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Depreciation
	and amortization included above
</TD>
<TD STYLE="COLOR: BLACK; PADDING-BOTTOM: 3PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	1,443
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX; COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; PADDING-BOTTOM: 3PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	2,254
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX; COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; PADDING-BOTTOM: 3PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	3
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX; COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; PADDING-BOTTOM: 3PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	89
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX; COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; PADDING-BOTTOM: 3PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	3,789
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX; COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="PADDING-LEFT: 10PT; TEXT-INDENT: -10PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; TEXT-INDENT: -10PT; PADDING-LEFT: 10PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Share-based
	compensation included in above:
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255); FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; TEXT-INDENT: -10PT; PADDING-LEFT: 10PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Cost
	of clinical laboratory services
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	5
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&mdash;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&mdash;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&mdash;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	5
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; TEXT-INDENT: -10PT; PADDING-LEFT: 10PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Research
	and development
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&mdash;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	2
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&mdash;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&mdash;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	2
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255); FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PX; TEXT-INDENT: -10PT; PADDING-LEFT: 10PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Selling,
	general and administrative
</TD>
<TD STYLE="COLOR: BLACK; PADDING-BOTTOM: 1PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	43
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; PADDING-BOTTOM: 1PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	15
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; PADDING-BOTTOM: 1PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; PADDING-BOTTOM: 1PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	364
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; PADDING-BOTTOM: 1PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	422
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="COLOR: BLACK; PADDING-BOTTOM: 3PX; TEXT-INDENT: -10PT; PADDING-LEFT: 10PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Total
</TD>
<TD STYLE="COLOR: BLACK; PADDING-BOTTOM: 3PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	48
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX; COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; PADDING-BOTTOM: 3PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	17
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX; COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; PADDING-BOTTOM: 3PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX; COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; PADDING-BOTTOM: 3PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	364
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX; COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; PADDING-BOTTOM: 3PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	429
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX; COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="PADDING-LEFT: 10PT; TEXT-INDENT: -10PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255); FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 3PX; TEXT-INDENT: -10PT; PADDING-LEFT: 10PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Capital
	expenditures
</TD>
<TD STYLE="COLOR: BLACK; PADDING-BOTTOM: 3PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	1,557
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX; COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; PADDING-BOTTOM: 3PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	226
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX; COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; PADDING-BOTTOM: 3PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX; COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; PADDING-BOTTOM: 3PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX; COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; PADDING-BOTTOM: 3PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	1,783
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX; COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_INCOME_STATEMENT>
<P STYLE="MARGIN: 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0.5IN; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
</P>
<!-- FIELD: PAGE; SEQUENCE: 2; VALUE: 28 -->
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 6PT; PADDING-BOTTOM: 10PT; BORDER-BOTTOM: SILVER 4PX SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	29
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage95"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 10PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: LEFT; WIDTH: 100%">
<PAGE>
</PAGE>
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="MARGIN: 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	ENZO BIOCHEM, INC.
</B>
<BR>
<B>
	NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
</B>
<BR>
<B>
	July 31, 2016
</B>
</P>
<P STYLE="MARGIN: 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0; FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	(Dollars in thousands except
	share data)
</B>
</P>
<P STYLE="TEXT-ALIGN: CENTER; TEXT-INDENT: 0; MARGIN: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<P STYLE="MARGIN: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	The following financial information represents the operating results
	of the reportable segments of the Company:
</P>
<P STYLE="TEXT-ALIGN: CENTER; TEXT-INDENT: 0; MARGIN: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<EFX_INCOME_STATEMENT>
<A NAME="FIS_INCOME_STATEMENT_4"></A>
<P STYLE="MARGIN: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Year ended July 31, 2014
</B>
</P>
<P STYLE="TEXT-ALIGN: CENTER; TEXT-INDENT: 0; MARGIN: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	Clinical
<BR>
	Labs
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	Life
<BR>
	Sciences
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	Therapeutics
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	Other
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	Consolidated
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255); FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Revenues:
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="WIDTH: 35%; COLOR: BLACK; TEXT-ALIGN: LEFT; TEXT-INDENT: -11PT; PADDING-LEFT: 11PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Clinical
	laboratory services
</TD>
<TD STYLE="WIDTH: 2%; COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</TD>
<TD STYLE="WIDTH: 9%; COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	58,689
</TD>
<TD STYLE="WIDTH: 1%; COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 2%; COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 9%; COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&mdash;
</TD>
<TD STYLE="WIDTH: 1%; COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 2%; COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 9%; COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&mdash;
</TD>
<TD STYLE="WIDTH: 1%; COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 2%; COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 9%; COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&mdash;
</TD>
<TD STYLE="WIDTH: 1%; COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 2%; COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</TD>
<TD STYLE="WIDTH: 9%; COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	58,689
</TD>
<TD STYLE="WIDTH: 1%; COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255); FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; TEXT-INDENT: -11PT; PADDING-LEFT: 11PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Product
	revenues
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&mdash;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	32,850
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&mdash;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&mdash;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	32,850
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PX; TEXT-INDENT: -11PT; PADDING-LEFT: 11PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Royalty
	and license fee income
</TD>
<TD STYLE="COLOR: BLACK; PADDING-BOTTOM: 1PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; PADDING-BOTTOM: 1PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	4,408
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; PADDING-BOTTOM: 1PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; PADDING-BOTTOM: 1PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; PADDING-BOTTOM: 1PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	4,408
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255); FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PX; TEXT-INDENT: -11PT; PADDING-LEFT: 11PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Total
	revenues
</TD>
<TD STYLE="COLOR: BLACK; PADDING-BOTTOM: 1PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	58,689
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; PADDING-BOTTOM: 1PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	37,258
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; PADDING-BOTTOM: 1PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; PADDING-BOTTOM: 1PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; PADDING-BOTTOM: 1PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	95,947
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="PADDING-LEFT: 11PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; TEXT-INDENT: -11PT; PADDING-LEFT: 11PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Operating
	costs, expenses and legal settlements, net:
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255); FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; TEXT-INDENT: -11PT; PADDING-LEFT: 11PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Cost
	of clinical laboratory services
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	38,948
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&mdash;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&mdash;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&mdash;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	38,948
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; TEXT-INDENT: -11PT; PADDING-LEFT: 11PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Cost
	of product revenues
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&mdash;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	15,320
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&mdash;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&mdash;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	15,320
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255); FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; TEXT-INDENT: -11PT; PADDING-LEFT: 11PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Research
	and development
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	14
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	2,350
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	777
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&mdash;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	3,141
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; TEXT-INDENT: -11PT; PADDING-LEFT: 11PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Selling,
	general and administrative
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	20,460
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	13,374
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&mdash;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	7,967
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	41,801
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255); FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; TEXT-INDENT: -11PT; PADDING-LEFT: 11PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Provision
	for uncollectible accounts receivable
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	3,115
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	(52
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	)
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&mdash;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&mdash;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	3,063
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; TEXT-INDENT: -11PT; PADDING-LEFT: 11PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Legal
	fee expense
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	736
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	940
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&mdash;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	5,278
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	6,954
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255); FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PX; TEXT-INDENT: -11PT; PADDING-LEFT: 11PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Legal
	settlements, net
</TD>
<TD STYLE="COLOR: BLACK; PADDING-BOTTOM: 1PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	2,000
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; PADDING-BOTTOM: 1PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	(5,100
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	)
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; PADDING-BOTTOM: 1PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	(3,100
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PX; TEXT-INDENT: -11PT; PADDING-LEFT: 11PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Total
	costs, expenses and legal settlements, net
</TD>
<TD STYLE="COLOR: BLACK; PADDING-BOTTOM: 1PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	65,273
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; PADDING-BOTTOM: 1PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	26,832
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; PADDING-BOTTOM: 1PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	777
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; PADDING-BOTTOM: 1PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	13,245
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; PADDING-BOTTOM: 1PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	106,127
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="PADDING-LEFT: 11PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255); FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; TEXT-INDENT: -11PT; PADDING-LEFT: 11PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Operating
	(loss) income
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	(6,584
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	)
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	10,426
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	(777
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	)
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	(13,245
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	)
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	(10,180
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="PADDING-LEFT: 11PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; TEXT-INDENT: -11PT; PADDING-LEFT: 11PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Other
	income (expense)
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255); FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="COLOR: BLACK; TEXT-INDENT: -11PT; PADDING-LEFT: 11PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Interest
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	(43
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	)
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	9
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&mdash;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	(174
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	)
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	(208
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="COLOR: BLACK; TEXT-INDENT: -11PT; PADDING-LEFT: 11PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Other
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	56
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	95
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&mdash;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	43
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	194
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255); FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PX; TEXT-INDENT: -11PT; PADDING-LEFT: 11PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Foreign
	exchange gain
</TD>
<TD STYLE="COLOR: BLACK; PADDING-BOTTOM: 1PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; PADDING-BOTTOM: 1PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	289
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; PADDING-BOTTOM: 1PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; PADDING-BOTTOM: 1PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; PADDING-BOTTOM: 1PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	289
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="PADDING-LEFT: 11PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 3PX; TEXT-INDENT: -11PT; PADDING-LEFT: 11PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	(Loss)
	income before income taxes
</TD>
<TD STYLE="COLOR: BLACK; PADDING-BOTTOM: 3PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	(6,571
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX; COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	)
</TD>
<TD STYLE="COLOR: BLACK; PADDING-BOTTOM: 3PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	10,819
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX; COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; PADDING-BOTTOM: 3PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	(777
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX; COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	)
</TD>
<TD STYLE="COLOR: BLACK; PADDING-BOTTOM: 3PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	(13,376
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX; COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	)
</TD>
<TD STYLE="COLOR: BLACK; PADDING-BOTTOM: 3PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	(9,905
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX; COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="PADDING-LEFT: 11PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255); FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 3PX; TEXT-INDENT: -11PT; PADDING-LEFT: 11PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Depreciation
	and amortization included above
</TD>
<TD STYLE="COLOR: BLACK; PADDING-BOTTOM: 3PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	1,415
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX; COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; PADDING-BOTTOM: 3PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	2,455
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX; COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; PADDING-BOTTOM: 3PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	7
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX; COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; PADDING-BOTTOM: 3PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	94
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX; COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; PADDING-BOTTOM: 3PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	3,971
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX; COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="PADDING-LEFT: 11PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; TEXT-INDENT: -11PT; PADDING-LEFT: 11PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Share-based
	compensation included in above:
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255); FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; TEXT-INDENT: -11PT; PADDING-LEFT: 11PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Cost
	of clinical laboratory services
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	8
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	1
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&mdash;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&mdash;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	9
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; TEXT-INDENT: -11PT; PADDING-LEFT: 11PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Research
	and development
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&mdash;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	1
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&mdash;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&mdash;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	1
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255); FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PX; TEXT-INDENT: -11PT; PADDING-LEFT: 11PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Selling,
	general and administrative
</TD>
<TD STYLE="COLOR: BLACK; PADDING-BOTTOM: 1PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	36
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; PADDING-BOTTOM: 1PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	6
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; PADDING-BOTTOM: 1PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; PADDING-BOTTOM: 1PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	542
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; PADDING-BOTTOM: 1PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	584
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="COLOR: BLACK; PADDING-BOTTOM: 3PX; TEXT-INDENT: -11PT; PADDING-LEFT: 11PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Total
</TD>
<TD STYLE="COLOR: BLACK; PADDING-BOTTOM: 3PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	44
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX; COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; PADDING-BOTTOM: 3PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	8
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX; COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; PADDING-BOTTOM: 3PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX; COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; PADDING-BOTTOM: 3PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	542
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX; COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; PADDING-BOTTOM: 3PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	594
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX; COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="PADDING-LEFT: 11PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255); FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 3PX; TEXT-INDENT: -11PT; PADDING-LEFT: 11PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Capital
	expenditures
</TD>
<TD STYLE="COLOR: BLACK; PADDING-BOTTOM: 3PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	643
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX; COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; PADDING-BOTTOM: 3PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	195
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX; COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; PADDING-BOTTOM: 3PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX; COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; PADDING-BOTTOM: 3PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX; COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; PADDING-BOTTOM: 3PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	838
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX; COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_INCOME_STATEMENT>
<!-- FIELD: PAGE; SEQUENCE: 3; VALUE: 28 -->
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 6PT; PADDING-BOTTOM: 10PT; BORDER-BOTTOM: SILVER 4PX SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	30
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage96"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 10PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: LEFT; WIDTH: 100%">
<PAGE>
</PAGE>
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="MARGIN: 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	ENZO BIOCHEM, INC.
</B>
<BR>
<B>
	NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
</B>
<BR>
<B>
	July 31, 2016
</B>
</P>
<P STYLE="MARGIN: 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0; FONT: 8PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	(Dollars in thousands except
	share data)
</B>
</P>
<P STYLE="MARGIN: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<P STYLE="MARGIN: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Geographic financial information is as follows:
</P>
<P STYLE="MARGIN: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_46"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; PADDING-BOTTOM: 1PX">
	Net sales to unaffiliated customers:
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	2016
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	2015
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	2014
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255); FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="WIDTH: 52%; COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	United States
</TD>
<TD STYLE="WIDTH: 3%; COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</TD>
<TD STYLE="WIDTH: 11%; COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	94,016
</TD>
<TD STYLE="WIDTH: 1%; COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 3%; COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</TD>
<TD STYLE="WIDTH: 11%; COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	87,875
</TD>
<TD STYLE="WIDTH: 1%; COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 3%; COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</TD>
<TD STYLE="WIDTH: 11%; COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	84,389
</TD>
<TD STYLE="WIDTH: 1%; COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Switzerland
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	2,709
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	3,131
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	4,130
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255); FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	United Kingdom
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	1,730
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	1,904
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	2,023
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Other international
	countries
</TD>
<TD STYLE="COLOR: BLACK; PADDING-BOTTOM: 1PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	4,318
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; PADDING-BOTTOM: 1PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	4,689
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; PADDING-BOTTOM: 1PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	5,405
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255); FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="COLOR: BLACK; PADDING-BOTTOM: 3PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Total
</TD>
<TD STYLE="COLOR: BLACK; PADDING-BOTTOM: 3PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	102,773
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX; COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; PADDING-BOTTOM: 3PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	97,599
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX; COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; PADDING-BOTTOM: 3PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	95,947
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX; COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; PADDING-BOTTOM: 1PX">
	Long-lived assets at July 31,
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	2016
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	2015
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255); FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	United States
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	18,730
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	19,799
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Switzerland
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	917
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	1,224
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255); FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	United Kingdom
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	244
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	357
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Other international
	countries
</TD>
<TD STYLE="COLOR: BLACK; PADDING-BOTTOM: 1PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	197
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; PADDING-BOTTOM: 1PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	175
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255); FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="COLOR: BLACK; PADDING-BOTTOM: 3PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Total
</TD>
<TD STYLE="COLOR: BLACK; PADDING-BOTTOM: 3PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	20,088
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX; COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; PADDING-BOTTOM: 3PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	21,555
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX; COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<P STYLE="MARGIN: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	The Company&rsquo;s reportable segments are determined based on
	the services they perform, the products they sell, and the royalties and license fee income they earn, not on the geographic area
	in which they operate. The Company&rsquo;s Clinical Labs segment operates 100% in the United States with all revenue derived there.
	The Life Sciences segment earns product revenue both in the United States and foreign countries and royalty and license fee income
	in the United States. The following is a summary of the Life Sciences segment revenues attributable to customers located in the
	United States and foreign countries:
</P>
<P STYLE="MARGIN: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_47"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	2016
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	2015
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	2014
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255); FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="WIDTH: 52%; COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	United States
</TD>
<TD STYLE="WIDTH: 3%; COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</TD>
<TD STYLE="WIDTH: 11%; COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	23,102
</TD>
<TD STYLE="WIDTH: 1%; COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 3%; COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</TD>
<TD STYLE="WIDTH: 11%; COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	24,461
</TD>
<TD STYLE="WIDTH: 1%; COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 3%; COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</TD>
<TD STYLE="WIDTH: 11%; COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	25,700
</TD>
<TD STYLE="WIDTH: 1%; COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Foreign countries
</TD>
<TD STYLE="COLOR: BLACK; PADDING-BOTTOM: 1PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	8,756
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; PADDING-BOTTOM: 1PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	9,724
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; PADDING-BOTTOM: 1PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	11,558
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255); FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="PADDING-BOTTOM: 3PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; PADDING-BOTTOM: 3PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	31,858
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX; COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; PADDING-BOTTOM: 3PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	34,185
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX; COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; PADDING-BOTTOM: 3PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 3PX DOUBLE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	37,258
</TD>
<TD STYLE="PADDING-BOTTOM: 3PX; COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<P STYLE="MARGIN: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Note 16 - Summary of Selected Quarterly Financial Data (unaudited)
</B>
</P>
<P STYLE="MARGIN: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<P STYLE="MARGIN: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	The following table contains statement of operations information
	for each quarter of the years ended July 31, 2016 and 2015. The Company believes that the following information reflects all normal
	recurring adjustments necessary for a fair presentation of the information for the periods presented. The operating results for
	any quarter are not necessarily indicative of results for any future period.
</P>
<P STYLE="MARGIN: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<P STYLE="MARGIN: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Unaudited quarterly financial data for fiscal 2016 and 2015 is
	summarized as follows:
</P>
<P STYLE="MARGIN: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_48"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD COLSPAN="14" STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: CENTER">
	Quarter
	Ended
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; PADDING-BOTTOM: 1PX">
	Fiscal 2016
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	October
	31,
<BR>
	2015
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	January
	31,
<BR>
	2016
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	April
	30,
<BR>
	2016
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	July
	31,
<BR>
	2016
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255); FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Total revenues
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	$
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	25,177
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	$
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	24,560
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	$
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	26,433
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	$
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	26,603
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="WIDTH: 40%; COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Gross profit
</TD>
<TD STYLE="WIDTH: 3%; COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 10%; COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	11,234
</TD>
<TD STYLE="WIDTH: 1%; COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 3%; COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 10%; COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	10,819
</TD>
<TD STYLE="WIDTH: 1%; COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 3%; COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 10%; COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	11,445
</TD>
<TD STYLE="WIDTH: 1%; COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 3%; COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 10%; COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	12,085
</TD>
<TD STYLE="WIDTH: 1%; COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255); FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Income (loss) before income taxes
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	4,521
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	7,039
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	(2,113
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	)
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	37,068
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Net income (loss)
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	4,434
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	6,832
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	(2,115
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	)
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	36,135
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255); FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Basic income (loss) per common share
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	0.10
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	0.15
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	(0.05
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	)
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	0.78
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Diluted income (loss) per common share
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	0.10
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	0.15
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	(0.05
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	)
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	0.77
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD COLSPAN="14" STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: CENTER">
	Quarter
	Ended
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; PADDING-BOTTOM: 1PX">
	Fiscal 2015
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	October
	31,
<BR>
	2014
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	January
	31,
<BR>
	2015
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	April
	30,
<BR>
	2015
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	July
	31,
<BR>
	2015
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX; FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255); FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Total revenues
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	$
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	24,824
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	$
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	23,092
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	$
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	23,986
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	$
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; TEXT-ALIGN: RIGHT">
	25,697
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="WIDTH: 40%; COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Gross profit
</TD>
<TD STYLE="WIDTH: 3%; COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 10%; COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	10,999
</TD>
<TD STYLE="WIDTH: 1%; COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 3%; COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 10%; COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	10,028
</TD>
<TD STYLE="WIDTH: 1%; COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 3%; COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 10%; COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	10,483
</TD>
<TD STYLE="WIDTH: 1%; COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 3%; COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 10%; COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	11,317
</TD>
<TD STYLE="WIDTH: 1%; COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255); FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	(Loss) income before income taxes
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	(3,606
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	)
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	(4,206
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	)
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	(3,003
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	)
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	8,523
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Net (loss) income
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	(3,729
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	)
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	(4,091
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	)
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	(2,907
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	)
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	8,442
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(229,255,255); FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Basic and diluted (loss) income per common
	share
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	(0.08
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	)
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	(0.09
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	)
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	(0.06
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	)
</TD>
<TD STYLE="COLOR: BLACK; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	0.18
</TD>
<TD STYLE="COLOR: BLACK; TEXT-ALIGN: LEFT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<!-- FIELD: PAGE; SEQUENCE: 4; VALUE: 28 -->
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 6PT; PADDING-BOTTOM: 10PT; BORDER-BOTTOM: SILVER 4PX SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	31
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
</EFX_NOTES_TO_FINANCIAL_STATEMENT>
<A NAME="eolPage97"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 10PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: LEFT; WIDTH: 100%">
<PAGE>
</PAGE>
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<EFX_VALUATION_AND_QUALIFYING_ACCOUNTS>
<A NAME="FIS_VALUATION_AND_QUALIFYING_ACCOUNTS"></A>
<P STYLE="MARGIN: 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	ENZO BIOCHEM, INC
</B>
<BR>
<B>
	SCHEDULE II
</B>
<BR>
<A NAME="C86264_10K_HTM_X2_C86264A033">
</A>
<B>
	VALUATION AND QUALIFYING ACCOUNTS
</B>
<BR>
<A NAME="C86264_10K_HTM_X2_C86264B009">
</A>
<B>
	Years ended July 31, 2016, 2015 and 2014
</B>
<BR>
<B>
	(in thousands)
</B>
</P>
<P STYLE="MARGIN: 0; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD NOWRAP STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<B>
	Year ended
</B>
<BR>
<B>
	July 31,
</B>
</TD>
<TD NOWRAP STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="COLOR: BLACK">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD NOWRAP STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="COLOR: BLACK">
<B>
	Description
</B>
</FONT>
</TD>
<TD NOWRAP STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	&nbsp;
</B>
</TD>
<TD NOWRAP COLSPAN="2" STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<B>
	Balance at
</B>
<BR>
<B>
	Beginning
</B>
<BR>
<B>
	of period
</B>
</TD>
<TD NOWRAP STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	&nbsp;
</B>
</TD>
<TD NOWRAP STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	&nbsp;
</B>
</TD>
<TD NOWRAP COLSPAN="2" STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<BR>
<B>
	Charged
</B>
<BR>
<B>
	&nbsp;(credited) to costs
</B>
<BR>
<B>
	and expenses
</B>
</TD>
<TD NOWRAP STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	&nbsp;
</B>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<B>
	Charged
</B>
<BR>
<B>
	to other
</B>
<BR>
<B>
	accounts
</B>
</TD>
<TD NOWRAP STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD NOWRAP COLSPAN="2" STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="COLOR: BLACK">
<B>
	Deductions
</B>
</FONT>
</TD>
<TD NOWRAP STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="COLOR: BLACK">
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD NOWRAP STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	&nbsp;
</B>
</TD>
<TD NOWRAP COLSPAN="2" STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<B>
	Balance at
</B>
<BR>
<B>
	end of period
</B>
</TD>
<TD NOWRAP STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	&nbsp;
</B>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 2%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 28%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 3%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 7%; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 2%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 9%; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 3%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 7%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 3%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 7%; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 2%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 2%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 9%; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: RGB(229,255,255)">
<TD STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="COLOR: BLACK">
	2016
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-LEFT: 8.65PT; TEXT-INDENT: -8.65PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="COLOR: BLACK">
	Allowance for doubtful
	accounts receivable
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="COLOR: BLACK">
	1,786
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="COLOR: BLACK">
	2,336
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="COLOR: BLACK">
	605
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="COLOR: BLACK">
	(1)
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="COLOR: BLACK">
	3,517
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: WHITE">
<TD STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="COLOR: BLACK">
	2015
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-LEFT: 8.65PT; TEXT-INDENT: -8.65PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="COLOR: BLACK">
	Allowance for doubtful
	accounts receivable
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="COLOR: BLACK">
	2,142
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="COLOR: BLACK">
	2,284
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="COLOR: BLACK">
	2,640
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="COLOR: BLACK">
	(1)
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="COLOR: BLACK">
	1,786
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: RGB(229,255,255)">
<TD STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="COLOR: BLACK">
	2014
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-LEFT: 8.65PT; TEXT-INDENT: -8.65PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="COLOR: BLACK">
	Allowance for doubtful
	accounts receivable
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="COLOR: BLACK">
	2,707
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="COLOR: BLACK">
	3,063
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="COLOR: BLACK">
	3,628
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="COLOR: BLACK">
	(1)
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="COLOR: BLACK">
	2,142
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: WHITE">
<TD STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="COLOR: BLACK">
	2016
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="COLOR: BLACK">
	Deferred tax valuation allowance
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="COLOR: BLACK; BACKGROUND-COLOR: WHITE">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="COLOR: BLACK; BACKGROUND-COLOR: WHITE">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="COLOR: BLACK">
	49,658
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="COLOR: BLACK; BACKGROUND-COLOR: WHITE">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="COLOR: BLACK">
	(14,746
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="COLOR: BLACK">
	)
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="BACKGROUND-COLOR: WHITE">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="BACKGROUND-COLOR: WHITE">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="BACKGROUND-COLOR: WHITE">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="BACKGROUND-COLOR: WHITE">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="COLOR: BLACK; BACKGROUND-COLOR: WHITE">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="COLOR: BLACK; BACKGROUND-COLOR: WHITE">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="COLOR: BLACK">
	34,912
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: RGB(229,255,255)">
<TD STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="COLOR: BLACK">
	2015
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="COLOR: BLACK">
	Deferred tax valuation allowance
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="COLOR: BLACK">
	49,465
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="COLOR: BLACK">
	193
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT>
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT>
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT>
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT>
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="COLOR: BLACK">
	49,658
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
</TR>
<TR STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: WHITE">
<TD STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="COLOR: BLACK">
	2014
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="COLOR: BLACK">
	Deferred tax valuation allowance
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="COLOR: BLACK">
	47,623
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="COLOR: BLACK">
	1,842
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="COLOR: BLACK">
	49,465
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="COLOR: BLACK">
	&nbsp;
</FONT>
</TD>
</TR>
</TABLE>
</EFX_VALUATION_AND_QUALIFYING_ACCOUNTS>
<P STYLE="MARGIN: 0; TEXT-ALIGN: CENTER; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: TOP; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="WIDTH: 4%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="COLOR: BLACK">
	(1)
</FONT>
</TD>
<TD STYLE="WIDTH: 96%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="COLOR: BLACK">
	Write-off of uncollectible accounts receivable.
</FONT>
</TD>
</TR>
</TABLE>
<!-- FIELD: PAGE; SEQUENCE: 5; OPTIONS: NEWSECTION; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 10PT; MARGIN-BOTTOM: 6PT; PADDING-BOTTOM: 12PT; BORDER-BOTTOM: SILVER 4PX SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	S-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	1
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
</EFX_FORM>

<DIV CLASS="eolNewPage"></DIV>
<A NAME="eolPage98"></A>
<A NAME="C86264_EX10-U_HTM"></A>
<EFX_EXHIBIT_10>
<A NAME="FIS_EXHIBIT_10"></A>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-STYLE: NORMAL">
<B>
<U>
	SETTLEMENT
	AND LICENSE AGREEMENT
</U>
</B>
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 18PT">
	This
	SETTLEMENT AND LICENSE AGREEMENT (this &ldquo;
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-WEIGHT: NORMAL">
<U>
	Agreement
</U>
</FONT>
	&rdquo;)
	is made and entered into as of the date of the last signature required by this Agreement (the &ldquo;
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-WEIGHT: NORMAL">
<U>
	Effective
	Date
</U>
</FONT>
	&rdquo;) by and between
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Enzo Life Sciences, Inc.,
</B>
</FONT>
	a
	corporation organized and existing under the laws of the State of New York, having offices at 10 Executive Boulevard, Farmingdale,
	NY 11735 (&ldquo;
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-WEIGHT: NORMAL">
<U>
	Enzo
</U>
</FONT>
	&rdquo;) and
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Illumina,
	Inc.,
</B>
</FONT>
	a corporation organized and existing under the laws of the State of Delaware, having offices at 5200 Illumina
	Way, San Diego, CA 92122 (&ldquo;
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-WEIGHT: NORMAL">
<U>
	Illumina
</U>
</FONT>
	&rdquo;).
	Enzo and Illumina are individually referred to herein as a &ldquo;
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-WEIGHT: NORMAL">
<U>
	Party
</U>
</FONT>
	,&rdquo;
	and collectively as the &ldquo;
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-WEIGHT: NORMAL">
<U>
	Parties
</U>
</FONT>
	.&rdquo;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 18PT">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	WITNESSETH
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	WHEREAS, Enzo has alleged that Illumina
	infringes U.S. Patent No. 7,064,197 (&ldquo;
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-WEIGHT: NORMAL">
<U>
	the
	&lsquo;197 Patent
</U>
</FONT>
	&rdquo;) in an action styled
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-WEIGHT: NORMAL">
<I>
	Enzo
	Life Sciences, Inc.
</I>
</FONT>
<I>
	v.
</I>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-WEIGHT: NORMAL">
<I>
	Illumina,
	Inc.,
</I>
</FONT>
	No. 1:12-cv-435-LPS, pending in the United States District Court for the District of Delaware (the &ldquo;
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-WEIGHT: NORMAL">
<U>
	Litigation
</U>
</FONT>
	&rdquo;);
	and
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	WHEREAS,
	Enzo represents and warrants that it is the owner of, with all substantive rights in and to, the Licensed Enzo Patent Rights (as
	defined below) and has the exclusive right to license, collect royalties, collect past, present, or future damages, and to enforce
	with legal standing, the Licensed Enzo Patent Rights; and
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	WHEREAS,
	Illumina denies all liability in the Litigation; and
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	WHEREAS,
	Illumina has alleged that it does not infringe the &lsquo;197 Patent, and further, that the &lsquo;197 Patent is invalid and unenforceable;
	and
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	WHEREAS,
	Enzo disputes Illumina&rsquo;s allegations of invalidity, unenforceability, and non-infringement; and
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	WHEREAS,
	without admitting infringement or liability and in part to avoid the necessity, expense, inconvenience, and uncertainty of additional
	or continued litigation, the Parties now desire to settle the Litigation and to provide and receive certain releases, licenses
	and covenants not to sue, all on the terms and conditions set forth herein; and
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	WHEREAS,
	this Agreement reflects a settlement and compromise between the Parties under Federal Rule of Evidence 408 with respect to Enzo&rsquo;s
	claims and Illumina&rsquo;s defenses in the Litigation, including without limitation on the disputed issues of patent validity,
	enforceability, and infringement;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	NOW, THEREFORE,
	in consideration of the above recitals and the mutual covenants hereinafter contained and other good and valuable consideration
	the receipt and sufficiency of which are hereby acknowledged, the Parties agree as follows:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD NOWRAP STYLE="WIDTH: 15%; BORDER: BLACK 1PX SOLID; PADDING: 5PT">
<P STYLE="FONT: 8PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	REVIEWED
	BY LEGAL
</P>
<P STYLE="FONT: 8PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	Initials:
<U>
	RHS
</U>
</P>
<P STYLE="FONT: 8PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	Date:
<U>
	6/29/16
</U>
</P>
<P STYLE="FONT: 8PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT">
	ILLUMINA
</P>
</TD>
<TD STYLE="WIDTH: 85%">
	&nbsp;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 50%; TEXT-ALIGN: RIGHT">
	1
</TD>
<TD STYLE="WIDTH: 50%; TEXT-ALIGN: RIGHT">
	SUBJECT TO FRE 408
</TD>
</TR>
</TABLE>
<!-- FIELD: PAGE; SEQUENCE: 1 -->
<DIV STYLE="MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: SILVER 4PX SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage99"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 10PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: LEFT; WIDTH: 100%">
<PAGE>
</PAGE>
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: ITALIC 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-STYLE: NORMAL">
<B>
<U>
	SECTION
	1: DEFINITIONS
</U>
</B>
</FONT>
</P>
<P STYLE="FONT: ITALIC 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	As used
	in this Agreement, the following terms shall have the following meanings:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&ldquo;
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-WEIGHT: NORMAL">
<U>
	Affiliate
</U>
</FONT>
	&rdquo;
	means, with respect to a Party and subject to Sections 2.1 and 2.7, any Person that, on or after the Effective Date, is directly
	or indirectly controlling, controlled by, or under common control with, such Party. For purposes of this Agreement, &ldquo;
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-WEIGHT: NORMAL">
<U>
	control
</U>
</FONT>
	&rdquo;
	means the ability to control the direction of the management and operations of the subject Person, whether through ownership, contract
	or otherwise. Control will be presumed where a Party has direct or indirect ownership of (or the contractual right to direct the
	voting of) 50% or more of the voting shares, equity or other interests of the Person. Notwithstanding anything to the contrary
	herein, the following Persons are not, and cannot be considered, Affiliates of Illumina for the purposes of this Agreement so long
	as any patent infringement litigation or royalty obligation existing as of the Effective Date concerning the Licensed Enzo Patent
	Rights remains pending between Enzo and that Person (or any Affiliate of that Person): Abbott Laboratories; Abbott Molecular, Inc.;
	Becton, Dickinson and Company; Becton, Dickinson Diagnostics, Inc.; Geneohm Sciences, Inc. (now part of Becton Dickinson); Gen-Probe,
	Inc. (now part of Hologic, Inc.); Hologic, Inc.; Roche Molecular Systems, Inc. (part of Hoffmann-La Roche AG); Roche Diagnostics
	Corporation (part of Hoffmann-La Roche AG); Roche Diagnostics Operations Inc. (part of Hoffmann-La Roche AG); and Roche Nimblegen,
	Inc. (part of Hoffmann-La Roche AG); or any Third Party that is directly or indirectly controlling, controlled by, or under common
	control with any of the foregoing Persons.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&ldquo;
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-WEIGHT: NORMAL">
<U>
	AmpiProbe
	Technology
</U>
</FONT>
	&rdquo; means nucleic acid amplification detection assays, such as quantitative polymerase chain reaction
	(qPCR) assays marketed and sold by Enzo under the tradename AmpiProbe, and nucleic acid probes used therein, in which a first
	amplification primer includes a first label/dye/moiety that interacts via FRET (F&ouml;rster/fluorescence resonance energy transfer)
	with a second label/dye/moiety attached to a second amplification primer, or to nucleic acid monomers, upon formation of a nucleic
	acid amplification product incorporating the first primer and the second primer, or the first primer and the labeled nucleic acid
	monomers.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&ldquo;
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-WEIGHT: NORMAL">
<U>
	Cellular
	Analysis Technology
</U>
</FONT>
	&rdquo; means cell flow cytometry assays, cell microscopy assays and cell-on-microplate assays that
	utilize nucleic acid hybridization probes. For the avoidance of doubt, Cellular Analysis Technology does not involve sequencing
	of nucleic acids.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&ldquo;
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-WEIGHT: NORMAL">
<U>
	Claims
</U>
</FONT>
	&rdquo;
	means all claims, counterclaims, counter-counterclaims, actions, causes of action, suits, demands, judgments, debts, expenses (including
	attorneys&rsquo; fees and costs), losses, liabilities, and obligations of any kind and of whatever nature or character, worldwide,
	whether known or unknown, asserted or unasserted, suspected or unsuspected, matured or unmatured, or whether accrued, actual, contingent,
	latent or otherwise, made, asserted, or brought for any purpose, including without limitation for the purpose of recovering any
	damages or for the purpose of obtaining equitable relief or any other relief or remedy of any kind.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&ldquo;
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-WEIGHT: NORMAL">
<U>
	Covered
	Third Party Products
</U>
</FONT>
	&rdquo; means (i) any Third Party products and services, product lines, devices, systems, assays,
	components, subassemblies, kits, hardware, software, or any combination of the foregoing provided to Illumina or its Affiliates
	for the benefit of Illumina or
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD NOWRAP STYLE="WIDTH: 15%; BORDER: BLACK 1PX SOLID; PADDING: 5PT">
<P STYLE="FONT: 8PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	REVIEWED
	BY LEGAL
</P>
<P STYLE="FONT: 8PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	Initials:
<U>
	RHS
</U>
</P>
<P STYLE="FONT: 8PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	Date:
<U>
	6/29/16
</U>
</P>
<P STYLE="FONT: 8PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT">
	ILLUMINA
</P>
</TD>
<TD STYLE="WIDTH: 85%">
	&nbsp;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 50%; TEXT-ALIGN: RIGHT">
	2
</TD>
<TD STYLE="WIDTH: 50%; TEXT-ALIGN: RIGHT">
	SUBJECT TO FRE 408
</TD>
</TR>
</TABLE>
<!-- FIELD: PAGE; SEQUENCE: 2 -->
<DIV STYLE="MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: SILVER 4PX SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage100"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 10PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: LEFT; WIDTH: 100%">
<PAGE>
</PAGE>
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	its Affiliates
	and constituting a component or element of, or that are used in combination with, any Illumina Product, but only to the extent
	of such use as incorporated into such Illumina Product, or (ii) any Third Party products and services that include as a component
	or element thereof any Illumina Product, but only to the extent that such Third Party products and services include as a component
	or element thereof such Illumina Product.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&ldquo;
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-WEIGHT: NORMAL">
<U>
	Illumina
	Products
</U>
</FONT>
	&rdquo; means any past, current and future products and services, product lines, devices, systems, assays, components,
	subassemblies, kits, hardware, software, or any combination of the foregoing which are made, used, sold, offered for sale, distributed,
	imported, or otherwise commercialized by or for Illumina or its Affiliates, and Natural Evolutions thereof, that, but for the license
	granted in this Agreement, infringe (actually or allegedly) a Valid Claim of the Licensed Enzo Patent Rights. For the avoidance
	of doubt, all accused products, manufactured articles, services, processes, systems, or methods that are the subject of the Litigation
	are included in and constitute Illumina Products.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&ldquo;
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-WEIGHT: NORMAL">
<U>
	Licensed
	Enzo Patent Rights
</U>
</FONT>
	&rdquo; means (i) the &lsquo;197 Patent; (ii) any patents and patent applications
	claiming priority to or through, or sharing a common priority claim with the &lsquo;197 Patent; and (iii) any foreign
	counterparts, re-issues, re-examinations, renewals, substitutes, claim amendments made in post-grant proceedings including
	IPR and PGR proceedings, extensions, continuations, continuations-in-part, continuing prosecution applications, divisionals,
	and national phase filings of any patents and patent applications covered in subparts (i) and (ii), whether any of the
	foregoing are filed before, on or after the Effective Date, in all countries of the world.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&ldquo;
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-WEIGHT: NORMAL">
<U>
	Liquid
	Phase Nucleic Acid Amplification Detection Technology
</U>
</FONT>
	&rdquo; means (i) AmpiProbe Technology and (ii) assays that directly
	compete (now or in the future) therewith (such as, without limitation, TaqMan, Molecular Beacons, Invader, RealTime PCR, Hybridization
	Protection Assay (HPA), or Scorpion technologies), where detection of the targets or analytes of interest occurs in liquid phase
	(e.g., where the analyte or target is not attached to or otherwise associated with a solid support). For the avoidance of doubt,
	Liquid Phase Nucleic Acid Amplification Detection Technologies do not include sample preparation or library preparation components,
	products or services that do not involve liquid phase detection of nucleic acid amplification.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&ldquo;
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-WEIGHT: NORMAL">
<U>
	Natural
	Evolutions
</U>
</FONT>
	&rdquo; means modifications, revisions, additions, enhancements, updates, upgrades, changes or similar alterations
	to an original product or service, in which the original product or service retains its essential character or remains identifiable.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&ldquo;
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-WEIGHT: NORMAL">
<U>
	NIPT
</U>
</FONT>
	&rdquo;
	means in vitro cell-free nucleic acid-based non-invasive prenatal testing (including, without limitation, testing by massively
	parallel sequencing or digital PCR) of a biological sample (including but not limited to plasma, serum, whole blood, and urine)
	obtained from a pregnant woman.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&ldquo;
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-WEIGHT: NORMAL">
<U>
	Person
</U>
</FONT>
	&rdquo;
	means an individual, trust, corporation, partnership, joint venture, limited liability company, association, unincorporated organization,
	or other legal entity.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD NOWRAP STYLE="WIDTH: 15%; BORDER: BLACK 1PX SOLID; PADDING: 5PT">
<P STYLE="FONT: 8PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	REVIEWED
	BY LEGAL
</P>
<P STYLE="FONT: 8PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	Initials:
<U>
	RHS
</U>
</P>
<P STYLE="FONT: 8PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	Date:
<U>
	6/29/16
</U>
</P>
<P STYLE="FONT: 8PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT">
	ILLUMINA
</P>
</TD>
<TD STYLE="WIDTH: 85%">
	&nbsp;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 50%; TEXT-ALIGN: RIGHT">
	3
</TD>
<TD STYLE="WIDTH: 50%; TEXT-ALIGN: RIGHT">
	SUBJECT TO FRE 408
</TD>
</TR>
</TABLE>
<!-- FIELD: PAGE; SEQUENCE: 4 -->
<DIV STYLE="MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: SILVER 4PX SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage101"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 10PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: LEFT; WIDTH: 100%">
<PAGE>
</PAGE>
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&ldquo;
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-WEIGHT: NORMAL">
<U>
	Related
	Persons
</U>
</FONT>
	&rdquo; means, with respect to any Person, collectively, (a) all directors, officers, managers and employees
	of such Person (to the extent acting in in such capacity); (b) all representatives, agents, attorneys and insurers of such Person
	(to the extent acting in such capacity); (c) with respect to Illumina or its Affiliates only, (i) all Persons engaged in the design,
	manufacture or supply of parts or components for Illumina Products on behalf of Illumina or its Affiliates (to the extent acting
	in such capacity), and (ii) all direct or indirect customers, users, dealers, distributors and other purchasers of Illumina Products
	from Illumina or its Affiliates (to the extent acting in such capacity); and (d) all predecessors-in-interest of such Person (in
	such capacity).
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&ldquo;
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-WEIGHT: NORMAL">
<U>
	Third
	Party
</U>
</FONT>
	&rdquo; means any Person or entity other than the Parties to this Agreement and their Affiliates.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&ldquo;
<U>
	Valid Claim
</U>
	&rdquo; means
	a claim of an issued patent that has not expired or been finally held invalid or unenforceable by a court or administrative body
	of competent jurisdiction from which no appeal can be or is taken.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-STYLE: NORMAL">
<B>
<U>
	SECTION
	2: LICENSE, RELEASES, AND COVENANTS
</U>
</B>
</FONT>
</P>
<P STYLE="FONT: ITALIC 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	2.1
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-WEIGHT: NORMAL">
<U>
	License
</U>
</FONT>
	.
	Subject to Illumina&rsquo;s timely payment of the Payment under Section 3.1, Enzo hereby grants (and agrees to grant) to Illumina
	and its Affiliates a perpetual, irrevocable, fully paid-up, non-exclusive, non-transferable (except as set forth in Section 5),
	worldwide license under the Licensed Enzo Patent Rights to, directly or indirectly, make, have made, use, import, export, market,
	distribute, sell, offer for sale, and otherwise commercialize the Illumina Products and Covered Third Party Products. For the avoidance
	of doubt, payment of the Payment will satisfy any and all past, present, and future obligations potentially owing to Enzo based
	upon or arising in connection with commercialization of any Illumina Products or other potential infringement (direct, induced,
	indirect, contributory, or otherwise) of the Licensed Enzo Patent Rights by or for Illumina and its Affiliates, and no additional
	payments will be owed to Enzo or its Affiliates in connection with the license granted in this Section 2.1.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Illumina
	and its Affiliates shall not have the right to sublicense or otherwise grant, in whole or in part, sublicenses under the Licensed
	Enzo Patent Rights. The license granted herein shall not extend to cover any products of a Third Party that acquires or is acquired
	by Illumina or its Affiliates on or after the Effective Date (whether by merger, consolidation, share acquisition, or acquisition
	of all or substantially all assets or otherwise), including without limitation products made, used, imported, exported, distributed,
	sold, offered for sale, developed, advertised, and practiced by such Third Party before the date of such acquisition. The license
	granted herein shall not include any rights to the Licensed Enzo Patent Rights other than those expressly provided by this section.
	No license or immunity is granted under this Agreement by Enzo, either directly or by implication, estoppel, or otherwise, to any
	Person acquiring Illumina Products for the modification or combination by such Person of Illumina Products with other items other
	than in the ordinary manner in the ordinary course of use of Illumina Products, or as specified in Sections 2.2 and 2.3, or as
	otherwise permitted by the law of patent exhaustion.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	2.2
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-WEIGHT: NORMAL">
<U>
	Enzo
	Release of Illumina
</U>
</FONT>
	. Subject to the terms and conditions hereof, including Illumina&rsquo;s timely payment of the Payment
	under Section 3.1, Enzo, on behalf of itself, its Affiliates, and
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD NOWRAP STYLE="WIDTH: 15%; BORDER: BLACK 1PX SOLID; PADDING: 5PT">
<P STYLE="FONT: 8PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	REVIEWED
	BY LEGAL
</P>
<P STYLE="FONT: 8PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	Initials:
<U>
	RHS
</U>
</P>
<P STYLE="FONT: 8PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	Date:
<U>
	6/29/16
</U>
</P>
<P STYLE="FONT: 8PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT">
	ILLUMINA
</P>
</TD>
<TD STYLE="WIDTH: 85%">
	&nbsp;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 50%; TEXT-ALIGN: RIGHT">
	4
</TD>
<TD STYLE="WIDTH: 50%; TEXT-ALIGN: RIGHT">
	SUBJECT TO FRE 408
</TD>
</TR>
</TABLE>
<!-- FIELD: PAGE; SEQUENCE: 5 -->
<DIV STYLE="MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: SILVER 4PX SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage102"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 10PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: LEFT; WIDTH: 100%">
<PAGE>
</PAGE>
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	their respective
	legal successors and assigns (collectively, &ldquo;
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-WEIGHT: NORMAL">
<U>
	Enzo
	Releasing Parties
</U>
</FONT>
	&rdquo;) hereby releases, acquits and absolutely and forever discharges Illumina and its Affiliates
	(collectively, &ldquo;
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-WEIGHT: NORMAL">
<U>
	Illumina Released Persons
</U>
</FONT>
	&rdquo;)
	of and from any and all Claims, whether now known or unknown, related to the alleged infringement of the Licensed Enzo Patent Rights.
	The Enzo Releasing Parties also release the Illumina Released Persons from any Claim related to the Litigation or the conduct of
	settlement negotiations for the Litigation (except for representations or obligations expressly included in this Agreement). The
	Enzo Releasing Parties further provide a limited release to Illumina&rsquo;s Related Persons for any Claim, based on conduct occurring
	up to the Effective Date, for infringement of the Licensed Enzo Patent Rights by Illumina Products or Covered Third Party Products.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	The scope
	of this release is fixed as of the Effective Date. Except as expressly set forth herein, this release shall not apply to any Person,
	including without limitation any Third Party, or any pre-acquisition business, assets, or products thereof, acquired by Illumina
	or its Affiliates (whether by merger, consolidation, share acquisition, or acquisition of all or substantially all assets or otherwise)
	after the Effective Date.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	2.3
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-WEIGHT: NORMAL">
<U>
	Limited
	Enzo Covenant Not To Sue On Covered Third Party Products
</U>
</FONT>
	. Subject to the terms and conditions hereof, including Illumina&rsquo;s
	timely payment of the Payment under Section 3.1, Enzo, on behalf of itself and its Affiliates, covenants during the term of this
	Agreement not to sue Illumina&rsquo;s Related Persons for (i) infringement of the Licensed Enzo Patent Rights by an Illumina Product,
	or (ii) infringement of the Licensed Enzo Patent Rights by a Covered Third Party Product. This covenant not to sue is non-assignable
	by Illumina, its Affiliates or any of their respective Related Persons who benefit from this covenant not to sue.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	2.4
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-WEIGHT: NORMAL">
<U>
	Illumina
	Release of Enzo
</U>
</FONT>
	. Subject to the terms and conditions hereof, Illumina, on behalf of itself, its Affiliates, and their
	respective legal successors and assigns (collectively, &ldquo;
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-WEIGHT: NORMAL">
<U>
	Illumina
	Releasing Parties
</U>
</FONT>
	&rdquo;) hereby releases, acquits and absolutely and forever discharges Enzo and its Affiliates (collectively,
	&ldquo;
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-WEIGHT: NORMAL">
<U>
	Enzo Released Persons
</U>
</FONT>
	&rdquo;)
	of and from any and all Claims, whether now known or unknown, related to the Licensed Enzo Patent Rights to the extent occurring
	before the Effective Date. The Illumina Releasing Parties also release the Enzo Released Persons from any Claim related to the
	Litigation or the conduct of settlement negotiations for the Litigation (except for representations or obligations expressly included
	in this Agreement).
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	2.5
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-WEIGHT: NORMAL">
<U>
	Covenant
	Not to Challenge
</U>
</FONT>
	. After the Effective Date and for so long as Illumina&rsquo;s license is in force, Illumina further
	covenants on behalf of itself and its Affiliates that, except as (i) required by law or (ii) in defense of an action for infringing
	the Licensed Enzo Patent Rights brought against Illumina, its Affiliates or their respective Related Persons (direct or indirect)
	involving any Illumina Products or Covered Third Party Products, neither Illumina nor its Affiliates shall knowingly and voluntarily
	contest (or assist in the contest) in any forum, including Federal Courts, whether under 28 U.S.C. &sect;&sect; 2201-2202 or not,
	the United States Patent and Trademark Office, and/or the International Trade Commission, that the Licensed Enzo Patent Rights
	are valid and enforceable; provided, however, nothing in this Agreement shall prevent Illumina or its Affiliates from complying
	with or responding to any court or governmental order or subpoena relating to the Licensed Enzo Patent Rights. Notwithstanding
	the foregoing, nothing in this Agreement will preclude Illumina and its Affiliates from making
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD NOWRAP STYLE="WIDTH: 15%; BORDER: BLACK 1PX SOLID; PADDING: 5PT">
<P STYLE="FONT: 8PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	REVIEWED
	BY LEGAL
</P>
<P STYLE="FONT: 8PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	Initials:
<U>
	RHS
</U>
</P>
<P STYLE="FONT: 8PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	Date:
<U>
	6/29/16
</U>
</P>
<P STYLE="FONT: 8PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT">
	ILLUMINA
</P>
</TD>
<TD STYLE="WIDTH: 85%">
	&nbsp;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 50%; TEXT-ALIGN: RIGHT">
	5
</TD>
<TD STYLE="WIDTH: 50%; TEXT-ALIGN: RIGHT">
	SUBJECT TO FRE 408
</TD>
</TR>
</TABLE>
<!-- FIELD: PAGE; SEQUENCE: 6 -->
<DIV STYLE="MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: SILVER 4PX SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage103"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 10PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: LEFT; WIDTH: 100%">
<PAGE>
</PAGE>
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	any disclosure,
	providing information or producing documents as required by law, court order or legal process (including, without limitation, litigation
	related to discovery and/or subpoena), even if made in connection with a Claim challenging the validity or enforceability of one
	or more of the Licensed Enzo Patent Rights, and any such disclosure will not be considered a breach of this Agreement. It is understood
	that Illumina&rsquo;s and its Affiliates&rsquo; providing factual statements regarding Illumina Products or any Covered Third Party
	Products in response to a validly propounded subpoena will not be considered as assisting in the context as used above. Illumina
	reserves the right to raise any and all defenses and counterclaims, including, but not limited to, invalidity and unenforceability
	of the Licensed Enzo Patent Rights, and to otherwise contest the validity and enforceability of the Licensed Enzo Patent Rights
	in any forum, that it could have raised in the Litigation, if the Licensed Enzo Patent Rights are asserted based on Illumina Products
	or Covered Third Party Products against Illumina, its Affiliates, Related Persons and partners after the Effective Date; and Enzo
	reserves the right to raise any and all claims and defenses in opposition.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	2.6
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-WEIGHT: NORMAL">
<U>
	Limited
	Standstill
</U>
</FONT>
	. Subject to the terms and conditions in this Section 2.6 and Section 2.7, for a period of four (4) years
	after the Effective Date of this Agreement or until the termination of this Agreement under Section 4.2, whichever is earlier (&ldquo;
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-WEIGHT: NORMAL">
<U>
	Standstill
	Period
</U>
</FONT>
	&rdquo;), a Party shall not (either by itself or through an Affiliate or Third Party) initiate, file, encourage,
	direct, fund or otherwise bring or participate in any claim alleging infringement (direct, indirect, induced, contributory or otherwise),
	misuse or any other violation of any patents against the other Party or its Affiliates by any Standstill Covered Products (the
	&ldquo;
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-WEIGHT: NORMAL">
<U>
	Standstill
</U>
</FONT>
	&rdquo;). &ldquo;
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-WEIGHT: NORMAL">
<U>
	Standstill
	Covered Products
</U>
</FONT>
	&rdquo; are (i) any products or services first made, used, sold, offered for sale, imported or otherwise
	commercialized by that Party or its Affiliates on or before the Effective Date, including, without limitation, with respect to
	Illumina, the Illumina Products, (ii) any products or services made or sold by such Party or its Affiliates that such Party or
	its Affiliates officially announced at an industry conference or other public forum before the Effective Date as part of such Party&rsquo;s
	or its Affiliates&rsquo; forthcoming product or service offerings, and (iii) any Natural Evolutions of a product or service covered
	by (i) or (ii).
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	In addition,
	as part of the Standstill, and subject to the terms and conditions in this Section 2.6 and Section 2.7, during the Standstill Period,
	a Party shall not (either by itself or through an Affiliate or Third Party) initiate, file, encourage, direct, fund or otherwise
	bring or participate in any claim alleging infringement of any patents against any customer (direct or indirect) of the other Party
	or its Affiliates by (i) any commercial products or commercial services first made or sold by that Party or its Affiliates on or
	before the Effective Date, or (ii) any commercial products or commercial services made or sold by that Party that such Party or
	its Affiliates officially announced at an industry conference or other public forum before the Effective Date as part of such Party&rsquo;s
	or its Affiliates&rsquo; forthcoming product or service offerings , or (iii) any Natural Evolutions of a product or service covered
	by (i) or (ii) (collectively, &ldquo;
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-WEIGHT: NORMAL">
<U>
	Customer
	Standstill Products
</U>
</FONT>
	&rdquo;). Notwithstanding anything to the contrary herein, Customer Standstill Products do not include,
	and expressly exclude, stand-alone Third Party products that infringe a Party&rsquo;s patents independent of any incorporation
	in or use with the other Party&rsquo;s commercial products or commercial services covered by (i) or (ii) above. For clarity, customers
	are protected from claims of infringement under the Standstill only with respect to such customers&rsquo; use or resale of Customer
	Standstill Products, either alone or as a component or element of such
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD NOWRAP STYLE="WIDTH: 15%; BORDER: BLACK 1PX SOLID; PADDING: 5PT">
<P STYLE="FONT: 8PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	REVIEWED
	BY LEGAL
</P>
<P STYLE="FONT: 8PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	Initials:
<U>
	RHS
</U>
</P>
<P STYLE="FONT: 8PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	Date:
<U>
	6/29/16
</U>
</P>
<P STYLE="FONT: 8PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT">
	ILLUMINA
</P>
</TD>
<TD STYLE="WIDTH: 85%">
	&nbsp;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 50%; TEXT-ALIGN: RIGHT">
	6
</TD>
<TD STYLE="WIDTH: 50%; TEXT-ALIGN: RIGHT">
	SUBJECT TO FRE 408
</TD>
</TR>
</TABLE>
<!-- FIELD: PAGE; SEQUENCE: 7 -->
<DIV STYLE="MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: SILVER 4PX SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage104"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 10PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: LEFT; WIDTH: 100%">
<PAGE>
</PAGE>
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	customer&rsquo;s
	products or services, but in the latter case only to the extent that any claim of infringement regarding such customer&rsquo;s
	products and/or services is based on the Customer Standstill Product(s) incorporated in such customer&rsquo;s products or services.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The Standstill
	shall not apply to and expressly excludes intellectual property rights that claim or cover NIPT and (i) claim priority to a patent
	or patent application that, as of the Effective Date, is owned or controlled by Illumina or any of its Affiliates that are existing
	and qualify as Affiliates as of the Effective Date or (ii) are subject to the Pooled Patents Agreement between Illumina and Sequenom,
	Inc. Notwithstanding the foregoing, in the event Illumina (either by itself or through an Affiliate) initiates, files, directs
	or otherwise brings any claim against Enzo, Enzo&rsquo;s Affiliates that are existing and qualify as Affiliates as of the Effective
	Date, or their respective customers (direct or indirect) with respect to the Standstill Covered Products, alleging infringement
	(direct, indirect, induced, contributory or otherwise), misuse or any other violation of any intellectual property rights claiming
	or covering NIPT, the Parties agree that this will end the Standstill Period with respect to intellectual property rights claiming
	or covering NIPT.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The Standstill
	shall not apply to and expressly excludes any intellectual property rights that claim or cover (i) Liquid Phase Nucleic Acid Amplification
	Detection Technologies, or (ii) Cellular Analysis Technologies. For the avoidance of doubt, all Illumina accused products, manufactured
	articles, services, processes, systems, or methods that were the subject of the Litigation, and all other products, services, systems,
	assays, components, subassemblies, kits, hardware, software, or combinations of the foregoing made or sold by Illumina or its Affiliates
	on or before the Effective Date and used in Illumina&rsquo;s sequencing or array workflows (excluding stand-alone Third Party products
	that infringe Enzo patents independent of any incorporation in or use with Customer Standstill Products), are included within the
	scope of the Standstill and, for purposes of this Agreement, are by definition not Liquid Phase Nucleic Acid Amplification Detection
	Technologies or Cellular Analysis Technologies. Notwithstanding the foregoing, in the event Enzo (either by itself or through an
	Affiliate) initiates, files, directs or otherwise brings any claim against either Illumina, Illumina&rsquo;s Affiliates that are
	existing and qualify as Affiliates as of the Effective Date with respect to the Standstill Covered Products, or their respective
	customers (direct or indirect) with respect to the Customer Standstill Products, alleging infringement (direct, indirect, induced,
	contributory or otherwise), misuse or any other violation of any intellectual property rights claiming or covering either (i) Liquid
	Phase Nucleic Acid Amplification Detection Technologies or (ii) Cellular Analysis Technologies, the Parties agree that this will
	end the Standstill Period with respect to intellectual property rights claiming or covering either (i) Liquid Phase Nucleic Acid
	Amplification Detection Technologies or (ii) Cellular Analysis Technologies.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Each Party
	hereby expressly waives and agrees to waive damages for any claims of infringement of intellectual property rights included in
	the Standstill through the expiration of the Standstill Period. Each Party shall be entitled to seek damages for any claims of
	infringement based on conduct occurring after the expiration of the Standstill Period, even if such conduct is identical in nature
	to conduct that occurred before the expiration of the Standstill Period.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	The foregoing
	provisions of this Section 2.6 are personal to the Parties and their respective Affiliates (but, as to Affiliates, only personal
	to any such Affiliates that are existing and qualify
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD NOWRAP STYLE="WIDTH: 15%; BORDER: BLACK 1PX SOLID; PADDING: 5PT">
<P STYLE="FONT: 8PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	REVIEWED
	BY LEGAL
</P>
<P STYLE="FONT: 8PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	Initials:
<U>
	RHS
</U>
</P>
<P STYLE="FONT: 8PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	Date:
<U>
	6/29/16
</U>
</P>
<P STYLE="FONT: 8PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT">
	ILLUMINA
</P>
</TD>
<TD STYLE="WIDTH: 85%">
	&nbsp;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 50%; TEXT-ALIGN: RIGHT">
	7
</TD>
<TD STYLE="WIDTH: 50%; TEXT-ALIGN: RIGHT">
	SUBJECT TO FRE 408
</TD>
</TR>
</TABLE>
<!-- FIELD: PAGE; SEQUENCE: 8 -->
<DIV STYLE="MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: SILVER 4PX SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage105"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 10PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: LEFT; WIDTH: 100%">
<PAGE>
</PAGE>
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	as Affiliates
	of a Party as of the Effective Date), are non-assignable (including through acquisition), and do not apply to any other Person.
	Further, these provisions shall not prevent either Party from engaging in discussions with the other Party or any other Person
	regarding the licensing of its patents or from enforcing its patents against any Person other than a Party, its Affiliates, and/or
	their respective customers as expressly set forth in this Section 2.6.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	If either
	Party violates this Standstill, the other Party shall be free to immediately end the Standstill Period. If a complaint for patent
	infringement based on conduct occurring after the expiration of the Standstill Period is filed after expiration of the Standstill
	Period, no Party may rely on the Standstill Period as a basis for any claim, counterclaim, or defense, including without limitation
	an assertion of laches. Notwithstanding the foregoing, a Party still may assert any claim, counterclaim, or defense available,
	including without limitation an assertion of laches, to the extent it does not specifically rely on the Standstill Period as a
	basis.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Except with
	respect to Customer Standstill Products, for purposes of this Agreement, none of the following Persons (nor their Affiliates and/or
	successors) shall be deemed subject to the Standstill set forth in this section for so long as any patent infringement litigation
	or royalty obligation existing as of the Effective Date remains pending between Enzo and that Person (or any Affiliate of that
	Person): Abbott Laboratories; Abbott Molecular, Inc.; Becton, Dickinson and Company; Becton, Dickinson Diagnostics, Inc.; Geneohm
	Sciences, Inc. (now part of Becton Dickinson); Gen-Probe, Inc. (now part of Hologic, Inc.); Hologic, Inc.; Roche Molecular Systems,
	Inc. (part of Hoffmann-La Roche AG); Roche Diagnostics Corporation (part of Hoffmann-La Roche AG); Roche Diagnostics Operations
	Inc. (part of Hoffmann-La Roche AG); and Roche Nimblegen, Inc. (part of Hoffmann-La Roche AG); or any Third Party that is directly
	or indirectly controlling, controlled by, or under common control with any of the foregoing Person.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	2.7
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-WEIGHT: NORMAL">
<U>
	Acquisitions
</U>
</FONT>
	.
	Notwithstanding anything to the contrary above, the licenses, releases, covenants, and Standstill set forth above shall exclude
	any pre-acquisition products (and Natural Evolutions thereof following the date of the acquisition) of another Person that acquires
	or is acquired by (whether by merger, consolidation, share acquisition, acquisition of all or substantially all assets or otherwise)
	a Party (or any other Person that is directly or indirectly controlling, controlled by, or under common control with such Party)
	on or after the Effective Date. The Standstill set forth above shall not apply to any action or lawsuit in which the acquired Person
	is a party and that is pending as of the date of the public announcement of the acquisition of the acquired Person.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	2.8
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-WEIGHT: NORMAL">
<U>
	Modifications
	and Combinations In Manner Other Than Ordinary Course
</U>
</FONT>
	. No license or immunity is granted under this Agreement by Enzo,
	either directly or by implication, estoppel, or otherwise, to any Person acquiring Illumina Products for the modification or combination
	by such Person of Illumina Products with other items other than (i) in the ordinary and intended manner in the ordinary course
	of use of Illumina Products, (ii) as specified by Sections 2.2 and 2.3, or (iii) as otherwise permitted by the law of patent exhaustion.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	2.9
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-WEIGHT: NORMAL">
<U>
	No
	Extinguishment Of Other Outstanding Royalty Obligations
</U>
</FONT>
	. For the avoidance of doubt, nothing in this Agreement shall
	operate to extinguish the obligation of any Person to pay
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD NOWRAP STYLE="WIDTH: 15%; BORDER: BLACK 1PX SOLID; PADDING: 5PT">
<P STYLE="FONT: 8PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	REVIEWED
	BY LEGAL
</P>
<P STYLE="FONT: 8PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	Initials:
<U>
	RHS
</U>
</P>
<P STYLE="FONT: 8PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	Date:
<U>
	6/29/16
</U>
</P>
<P STYLE="FONT: 8PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT">
	ILLUMINA
</P>
</TD>
<TD STYLE="WIDTH: 85%">
	&nbsp;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 50%; TEXT-ALIGN: RIGHT">
	8
</TD>
<TD STYLE="WIDTH: 50%; TEXT-ALIGN: RIGHT">
	SUBJECT TO FRE 408
</TD>
</TR>
</TABLE>
<!-- FIELD: PAGE; SEQUENCE: 9 -->
<DIV STYLE="MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: SILVER 4PX SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage106"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 10PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: LEFT; WIDTH: 100%">
<PAGE>
</PAGE>
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	royalties
	to Enzo or Illumina arising from an obligation outside of this Agreement (including via contract, operation of law, judicial ruling,
	or otherwise).
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	2.10
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-WEIGHT: NORMAL">
<U>
	No
	Other Rights
</U>
</FONT>
	. No rights or covenants are granted under any patents except as expressly provided herein, whether by implication,
	estoppel or otherwise. Except as expressly provided herein, no right to grant covenants, rights, sublicenses, or to become a foundry
	for Third Parties is granted under this Agreement. The Parties agree that, except as expressly set forth herein for Covered Third
	Party Products and Customer Standstill Products, the licenses, releases and covenants set forth in this Agreement (including Section
	2) expressly exclude any methods, systems, products, services and/or components of any Third Party. The Parties further agree that,
	except as expressly provided herein for Covered Third Party Products and Customer Standstill Products, this Agreement does not
	cut off Enzo&rsquo;s rights to enjoin, control or extract royalties with respect to such Third Party&rsquo;s methods, systems,
	products, services and/or components.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-STYLE: NORMAL">
<B>
<U>
	SECTION
	3: MONETARY CONSIDERATION
</U>
</B>
</FONT>
</P>
<P STYLE="FONT: ITALIC 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	3.1
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-WEIGHT: NORMAL">
<U>
	Payment
</U>
</FONT>
	.
	As partial consideration and total compensation for the release, license, covenant and Limited Standstill under this Agreement
	and the dismissal by Enzo of the Litigation hereunder, Illumina agrees to pay to Enzo a one-time total payment of twenty-one million
	U.S. Dollars ($21,000,000.00) (&ldquo;
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-WEIGHT: NORMAL">
<U>
	Payment
</U>
</FONT>
	&rdquo;),
	payable by Illumina to Enzo no later than seven (7) business days following the Effective Date of this Agreement in lawful money
	of the United States, in immediately available funds, by wire transfer to the following account:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Bank: Citibank,
	N.A.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Bank Address:
	666 5
<SUP>
	th
</SUP>
	Avenue, New York, NY 10103
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Routing
	No.: 021000089
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Int&rsquo;l
	Wires: (Swift) CITIUS33
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Account
	Name: Desmarais LLP IOLA
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Account
	No.: 9981486845
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	3.2
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-WEIGHT: NORMAL">
<U>
	Taxes
	/ Costs
</U>
</FONT>
	. Each Party acknowledges that this Agreement may have U.S. federal and state tax (collectively, &ldquo;
<U>
	Tax
</U>
	&rdquo;)
	or other consequences, and that the Party is not relying on any other Party for advice, representations or communications as to
	any potential Tax or other consequences. This Agreement is enforceable regardless of its Tax or other consequences. The Parties
	agree that they shall bear their own costs and attorneys&rsquo; fees relating to or arising from the Litigation and to the documentation
	and negotiation of this Agreement. Enzo is solely responsible for its own Tax liability, if any, resulting from this Agreement.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	3.3
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-WEIGHT: NORMAL">
<U>
	Dismissal
</U>
</FONT>
	.
	Within three (3) court days after the Payment of the consideration to Enzo under this Section 3 has cleared, the Parties shall
	cause their respective counsel to execute and file the stipulated motion in the form set forth in
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
<U>
	Exhibit
	A
</U>
</B>
</FONT>
	dismissing with prejudice all of Enzo&rsquo;s Claims against Illumina in the Litigation. The Parties shall promptly
	proceed with any and all additional procedures needed to dismiss the Litigation as set forth above, with each Party to bear its
	own costs and attorneys&rsquo; fees. The Parties also agree to submit to the court appropriate stipulations and proposed orders
	for extensions of time for all due dates in the Litigation so that
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD NOWRAP STYLE="WIDTH: 15%; BORDER: BLACK 1PX SOLID; PADDING: 5PT">
<P STYLE="FONT: 8PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	REVIEWED
	BY LEGAL
</P>
<P STYLE="FONT: 8PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	Initials:
<U>
	RHS
</U>
</P>
<P STYLE="FONT: 8PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	Date:
<U>
	6/29/16
</U>
</P>
<P STYLE="FONT: 8PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT">
	ILLUMINA
</P>
</TD>
<TD STYLE="WIDTH: 85%">
	&nbsp;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 50%; TEXT-ALIGN: RIGHT">
	9
</TD>
<TD STYLE="WIDTH: 50%; TEXT-ALIGN: RIGHT">
	SUBJECT TO FRE 408
</TD>
</TR>
</TABLE>
<!-- FIELD: PAGE; SEQUENCE: 10 -->
<DIV STYLE="MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: SILVER 4PX SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage107"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 10PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: LEFT; WIDTH: 100%">
<PAGE>
</PAGE>
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	neither
	Party is required to incur unnecessary expenses in the Litigation between the Effective Date and the date the Litigation is dismissed.
	The Parties acknowledge and agree that this Agreement is enforceable according to its terms with respect to final dismissal with
	prejudice of all Claims in the Litigation.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	3.4
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-WEIGHT: NORMAL">
<U>
	No
	Admission of Liability
</U>
</FONT>
	. This Agreement is the result of a compromise and settlement for the purpose of avoiding the
	expense, inconvenience, and uncertainty of additional or continued litigation, and will not at any time be considered as an admission
	of liability or responsibility, or lack thereof, on the part of Enzo or Illumina. By entering into this Agreement, neither Illumina
	nor any of its Affiliates is conceding that it acted wrongfully in any fashion whatsoever. Except as expressly set forth in Section
	3.1, Illumina and its Affiliates expressly deny that they are liable to Enzo in any way.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	3.5
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-WEIGHT: NORMAL">
<U>
	Total
	Compensation / Full Settlement
</U>
</FONT>
	. The Parties agree that this Agreement is in full and complete settlement of the rights
	and obligations of the Parties in connection with the Litigation. This Agreement may be pleaded as a defense to any action, suit
	or claim and may be used as a basis for an injunction against any such action, suit, claim, or other proceeding of any type which
	may be prosecuted, initiated or attempted in violation of the terms hereof. A prevailing Party is entitled to recover from the
	other adverse Party its reasonable attorneys&rsquo; fees and other related legal expenses incurred in defending against any suit,
	action or claim brought or attempted by the other Party in violation of the terms of this Agreement.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	3.6
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-WEIGHT: NORMAL">
<U>
	Maintenance
	Fees and Annuities
</U>
</FONT>
	. Enzo, at its expense, shall pay all maintenance fees and/or annuities for all issued patents within
	the Licensed Enzo Patent Rights (that are not currently expired) and shall otherwise maintain all such issued patents.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-STYLE: NORMAL">
<B>
<U>
	SECTION
	4: TERM AND TERMINATION
</U>
</B>
</FONT>
</P>
<P STYLE="FONT: ITALIC 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	4.1
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-WEIGHT: NORMAL">
<U>
	Term
</U>
</FONT>
	.
	The term of this Agreement shall commence upon the Effective Date and shall continue until the expiration of the enforceability
	period of the last to expire patents within the Licensed Enzo Patent Rights, unless earlier terminated as set forth in Section
	4.2 below.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	4.2
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-WEIGHT: NORMAL">
<U>
	Termination
</U>
</FONT>
	.
	If Illumina fails to make the Payment set forth in Section 3.1 in the time frame required by Section 3.1, then Enzo may terminate
	this Agreement immediately upon further written notice to that effect and the license, releases, and covenants granted by Section
	2 of this Agreement shall immediately terminate, be deemed null and void
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-WEIGHT: NORMAL">
<I>
	ab
	initio
</I>
</FONT>
	, and be of no force and effect. The licenses, covenants, and releases set forth in this Agreement are effective
	as of the Effective Date and may only be terminated if Illumina fails to make the timely Payment as set forth in Section 3.1 above.
	The Limited Standstill set forth in Section 2.6 is effective as of the Effective Date and may only be terminated (i) if Illumina
	fails to make the timely Payment as set forth in Section 3.1 above, or (ii) as set forth in Section 2.6.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-STYLE: NORMAL">
<B>
<U>
	SECTION
	5: ASSIGNMENT
</U>
</B>
</FONT>
</P>
<P STYLE="FONT: ITALIC 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	5.1
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-WEIGHT: NORMAL">
<U>
	Assignment
</U>
</FONT>
	.
	Except as otherwise permitted in this Section, Illumina may not assign, delegate, or otherwise transfer this Agreement or any license
	or rights hereunder without the
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD NOWRAP STYLE="WIDTH: 15%; BORDER: BLACK 1PX SOLID; PADDING: 5PT">
<P STYLE="FONT: 8PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	REVIEWED
	BY LEGAL
</P>
<P STYLE="FONT: 8PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	Initials:
<U>
	RHS
</U>
</P>
<P STYLE="FONT: 8PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	Date:
<U>
	6/29/16
</U>
</P>
<P STYLE="FONT: 8PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT">
	ILLUMINA
</P>
</TD>
<TD STYLE="WIDTH: 85%">
	&nbsp;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 50%; TEXT-ALIGN: RIGHT">
	10
</TD>
<TD STYLE="WIDTH: 50%; TEXT-ALIGN: RIGHT">
	SUBJECT TO FRE 408
</TD>
</TR>
</TABLE>
<!-- FIELD: PAGE; SEQUENCE: 11 -->
<DIV STYLE="MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: SILVER 4PX SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage108"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 10PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: LEFT; WIDTH: 100%">
<PAGE>
</PAGE>
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	prior written
	consent of Enzo. The limitations on assignment set forth in this Section 5 do not apply to an internal reorganization of a Party
	or its Affiliates (e.g., re-incorporation or the like). Any other purported assignment, delegation, or transfer without the prior
	written consent of Enzo will be null and void
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-WEIGHT: NORMAL">
<I>
	ab
	initio
</I>
</FONT>
	and without effect. Except as expressly provided for in Sections 2.3 and 2.6, nothing herein expressed or implied
	will give or be construed to give any Third Party any legal or equitable rights hereunder.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	5.2
<U>
	Permitted Assignment by Illumina
</U>
	.
	Notwithstanding the provisions of Section 5.1, Illumina may assign its rights under this Agreement, in whole or in part, without
	Enzo&rsquo;s prior written or oral consent, to a Person with whom Illumina is merged or consolidated, or who acquires all or substantially
	all of Illumina&rsquo;s array or sequencing product lines subject to the Litigation; provided however, that (i) any such assignment
	of rights will not extend to products or services of such Person that pre-existed the acquisition (or to Natural Evolutions thereof
	following the date of acquisition); and (ii) any such assignment of rights shall not relieve such Person from any obligations
	that such Person may have under this Agreement or to Enzo outside of this Agreement. Any assignment or other transfer by Illumina,
	or any of its Affiliates, of any rights under this Agreement to any other Person shall be subject in writing to this Agreement
	and a written acknowledgment and agreement that the assignee or other transferee shall be bound by such releases and other rights
	and covenants. In the event that Illumina does not continue to exist as a distinct operating entity (such as a wholly-owned subsidiary)
	after the transaction, the rights of Illumina hereunder so assigned only extend to Illumina Products and Covered Third Party Products
	existing as of the date of the transaction and Natural Evolutions of Illumina Products and Covered Third Party Products created
	after the date of the transaction, and will not otherwise extend to any products, services, or activities of the Person prior
	to, on or after the date of the transaction. The releases and covenants provided by Illumina and its Affiliates to Enzo and its
	Affiliates under this Agreement shall run with the rights being assigned or transferred by Illumina and its Affiliates pursuant
	to this Section 5.2 and shall be binding on any permitted successors-in-interest, transferees, or assigns thereof. For avoidance
	of doubt, any such assignment of rights will not extend to any Third Party products or services existing prior to the time of
	transaction or Natural Evolutions thereof. Any purported assignment, delegation, or transfer under this Section 5.2 that does
	not comply with the foregoing will be null and void
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-WEIGHT: NORMAL">
<I>
	ab
	initio
</I>
</FONT>
	and without effect.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	5.3
<U>
	Further Restriction on Assignment
	by Illumina
</U>
	: Notwithstanding the provisions of Sections 5.1 and 5.2, in no event may this Agreement, including the license,
	covenants, and rights granted hereunder, be assigned, delegated, or otherwise transferred without Enzo&rsquo;s prior written consent
	to any of the following: Abbott Laboratories; Abbot Molecular, Inc.; Becton, Dickinson and Company; Becton, Dickinson Diagnostics,
	Inc.; Geneohm Sciences, Inc. (now part of Becton Dickinson); Gen-Probe, Inc. (now part of Hologic, Inc.); Hologic, Inc.; Roche
	Molecular Systems, Inc. (part of Hoffmann-La Roche AG); Roche Diagnostics Corporation (part of Hoffmann-La Roche AG); Roche Diagnostics
	Operations Inc. (part of Hoffmann-La Roche AG); and Roche Nimblegen, Inc. (part of Hoffmann-La Roche AG); or any of the respective
	Affiliates of any of the foregoing (each a &ldquo;
<U>
	Restricted Entity
</U>
	&rdquo;), so long as any patent infringement litigation
	(instituted as of the Effective Date) remains pending between Enzo and the respective aforementioned Restricted Entities. For
	the avoidance of doubt, a Restricted Entity&rsquo;s acquisition of Illumina by stock purchase, reverse triangular merger, or similar
	transaction does not
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD NOWRAP STYLE="WIDTH: 15%; BORDER: BLACK 1PX SOLID; PADDING: 5PT">
<P STYLE="FONT: 8PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	REVIEWED
	BY LEGAL
</P>
<P STYLE="FONT: 8PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	Initials:
<U>
	RHS
</U>
</P>
<P STYLE="FONT: 8PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	Date:
<U>
	6/29/16
</U>
</P>
<P STYLE="FONT: 8PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT">
	ILLUMINA
</P>
</TD>
<TD STYLE="WIDTH: 85%">
	&nbsp;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 50%; TEXT-ALIGN: RIGHT">
	11
</TD>
<TD STYLE="WIDTH: 50%; TEXT-ALIGN: RIGHT">
	SUBJECT TO FRE 408
</TD>
</TR>
</TABLE>
<!-- FIELD: PAGE; SEQUENCE: 12 -->
<DIV STYLE="MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: SILVER 4PX SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage109"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 10PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: LEFT; WIDTH: 100%">
<PAGE>
</PAGE>
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	constitute
	an assignment of the Agreement by Illumina where Illumina (or its successor entity) continues to exist as a distinct operating
	entity (for example, as a wholly-owned subsidiary of the Restricted Entity) after the date of the acquisition, and the licenses,
	covenants, and releases granted herein shall extend only to Illumina Products and Covered Third Party Products existing as of the
	date of the acquisition (and Natural Evolutions thereof) and will not otherwise extend to any products, services, or activities
	of the acquiring Restricted Entity prior to, on or after the date of the acquisition.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	5.4
<U>
	Permitted Assignment by Enzo
</U>
	.
	All releases, licenses and other rights and covenants contained herein shall run with and burden the Licensed Enzo Patent Rights
	and other intellectual property described in Section 2.6, as it applies to the releases, license and other rights and covenants
	contained in Sections 2.1 through 2.6, inclusive, and shall also be binding on any successors-in-interest or assigns thereof.
	Any assignment or other transfer of any of the Licensed Enzo Patent Rights to any other Person shall be subject in writing to
	this Agreement and a written acknowledgment and agreement that the assignee or other transferee shall be bound by such releases,
	licenses and other rights and covenants. Any purported assignment, delegation, or transfer under this Section 5.4 that does not
	comply with the foregoing will be null and void
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-WEIGHT: NORMAL">
<I>
	ab
	initio
</I>
</FONT>
	and without effect.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-STYLE: NORMAL">
<B>
<U>
	SECTION
	6: MISCELLANEOUS PROVISIONS
</U>
</B>
</FONT>
</P>
<P STYLE="FONT: ITALIC 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	6.1 Representations:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	6.1.1
<U>
	Representations by Enzo
</U>
	:
	Enzo hereby represents and warrants that: (i) as of the Effective Date, Enzo and/or its Affiliates own the Licensed Enzo Patent
	Rights, with all substantive rights in and to same, including the exclusive right to grant the license, collect royalties, collect
	past, present and future damages, grant the releases and covenants with respect to the Licensed Enzo Patent Rights set forth herein,
	and enforce those rights with legal standing; (ii) as of the Effective Date, it has not assigned or otherwise transferred to any
	other Person any rights to the Licensed Enzo Patent Rights that would prevent Enzo from conveying the rights, releases and covenants
	set forth herein; (iii) there are no liens or other encumbrances on the Licensed Enzo Patent Rights that would prevent Enzo from
	entering into this Agreement; (iv) Enzo&rsquo;s execution of this Agreement and the performance of Enzo&rsquo;s obligations hereunder
	will not violate any agreement, whether oral or written, to which Enzo or its Affiliates is a party; (v) neither Enzo nor any
	of its Affiliates has granted, nor will grant, any licenses or other rights, under the Licensed Enzo Patent Rights, that would
	conflict with or prevent the rights granted to Illumina and its Affiliates; and (vi) the person executing this Agreement on behalf
	of Enzo has the full right and authority to enter into this Agreement on Enzo&rsquo;s behalf. Notwithstanding the foregoing, if
	any of Enzo&rsquo;s patents are found invalid, this shall not cause a breach of the foregoing representation regarding Enzo or
	its Affiliates&rsquo; right to grant the license, release, or other rights provided herein.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 18PT">
	6.1.2
<U>
	Illumina Representations
</U>
	:
	Illumina represents and warrants that: (i) as of the Effective Date, Illumina has the right to grant the releases and covenants
	set forth herein; and
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD NOWRAP STYLE="WIDTH: 15%; BORDER: BLACK 1PX SOLID; PADDING: 5PT">
<P STYLE="FONT: 8PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	REVIEWED
	BY LEGAL
</P>
<P STYLE="FONT: 8PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	Initials:
<U>
	RHS
</U>
</P>
<P STYLE="FONT: 8PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	Date:
<U>
	6/29/16
</U>
</P>
<P STYLE="FONT: 8PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT">
	ILLUMINA
</P>
</TD>
<TD STYLE="WIDTH: 85%">
	&nbsp;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 50%; TEXT-ALIGN: RIGHT">
	12
</TD>
<TD STYLE="WIDTH: 50%; TEXT-ALIGN: RIGHT">
	SUBJECT TO FRE 408
</TD>
</TR>
</TABLE>
<!-- FIELD: PAGE; SEQUENCE: 13 -->
<DIV STYLE="MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: SILVER 4PX SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage110"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 10PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: LEFT; WIDTH: 100%">
<PAGE>
</PAGE>
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	(ii) the
	person executing this Agreement on behalf of Illumina has the full right and authority to enter into this Agreement on Illumina&rsquo;s
	behalf.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 18PT">
	6.1.3
<U>
	Disclaimer
	of Representation
</U>
	. Nothing in this Agreement shall be construed as (i) a representation or warranty by Enzo as to the scope,
	validity, or enforceability of any patent; and (ii) a representation or warranty that the manufacture, use, or sale of any products
	will not utilize or infringe any intellectual property rights.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 18PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	6.2
<U>
	Confidentiality
</U>
	. From and after
	the Effective Date, neither Party nor its Affiliates shall disclose the existence or terms of this Agreement except:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 18PT">
	6.2.1 with
	the prior written consent of the other Party;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 18PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 18PT">
	6.2.2 to
	any governmental body having jurisdiction and specifically requiring such disclosure, but only to the extent that such disclosure
	is so required;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 18PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 18PT">
	6.2.3 in
	response to a valid document request or subpoena or as otherwise may be required by law, legal process or order of a court, provided
	a protective order is in place that limits disclosure of such information to counsel only and the disclosing Party provides the
	other Party with written notice at least ten (10) business days prior to disclosure to permit the other Party the opportunity to
	object and/or to seek a court-entered protective order or comparable court-ordered restriction, and shall reasonably cooperate
	with the other Party in its efforts to obtain that protective order and take all other reasonable actions in an effort to minimize
	the nature and extent of such disclosure and obtain confidential treatment to the extent available;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 18PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 18PT">
	6.2.4 for
	the purposes of disclosure in connection with the Securities and Exchange Act of 1934, as amended, the Securities Act of 1933,
	as amended, and any other reports filed with the Securities and Exchange Commission (expressly including, but not limited to, Form
	8K disclosures), or any other filings, reports or disclosures that may be required under applicable laws or regulations, but only
	to the extent that such disclosure is required under said applicable laws or regulations;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 18PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 18PT">
	6.2.5 to
	a Party&rsquo;s accountants, legal counsel, tax advisors and other financial and legal advisors and other professional advisors
	in their capacity of advising the Party in such matters, subject to obligations of confidentiality and/or privilege at least as
	stringent as those contained herein;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 18PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 18PT">
	6.2.6 with
	obligations of confidentiality at least as stringent as those contained herein, to a counterparty in connection with a proposed
	merger, acquisition, financing or similar transaction;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 18PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 18PT">
	6.2.7 in
	connection with tax audits or to fulfill its corporate financial reporting obligations under GAAP;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD NOWRAP STYLE="WIDTH: 15%; BORDER: BLACK 1PX SOLID; PADDING: 5PT">
<P STYLE="FONT: 8PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	REVIEWED
	BY LEGAL
</P>
<P STYLE="FONT: 8PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	Initials:
<U>
	RHS
</U>
</P>
<P STYLE="FONT: 8PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	Date:
<U>
	6/29/16
</U>
</P>
<P STYLE="FONT: 8PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT">
	ILLUMINA
</P>
</TD>
<TD STYLE="WIDTH: 85%">
	&nbsp;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 50%; TEXT-ALIGN: RIGHT">
	13
</TD>
<TD STYLE="WIDTH: 50%; TEXT-ALIGN: RIGHT">
	SUBJECT TO FRE 408
</TD>
</TR>
</TABLE>
<!-- FIELD: PAGE; SEQUENCE: 14 -->
<DIV STYLE="MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: SILVER 4PX SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage111"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 10PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: LEFT; WIDTH: 100%">
<PAGE>
</PAGE>
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 18PT">
	6.2.8 with
	obligations of confidentiality at least as stringent as those contained herein, by any Party and its Affiliates as required to
	enforce this Agreement or establish rights hereunder;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 18PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 18PT">
	6.2.9 to
	officers, key shareholders and/or employees with a need to know, attorneys, accountants and directors, who are under obligations
	of confidentiality (which may include professional responsibility obligations) at least as stringent as those contained herein;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 18PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 18PT">
	6.2.10 to
	its Affiliates, who are similarly bound by this Agreement or under obligations of confidentiality at least as stringent as those
	contained herein; and
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 18PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 18PT">
	6.2.11 to
	Third Parties who make, sell, offer to sell, export, import, distribute or otherwise commercialize any Illumina Product or who
	make, sell, offer to sell, export, import, distribute or otherwise commercialize any Covered Third Party Product or Customer Standstill
	Product, and who have a need to know, but only to the extent of such need to know and only under obligations of confidentiality
	at least as stringent as those contained herein.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 18PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Notwithstanding
	anything else in this Agreement to the contrary, a Party may also disclose to anyone any information that is publicly available
	through no breach by that Party or its Affiliates of the confidentiality obligations hereunder.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	6.3
<U>
	Notices
</U>
	. All notices required
	or permitted to be given hereunder shall be in writing and shall be delivered by hand, or, if dispatched by prepaid air courier,
	with package tracing capabilities or by registered or certified airmail, postage prepaid, addressed as follows:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-STYLE: NORMAL">
<B>
	If
	to Enzo:
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Dr. Elazar
	Rabbani
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Enzo Life
	Sciences, Inc.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	527 Madison
	Avenue
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	New York,
	NY 10022
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Copy to
	(which does not constitute notice):
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Michael
	Stadnick
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Desmarais
	LLP
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	230 Park
	Avenue
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	New York,
	NY 10169
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-STYLE: NORMAL">
<B>
	If
	to Illumina:
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Illumina,
	Inc.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	5200 Illumina
	Way
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	San Diego,
	California 92122
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Attn: General
	Counsel
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD NOWRAP STYLE="WIDTH: 15%; BORDER: BLACK 1PX SOLID; PADDING: 5PT">
<P STYLE="FONT: 8PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	REVIEWED
	BY LEGAL
</P>
<P STYLE="FONT: 8PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	Initials:
<U>
	RHS
</U>
</P>
<P STYLE="FONT: 8PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	Date:
<U>
	6/29/16
</U>
</P>
<P STYLE="FONT: 8PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT">
	ILLUMINA
</P>
</TD>
<TD STYLE="WIDTH: 85%">
	&nbsp;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 50%; TEXT-ALIGN: RIGHT">
	14
</TD>
<TD STYLE="WIDTH: 50%; TEXT-ALIGN: RIGHT">
	SUBJECT TO FRE 408
</TD>
</TR>
</TABLE>
<!-- FIELD: PAGE; SEQUENCE: 15 -->
<DIV STYLE="MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: SILVER 4PX SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage112"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 10PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: LEFT; WIDTH: 100%">
<PAGE>
</PAGE>
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Copy to
	(which does not constitute notice):
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Craig Countryman
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Fish &amp;
	Richardson P.C.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	12390 El
	Camino Real
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	San Diego,
	California 92130
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Such notices
	shall be deemed to have been served when received by addressee. Either Party may give written notice of a change of address and,
	after notice of such change has been received, any notice or request shall thereafter be given to such Party as above provided
	at such changed address.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	6.4
<U>
	Publicity
</U>
	. Neither Party will
	issue a press release or any other public announcement regarding this Agreement or the settlement of the Litigation unless the
	other Party provides prior consent in writing. Notwithstanding the foregoing and Section 6.2 above, upon inquiry either Party
	may state that Enzo and Illumina have entered into a settlement agreement.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	6.5
<U>
	Governing Law / Jurisdiction
</U>
	.
	This Agreement and matters connected with the performance thereof shall be construed, interpreted, applied and governed in all
	respects in accordance with the laws of the United States of America and the State of Delaware, without reference to conflict
	of laws principles. Enzo and Illumina agree (a) that all disputes and litigation regarding this Agreement, its construction and
	matters connected with its performance be subject to the exclusive jurisdiction of the state and federal courts in the District
	of Delaware (the &ldquo;
<U>
	Court
</U>
	&rdquo;), and (b) to submit any disputes, matters of interpretation, or enforcement actions
	arising with respect to the subject matter of this Agreement exclusively to the Court. The Parties hereby waive any challenge
	to the jurisdiction or venue of the Court over these matters.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	6.6
<U>
	Sophisticated Parties Represented
	by Counsel
</U>
	. Each Party warrants and represents that (i) it is a sophisticated party represented at all relevant times during
	the negotiation and execution of this Agreement by counsel of its choice, and that it has executed this Agreement with the consent
	and on the advice of such independent legal counsel; (ii) it and its counsel have determined through independent investigation
	and robust, arm&rsquo;s-length negotiation that the terms of this Agreement shall exclusively embody and govern the subject matter
	of this Agreement, (iii) it investigated the facts pertinent to this Agreement as it deemed necessary, (iv) no other Person or
	Party, nor any agent or attorney of a Party, made any promise, representation or warranty whatsoever, express or implied, not
	contained in this Agreement concerning the subject matter of this Agreement to induce it to execute this Agreement, (v) it has
	not executed this Agreement in reliance on any promise, representation or warranty whatsoever, express or implied, not contained
	in this Agreement concerning the subject matter of this Agreement, and (vi) it has not executed this Agreement in reliance on
	any promise, representation or warranty not contained herein. The Parties included this paragraph to preclude any claim that any
	Party was fraudulently induced to execute this Agreement and to preclude the introduction of parol evidence to vary, interpret,
	supplement or contradict the terms of this Agreement.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	6.7
<U>
	Bankruptcy
</U>
	. The Parties acknowledge
	and agree that all releases, rights, covenants and licenses granted by Enzo under or pursuant to this Agreement, including the
	Limited Standstill in
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD NOWRAP STYLE="WIDTH: 15%; BORDER: BLACK 1PX SOLID; PADDING: 5PT">
<P STYLE="FONT: 8PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	REVIEWED
	BY LEGAL
</P>
<P STYLE="FONT: 8PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	Initials:
<U>
	RHS
</U>
</P>
<P STYLE="FONT: 8PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	Date:
<U>
	6/29/16
</U>
</P>
<P STYLE="FONT: 8PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT">
	ILLUMINA
</P>
</TD>
<TD STYLE="WIDTH: 85%">
	&nbsp;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 50%; TEXT-ALIGN: RIGHT">
	15
</TD>
<TD STYLE="WIDTH: 50%; TEXT-ALIGN: RIGHT">
	SUBJECT TO FRE 408
</TD>
</TR>
</TABLE>
<!-- FIELD: PAGE; SEQUENCE: 16 -->
<DIV STYLE="MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: SILVER 4PX SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage113"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 10PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: LEFT; WIDTH: 100%">
<PAGE>
</PAGE>
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	Section 2.6, are, and will otherwise be
	deemed to be, for purposes of Section 365(n) of the United States Bankruptcy Code, as amended (the &ldquo;
<U>
	Bankruptcy Code
</U>
	&rdquo;),
	rights of and to &ldquo;intellectual property&rdquo; as defined under Section 101 of the Bankruptcy Code. The Parties agree that,
	notwithstanding anything else in this Agreement, Illumina and its Affiliates, as the licensee or recipients of such intellectual
	property rights under this Agreement, will retain and may fully exercise all of its rights and elections under the Bankruptcy
	Code (including, without limitation, Illumina and its Affiliates&rsquo; right to the continued enjoyment of the rights and licenses
	granted by Enzo under this Agreement). Notwithstanding the foregoing, this Agreement shall be deemed and treated as an executory
	contract under Section 365 of the Bankruptcy Code and is subject to the restrictions on assumption and assignment in Section 365(c).
	Further, this provision shall not alleviate or contravene the restrictions on assignments and acquisitions set forth in this Agreement.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	6.8
<U>
	No
	Laundering
</U>
	. The Parties understand and acknowledge that the licenses, releases, and covenants granted to Illumina and its Affiliates
	by Enzo hereunder are intended to cover only the bona fide products and services of Illumina, its Affiliates and their respective
	Related Persons and are not intended to cover patent laundering activities (i.e., activities that are undertaken solely for the
	purpose of improperly extending licensed and other rights to cover any activity of any Third Party acting outside the scope of
	Illumina&rsquo;s, its Affiliates&rsquo;, or their respective Related Persons&rsquo;, licensed and otherwise covered activities).
	The Parties further agree that a purchase of a product from a supplier and resale of such product in substantially the same form
	back to the same supplier is not licensed under this Agreement. Nothing in this Agreement shall be construed to license sham sales
	or sham service contracts executed by Illumina or any of its Affiliates with any Third Party solely for the purpose of improperly
	extending licensed rights to cover any activity of any Third Party acting outside the scope of Illumina&rsquo;s (or its Affiliates&rsquo;)
	licensed or otherwise covered activities.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	6.9
<U>
	Severability
</U>
	.
	If any provision of this Agreement is held to be invalid, illegal or unenforceable, such provision shall be limited or eliminated
	to the minimum extent necessary so that the remainder of this Agreement will continue in full force and effect and be enforceable.
	The Parties agree to negotiate in good faith an enforceable substitute provision for any invalid, illegal or unenforceable provision
	that most nearly achieves the intent of such provision.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	6.10
<U>
	Entire
	Agreement
</U>
	. The Parties hereby agree that (i) this is an enforceable agreement; (ii) this Agreement constitutes the entire
	and only understanding of each of them with respect to the subject matter of the Agreement, and merges, supersedes and cancels
	all previous agreements and understandings, whether oral or written, with respect to the subject matter of the Agreement; (iii)
	no oral explanation or oral information by any Party hereto shall alter the meaning or interpretation of this Agreement; (iv) the
	terms and conditions of this Agreement may be altered, modified, changed or amended only by a written agreement that identifies
	itself as an amendment to this Agreement and is executed by duly authorized representatives of each of them; (v) the language of
	this Agreement has been approved by counsel for each of them, and shall be construed as a whole according to its fair meaning;
	and (vi) none of the them (nor their respective counsel) shall be deemed to be the draftsman of this Agreement in any action which
	may hereafter arise with respect to the Agreement.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD NOWRAP STYLE="WIDTH: 15%; BORDER: BLACK 1PX SOLID; PADDING: 5PT">
<P STYLE="FONT: 8PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	REVIEWED
	BY LEGAL
</P>
<P STYLE="FONT: 8PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	Initials:
<U>
	RHS
</U>
</P>
<P STYLE="FONT: 8PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	Date:
<U>
	6/29/16
</U>
</P>
<P STYLE="FONT: 8PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT">
	ILLUMINA
</P>
</TD>
<TD STYLE="WIDTH: 85%">
	&nbsp;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 50%; TEXT-ALIGN: RIGHT">
	16
</TD>
<TD STYLE="WIDTH: 50%; TEXT-ALIGN: RIGHT">
	SUBJECT TO FRE 408
</TD>
</TR>
</TABLE>
<!-- FIELD: PAGE; SEQUENCE: 17 -->
<DIV STYLE="MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: SILVER 4PX SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage114"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 10PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: LEFT; WIDTH: 100%">
<PAGE>
</PAGE>
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	6.11
<U>
	Modification;
	Waiver
</U>
	. No modification or amendment to this Agreement, nor any waiver of any rights, will be effective unless assented to
	in writing by the Party to be charged, and the waiver of any breach or default will not constitute a waiver of any other right
	hereunder or any subsequent breach or default.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	6.12
<U>
	Construction;
	Language
</U>
	. Any rule of construction to the effect that ambiguities are to be resolved against the drafting Party will not be
	applied in the construction or interpretation of this Agreement. As used in this Agreement, the words &ldquo;include&rdquo; and
	&ldquo;including&rdquo; and variations thereof, will not be deemed to be terms of limitation, but rather will be deemed to be followed
	by the words &ldquo;without limitation.&rdquo; The terms &ldquo;will&rdquo; and &ldquo;shall&rdquo; are used synonymously. The
	headings in this Agreement will not be referred to in connection with the construction or interpretation of this Agreement. This
	Agreement is in the English language only, which language shall be controlling in all respects, and all notices under this Agreement
	shall be in the English language.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	6.13
<U>
	Counterparts
</U>
	.
	This Agreement may be executed in counterparts or duplicate originals, both of which shall be regarded as one and the same instrument,
	and which shall be the official and governing version in the interpretation of this Agreement. This Agreement may be executed by
	facsimile signatures or other electronic means and such signatures shall be deemed to bind each Party as if they were original
	signatures.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	6.14
<U>
	Further
	Assurances
</U>
	. Each Party shall execute, acknowledge and deliver such further documents and instruments and perform such other
	acts as may be necessary or appropriate in order to carry out the purposes and intent of this Agreement.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD NOWRAP STYLE="WIDTH: 15%; BORDER: BLACK 1PX SOLID; PADDING: 5PT">
<P STYLE="FONT: 8PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	REVIEWED
	BY LEGAL
</P>
<P STYLE="FONT: 8PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	Initials:
<U>
	RHS
</U>
</P>
<P STYLE="FONT: 8PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	Date:
<U>
	6/29/16
</U>
</P>
<P STYLE="FONT: 8PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT">
	ILLUMINA
</P>
</TD>
<TD STYLE="WIDTH: 85%">
	&nbsp;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 50%; TEXT-ALIGN: RIGHT">
	17
</TD>
<TD STYLE="WIDTH: 50%; TEXT-ALIGN: RIGHT">
	SUBJECT TO FRE 408
</TD>
</TR>
</TABLE>
<!-- FIELD: PAGE; SEQUENCE: 1 -->
<DIV STYLE="MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: SILVER 4PX SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage115"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 10PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: LEFT; WIDTH: 100%">
<PAGE>
</PAGE>
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	IN WITNESS
	WHEREOF, the Parties hereto have caused this Agreement to be signed below by their respective duly authorized officers.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Enzo Life Sciences, Inc.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE; FONT-SIZE: 10PT">
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 5%; TEXT-ALIGN: JUSTIFY; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; LETTER-SPACING: 0PT; ">
	By:
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 35%; FONT-FAMILY: ARIAL UNICODE MS; TEXT-ALIGN: JUSTIFY; PADDING-BOTTOM: 1PX; BORDER-BOTTOM: BLACK 1PX SOLID">
<FONT STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; LETTER-SPACING: 0PT">
	/s/
	Dr. Elazar Rabbani
</FONT>
</TD>
<TD STYLE="WIDTH: 60%; PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: JUSTIFY; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; FONT-FAMILY: ARIAL UNICODE MS; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; ">
<TD STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PX">
<FONT STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; LETTER-SPACING: 0PT; ">
	Name:
</FONT>
	&nbsp;&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; BORDER-BOTTOM: BLACK 1PX SOLID">
<FONT STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; LETTER-SPACING: 0PT; ">
	Dr. Elazar Rabbani
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; ">
<TD STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; ">
<TD STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PX">
<FONT STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; LETTER-SPACING: 0PT; ">
	Title:
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; BORDER-BOTTOM: BLACK 1PX SOLID">
<FONT STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; LETTER-SPACING: 0PT; ">
	Chief Executive Officer
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; ">
<TD STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; ">
<TD STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PX">
<FONT STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	Date:
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; BORDER-BOTTOM: BLACK 1PX SOLID">
<FONT STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; LETTER-SPACING: 0PT">
	July 1, 2016
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="LETTER-SPACING: 0PT; ">
	Illumina,
	Inc.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE; FONT-SIZE: 10PT">
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="WIDTH: 5%; TEXT-ALIGN: JUSTIFY; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PX; VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; LETTER-SPACING: 0PT; ">
	By:
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 35%; FONT-FAMILY: ARIAL UNICODE MS; TEXT-ALIGN: JUSTIFY; PADDING-BOTTOM: 1PX; BORDER-BOTTOM: BLACK 1PX SOLID">
<FONT STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; LETTER-SPACING: 0PT">
	/s/
	Francis deSouza
</FONT>
</TD>
<TD STYLE="WIDTH: 60%; PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; FONT-FAMILY: ARIAL UNICODE MS; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PX">
<FONT STYLE="FONT-SIZE: 10PT; COLOR: BLACK">
	Name:
</FONT>
	&nbsp;&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; FONT-FAMILY: ARIAL UNICODE MS; TEXT-ALIGN: JUSTIFY; BORDER-BOTTOM: BLACK 1PX SOLID">
<FONT STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; LETTER-SPACING: 0PT">
	Francis deSouza
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; FONT-FAMILY: ARIAL UNICODE MS; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; LETTER-SPACING: 0PT; ">
	Title:
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; FONT-FAMILY: ARIAL UNICODE MS; TEXT-ALIGN: JUSTIFY; BORDER-BOTTOM: BLACK 1PX SOLID">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; LETTER-SPACING: 0PT; ">
	President
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; FONT-FAMILY: ARIAL UNICODE MS; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: JUSTIFY; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK; LETTER-SPACING: 0PT; ">
	Date:
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: JUSTIFY; BORDER-BOTTOM: BLACK 1PX SOLID">
	6/29/16
</TD>
<TD STYLE="PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD NOWRAP STYLE="WIDTH: 15%; BORDER: BLACK 1PX SOLID; PADDING: 5PT">
<P STYLE="FONT: 8PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	REVIEWED
	BY LEGAL
</P>
<P STYLE="FONT: 8PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	Initials:
<U>
	RHS
</U>
</P>
<P STYLE="FONT: 8PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	Date:
<U>
	6/29/16
</U>
</P>
<P STYLE="FONT: 8PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT">
	ILLUMINA
</P>
</TD>
<TD STYLE="WIDTH: 85%">
	&nbsp;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 50%; TEXT-ALIGN: RIGHT">
	18
</TD>
<TD STYLE="WIDTH: 50%; TEXT-ALIGN: RIGHT">
	SUBJECT TO FRE 408
</TD>
</TR>
</TABLE>
<!-- FIELD: PAGE; SEQUENCE: 2 -->
<DIV STYLE="MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: SILVER 4PX SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage116"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 10PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: LEFT; WIDTH: 100%">
<PAGE>
</PAGE>
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: ITALIC 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-STYLE: NORMAL">
<B>
	EXHIBIT
	A
</B>
</FONT>
</P>
<P STYLE="FONT: ITALIC 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-STYLE: NORMAL">
<B>
<U>
	STIPULATED
	MOTION FOR DISMISSAL OF LITIGATION
</U>
</B>
</FONT>
</P>
<P STYLE="FONT: ITALIC 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-STYLE: NORMAL">
<B>
	UNITED
	STATES DISTRICT COURT
<BR>
	OF DELAWARE
</B>
</FONT>
</P>
<P STYLE="FONT: ITALIC 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_49"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: BOTTOM; ">
<TD STYLE="WIDTH: 48%; PADDING-RIGHT: 0.5PT; PADDING-LEFT: 0.5PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	ENZO LIFE SCIENCES, INC.
</FONT>
</TD>
<TD STYLE="WIDTH: 3%; PADDING-RIGHT: 0.5PT; PADDING-LEFT: 0.5PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; LETTER-SPACING: 0PT">
	)
</FONT>
</TD>
<TD STYLE="WIDTH: 49%; PADDING-RIGHT: 0.5PT; PADDING-LEFT: 0.5PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	CASE NO. CV 12-CV-435-LPS
</FONT>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.5PT; PADDING-LEFT: 0.5PT; FONT-FAMILY: ARIAL UNICODE MS; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.5PT; PADDING-LEFT: 0.5PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; LETTER-SPACING: 0PT">
	)
</FONT>
</TD>
<TD ROWSPAN="3" STYLE="PADDING-RIGHT: 0.5PT; PADDING-LEFT: 0.5PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; LETTER-SPACING: 0PT; ">
<B>
	JOINT STIPULATION OF DISMISSAL
<BR>
	WITH PREJUDICE
</B>
</FONT>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.5PT; PADDING-LEFT: 90PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	Plaintiff,
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.5PT; PADDING-LEFT: 0.5PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF; LETTER-SPACING: 0PT">
	)
</FONT>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD ROWSPAN="2" STYLE="VERTICAL-ALIGN: MIDDLE; PADDING-RIGHT: 0.5PT; PADDING-LEFT: 50PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	vs.
</FONT>
</TD>
<TD STYLE="PADDING-RIGHT: 0.5PT; PADDING-LEFT: 0.5PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; LETTER-SPACING: 0PT">
	)
</FONT>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.5PT; PADDING-LEFT: 0.5PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; LETTER-SPACING: 0PT">
	)
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.5PT; PADDING-LEFT: 0.5PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; LETTER-SPACING: 0PT; ">
<B>
	The Hon. Leonard Stark
</B>
</FONT>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.5PT; PADDING-LEFT: 0.5PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	ILLUMINA, INC.
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.5PT; PADDING-LEFT: 0.5PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; LETTER-SPACING: 0PT">
	)
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.5PT; PADDING-LEFT: 0.5PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; LETTER-SPACING: 0PT; ">
<B>
	Chief United States District Court Judge
</B>
</FONT>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.5PT; PADDING-LEFT: 0.5PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.5PT; PADDING-LEFT: 0.5PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; LETTER-SPACING: 0PT">
	)
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.5PT; PADDING-LEFT: 0.5PT; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.5PT; PADDING-LEFT: 90PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	Defendant.
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.5PT; PADDING-LEFT: 0.5PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; LETTER-SPACING: 0PT">
	)
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.5PT; PADDING-LEFT: 0.5PT; FONT-FAMILY: ARIAL UNICODE MS; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.5PT; PADDING-LEFT: 0.5PT; FONT-FAMILY: ARIAL UNICODE MS; TEXT-ALIGN: JUSTIFY; BORDER-BOTTOM: BLACK 1PX SOLID">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-RIGHT: 0.5PT; PADDING-LEFT: 0.5PT; TEXT-ALIGN: JUSTIFY; PADDING-BOTTOM: 1PX">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; LETTER-SPACING: 0PT">
	)
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-RIGHT: 0.5PT; PADDING-LEFT: 0.5PT; FONT-FAMILY: ARIAL UNICODE MS; TEXT-ALIGN: JUSTIFY; PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 18PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 18PT">
	Pursuant
	to Rule 41(a)(1)(A)(ii) of the Federal Rules of Civil Procedure, Plaintiff, Enzo Life Sciences, Inc., and Defendant, Illumina,
	Inc., by and through their respective counsel, hereby stipulate to the dismissal with prejudice of all claims in this action. Each
	party shall bear its own attorneys&rsquo; fees and costs.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 18PT">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP; ">
<TD COLSPAN="2" STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	Respectfully submitted,
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; ">
<TD COLSPAN="2" STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; ">
<TD COLSPAN="2" STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	FISH &amp; RICHARDSON P.C.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; ">
<TD COLSPAN="2" STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; ">
<TD COLSPAN="2" STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	FARNAN LLP
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD COLSPAN="2" STYLE="TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; ">
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PX SOLID; WIDTH: 23%">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PX; WIDTH: 22%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 15%">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; WIDTH: 2%">
<FONT STYLE="FONT-SIZE: 10PT">
	By:&nbsp;&nbsp;
</FONT>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PX SOLID; WIDTH: 38%">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD COLSPAN="2">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	Brian E. Farnan
	(#4089)
<BR>
	919 North Market Street, 12
<SUP>
	th
</SUP>
	Flr
<BR>
	Wilmington, DE 19801
<BR>
	(302) 777-0336
<BR>
	bfarnan@farnanlaw.com
<BR>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	Attorneys for
	Plaintiff
<BR>
	Enzo Life Sciences, Inc.
<BR>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	Of Counsel:
<BR>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	John M. Desmarais
	(admitted pro hac vice)
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
<!-- FIELD: PAGE; SEQUENCE: 3 -->
<DIV STYLE="MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: SILVER 4PX SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage117"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 10PT">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: LEFT; WIDTH: 100%">
<PAGE>
</PAGE>
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_50"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 52%">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	Michael P.
	Stadnick (admitted pro hac vice)
<BR>
	Justin P.D. Wilcox (admitted pro hac vice)
<BR>
	Jordan N. Malz (admitted pro hac vice)
<BR>
	Peter C. Magic (admitted pro hac vice)
<BR>
	Desmarais LLP
<BR>
	230 Park Avenue
<BR>
	New York, NY 10169
<BR>
	(212) 351-3400 (Tel)
<BR>
	(212) 351-3401 (Fax)
<BR>
	jdesmarais@desmaraisllp.com
<BR>
	mstadnick@desmaraisllp.com
<BR>
	jwilcox@desmaraisllp.com
<BR>
	jmalz@desmaraisllp.com
<BR>
<U>
	pmagic@desmaraisllp.com
</U>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Attorneys
	for Plaintiff
<BR>
	Enzo Life Sciences, Inc.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 5%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; WIDTH: 43%">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 10PT; TEXT-ALIGN: LEFT">
	Douglas E.
	McCann (#3852)
<BR>
	Martina Tyreus Hufnal (#4771)
<BR>
	Kelly Allenspach Del Dotto (#5969)
<BR>
	222 Delaware Avenue, 17th Floor
<BR>
	Wilmington, DE 19801
<BR>
	(302) 652-5070
<BR>
	dmccann@fr.com
<BR>
	hufnal@fr.com
<BR>
	allenspach.del.dotto@fr.com
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 10PT; TEXT-ALIGN: LEFT">
	Juanita Brooks
<BR>
	Michael A. Amon
<BR>
	Craig Countryman
<BR>
	Robert M. Yeh
<BR>
	Markus Weyde
<BR>
	FISH &amp; RICHARDSON P.C.
<BR>
	12390 El Camino Real
<BR>
	San Diego, CA 92130
<BR>
	Phone: 858-678-5070
<BR>
	brooks@fr.com; amon@fr.com;
<BR>
	countryman@fr.com; yeh@fr.com;
<BR>
	weyde@fr.com
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-VARIANT: SMALL-CAPS; LETTER-SPACING: 0PT; ">
<B>
	Attorneys
	for Defendant
<BR>
	Illumina, Inc.
</B>
</FONT>
</P>
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<!-- FIELD: PAGE; SEQUENCE: 4 -->
<DIV STYLE="MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: SILVER 4PX SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
</EFX_EXHIBIT_10>

<DIV CLASS="eolNewPage"></DIV>
<A NAME="eolPage118"></A>
<A NAME="C86264_EX21_HTM"></A>
<EFX_EXHIBIT_21>
<A NAME="FIS_EXHIBIT_21"></A>
<P STYLE="MARGIN: 0">
</P>
<P STYLE="FONT: 10PT/NORMAL ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0 12PT; TEXT-ALIGN: RIGHT">
	EXHIBIT 21
</P>
<P STYLE="FONT: 10PT/NORMAL ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0 12PT; TEXT-ALIGN: CENTER">
<U>
	List of subsidiaries of the
	Company
</U>
</P>
<P STYLE="FONT: 10PT/NORMAL ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0 12PT">
	Enzo Clinical Labs, Inc., a New York Corporation
</P>
<P STYLE="FONT: 10PT/NORMAL ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0 12PT">
	Enzo Life Sciences, Inc., a New York Corporation
</P>
<UL STYLE="LIST-STYLE-TYPE: DISC">
<LI STYLE="FONT: 10PT/NORMAL ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0 12PT">
	Enzo Life Sciences (ELS) AG, in Lausen, Switzerland,
	a wholly-owned subsidiary of Enzo Life Sciences, Inc.
</LI>
</UL>
<P STYLE="FONT: 10PT/NORMAL ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0 12PT">
	Enzo Therapeutics, Inc., a New York Corporation
</P>
<P STYLE="FONT: 10PT/NORMAL ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0 12PT">
	Enzo Realty, LLC, a New York Corporation
</P>
<P STYLE="FONT: 11PT/115% CALIBRI, HELVETICA, SANS-SERIF; MARGIN: 0 0 10PT">
	&nbsp;
</P>
<P STYLE="MARGIN: 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 1 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; PADDING-TOP: 0PT; PADDING-BOTTOM: 6PT; BORDER-BOTTOM: SILVER 4PX SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
</EFX_EXHIBIT_21>

<DIV CLASS="eolNewPage"></DIV>
<A NAME="eolPage119"></A>
<A NAME="C86264_EX23-1_HTM"></A>
<EFX_EXHIBIT_23>
<A NAME="FIS_EXHIBIT_23"></A>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: RIGHT">
	Exhibit 23.1
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: RIGHT">
	&nbsp;
</P>
<EFX_EXPERTS_CONSENT>
<A NAME="FIS_EXPERTS_CONSENT"></A>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	CONSENT OF INDEPENDENT REGISTERED PUBLIC
	ACCOUNTING FIRM
</B>
</P>
<P STYLE="FONT: 11PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	We hereby consent to the incorporation by
	reference in the Registration Statements of Enzo Biochem, Inc. and subsidiaries (the &ldquo;Company&rdquo;) on Form S-8 (File Nos.
	333-87153, 333-89308, 333-123712, 333-172127, and 333-197028) and on Form S-3 (File No. 333-213440) (pending) of our reports dated
	October 13, 2016 on our audits of the consolidated financial statements and financial statement schedules as of July 31, 2016 and
	2015 and for each of the years in the three-year period ended July 31, 2016, and the effectiveness of the Company&rsquo;s internal control
	over financial reporting as of July 31, 2016, which reports are included in this Annual Report on Form 10-K.
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	/s/ EisnerAmper LLP
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	New York, New York
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	October 13, 2016
</P>
</EFX_EXPERTS_CONSENT>
<!-- FIELD: PAGE; SEQUENCE: 5 -->
<DIV STYLE="MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: SILVER 4PX SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
</EFX_EXHIBIT_23>

<DIV CLASS="eolNewPage"></DIV>
<A NAME="eolPage120"></A>
<A NAME="C86264_EX31-A_HTM"></A>
<EFX_EXHIBIT_31>
<A NAME="FIS_EXHIBIT_31"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PX SOLID">
	EXHIBIT 31 (a)
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<EFX_CERTIFICATION>
<A NAME="FIS_CERTIFICATION"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	CERTIFICATIONS
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	In connection with the Annual Report on Form 10-K of Enzo Biochem,
	Inc. (&#8220;the Company&#8221;) for the fiscal year ended July 31, 2016 as filed with the Securities and Exchange Commission on
	the date hereof, I, Elazar Rabbani, Ph.D., Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. &sect; 1350,
	as adopted pursuant to &sect; 302 of the Sarbanes-Oxley Act of 2002, that:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	1. I have reviewed this Annual Report on Form 10-K of Enzo Biochem,
	Inc.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	2. Based on my knowledge, this report does not contain any untrue
	statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances
	under which such statements were made, not misleading with respect to the period covered by this report;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	3. Based on my knowledge, the financial statements, and other
	financial information included in this report, fairly present in all material respects the financial condition, results of operations
	and cash flows of the Company as of, and for, the periods presented in this report;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	4. The Company&#8217;s other certifying officer and I are responsible
	for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a - 15(e) and 15d - 15(e))
	and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the Company and have:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	(a) Designed such disclosure controls and procedures, or caused
	such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the
	Company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the
	period in which this report is being prepared;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	(b) Designed such internal control over financial reporting,
	or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance
	regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance
	with generally accepted accounting principles;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	(c) Evaluated the effectiveness of the Company&#8217;s disclosure
	controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures,
	as of the end of the period covered by this report based on such evaluation; and
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	(d) Disclosed in this report any change in the Company&#8217;s
	internal control over financial reporting that occurred during the Company&#8217;s most recent fiscal quarter (the Company&#8217;s
	fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect,
	the Company&#8217;s internal control over financial reporting; and
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	5. The Company&#8217;s other certifying officer and I have disclosed,
	based on our most recent evaluation of internal control over financial reporting, to the Company&#8217;s auditors and the audit
	committee of the Company&#8217;s board of directors (or persons performing the equivalent functions):
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	(a) All significant deficiencies and material weaknesses in
	the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Company&#8217;s
	ability to record, process, summarize and report financial information; and
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	(b) Any fraud, whether or not material, that involves management
	or other employees who have a significant role in the Company&#8217;s internal control over financial reporting.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT CAMBRIA, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD COLSPAN="2">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Date: October 13, 2016
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 25%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 22%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	By:
</FONT>
</TD>
<TD STYLE="WIDTH: 49%; BORDER-BOTTOM: BLACK 1PX SOLID">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	/s/ Elazar Rabbani, Ph.D.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Elazar Rabbani, Ph.D.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Chairman of the Board, Chief Executive Officer and Director
</FONT>
</TD>
</TR>
</TABLE>
</EFX_CERTIFICATION>
<!-- FIELD: PAGE; SEQUENCE: 1 -->
<DIV STYLE="MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: SILVER 4PX SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
</EFX_EXHIBIT_31>

<DIV CLASS="eolNewPage"></DIV>
<A NAME="eolPage121"></A>
<A NAME="C86264_EX31-B_HTM"></A>
<EFX_EXHIBIT_31>
<A NAME="FIS_EXHIBIT_31_2"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PX SOLID">
	EXHIBIT
	31 (b)
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: RIGHT">
	&nbsp;
</P>
<EFX_CERTIFICATION>
<A NAME="FIS_CERTIFICATION_2"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	CERTIFICATIONS
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	In connection with the Annual Report on Form 10-K of Enzo Biochem,
	Inc. (&#8220;the Company&#8221;) for the fiscal year ended July 31, 2016 as filed with the Securities and Exchange Commission on
	the date hereof, I, Barry Weiner, Chief Financial Officer and Principal Accounting Officer of the Company, certify, pursuant to
	18 U.S.C. &sect; 1350, as adopted pursuant to &sect; 302 of the Sarbanes-Oxley Act of 2002, that:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	1. I have reviewed this Annual Report on Form 10-K of Enzo Biochem,
	Inc.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	2. Based on my knowledge, this report does not contain any untrue
	statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances
	under which such statements were made, not misleading with respect to the period covered by this report;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	3. Based on my knowledge, the financial statements, and other
	financial information included in this report, fairly present in all material respects the financial condition, results of operations
	and cash flows of the Company as of, and for, the periods presented in this report;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	4. The Company&#8217;s other certifying officer and I are responsible
	for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a - 15(e) and 15d - 15(e))
	and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the Company and have:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	(a) Designed such disclosure controls and procedures, or caused
	such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the
	Company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the
	period in which this report is being prepared;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	(b) Designed such internal control over financial reporting,
	or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance
	regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance
	with generally accepted accounting principles;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	(c) Evaluated the effectiveness of the Company&#8217;s disclosure
	controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures,
	as of the end of the period covered by this report based on such evaluation; and
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	(d) Disclosed in this report any change in the Company&#8217;s
	internal control over financial reporting that occurred during the Company&#8217;s most recent fiscal quarter (the Company&#8217;s
	fourth quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the
	Company&#8217;s internal control over financial reporting; and
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	5. The Company&#8217;s other certifying officer and I have disclosed,
	based on our most recent evaluation of internal control over financial reporting, to the Company&#8217;s auditors and the audit
	committee of the Company&#8217;s board of directors (or persons performing the equivalent functions):
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	(a) All significant deficiencies and material weaknesses in
	the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Company&#8217;s
	ability to record, process, summarize and report financial information; and
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	(b) Any fraud, whether or not material, that involves management
	or other employees who have a significant role in the Company&#8217;s internal control over financial reporting.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT CAMBRIA, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; WIDTH: 25%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Date: October 13, 2016
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 22%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 3%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; WIDTH: 50%">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	By:
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: BLACK 1PX SOLID">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	/s/ Barry Weiner
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Barry Weiner
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	President, Chief Financial Officer, Principal Accounting Officer, Treasurer and Director
</FONT>
</TD>
</TR>
</TABLE>
</EFX_CERTIFICATION>
<!-- FIELD: PAGE; SEQUENCE: 2 -->
<DIV STYLE="MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: SILVER 4PX SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
</EFX_EXHIBIT_31>

<DIV CLASS="eolNewPage"></DIV>
<A NAME="eolPage122"></A>
<A NAME="C86264_EX32-A_HTM"></A>
<EFX_EXHIBIT_32>
<A NAME="FIS_EXHIBIT_32"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PX SOLID">
	EXHIBIT
	32 (a)
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: RIGHT">
	&nbsp;
</P>
<EFX_CERTIFICATION>
<A NAME="FIS_CERTIFICATION_3"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	CERTIFICATE PURSUANT TO
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	18 U.S.C. SECTION 1350,
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	AS ADOPTED PURSUANT TO
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	SECTION 906 OF THE SARBANES-OXLEY ACT
	OF 2002
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	In connection with the Annual Report of Enzo Biochem, Inc.,
	and Subsidiaries (&#8220;the Company&#8221;) on Form 10-K for the fiscal year ended July 31, 2016 as filed with the Securities
	and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, Elazar Rabbani, Ph.D., Chief Executive Officer of the
	Company, certify, pursuant to 18 U.S.C. &sect; 1350, as adopted pursuant to &sect; 906 of the Sarbanes-Oxley Act of 2002, that:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 18PT">
	(1)
</TD>
<TD>
	The Report fully complies with the requirements of Section 13 (a) or 15 (d) of the Securities Exchange Act of 1934; and
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 18PT">
	(2)
</TD>
<TD>
	The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations
	of the Company.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT CAMBRIA, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 25%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Dated: October 13, 2016
</FONT>
</TD>
<TD STYLE="WIDTH: 23%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 50%">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	By:&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	/s/ Elazar Rabbani, Ph.D.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Elazar Rabbani, Ph.D.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Chairman of the Board, Chief Executive Officer and Director
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	A signed original of this written statement required by Section
	906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the
	electronic version of this written statement required by Section 906, has been provided to the Company and will be retained by
	the Company and furnished to the Securities and Exchange Act Commission or its staff upon request.
</P>
</EFX_CERTIFICATION>
<!-- FIELD: PAGE; SEQUENCE: 3 -->
<DIV STYLE="MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: SILVER 4PX SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
</EFX_EXHIBIT_32>

<DIV CLASS="eolNewPage"></DIV>
<A NAME="eolPage123"></A>
<A NAME="C86264_EX32-B_HTM"></A>
<EFX_EXHIBIT_32>
<A NAME="FIS_EXHIBIT_32_2"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PX SOLID">
	EXHIBIT
	32 (b)
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: RIGHT">
	&nbsp;
</P>
<EFX_CERTIFICATION>
<A NAME="FIS_CERTIFICATION_4"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	CERTIFICATE PURSUANT TO
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	18 U.S.C. SECTION 1350,
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	AS ADOPTED PURSUANT TO
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	SECTION 906 OF THE SARBANES-OXLEY ACT
	OF 2002
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	In connection with the Annual Report of Enzo Biochem, Inc.,
	and Subsidiaries (&#8220;the Company&#8221;) on Form 10-K for the fiscal year ended July 31, 2016 as filed with the Securities
	and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, Barry Weiner, Chief Financial Officer and Principal Accounting
	Officer of the Company, certify, pursuant to 18 U.S.C. &sect; 1350, as adopted pursuant to &sect; 906 of the Sarbanes-Oxley Act
	of 2002, that:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 18PT">
	(1)
</TD>
<TD>
	The Report fully complies with the requirements of Section 13 (a) or 15 (d) of the Securities Exchange Act of 1934; and
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 18PT">
	(2)
</TD>
<TD>
	The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations
	of the Company.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT CAMBRIA, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 25%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Date: October 13, 2016
</FONT>
</TD>
<TD STYLE="WIDTH: 22%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 3%">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	By:
</FONT>
</TD>
<TD STYLE="WIDTH: 50%; BORDER-BOTTOM: BLACK 1PX SOLID">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	/s/ Barry Weiner
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Barry Weiner
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	President, Chief Financial Officer, Principal Accounting Officer, Treasurer and Director
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
	A signed original of this written statement required by Section
	906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the
	electronic version of this written statement required by Section 906, has been provided to the Company and will be retained by
	the Company and furnished to the Securities and Exchange Act Commission or its staff upon request.
</P>
</EFX_CERTIFICATION>
<!-- FIELD: PAGE; SEQUENCE: 4 -->
<DIV STYLE="MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: SILVER 4PX SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF">
<TR>
<TD STYLE="TEXT-ALIGN: CENTER; WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<!-- FIELD: /PAGE -->
</EFX_EXHIBIT_32>

<!-- FOOTER LOGO -->
</BODY>
</HTML>
